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Abstract 
Background: Prostate cancer risk has been associated with several environmental 
factors but there is little information to indicate the effects of timing and of lifetime 
exposures that may add to the risk. This thesis aims to investigate the association of 
six main areas that may contribute to prostate cancer risk (1) body shape & fat 
distribution, (2) chronic diseases/conditions (diabetes mellitus, hypertension, 
ischaemic heart diseases and hypercholesterolemia), (3) statin medications (4) 
painkillers (NSAIDs and paracetamol), (5) skin & sunlight exposure and (6)diet 
(isoflavones, selenium, vitamin D & Iycopene). The exposures will be investigated at 
different stages of life for subsequent effects on cumulative prostate cancer risk. 
Methodology: This study is a part of "The UK Prostate Cancer Study: Gene-
Environment Interactions", which is an ongoing large scale case-control study and a 
collaboration between the University of Nottingham, University of Warwick and the 
Institute of Cancer Research UK. Data were collected using questionnaires. Subjects 
were recruited between the years of 1999 to 2009 as cases and controls from 
hospitals and GPs' referrals in England. Possible risk factors for prostate cancer are 
investigated through statistical analyses using unconditional logistic regression to 
obtain odds ratios (OR) and confidence intervals. 
Results: The response rate was 85.0% among cases and 74.4% among controls, 
with a total of 4041 males (1963 cases and 2078 controls) recruited into the study. 
The mean age among cases and controls was 59.6 and 59.1 years respectively. 
Multivariate analysis of socio-demographic factors showed education, ethnic group 
and family history were statistical significantly associated with prostate cancer risk 
and therefore are treated as confounders. Further, (1) Body fat distribution of 
'apple' and 'oval' shapes were found to have protective effect towards prostate 
cancer when compared with a symmetrical shape with an OR of 0.69 (95% CI: 0.55-
0.87) and 0.73 (95% CI 0.53-1.00) respectively, however body shape at age 20's, 
30's, 40's and last 5 years showed no statistical difference between cases and 
controls. (2) The cumulative duration of diabetes mellitus categorised as 5 years or 
more and 10 years or more when compared to non-diabetic individuals had a 
ii 
protective effect towards prostate cancer risk at OR 0.45 (95%CI: 0.27-0.75) and 
0.44 (95% CI: 0.22-0.86) respectively while hypertension, hypercholesterolemia and 
ischaemic heart disease did not associate with prostate cancer risk. (3) Use of 
Statins for less than 5 years compared to non-users, produced an OR 0.61 (95%CI: 
0.47-0.82). A dose response relationship for duration of use was also seen. (4) 
Paracetamol showed a protective effect for prostate cancer risk when used for 20 
years to 30 years when compared to none-users, OR 0.54 (95%C1: 0.28-1.00). 
Similarly paracetamol showed a cumulative risk reduction against prostate cancer for 
all categories of use of up to 20 years or more. However aspirin and ibuprofen did 
not show any statistical significant associations with prostate cancer risk. (5) Higher 
exposure to sunlight received in non-working situations and more frequent use of 
suntan cream showed protective effects against prostate cancer and also when 
accounted for exposure at different stages of life age. (6)Dietary isoflavones and 
tablet supplements of selenium at higher intake quartiles levels showed a protection 
effect against prostate cancer risk when compared to lowest quartile intake. 
New surrogate indicators for body size and sunlight exposure and a proposed model 
for overall vitamin D levels from sunlight and dietary sources were also introduced. 
Conclusions: Body fat distribution of 'apple' and 'oval' body forms, diabetes 
mellitus, statin usage, higher exposure to sunlight and higher dietary intakes of 
isoflavones were shown to associate with a decreased risk for prostate cancer. The 
findings of this case-control study strengthen and support the current understanding 
of environmental factors associated with prostate cancer risk, whilst at the same 
time provides further evidence on the effects of exposure at different stages in life 
and their cumulative effect, as well identifying new surrogate indicators as 
parameters measurement for such exposures. 
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Chapter 1 Introduction 
1.1 Introduction 
1.1.1 Literature Review 
Male Reproductive Tract 
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Figure 1-1 Male Reproductive Tract 
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(Reproduced with permission from www.mainlinehealth.org (Dec 2, 2010» 
1.1.2 Anatomy and physiology of Prostate gland 
The prostate is a walnut size gland in the male located in the pelvis at the base of 
the urinary bladder. It grows and develops during infant life by testosterone and 
growth hormones. During adolescence or puberty, there is a rise in androgen level 
and a second peak occurrs around age of 50 when there is an increase of estrogen to 
androgen ratio (Syrigos, 2001) 
Prostate growth continues with age and enlargement of the gland can result in 
urination problems because the urethra passes through the prostate gland and may 
be obstructed at the neck of bladder. Common prostate problems include Benign 
Prostatic Hyperthrophy (BPH), Prostatitis, associated with infection or acquired as a 
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result of sexual activity and Prostate cancer. Development within prostate will 
produce prostatic specific antigen (PSA), a fluid with an important role in sexual 
activity by nourishing the sperm for its function in reproduction. The level of PSA 
present in the bloodstream reflects the activity and health of the prostate gland 
(Waxman, 2002). 
1.1.2.1 Pathophysiology of Prostate cancer 
The exact change from normal prostate gland (a secretory gland) to prostatic 
intraepithelial neoplasia (PIN) is not well established. The PIN is considered as pre-
invasive change of prostate cancer and normally detected only through needle biopsy 
(Ramon, 2007). Further follow up of the patient is required as progression could 
occur but could regress back to normal is also possible. High grade PIN is the most 
likely precursor of prostate cancer, therefore PIN is useful as a predictive cancer 
marker. Repeated biopsy of prostate specimen may be warranted (Montironi et aI, 
2000). 
Once progressed to prostate cancer, the malignant neoplasm would most commonly 
be of adenocarcinoma in histological findings. There is evidence to support the 
association between inflammation and prostate cancer, but exact mechanisms are 
not well defined. Molecular markers specific at early and late events are critical to 
the progress of prostate cancer to improve detection and prognostic strategy 
(Gonzalgo, 2003). 
When Gleason score was introduced as a model for prostate cancer progression, the 
study of aggressiveness of cancer was made possible (Epstein et aI, 2005). When 
cancer is invasive, the nuclear matrix also changes with differentiation, hence there 
is a progressive loss of the normal prostate gland pattern and increased stromal 
invasion. 
There is increasing evidence that predisposing genetic factors, oxidative damage and 
dietary or environmental factors play account or role in the steps of neoplastic 
transformation. These factors will be discussed further in the chapter on associated 
risk factors of prostate cancer. 
1.1.3 Clinical features of Prostate cancer 
Prostate cancer is a heterogeneous disease and can remain silent for years before 
presenting with metastatic diseases features. However, any obstructive or irritation 
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in urine voiding would present itself early such as in localized prostate cancer. 
Development of prostate cancer doesn't present typical clinical symptoms that would 
warrant immediate referral to a urologist (Syrigos, 2001). 
Presentation of patients with prostate cancer varies and can be broadly divided into 
three sets of level namely at local disease, local advanced or invasive and 
metastatic. 
Table 1-1 Clinical presentation/signs or symptoms of Prostate Cancer 
Local disease Local Metastatic disease 
invasive/ advanced 
disease 
• Asymptomatic • Dysuria • Bone pain 
• Elevated PSA • Haematuria • Sciatica or 
• Perineal and paraplegia due to 
suprapubic spinal cord or 
pain/discomfort nerve compression 
• Erectile dysfunction • Lymph node 
• Bladder enlargement 
incontinence • Weight loss and 
• Renal failure cachexia 
symptoms e.g. loin • Lethargy due to 
pain, anuria, anaemia or 
uraemia uraemia 
• Rectal symptoms 
e.g. tenesmus 
Adapted from Kirby, R. S. 2009. Fast facts: Prostate cancer. Oxford Health Press 
(Kirby, 2009) 
1.1.4 Investigation. Diagnosis of Prostate cancer 
Digital rectal examination (DRE) is the simplest form and cheapest form of 
detecting prostate cancer provided that the tumour growth is posteriorly located in 
palpable or sufficiently enlarged prostate. This examination or test can be done 
while patient lying left lateral position leaning forward. Findings that could indicate 
prostate cancer include palpable nodule, asymmetry of the prostate gland, reduced 
mobility due to adhesion to surrounding tissue and palpable seminal vesicles (Kirby, 
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2009). False positive diagnosis could be due to BPH, prostatic calculi, prostatitis 
(especially granulomatous type), duct or vesicle abnormality and rectal polyps. 
Prostatic specific antigen (PSA) measurement of blood serum specimen is the 
most important and widely used tumour marker in urological oncology (Syrigos, 
2001). It is used in diagnosis, staging and monitoring prostate cancer. However PSA 
is organ-specific to prostate gland and not cancer specific. A traditional cut-off value 
of PSA serum 4.0ng/ml is normally used however almost one-fifth of prostate cancer 
patients have serum PSA below that level. A higher PSA value may also be due to 
BPH or other prostatic diseases and urinary retention not limited to prostate cancer. 
PSA sensitivity and specificity can be enhanced through usage of several parameters 
including PSA density, PSA age-specific, PSA velocity, percentage of free-PSA. 
Ultrasound examination including transrectal ultrasound examination (TRUS) of 
the prostate through probe inserted into the rectum of subject. This method gives 
an idea to the outline and internal structure of the gland, as well the structures 
surrounding the prostate such as seminal vesicles, and also changes in the prostate 
capsule which could suggest that the gland has been breached by tumour. However 
there's no correlation between TRUS appearance and macroscopically pathological 
findings (Waxman, 2002). 
Biopsy or removal of samples of tissue of the prostate gland is performed by 
inserting small spring loaded needles in the ultrasound probe during TRUS and into 
prostate through rectum wall. Six core biopsies are normally taken. The specimens 
collected are then sent for process in pathology lab and examined under microscope 
by a pathologist who will confirm if there's cancer growth, the degree of infiltration of 
the prostate by the tumour, type of tumour and staging or grading of the prostate 
cancer (Waxman, 2002). 
1.1.5 Staging/Grading of Prostate cancer 
There are a couple of staging systems for prostate cancer including Whitmore Jewett, 
American Joint Cancer Committee (AJCC), American Urological System and Prout. 
However the most widely used is the TNM (Tumour, Nodes & Metastatic) 
classification (Syrigos, 2001). 
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1.1.S.1 TNM Classification 
The International Union Against Cancer (UICC) and American Joint Committee on 
Cancer (AJCC) started using the TNM (Tumour, Nodes and Metastases) Classification 
since 1970's but over the years has been united and undergone 1992 Consensus to 
come out with TNM Classification for prostate cancer (Schroder et aI, 1992). It 
serves both clinical and pathological staging. 
Clinical staging includes digital rectal examination (DRE) of the prostate and 
cytological confirmation of prostate cancer. Clinical examination, serum PSA level 
and imaging investigation such as TRUS are suggested. Pathological staging mostly 
requires histological examination of resected specimen of prostate, seminal vesicles 
and pelvic lymph node. 
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In terms of grading systems for prostate cancer, Gleason is the most used. The other 
grading systems include Mostofi, MD Anderson, Bocking, Gaeta and Broders. 
1.1.5.2 Gleason Grade for Prostate Cancer 
Table 1-3 Prostate Cancer Grading using Gleason Grading System 
(Adapted from Fast facts: Prostate cancer. Oxford Health Press)(Kirby, 2009) 
Grade Description 
-----
Grade 1 Well differentiated cancer cells consist of small uniform glands with 
minimal nuclear changes and likely to be of a less aggressive nature as 
they are slow growing. 
Grade 2 Medium sized acini but irregular with stromal separation but closely 
arranged. 
Grade 3 Moderately differentiated cells with marked variation of glandular size 
and organization with infiltration of stromal and neighboring tissues; at 
this grade cancerous cells may have invaded surrounded prostate 
tissue. This is the most common grade of prostate cancer. 
Grade 4 Cytological atypia cells of undifferentiated cancer cells with extensive 
infiltration to the gland. 
Grade 5 Sheets of undifferentiated anaplastic cancer cells, which are likely to be 
fast growing and spreading. 
1.1.5.3 Gleason Score 
The Gleason score is the sum of the two most prominent grades found on cytology 
findings of the biopsy specimen of prostate tumour with scores between 2 to 10. This 
score can predict the likelihood of growth and spread of the cancer cells. 
Table 1-4 Gleason Score for Prostate Cancer 
(Adapted from Fast facts: Prostate cancer. Oxford Health Press)(Kirby, 2009) 
Gleason score Histological Features 10-year likelihood of 
arowth and spread (0/0) 
2-6 Well differentiated cells 25 
7 Moderately differentiated cells 50 
8-10 Poorly differentiated cells 75 
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1.1.6 Management and Prognosis of Prostate cancer 
(Adapted from Fast facts: Prostate cancer. Oxford Health Press)(Kirby, 2009) 
Management of prostate cancer cases are best divided into localized, localized 
advance and high risk group. For the localized prostate cancer group they may 
further be categorized as low, intermediate and high risk of recurrence, based on 
Gleason score, PSA level and clinical stage. However it is not possible to say which 
treatment will produce the optimum result on individuals. 
Radical prostatectomy is a procedure whereby the entire prostate, seminal 
vesicles and adjacent tissues are surgically removed, also helps to excise precisely all 
confined cancer cells for surety removal of all prostatiC tissues. This procedure is 
normally indicated for histological evidence of prostate cancer with localized disease 
Tl-T2, patient longer life expectancy of more than 10 years with no surgery 
contra indications. 
External-beam radiotherapy is indicated in patients who cannot undergo surgery 
or has extra prostatic extension of cancer tissue but still regionally localized. The new 
coming of intensity-modulated radiotherapy (IMRT) has allowed more precise to 
prostate gland and radiation can be given in higher doses without significant toxicity. 
Low-dose seed brachytherapy a procedure putting seeds of iodine-125 or 
paliadium-l03 into the prostate through transperineal route and TRUS guidance. It 
is indicated for low risk group of prostate cancer patients. 
High-dose-rate (HDR) brachytherapv using high intensity iridium is indicated for 
intermediate and high risk cancer group of localized cancer. 
Watchful waiting is ideal for men who are at advanced age or those who have 
shorter life-expectancy and who will unlikely to have shortened life span due to 
prostate cancer. Those with high risk category also it will be a valid treatment. This 
management requires patients reviewed regularly with clinical examination and PSA 
testing. Palliative androgen deprivation treatment is given for those identified with 
cancer disease progression. 
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High-intensity focused ultrasound (HIFU) uses a probe transrectally to the 
prostate to destroy cancer cells. Although new, it is quite promising and also used for 
cancer recurrence patients even after radiotherapy at low risk group. 
Cryoablation is by way of freezing the prostatic tissue under TRUS guidance using 
cryogenic probes circulating liquid nitrogen inserted via perineum. This treatment is 
currently used in low risk group or recurrence cases even after radiotherapy. 
Hormonal therapy (cytoreduction) for prostate is achievable by using luteinizing 
hormone-releasing hormone (LHRH) analogs with an anti-androgen to reduce tumour 
burden. This is done prior to radical prostatectomy. It is normally indicated for 
advanced cases. Similarly hormonal therapy is used prior to external-beam 
radiation. 
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1.2 Epidemiology of Prostate Cancer 
1.2.1 Introduction 
Prostate Cancer has become of higher importance among the male cancers because 
of the improved medicine and health care in developed and developing countries and 
even most parts of the third world which had led to the increase of life expectancy. 
The Cancer Research UK (2010) age specific incidence rates for prostate cancer in 
United Kingdom in 2007 show steep increases with age (CRUK, 2010). In response 
to these pertinent events, the study of the associated risk factors and the preventive 
predictive factors has been progressing rather rapidly. The study of prostate Cancer 
preventive and risk factors in the United Kingdom has also progressed and on-going 
(Dimitropoulou et aI, 2009; Lophatananon et aI, 2010; Myles et aI, 2008; Rahman et 
al,2010). 
1.2.2 Burden of Disease 
Prostate cancer is the second most common cancer diagnosed in men globally about 
14% based on estimation of 2008 Cancer burden study (Ferlay et aI, 2008), but 
based on 2007 actual incidence in United Kingdom (UK) the percentage is 24%, 
almost a quarter in terms of proportion. Prostate cancer is the most common 
cancer diagnosed in men in the UK, followed by lung and colorectal cancer at 15% 
and 14% respectively (CRUK, 2010). 
1.2.3 Incidence 
A rise in the prostate cancer incidence over the last 30 years in UK has been due to 
the increased detection of prostate cancer following procedure transurethral 
resection of the prostate (TURP) and the use of prostate specific antigen (PSA) 
testing (CRUK, 2010). 
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Figure 1-2 Numbers of new cases and age-specific incidence rates of 
prostate cancer UK 2007 
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The incidence rate of prostate cancer in 2007 for United Kingdom was 97.5 per 
100,000 male population(age standardized European population) (CRUK, 2010). 
1.2.4 Mortality 
In terms of mortality from cancer in men, worldwide estimate is 4.2 million in 2008, 
mainly from lung cancer (23%), with prostate cancer in the 6 th place at 6%. The UK 
2007 cancer mortality data reported prostate cancer deaths of 10,170 people, as the 
2nd highest among men at 12%, behind lung cancer of 24%. It is obvious that 
Prostate cancer is responsible for relatively higher number deaths in the UK than the 
worldwide (CRUK, 2010). 
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1.3 Overview Factors Associated with Prostate Cancer 
1.3.1 Socio-demographic Factors 
The factors involving age, marital status, born country, education, race/ethnicity, 
social class and family history will be discussed in detail in Chapter 3 on Socio-
demographic factors. 
1.3.2 Occupation 
Many studies have associated the environmental exposures at workplace that 
could have been carcinogenic materials or could affect or modified the risk to 
development of cancers. Some of the most recognized exposure includes 
pesticides for those in farming or applicators, chemicals substances in 
manufacturing industries or laboratories, and ionizing radiation for those in 
medical, paramedical or in radiation related manufacturing industries. Since 
these forms of exposures could also account for non occupational hazards such as 
through leisure gardening activities involving usage pesticide either or patients 
who had to undergo imaging investigation as part of medical examination, thus 
the review on these topics are described in separate paragraphs on pesticides, 
chemicals and radiation. 
1.3.3 Physical features or characteristics 
Height and prostate cancer studies have shown inconsistent associations and 
most probably has a positive Interaction with family history, where a combination 
of the factors of height and family history of prostate cancer would increase 
relative risk as much as 5.49 (Cl: 1.31-22.94) to all types of prostate cancer or 
7.41 (Cl: 1.68-32.7) for advanced prostate cancer in compared with those of 
lower height and no family history (Norrish et aI, 2000b). More recent study of 
PLCa (Prostate lung colorectal and ovarian cancer) Screening Trial showed the 
risk of aggressive prostate cancer of Gleason score 7 or more, were greater in 
taller men with statistical significant trend across height categories, and 
significant in those diagnosed before age 65 with RR 1.76 (CI: 1.06-2.93) for 
those with 190cm and above in height versus those less than 170cm, suggestive 
that the height association to prostate cancer for younger onset aggressive type 
of prostate cancer (Ahn et at, 2009). A cancer risk cohort study on Korean 
population also revealed height adjusted ratio for age, body mass index, smoking 
1-14 
and alcohol and exercise, to be positively associating with prostate cancer with 
increased risk 13% for every 5cm increment in height (Sung et aI, 2009). 
1.3.4 Physical activity 
There are many inconsistent findings of the relationship between leisure activity 
of exercise and prostate cancer, some appear statistically protective (Moore et al. 
2009), although many appear of non-significant statistically, but suggesting of 
reduction of risk (Nilsen et aI, 2000) and others an increase in risk (Platz et ai, 
2003). A recent study in Canada showed that high physical activity which is 
associated with occupation has a decreased odds ratio of prostate cancer OR 0.54 
(Cl: 0.31-0.95) while recreational physical activity was found not statistically 
significant (Parent et aI, 2010). 
1.3.5 Sexual history 
Frequency of sexual activity and number of sexual partners also positively 
associated with increasing risk of prostate cancer (Dennis, 2002a). It was also 
discovered a statistically significant trend of increase risk to prostate cancer on 
more frequent amount of sexual intercourse per week, while those having 7 or 
more times of sexual intercourse per week will double the risk compared to those 
at 3 times or less (Fernandez et aI, 2005). Rosenblatt and colleagues reported 
that having two or more female sexual partners was also fou nd to show 
statistically significant trend in frequency to non-aggressive prostate cancer 
(Rosenblatt et aI, 2001). 
In 2002, a meta-analysis on sexual activity included 40 studies between 1966-
2000 showed an increased risk of men with history of sexually transmitted 
diseases (STD) to develop prostate cancer, especially Syphilis infection at relative 
risk 2.3 (Cl: 1.3-3.9). Gonorrhoea infection was found to increase the risk to 
prostate cancer at OR 1.5 (CI: 1.02-2.18) (DenniS, 2002a). Another study also 
described history of gonorrhoea and syphilis with increased risk to prostate 
cancer to 60% and 80% respectively, while threefold increase risk if have history 
of gonorrhoea three or more times (Hayes et aI, 2000). Another published data 
of meta-analysis of 29 case control studies showed significant combined 
calculated odds ratio for any STD, gonorrhoea and human papillomavirus at 
1.48(CI: 1.26-1.73), 1.35(CI: 1.05-1.83) and 1.39(Cl: 1.12-2.06) respectively 
(Taylor et al. 2005). Other STD such as herpes simplex virus type 2 was also 
aSSOCiated with increased prostate cancer risk (Dennis et aI, 2009), while 
1-15 
trichomonas vaginalis infection was associated with extraprostatic cancer and 
lethal or bony metastases death (Stark et ai, 2009). History of prostatitis in one 
meta-analysis study showed increased risk to prostate cancer with pooled relative 
risk estimates of 1.57 (1.01-2.45) in random effects model (Dennis et ai, 2002b). 
In terms ejaculation count, an Australian study showed that at age 20's, subjects 
with ejaculation frequency of 5 times or more per week were at reduced risk (OR 
0.66, CI: 0.49-0.87) compared to those who reported less frequent (Giles et ai, 
2003b). Another study of all forms of sexual activity showed that frequent sexual 
activity at younger age i.e. 20's showed higher risk of prostate cancer while at 
age 50's, frequent sexual activity would provide protective effect. However, the 
possibility of reverse causation could explain for these results. As the mean age 
of prostate cancer diagnosis among the cases in the study was 54.7 years, 
therefore due to prostate problems or diseases, they would experienced reduce 
sexual activity compared to the control group at their 50's. (Dimitropoulou et ai, 
2009). 
1.3.6 Radiation or imaging 
Ionizing radiation has been recognized to be carcinogenic to humans including 
exposure to imaging. A case control study in the United Kingdom by Myles on the 
effect of diagnostic radiation procedures has revealed statistically significant 
positive association with risk of prostate cancer. For an exposure to barium 
enema and hip x-rays at least 5 years prior to diagnosis, the odds ratio were 
2.06(CI: 1.01-4.20) and 2.23(CI: 1.42-3.49) respectively. Upon selection among 
those with family history of cancer, only hip or pelvic x-ray remained having 
positive association with prostate cancer risk dating 5, 10 and 20 years before 
diagnosis at adjusted OR=3.S5 (95%CI: 1.46-8.58), 5.01 (95%Cl: 1.64-15.31) 
and 14.23 (95%CI: 1.83-110.74) respectively (Myles et aI, 2008). Rahman did 
the analyses of the same exposures but based on the larger sample size and the 
results showed statistically significant increased risk of prostate cancer when 
exposed at anyone time of hip or pelvic x-ray regardless of time of exposure if 
OR=3.15 (95%CI: 1.81-5.47) (Rahman, 2010). 
1.3.7 Hormonal 
The study of androgen hormonal level especially testosterone and its association 
with prostate cancer has used several surrogate markers in males such as 
presence of baldness, right hand pattern or 2nd to 4th digit length ratio in males, 
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and acne. In the right hand pattern, it has been explained in previous studies as 
due to higher levels of androgen such as testosterone prenatally causing men 
with phenotype of lower 2nd to 4th digit ratio (Manning et ai, 2002). This could 
explain why quite a number studies showed those with lower ratio of 2nd to 4th 
digit, has increased prostate cancer risk. A Korean population study showed 
statistical significant odds ratio of 3.22 (CI: 1.33-7.78) for those with 
measurement 2nd to 4th digit ratio of less than 0.95 compared to those with ratio 
0.95 and above (Jung et ai, 2010). Alternatively, Rahman et al with the same 
data set used in this thesis showed a protective effect of 33% (OR 0.67, CI: 0.57-
0.80) of those with higher 2nd to 4th digit ratio compared to those with lower ratio 
towards prostate cancer risk (Rahman et ai, 2010). 
1.3.8 Genetic mutation 
Genetic studies are found to be less susceptible to confounding than observational 
epidemiology and can suggest associations between phenotype and diseases 
(Davey Smith & Ebrahim, 2003) to further suggest cause and effect. The 
existence of genetic variations can alter risk of developing phenotype as in 
obesity and diseases prostate cancer (Lewis et ai, 2010). Hereditary prostate 
cancer cases are able to identify suggestive evidence for genetic linkage and can 
then be used as markers for absolute risk (Stanford et ai, 2009; Xu et ai, 2009). 
Some studies on genetics have identified prostate cancer susceptible loci i.e. 
single nucleotide polymorph isms (SNP) with relationship to family history and 
Gleason score of prostate cancer (Fitzgerald et ai, 2009). 
1.3.9 Pesticides 
A case control study in Montreal Canada between 1979 to 1985, revealed leisure 
exposure to pesticides or garden sprays showed an increase OR of 2.3 (el: 1.3-
4.2) with prostate cancer risk (Sharpe et ai, 2001). In an Agriculturai Health 
Study(AHS) of 45 common pesticides used in agricultural industries of subjects 
between 1993 to 1997, only methyl bromide showed a statistically significant 
association with increase risk to prostate cancer as levels of exposure increased 
(Alavanja, 2003). A sub-study of Fonofos used by pesticide applicators showed 
increased rate ratio 1.77 (CI: 1.03-3.05) of those at highest lifetime exposure or 
intensity compared to those never been exposed as well as a significant dose 
response trend. However this was found to be true only in the stratified group 
with family history of prostate cancer showing a significant interaction of RR 1.28 
(Mahajan et ai, 2006). Agent Orange, a type of herbicide exposure used in the 
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Vietnam war veterans also showed an increased risk of prostate cancer at OR 
2.19 (Cl: 1.75-2.75) and development of prostate cancer at younger age and 
higher risk of two fold of developing more aggressive disease (Gleason score 8 -
10) compared to the unexposed (Chamie et ai, 2008). A review and meta-
analysis on the relationship between pesticide exposure in manufacturing workers 
showed quantitative meta-rate ratio of 1.28 (CI: 1.05-1.58) for risk of prostate 
cancer (Van Maele-Fabry et ai, 2006). 
1.3.10 Chemicals 
Sharpe et al showed that leisure exposure to chemical lubricating oils or greases 
increased prostate cancer risk, OR 2.2 (CI: 1.2-3.7) (Sharpe et ai, 2001). Diesel 
engine emissions exposure during farming in a study was also found to increase 
the risk of prostate cancer at OR 5.7 (CI: 1.2-26.5) (Parent et ai, 2009). A 
significant dose respond trend association was found with the exposure to 
Trichloroethylene(TLC) and high exposure the risk of prostate cancer, OR 2.1 (el: 
1.2-3.9) (Krishnadasan et aI, 2007). 
1.3.11 Other factors 
Vasectomy was found not significantly associated with prostate cancer in two case 
control studies (Cox et aI, 2002; Holt et ai, 2008). 
Alcohol has been suggested in many epidemiological studies as causes of several 
cancers especially those of the digestive tract. However, findings on alcohol 
intake and prostate cancer risk have been inconsistent. Dennis & Hayes in their 
review article has suggested that only alcohol at high level intakes is associated 
with an attribute risk towards prostate cancer (Dennis & Hayes, 2001). A meta-
analysis by Bagnardi concerning the association of alcohol and cancers, revealed 
no statistically significant association with prostate cancer (Bagnardi et ai, 2001). 
Similar findings was found in cohort studies of Health Professional Follow up 
study by Platz (Platz et ai, 2004) and European Prospective Investigation into 
Cancer and Nutrition (EPIC) by Rohrmann (Rohrmann et ai, 2008). However a 
more recent study on Prostate Cancer Prevention Trial (PCPT) showed heavy 
consumption of alcohol was associated with double risk of developing high grade 
prostate cancer (Gong et aI, 2009). 
Smoking is an important risk to many cancers, but shows inconsistent 
associations with prostate cancer. An Australian study of case control subjects 
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found no significant association between smoking and prostate cancer (Giles et ai, 
2001). While a cohort study in US showed current smokers had an increased 
hazard risk for fatal prostate cancer at HR 1.69(CI: 1.25-2.27), but both current 
and former smokers are at reduced risk for non-advanced prostate cancer at HR 
0.82(CI: 0.77-0.88) and 0.89(CI: 0.86-0.93) respectively, while no association 
with advanced prostate cancer (Watters et ai, 2009). 
Meat or meat related compounds have been associated with quite number of 
chronic diseases. A cohort study with nine years follow up with baseline diet 
intake taken, done in US for those age 50-71 years, revealed a statistically 
significant trend of increased hazard ratio for prostate cancer at higher level 
intake of red and processed meat. It was also found that both red meat and 
processed meat increased intake have higher risk for advanced prostate cancer 
(Sinha et aI, 2009). However, a recent meta-analysis reported In 2010 on 
specific red or processed meat intake and dose response analysis to risk of 
prostate cancer, using random effects model to generate summary relative risk 
estimates (SRRE) has shown no association between high and low intake to 
prostate cancer risk (Alexander et aI, 2010). 
1.4 Background Work In Malaysia 
This background work has been added to the first chapter in recognition of the 
substantial amount of work and time spent during the first year of my PhD 
program. A research project on prostate cancer was proposed under the 
Malaysia-Nottingham Doctoral Programme (MNDP Split programme) to be carried 
out In Sabah, Malaysia. However due to unforeseen circumstances and difficulties 
faced with limited time duration and an unsuccessful application of project 
funding, a study idea with similar topic, but based here in the UK, was provided 
as an alternative by my external supervisors. 
The UK Prostate Cancer Case Control: Gene-Environment Interaction study a 
consortium of collaboration work between the University of Nottingham , 
University of Warwick and the Institute of Cancer Research UK. It began in 1999 
and aimed to investigate environmental exposures associated with risk prostate 
cancer and to explore genetic aspects of prostate cancer aetiology. Since this UK 
study project Is similar to my earlier agreed proposed study in Malaysia, and had 
already had data collected my supervisors allowed me to the use this data as an 
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alternative research project to ensure the achievable of PhD completion within 4 
years. 
Hence, the literature review, methodology, analysis, results and discussion of this 
thesis report are based on the UK experience. 
The proposed Sabah (Malaysia) Prostate Cancer Risk Factors study report is 
depicted here as below. 
WORK PONE WHILE IN MALAYSIA lUlY 2008 - AUG 2010 
Background Study site. Research Questions 
Study site background 
The state of Sabah, Malaysia was chosen as I'm from there and based at the 
University Malaysia Sabah, School of Medicine for the 2nd phase of my PhD study. 
Since Sabah has only one tertiary hospital situated in Kota Kinabalu, and one 
state urologist surgeon attached with Queen Elizabeth Hospital, it presented an 
ideal study site within this hospital; a" patients from Sabah wi" be under the 
single state urologist. It was intended that district hospitals and health clinics 
may be involved during the course of the project. 
Stydy DeSign & Sample size 
The proposed study was a case-control study aiming to recruit 400 cases from 
government health clinics /hospitals within 5 years (a"owing 3 years of previous 
diagnosed cases and 2 years of new incidence cases), and similar number 
subjects for controls. 
Study Aims 
To study possible role of diet, pesticide exposure, lifestyle habits and genetiC 
factors on the risk of developing prostate cancer in Sabah, Malaysia 
Tools for Research 
Preparing the prostate Cancer Questionnaire 
The Questionnaire used in this study is adapted from the ones used in Gene-
Environment Interactions in Prostate Cancer copyright of Division of Epidemiology 
and Public Health, University of Nottingham, Institute of Cancer Research and 
Royal Marsden Hospital, NHS Trust, United Kingdom. 
The Questionnaire has been prepared both in English and Bahasa Malaysia. The 
Questionnaire was designed to suit both; self completed or by interview 
completion. Since majority of people in Sabah may prefer interview technique, 
1-20 
due to diversity of ethnic language and dialect, the researcher decided that both 
methods would be used for information gathering. 
The questionnaire for the study would take about 30-45 minutes to complete by 
interview technique. Participants may decide to complete the questionnaire on 
their own if they are preferred. However they will be supervisor available in case 
of inquiry or unanswered sections. 
The initial preparation of the Questionnaire was done in English, and then 
translated to Bahasa Malaysia. Work was carried to retranslate the Bahasa 
Malaysia version back to English. Corrections were made to in order to get the 
best suited terms, to obtain the same information with either language. This was 
done with the help and expertise of several language lecturers/tutors and 
translators. 
To assure content validity of the Questionnaire, experts' help were obtained from 
local Nutritionist epidemiologists, Surgeons and Public Health epidemiologists. 
Corrections were made based on consensus and majority recommendation. 
Preparing the Research Protocol It Budget 
Research protocol 
The research protocol was prepared with the help of review by PhD supervisors. 
Budget ReQuirement 
Budget for the study in Malaysia was estimated to be RM211,800 (equivalent to 
£43,000). 
Collaboration work with participating centres 
Identjfvjng sources of data 
Data sources on prostate cancer Incidence were obtained from National Cancer 
Registry 2002 & 2003 of Clinical Research Centre (Kuala Lumpur General 
Hospital), Penang & Sarawak State Regional Cancer Registry, Public Health 
Department of Ministry of Health Malaysia, and Globocan. 
Collaboration effort 
The research project on prostate cancer in Sabah, Malaysia was proposed through 
collaboration of the following agenCies/centres. 
I. School of Medicine, University Malaysia Sabah, Kota Kinabalu, Sabah 
II. Queen Elizabeth Hospital, Kota Kinabalu, Sabah 
iii. Sabah State Health Department, Sabah 
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iv. University of Nottingham, UK 
A memorandum of understanding was prepared that bears the signatures the 
main investigator (myself) representing University Malaysia Sabah, co-
investigator (state urologist), the Head of Surgical Department and Director of 
Queen Elizabeth Hospital, stating clearly the duties and rights of each 
agency/centre, also the ownership of data, publication authorship, etc. 
Ethical Approval 8t Ministry of Health Malaysia Approval 
Medical Ethical Approyal 
The project received its unconditional approval from the highest level of medical 
research ethical committee authority in Malaysia, namely MREC, Malaysia Ministry 
of Health, on 3rd August 2009. 
Minjstrv Approyal 
The study project received its approval to start work with consent letter from the 
Queen Elizabeth Hospital Director and also the Sabah State Health Department 
Deputy Director (Hospital Services) in March 2009. 
Grant/ Funding Application 
Potential Sources of Funding & Application made 
Several applications for funding were done during the course of events beginning 
in UK, with help from my PhD supervisors. I've also personally made several 
enquiries of funding possibilities while in Malaysia with University Fundamental 
Research Grant, e-science Ministry of Science & Technology, then Ministry of 
Health. Since this research project is done by a lecturer on full study leave, the 
grant application could not be proceed further at that time for university 
fundamental research grant and e-science Ministry of Science & Technology. 
Furthermore, I'm doing a split PhD programme between UK and Malaysia, not 
fully based in Malaysia. The Ministry of Health Malaysia ranked cancer study as 
3rd level priority therefore approval was not granted at the 1st round of review 
board committee without explanation. Other funding possibilities were explored 
but were unsuccessful as prostate cancer was not major cancer in Malaysia, and 
the economic climate was not conducive at that time in 2008-2010. 
Discussion. Outcome of First/Second Year Work 
Results 
The disappointment of the failed funding application was further compounded by 
the recognition of significant risks. Some of the issues that could hinder the 
prostate cancer risk factors study in Sabah Malaysia were: 
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i. Logistics & Transportation 
The feasibility of conducting the study is quite a challenge which requires 
availability of transportation to reach patients in their own homes or nearest 
health clinics either by motor road, on foot if hilly mountains and by boat. Since 
most of the patients are old and poor, it is a major issue for them to move around 
even to the closest health centre due to both financial and transportation issues. 
The logistics and transportation factors would also be an issue for relaying blood 
samples for genetic studies after collection because of the requirement for fast 
freezing at -80 degree celsius within the same day of collection to ensure the 
samples'viability. For patients living in remote locations away from centres for 
blood collection, poor accessibility, or unreliable transportation, would possibly 
preclude the involvement of biological protocol for the study. 
ii. Language barrier & Literacy 
As population of Sabah is of diverse races and ethnicity, even though Malay is the 
national language of Malaysia, the people in Sabah are only 10% of Malay origin, 
while the rest are of native/indigenous group or Chinese. For those aged 50 and 
above, many would struggle with usage of Malay in their daily conversation so 
this would affect recruitment. 
Even though the reported literacy rate in Sabah as of 2008 was at 87%, the 
lowest among all the states in Malaysia, the actual literacy rate is lower. It could 
be expected that there have been unfamiliarity of intermediate to advanced 
vocabulary; which would further reduce recruitment. Previous attempts at postal 
questionnaires have been unsuccessful, favouring face to face interviews, but this 
requires apPointment, more personnel/enumerators and most importantly reliable 
interpreters. 
iii. HIV Screening for blood sample 
This study involved the collection of 10-20ml of blood from subjects for genetic 
chromosomal studies. Before it can enter UK for processing either DNA extraction 
or chromosomal studies, the law requires the identification of HIV status of each 
sample for biohazard reasons. In Malaysia, HIV testing or screening is not a 
routine procedure and requires consent and counselling to patients as guidelines 
were given by Ministry of Health. HIV screening without consent only done to 
prisoners under special circumstances, otherwise in cases of Tuberculosis or 
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women 1st pregnancy, it is a routine procedure, but patient can still refuse to 
undergo such test/screening. 
iv. Storage of blood samples 
Based on the survey done on the availability of freezer with -80 degree Celsius 
capability, only University Malaysia provides the facility free of charge but with 
limited storage. Although I obtained approval to use this special freezer based in 
the Institute of Tropical Biology and Institute of Biotechnology, the actual volume 
with blood 10ml test tube would take up lots of space, as the centres only allowed 
usage of pipette tip tubes 2m!. The fridges, approximately three in total are also 
of common use of all researchers. The government hospitals in Sabah, do not 
have these special fridges. The coldest freezers they have are only capable to 
reach -20 to -30 degree Celsius maximum. 
v. Funding 
This is the most critical factor to consider. The budget for this study costing 
approximately £43K is based on estimation of two years with most expenditure 
spent on salary and honorarium, which account for almost 65%. However 
considering the need for interpreters of various languages would require 
additional funding, as the proposed budget only casted 1 person to do 
interviewing or as enumerator. 
Due to the lack of research money in the sector of cancer prevention research, 
most government doctors and clinicians are referring to academicians for help in 
getting the grant as well as leading the research work. Funding from Ministry of 
Health or other grants are only offered for level 1 priority applications. 
Furthermore, previous epidemiological studies in MalaYSia justified grants of no 
more than £20,000. 
DIscussion how to move forward 
Although it would be a great challenge to start an ambitious yet achievable 
research project on prostate cancer in Sabah, Malaysia, the preparatory work had 
identified ground arrangements and sites had been identified, there were major 
and minor issues that needed to be smoothed out in order to ensure the project 
could progress which would have led to new scientific discoveries and learning as 
well as experiences to be used to help other similar in the near future. 
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Since I've brought up the issues as in the results paragraph, I might as well try to 
discuss for any possibility of any of these areas within my control of improvement 
or self solving. 
i. Logistics & Transportation 
The issues of logistics and transportation became an important obstacle in 
carrying the prostate cancer study because the crucial tasks of trying to obtain all 
reported cases of prostate cancer in the state of Sabah, since the incidence rate 
in Sabah is low approximately of 3.8 per 100,000 male populations or 65 new 
cases yearly. The issue is to balance between not losing any cases subject while 
at the same time saving cost for transportation. 
The improvement and cost saving methods would be to set up appointments at 
health centres which are easily accessible by road for the research team, and 
probably need help with the local town healthcare system's staffs to assist in the 
issue of patients coming from areas Inaccessible by road. The appointment for 
each individual subject should be minimized, so that within a single appointment 
all procedures such as consent, questionnaire filling and blood sample be 
collected, so that subject need not return for a second appointment. 
If the blood collection were done on weekdays, it should be stored temporarily in 
cool box with ice and within 6 hours or less be sent to a proper freezer, or stored 
Immediately to a -80 degree centigrade freezer. However as said earlier, the only 
free storage of the blood samples in this special freezer is available in University 
Malaysia Sabah, Kota Kinabalu. 
ii. Language barrier & Literacy 
In order to best address this problem of multiple languages recruitment local 
people from each district with fluent grasp of the local language and dialects to be 
employed as enumerators. They would need to be trained to be able to interpret 
any specific terms used during the interview. The primary language used would 
still be Malay or English (as these two versions have been prepared by the 
principal Investigator much earlier). 
The advantages of Interviewing patients would be to minimise the loss any 
information and to ensure subjects understood the content of the questionnaire. 
The only disadvantage would be lack of openness or disclosure of the truth in 
information by the subject especially when the questions are of intimate or 
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private such as number of sexual partners or other prohibited habits/behaviour by 
religion. 
iii. HIV Screening for blood sample 
HIV screening if required can still be done with proper consent and counselling to 
subjects by specific trained healthcare staff. However the cost of doing HIV 
testing would be high as it is normally taken up by private labs, and at the same 
time would require steps to follow up subjects who are found to be HIV 
reactive/positive. Arrangement can be done for such subjects by referring them 
to the system of healthcare available in the district. 
iv. Storage of blood samples 
This is a worrying issue as the availability of special freezer with capability 
temperature -80 degree Celsius which provide free storage are scarce, at the 
same time provide minimal storage volume. The best solution would be to buy 
such freezer and be placed at the University in Sabah as it would be valuable for 
any research involving life cells. This would take time and lots of justification as 
School of Medicine in the University Malaysia Sabah has not geared much into 
areas of molecular or genetic medicine or research, therefore only time will tell. 
Another option would be to try to store the blood sample collected in private 
fridges but would incur cost over the course of time, but quite safe. 
v. Funding 
The cost of hiring staff technicians and enumerators as well as travelling claims 
for patients requires proper budgeting. The inclusion of blood sample collection 
Increased the cost because of the raw materials, containers, ice, transportation 
etc. 
Based on the latest news on funding for genome/chromosomal analysis, a group 
of funders of the United States provide minimal amount of money, measured by 
the number of blood test tube collected. This might be able to cover some of the 
cost of the raw materials and transportation to overseas, but doesn't necessarily 
cover the whole expenditure of the research project. 
Another way would be to seek seed money from small funders such as local 
medical association/society (RM5000 or £1000) for a pilot project of 
epidemiological study of the prostate cancer, and producing initial findings and 
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publishing an article that would hope to get the government's attention on the 
importance of such research and gain the bigger funders in Malaysia to allow 
approval for grant in prostate cancer risks study at bigger scale. 
Redefining the prostate cancer risks study to the approach of prevention and 
contributing to world statistics information on genetic or hereditary predisposition 
in Malaysia is still new, as most of such studies are initiated by foreign countries 
collaborators. Malaysia Genome Institute (GENOMalaysia) is a network-based 
not-for-profit research organization engaging in discovery research on tropical 
bio-resources through projects on genome sequencing, comparative and 
functional genomics, and structural biology. There could be a potential approach 
to collaborate with this institute in the near future. 
Conclusions 
In order to assure the success of the above according to the created standards 
equivalent to similar studies done in more developed countries such as in the 
Europe, there will be a need to iron out all the above issues as well as scrutinize 
the finer details before the research ever commence. 
The uptake of the prostate cancer risks study would be a good collaboration work 
between the consortiums of Prostate Cancer Study in UK, and would benefit 
towards the building of information on the associated risks of prostate cancer 
whether in South East Asian countries or Europe. The short term goal of this 
project would be to explore common risks factors In different population, while 
associating the genetic interaction with environmental factors. The middle term 
goal would be to find specific risks factors which are unique for Sabah (Malaysia) 
population, smoothing the project with a view to expand to wider areas and 
building larger database as to create for more study strength. The long term goal 
would be the look at the cause and effect of prostate cancer, as well as setting up 
public health guidelines on preventive measures. 
1-27 
Chapter 2 Rationale, Hypothesis &. Objectives 
2.1 Rationale 
Prostate cancer is the most common male cancer in Europe and the United 
Kingdom. Due to the higher number of men diagnosed with prostate cancer, 
knowledge on factors associated with risk towards this cancer is important. 
Prostate cancer risk has been associated with several environmental factors, 
although genetic factors are also suggested to be involved. Literature review 
suggests some of these environmental exposures (both modifiable and non-
modifiable) including physical features/characteristics, lifestyle behavior, diet or 
medication intake as well as presence of medical conditions which could be 
associated with prostate cancer risk. 
The current knowledge on the environmental factors that could be associated with 
prostate cancer remain poorly understood when compared to other common 
cancers such as breast or lung cancers. Furthermore, the exploration of dose 
response aspects based on the effects of timing and of lifetime exposures that 
may add to the risk are lacking and therefore explored further in this study. 
Our hypotheses focused on certain environmental exposures which may increase 
or reduce the risk of prostate cancer are largely based on previous publication in 
prominent journals during the last decade. Hypotheses are generated based on 
the biological plausibility of current understanding. 
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Figure 2-1.Possible Factors Associated with Prostate Cancer Risk 
Environmental Factors (Probable) 
• Sociodemographic factors e.g. age, marital status, country 
born, education level, race/ethnicity, social class and family 
history 
• Physical features or characteristics e.g. height, weight, waist-
hip ratio, body shape or size, body fat distribution, skin colour, 
or complexion, etc 
• Lifestyle or behaviour e.g. sexual history, physical activity, 
sunlight exposure, occupation, radiation, chemicals, pesticides, 
diet/nutritional intake, medication/ supplements intake, 
smoking status etc. 
• Conditions presence e.g. Diabetes mellitus, Hypertension, 
Hypercholesterolemia, Ischaemic heart disease, sexual 
transmitted diseases etc. 
• Hormonal e.g. androgen level such as testosterone during 
prenatally, before puberty and post-puberty, IGF etc 
Interactions 
Genetic Factors (Probable) 
• Genetic mutations 
• Single necleotide polymorph isms variation 
• Genetic pathways 
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2.2 Hypotheses 
Hypotheses generated are: 
i. Diabetes mellitus is associated with decreased in prostate cancer risk. 
ii. Body fat distribution of 'apple' shape is associated with decreased 
prostate cancer risk. 
iii. Statins are associated with reduction in prostate cancer risk. 
iv. Higher sunlight exposure is associated with reduced prostate cancer 
risk. 
v. Higher consumption of dietary intakes of isoflavones (phytoestrogens), 
selenium, vitamin D and Iycopene are associated with reduced risk of 
prostate cancer. 
2.3 Objectives 
This thesis aimed to investigate the association of six main areas that may 
contribute to prostate cancer risk: 
i. Body shape & fat distribution 
ii. Chronic diseases/conditions (diabetes mellitus, hypertension, ischaemic 
heart diseases and hypercholesterolemia) 
iii. Statins medications 
iv. Painkillers (NSAIDs and paracetamol) 
v. Skin types & sunlight exposure and 
vi. Diet (isoflavones, selenium, vitamin 0 & Iycopene) 
This study also aimed to explore the dose response based on the effects of timing 
and of lifetime exposures at age 20's, 30's, 40's, 50's and last 5 years as well as 
the cumulative exposure effect towards prostate cancer risk. 
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Chapter 3 Methodology 
3.1 Sabah Malaysia Prostate Cancer Study Protocol 
The early work and initial proposed PhD study protocol was based on a Prostate 
Cancer Case-Control in Sabah, Malaysia and is briefly presented here. 
Title of project 
Possible role of diet, pesticide exposure, lifestyle habits and genetic factors to risk 
of developing prostate cancer in Sabah, Malaysia. 
A.ilm 
i. To assess the association between prostate cancer and diet. 
ii. To explore the potential risk of prostate cancer due to pesticide and 
environmental factors. 
iii. To determine the relationship of lifestyle habits such as exercise, smoking, 
etc to prostate cancer. 
iv. To determine genetic role in prostate cancer. 
Project Background & Rationale 
In the Malaysia Cancer Registry 2002 and 2003, prostate cancer is recorded the 
6th highest incidence and rate of cancers among men after lung, nasopharynx, 
colon, leukemia and rectum. We proposed a three year project on the basis that 
the study will inform Malaysia, UK and the world generally about the risk factors 
that associate with prostate cancer In Sabah, Malaysia. Given that this study 
would probably be the biggest study on cancer on this population and in 
particular prostate cancer risk factors, it would provide useful information on 
different ethnic groups of Asia in particular state of Sabah in Malaysia about the 
potential risk and interaction of endocrine disrupters towards prostate cancer. 
The study would be on successful collaboration work between the University of 
Nottingham, UK, University Malaysia Sabah and Ministry of Health, Malaysia. 
Furthermore, the study would further look at genetic factors that could post a risk 
of prostate in the Malaysian population. 
Study Design 
Matched case-control study of 1: 2 ratio 
3-31 
Study Duration 
Three years beginning January 2009. 
Sample Size, Power & Statistical analysis 
A sample size of 383 cases and 766 controls is required to detect odds ratios 
greater than 2.0 or less than 0.6 with a power of 80%. The calculation is based 
on the following assumption: matched ratio 1:2, exposure rate 15% in control 
group, type-I error 5% and a correlation coefficient of 0.6 for exposure between 
matched cases and controls. 
According to Malaysian National Cancer Registry in 2002 the total cancer 
incidence in Sabah population is about 59.3 per 100,000 male populations. If 
6.4% of all male cancers are prostate cancer, based on Peninsular Malaysia 
figure, therefore the incidence rate of prostate cancer in Sabah is 3.8 per 100,000 
male populations. Population in Sabah is about 3.3 million in 2007 based on 
prOjection population census 2000 with 4.0% growth annually. 
Therefore with population of males around 1. 7 million in Sabah and prostate 
cancer incidence rate of 3.8 per 100,000 male populations, the no. of prostate 
cancer cases would be approximately 65 cases per year. In order to obtain 400 
cases for the study, the subjects enrolled would need to accumulate 5 years of 
prostate cancer cases (2004-2008) from registered lists of cancer patients from 
Sabah state Cancer Registry and hospitals which diagnosed and manages 
prostate cancer patients, then another two years after the study began, 
considering some patients would have died subsequent years after diagnosis. 
Only Incident and primary cases will be Included. In case of shortfall in the 
number of cases, the researcher would include neighbouring state of Sarawak, or 
Kuala Lumpur, Malaysia, 
Selection of Cases and Controls 
i. Source and identification of cases: 
Case is defined as pathologically confirmed prostate cancer newly diagnosed in 
Sabah during the study period for data and specimen collection which would be 
1.5 years duration as well as confirmed cases reported earlier within five years 
since the study began. This is done to ensure the number of subjects would be 
adequate. 
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The subjects enrolled would accumulate 5 years of prostate cancer cases from 
registered lists of cancer patients from Sabah state Cancer Registry and hospitals 
which diagnosed and manages prostate cancer patients, if alive 2004-2008 then 
another two years after the study began sometime in 2009, considering some 
patients would have died subsequent years after diagnosis. Only incident and 
primary cases will be included. 
ii. Source and identification of control: 
Controls and cases will be matched on age (within 5 years), residence area (in 
the same district area) and major ethnic group. They will be randomly selected 
from the outpatient list in the same hospital where the index cases diagnosed 
however differ in diagnosis which is not related with prostate cancer. Subjects 
will be excluded if they had any previous history of cancer. 
Eligibility of Cases and Control 
Inclusion criteria are: 
Men newly diagnosed with primary prostate cancer confirmed histology during the 
research period; or 
Prostate cancer patients who were diagnosed with confirmed histology as primary 
cases between 2004-2008 and still alive 
Cases who have given informed oral or signature consent. 
All age group as long as they're able to understand and response to the interview. 
Control eligibility: 
Five years age matched men from same hospital or district registry of cases in 
the outpatient list who has never been diagnosed of any cancer except skin 
cancer 
Controls who have given informed oral or signature consent. 
All age groups as long as they're able to understand and response to the 
interview. 
For those above 60 years old, only normal PSA test result would be invited to 
become controls. 
Case and control ineligibility: 
Inability to understand and respond to the Interview. 
Those who have not given their consent either orally or signature. 
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Recruitment 
Case Recruitment: 
This study obtained its permission to conduct the research from the Malaysia 
Ministry of Health and Ethic committee. This study would seek further approval 
from respective hospitals and Sabah state health department to view cancer 
registry list, hospital records of diagnoses, as well as persons, subjects or 
patients' medical records. 
The cancer registry list at the state health office of Sabah will provide the 
prostate cancer patients, however since these may not be an up to date and 
complete list of all reported cases, further scrutiny for unlisted cases will be done 
at hospitals which diagnose or manage prostate cancer patients through their 
discharge diagnosis record or medical records of the hospital. The hospitals that 
would be covered in Sabah would be hospitals with prostate cancer patients care 
namely Queen Elizabeth Hospital. After prostate cancer patients have been 
identified, they will be recorded in a new list of prostate cancer patients in Sabah 
or in the individual hospital. Main variables of interest would be to identify the 
time of the diagnosis which would be year 2003 onwards, as well as identifying 
their date of birth and current addresses in order to match them with control 
group selection. 
All subjects would be contacted by phone call or letter to invite them to 
participate in the study. An appointment would be set up in the nearest hospital 
or health centre to meet up with them and explain to them about the study 
before requesting their consent to participate. To all who agree to participate, 
interviews using the questionnaire would be carried out, as well as venous blood 
samples extraction. 
Control recruitment: 
Control subjects will be matched on age (within 5 years) and residence area (in 
the same province). They will be randomly selected from the outpatient list in 
the same hospital where the Index cases were diagnosed and differ in that they 
had a diagnosis which is not related with prostate cancer. Subjects will be 
excluded if they had any previous cancer history apart from skin cancer. 
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All subjects would be contacted by phone call or letter to invite them to 
participate in the study. An appointment would be set up in the nearest hospital 
or health centre to meet up with them and explain to them about the study 
before requesting their consent to participate. To all who agree to participate, 
interview through questionnaire would be carried out, as well as venous blood 
samples extraction. 
The Qyestionnaire 
The questionnaire used in this study is adapted from the ones used in Gene-
Environment Interactions in Prostate Cancer copyright of Division of Epidemiology 
and Public Health, University of Nottingham, Institute of Cancer Research and 
Royal Marsden Hospital NHS Trust, United Kingdom. 
The questionnaire has been prepared both in English and Bahasa Malaysia. The 
questionnaire was designed to suit both; self completed or interview. Since the 
majority of people in Sabah may prefer an interview due to diversity of ethnic 
language and dialect, the researcher decided to use both methods for information 
gathering. 
The questionnaire for the study would take about 45 minutes to one half hour to 
complete through interview. Participants may decide to fill up the questionnaire 
on their own if they are more comfortable to do so. However they will be 
supervised closely in case of inquiry and unanswered sections. 
The initial preparation of the questionnaire was done in English, and then 
translated to Bahasa Malaysia. Work was carried to retranslate the Bahasa 
Malaysia version to English to check for consistency. Corrections were made in 
order to get the best suited terms and to obtain the same information required. 
This was done with the help and expertise of several language lecturers/tutors 
and translators. 
To assure content validity on the questionnaire, help was obtained from local 
Nutritionist epidemiologists, Surgeons and Public Health epidemiologists. 
Corrections are made based on consensus and majority recommendation. 
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The questionnaire used in the research would be tested on people of the common 
population in Sabah, similar to the case subjects and covers main ethnic groups 
in Sabah. Corrections were made after pre-testing. Finally it would be pretested 
on actual 30 cases and control subjects and tested for reliability through 
Cronbach alpha test. These pretested groups will not be included in the final 
analysis of the result of this study. 
The structured questionnaire will consist of the following sections: 
Clinical Data (completed separately by researcher) 
Personal details and socio-economic background 
Job history and chemical substance exposure 
Physical features 
Social history 
Physical activity 
Diet history 
History of medical illness & family history of prostate cancer 
Biological Samples 
Written consent would be sought prospectively from all cases and controls who 
agree to participate including questionnaire and blood samples taken in this 
study. 
The main biological sample obtained in this study is 10mls of venous blood 
collected from both cases and controls through phlebotomy/Venupuncture done 
by a medical officer, nurse or lab technologist. Samples collected will be labeled 
with codes and dates, preserved in 400 micro-units of heparin and stored in a 
tube box temporarily before transferred to the laboratory. The blood specimens 
will then be centrifuged and separated into three components, red blood cells or 
blood clot, buffy coat and serum. Each component for the blood samples from 
individuals was then contained in a 1.5 ml micro-tube with its cover and stored in 
the freezer at temperature of -80 celcius. in two different freezers in Universiti 
Malaysia Sabah, Kota Kinabalu until the end period of data collection before being 
sent to the principal investigator in United Kingdom for genome scan analysis and 
DNA extraction. 
The genetiC analyses done on the blood samples are to find the prostate cancer 
predisposition genes, however the results will not be conveyed to the cases and 
controls research subjects. 
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Study Outcome 
Due to unforeseen circumstances namely inability in obtaining grants to fund the 
Prostate Cancer study in Sabah, as well as limited time to complete my PhD, this 
study was halted until a further suitable time. As a continuation of the much 
initial groundwork planning done in Sabah, my supervisors has offered an 
alternative similar study by providing the data from the UK Prostate Cancer Case-
Control Study. Data is in its' raw form for data entering, cleaning, analysis, 
interpretation and write-up. The focus of the analysis was centred on chronic 
diseases, medications, sunlight and diet. 
The UK Prostate Cancer Study Background 
All data analysed and presented in this thesis were from the Prostate Cancer 
Study on Gene-Environment Interactions. The study is an ongoing and a large 
scale case-control study. The study is in collaboration between the University of 
Nottingham, the University of Warwick and the Institute of Cancer Research UK. 
It began in 1999 and is aim to investigate environmental exposures associated 
with risk prostate cancer and to also collect biological samples/markers for further 
genotyplng aspect of prostate cancer aetiology. 
The data collection was divided into two phases, the first phase collection being 
focussed on young onset cases ( ~ 6 0 0 years), began in March 1999 through to 
December 2004, data set was frozen for the purpose of interim analyses, critical 
reviewed/modified questionnaire, simplified/improved data collection process. The 
second phase collection was started In December 2007 through to September 
2009. This was done to assess any new leads of both genetiCS and environmental 
exposures. The second phase extended the cover subjects at all ages. 
Aims 
This Prostate Cancer Case-Control study design aims to study the epidemiological 
association between environmental factors and risk to prostate cancer. The study 
also aimed to examine the aspects of time of exposure at different age period and 
cummulative effect as to prostate cancer risk. 
Specific Objectives 
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Part of the extensive dataset was analysed by previous PhD student, Dr Aneela A 
Rahman (Rahman, 2010). In this present thesis, a further six main areas were 
analysed thus the study objectives are as follows; 
To study the association of the following variables of interest on prostate cancer 
risk: 
- Chronic diseases: Diabetes Mellitus, Hypertension, Ischaemic Heart Diseases 
and Hypercholesterolemia 
- Body shape and Body Fat distribution 
- Statins medication 
- Painkiller NSAIDs Aspirin & Ibuprofen and Paracetamol 
- Skin colour, sun effects and Sunlight exposure 
- Diet nutrition of Isoflavones (Phytoestrogens), Selenium, Vitamin D and 
Lycopene 
Literature review 
Searches for articles of sCientific, relevant and most up to date materials were 
carried out through the search engines in Medline and Pubmed. However 
relevant publication such as theses and textbooks were also searched through 
Unloc search engine of medical school university library. Only scientifically sound 
published articles of journals, textbooks, scientific documents including theses 
and reports, as well as online documents from nationally or internationally well 
regarded and recognized websites of good reputability were used for information 
resources in this PhD thesis. 
Study Design 
The Prostate Cancer Gene-Environment Interaction is a case-control study design. 
Power and Sampling technique 
Sample size and power was calculated using power and sample size programme 
(PS) version 3.0.43. The total number of cases and controls in the study are 1963 
and 2078 respectively. This setting will have 80% power to detect odds ratios of 
1.502, 1.363, 1.314 or the same power is also able to detect risk reduction with 
odds ratios of 0.643,0.723 and 0.756 when the exposure rates in controls are at 
10%, 20% and 30% respectively when Alpha level was set at 0.05, correlation 
coefficient at 0.5 for the calculations (Refer Figure 3-1 page 3-39, Figure 3-2 
page 3-39 and Figure 3-3 page 3-39). 
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3.2 Data collection 
Data were collected using self administered questionnaire. Biological samples 
including toenail clippings and 18 ml blood samples were collected. 
Details of data collection of both phases are described as below: 
3.2.1 Subjects identification in the first phase 
3.2.1.1 Cases 
First phase cases were identified from the British Association of Urological 
Surgeon's (BAUS) database and the Royal Marsden Hospital, London. These 
patients are registered with the UK Genetic Prostate Cancer Study (UKGPCS). The 
BAUS database Is a nationwide cancer registry for urologists who have notified 
urological cancers to the BAUS organisation. If cases had been diagnosed with 
prostate cancer from January 1997 to September 2004 and were :560 years of 
age they were eligible for the study. The General Practice (GP) of each of the 
eligible cases was then identified and approached. 
Criteria for case recruitment 
Inclusion Criteria: 
i. Age :560 years at diagnosis. 
ii. Men diagnosed with primary prostate cancer (histological confirmed). 
iii. Currently living in the UK. 
iv. Able to understand the Information sheet and give informed consent 
directly or via an interpreter. 
Exclusion criteria: 
i. Age >60 years at diagnosis. 
ii. The consultant or GP in charge considers that it would be inadvisable, for 
some reason, not to contact them e.g. too ill to complete the questionnaire. 
iii. The subject's English is inadequate to understand the information provided 
and no translator is available. 
3.2.1.2 Controls 
Men aged S 60 years without any history of prostate cancer were selected as a 
control for the first phase of study. They were randomly selected from GP 
practices where cases were registered. Controls were matched by age and 
geography. Controls were only excluded by their GPs if they are too III or 
unwilling to partiCipate. 
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3.2.2 Subject identification in the second phase 
3.2.2.1 Case 
Second phase cases were identified from The Royal Marsden Hospital, London. 
These patients registered with the UK Genetic Prostate Cancer Study (UKGPCS). 
The list of cases had been received through series of case downloads from the 
Royal Marsden Hospital, London. These cases are either referral cases or had 
been notified by their consultant to the study team at the Royal Marsden Hospital. 
Inclusion criteria: 
i. Men diagnosed with primary prostate cancer at any age. 
ii. Histological confirmed diagnosis. 
iii. Currently living in the UK. 
iv. Able to understand the information sheet and give informed consent. 
Exclusion criteria: 
i. The consultant or GP in charge considers that it would be inadvisable for 
some reason, not to contact them e.g. too ill to complete the 
questionnaire. 
ii. The subject's English is inadequate to understand the information provided 
and no translator is available. 
3.2.2.2 Control 
Age-frequency-matched men were randomly selected from the GP practices 
without any history of prostate cancer. All partiCipants have to be able to 
understand the information sheet and give informed consent. Exclusion criteria 
for controls were identical as for cases. In addition, those who were ineligible or 
were unwilling to partiCipate were recorded and further removed from the 
working database. 
3.2.3 Recruitment Procedure 
3.2.3.1 Case recruitment for the first phase 
The initial approach to GPs was made to explain the study and seek their co-
operation. Those GPs willing to take part in the study, the study group would 
arrange patient information sheets and consent forms to be dispatched to 
practices. The invitation letter was signed by the GP and printed on practice 
headed paper. All documents including Invitation letter, patient information sheet, 
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consent form and one reminder letter were sent out via GP practices until the 
consent was given or if no reply received within 4 weeks, no further follow-up 
would be made. Patient consent forms were returned to the centre; and personal 
information including study 10, NHS number, name, date of birth, and contact 
details was then be recorded onto database. Once patients consented to fill the 
questionnaire and provide biological samples including blood, toe nail clippings, 
the questionnaires would be sent to participants and blood kit and plastic vial was 
sent to the practice and with the arranged phlebotomist of the practice, the blood 
sample was taken and sent back to the research team at the Royal Marsden 
Hospital. Toenail samples were sent back to the epicentre. 
3.2.3.2 Case recruitment for the second phase 
The Royal Marsden hospital were in charge of identifying and getting consent 
from eligible cases, taking blood samples and notifying epicentre if the patients 
gave consent to provide questionnaire data. Data was sent to epicentre through 
secure FTP server. Personal information including study 10, NHS number, name, 
date of birth, date of blood collection and contact details was recorded on the 
epicentre database. 
As the UKGPCS consent form only covers blood sample collection and permission 
to participate in epidemiological study, a separate invitation letter together with 
the patient information sheet and consent form was sent out from epicentre. One 
reminder was sent via epicentre, if no reply was received within 4 weeks, no 
further follow-up was made. Consent form includes: 
i. Completing the study questionnaire 
ii. Giving a toenail clipping sample (optional) 
iii. Providing the blood sample (optional) 
iv. Giving the permission for the study group to access their medical records 
(optional). 
Once the consent form was received, a written instruction to explain the 
procedure, a copy of the questionnaire and/or a plastic vial/bag for toenail sample 
collection together with a self-addressed envelope for returning questionnaire and 
toenail clipping sample were sent to the subject home address. 
A telephone helpline was provided at the back of the questionnaire to help clarify 
any further queries regarding the study (see the appendix). If questionnaire/ 
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toenails were not received within four weeks, one reminder was sent without 
further follow-up. 
Blood collection for cases was carried out by Research team at the Royal Marsden 
Hospital, London. 
3.2.3.3 Control recruitment procedure 
For both phases of data collection, there were similar approaches only the second 
phase controls were sought locally within the Nottingham area as well as 
nationally. Initially, the study was designed to use individual-matched controls 
(matched on age within five years and GP surgery). However, due to low 
response rate of GP practices, an alternative approach was introduced later on by 
selecting GPs from ten representative areas (one GP per one area) in the country 
to help identify age-frequency matched controls. Practices were asked to 
randomly select 50 healthy controls with no prostate cancer history from their 
patient list. Initial approach was made by GP and participants were invited to fill 
out the study questionnaire, to give 2 x 9 ml of blood sample (optional) or give 
toenail clipping samples (optional) for further analysis. All blood samples were 
taken at GP practice then posted to the Royal Marsden Hospital (first phase) or 
the epicentre (second phase) on the same day or the next working day. All 
samples were logged and kept at -70 degree Celsius secured deep freezer. 
It is noted that the study had offered to cover administrative costs for each 
practice. As mentioned above, controls selection was expanded to cover local 
area in Nottinghamshire. The reason is that the study applied a newly developed 
computer program aiming to help saving GP time/workloads and as it was done 
locally, any technical problems could be sorted out in person very quickly to make 
sure the program functioned well. 
3.2.3.4 The Nottingham Centre 
Controls from city of Nottingham had been selected from GP electronic records 
using series of Medical "Read" codes. The Read Codes cover a wide range of 
clinical terms from signs and symptoms, diagnostic tests, drug appliances, 
treatment and therapies received to diagnosis. A list of codes was set up to 
identify both prostate cancer patients and healthy control based on Read Codes 
versions 2 and 3. A computerised programme compatible with the GP practices 
working system EMIS and System One had been designed to generate a list of 
potential control subjects. The list was then passed onto the GP for further 
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checking/confirmation of their well-being. After GP validation, any subjects that 
were not suitable were removed from the database. Invitation letters were 
generated automatically from the list at the practice using installed letter 
template that accompanied with the program. All documents were then packed 
and sent out from the practice to each individual. Once subject sent their consent 
form back to the researcher; the next steps followed the same procedures as 
described above. 
3.2.3.5 Blood Collection for local controls (Nottinghamshire) 
After receiving questionnaire, the letter was sent to the participant (along with a 
blood sample collection pack together with an instruction letter to practice 
nurse/phlebotomist) to book an apPointment for blood collection with their GP 
practice. 
To facilitate the phlebotomist at different GP practices in Nottingham and to help 
other prostate study running simultaneously by the study group such as Benign 
Prostatic Hyperplasia study, the research team had taken phlebotomy course at 
King's Mill hospital, Mansfield for seven days; this was carried out to comply with 
the UK regulations. A separate honorary contract was obtained to work as 
phlebotomist. 
Blood samples were sent back to study base in Nottingham, from there, samples 
were sent back to the Royal Marsden Hospital for DNA extraction and further 
genetiC analysis. 
3.2.4 The Study questionnaire 
The questionnaire was design in 1999 and comprised sub-sections of formerly 
validated questionnaires or sections have been used before in other large scale 
previous studies. The usage of pictogram and pictures was also validated and 
has been described elsewhere (Must et al. 1993). Paper published using the 
current questionnaire are as described In the Appendix section on Progress of 
Gene-Environment Interactions in Prostate Cancer Research (United Kingdom). 
The questionnaire was designed to investigate the potential factors attributed to 
the prostate cancer including lifestyle and diet. The design of the questions was 
inspired by questionnaires from reputable national studies. The permission from 
the leader of each individual study was obtained prior to question inclusion. The 
following studies were used for questions: 
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- The UK Aplastic Anemia study 
- The UK Testicular Cancer study 
- The UK Knee Pain study 
- The UK Osteo-arthritis study 
- The Trent Lifestyle survey 
- European prospective investigation of cancer (EPIC) 
The questionnaire covers a wide range of topics and took approximately 45 
minutes on average to complete. It was well received by the target population 
and no complaint was raised during the study period. Information under the 
following broad headings from cases and controls using a structured 
questionnaire designed for this study were collected. 
The first phase and the second phase of questionnaire used have some slight 
differences. With updated knowledge on the prostate cancer, possible new risk 
factors based on literature review search were added. The main content 
construction of questionnaire used in 1st and 2nd phase of study is displayed in 
Table 3-1 page 3-46. 
The second phase questionnaire was modified by inclusion of skin type & sunlight 
exposure, chronic diseases, medication statin, painkiller NSAIDs & paracetamol, 
and body fat distribution. 
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Table 3-1 Main Difference in Contents of Phase I and Phase II Questionnaires used in this study 
No. Section/Topic Subtopic Difference Phase I 
1 Socio-demographic Nil V 
2 Employment/Occupation Nil V 
3 Hormone markers Nil V 
4 Smoking habits Nil V 
5 Sexual behaviour Additional information on problem related to sexual activity V 
in Phase II 
6 Skin and sun exposure X 
7 Family history Nil v 
8 Physical activity Nil v 
9 Pesticide Pesticide topic was removed in Phase II v 
10 General health and Medical diagnostic procedures such as X-ray information v 
medication taken more detail in Phase II 
Chronic Diseases X 
Statin X 
Painkiller NSAIDs & Paracetamol X 
11 Further details Other contents V 
Information on Waist/trouser size and hip size X 
-- -- --
-_ .. _- ._._ .... - ---- --------------- --- ---- -- ---
- -
Total no. 
Phase II Subjects 
(N=4041) 
V 4041 
V 4041 
V 4041 
V 4041 
V 4041 
v 2209 
v 4041 
v 4041 
X 1832 
v 4041 
v 2209 
v 2209 
V 2209 
V 4041 
v 2209 
W 
I 
~ ~
-...J 
No. Section/Topic 
12 Food Frequency 
Subtopic Difference 
Information Body Fat Distribution 
Additional items included in Main Food Table are soy milk 
and spices, while in Vitamins & Supplements Table include 
saw palmetto, garlic, pomegranate, soy-based drink and 
tomato juice in Phase II questionnaire 
Total no. 
Phase I Phase II Subjects 
(N=4041) I 
X Y 2209 
I 
X Y 4041 
.- -_.- - - .. 
3.3 Data management 
Data from the first phase was already entered and cleaned. For the second 
phase data entry database was created in Microsoft Access. Data was then 
entered in Microsoft access database and then transferred to Microsoft Excel. 
Data was checked thoroughly using filters in Excel. As data were entered by 
different people, data input was re-checked for quality control purpose. Data 
was checked to exclude any error using Microsoft Excel by re-entering 
randomly 10% selected questionnaires and compare them with the actual data. 
Upon findings of inconsistencies, the original questionnaires where data were 
obtained from were referred, corrections were made. These processes were 
repeated until there was less than 0.5% error. After that data of first and 
second phase was merged taking in account the difference in questionnaires of 
both phases. 
Social class coding was manually cross checked by an expert. Data cleaning 
was done prior to recoding with intention to salvage any raw data especially 
subjective answers of loose words or misspelled data for purpose of 
classification later. Recoding of variables was also done based on category of 
ordinal or nominal as the next important step to make the analyses easier and 
flawless. 
3.4 Analysis 
For statistical analysis, SPSS (Statistical Package for the Social Sciences) 
version 17 was used. To compare the demographic characteristics of cases and 
controls, such as age, ethnicity, social class, education and marital status, 
univariate logistiC regression were performed. All statistically significant 
univariate analysis of socio-demographic variables were re-entered into 
multivariate logistic regression method to obtain the remaining statistically 
Significant variable for association to prostate cancer risk. The next nearest to 
statistically significant variable was retested and re-entered for backward 
logistic regreSSion into the logistic regression model. 
The statistically Significant remaining variables in multivariate regreSSion model 
(reSidual variance confounders) was put up as the middle model and was used 
to fit in all other environmental factors/variables of interest in subsequent 
analysis. Unconditional logistic regreSSion was used to generate odds ratios and 
95% confidence intervals (el). To assess for a trend in prostate cancer risk 
across, the categories test for linear p trend was also performed. 
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The following variables were analysed for the purpose of the PhD thesis: 
i. Demographic features 
ii. Skin type 
iii. Sunlight exposure 
iv. Chronic diseases of diabetes, hypertension, cardiovascular disease, etc 
v. Pain killer medication-NSAIDS and Paracetamol 
vi. Statin medication 
vii. Diet of Iycopene, phytoestrogens and selenium 
3.5 Possible confounders 
Possible confounders were identified using methods of multivariate analysis as 
described above. These confounders could derive from demographic factors as 
well as other studied variables. Adjusted and best fitting models were done to 
reduce the potential influences of these confounders and seek the factors' 
association in prostate cancer risk. 
3.6 Ethical approval 
The study has been ethically approved by the Trent Multi Research Ethics 
Committee MREC/99/4/013(Mar) and 07/MRE04/29. 
3.7 Funding 
There were main funding streams to support all epidemiological data collection 
and control biological sample collections including the Prostate Action Charity 
formerly known as the Prostate Cancer Research Foundation (PCRF), the 
Cancer Research UK (CR UK). For the genetic part of the study, the study 
partner, the ICR UK was responsible for case blood collections and further 
genetic analysis. The genetic work was funded by the Cancer Research UK 
grant CS047/A33S. 
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Chapter 4 Sociodemographic Factors 
4.1 Literature Review 
4.1.1 Age 
Age is a significant factor strongly associated with the risk of prostate cancer 
(Pourmand et ai, 2007; Tseng, 2011). As men grow older, the probability of 
developing prostate cancer increases. The Cancer Research UK (2010) age 
specific incidence rates for prostate cancer in United Kingdom in 2007 showed 
rate of steeply increases with age. Men aged 55-59 had incidence rate of 155 
per 100,000 men, then at age 65-69, had triple incidence rate to 510 per 100, 
000 and at age 75-78, the rate was further up to 751 per 100,000 men (CRUK, 
2010). The Surveillance Epidemiology and End Results (SEER) data based in 
USA, showed between 2002 to 2007, the mean age of diagnosis of prostate 
cancer in men is 67 years old (Altekruse et ai, 2010) 
4.1.2 Marital status 
Married adults were generally found to be healthier than other marital status 
categories according to a study by Schoenborn (Schoenborn, 2004). However 
being married is also associated with negative health indicators, for example 
being more prone for being overweight or obese. Married adults, particularly 
men, had higher rates of overweight or obesity relative to adults of other 
marital status. Never married adults were among the least likely to be 
overweight or obese. 
Marital status could also be associated with socioeconomic stability, lifestyle 
behaviour such sexual activities and habits and personal health care. Some 
studies used indicators such as being single but married late or number of 
marital partners, and showed associations of these sexual and lifestyle factors. 
The positive associations were evident in studies, such as being married more 
than once (La Vecchia et aI, 1993), or having higher number of sexual partners 
and frequency of sexual activity, based on a meta-analysis study (DenniS, 
2002a). 
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4.1.3 Country born 
Country of origin could indicate the prevalence or incidence of prostate cancer 
and study whether there is any change to the likelihood of contracting cancer if 
migrated to other countries outside of origin. 
A study by Wild et ai, on the cancer mortality in England and Wales by their 
country of birth has shown lower combined cancer deaths including prostate 
cancer deaths among those born in Bangladesh, India, Pakistan, China or Hong 
Kong and higher prostate cancer mortality among men born in West Africa or 
the West Indies, when using those born in England and Wales as reference 
(Wild et ai, 2006). These findings could provide further study on the aspect of 
migration to prostate cancer risk in the population. 
4.1.4 Always lived in United Kingdom (UK) 
Being in UK all one's lifetime could only mean similar enVironmental exposures 
in many ways for the subjects especially exposure to food, healthcare, air and 
water supply, lifestyle, type of house and entertainment, etc. For someone 
who had been abroad either for studying, working or migrating for good could 
mean a whole new or different lifestyle, environmental exposures, education 
and healthcare offered altogether. 
4.1.5 Education 
The American Cancer Society (2011) has published an article on the cancer 
death rates by educational attainment of United States population for year 
2007 based on data obtained from National Center for Health Statistics. The 
report indicated that prostate cancer deaths relative risk among those lowest 
level of education compared to those with highest level was 1.66 (95%CI: 
1.44-1. 93) constitute of all races. 
However In the study of prostate cancer incidence and education level, some 
studies have concluded that higher education level has higher risk of prostate 
cancer (Lund Nilsen et ai, 2000; Mouw et ai, 2008; Vidarsdottir et ai, 2008). 
4.1.6 Ethnic Group 
The study of racial differences and prostate cancer has been done in USA and 
recent study has shown that black non-hispanic are of greater risk compared to 
white non-hispanic and their incidence rate are higher (Wells et ai, 2010). 
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With regard to larger comparison between populations in world regions, and 
the age adjusted incidence rate of prostate cancer, based on Cancer Incidence 
in Five Continents Vol. IX, on average North America countries top the rate 
followed by Europe, South America and Oceania, then Africa with Asia showing 
the lowest rate (Curado. M. P. et ai, 2007). Although these are true reported 
cases, and could really be associated with true risk of prostate cancer, but bear 
in mind there's still high possibility of undiagnosed and unreported cases 
particularly in less developed countries due to poor reporting systems. 
4.1.7 Social class 
It was found that the better social economic status encompassing education, 
income and occupation, will have higher risk of developing prostate cancer as it 
is linked with lifestyle behaviour and environmental risk, as well as ability to 
access better healthcare facilities for medical screening and diagnosis (Harvei & 
Kravdal, 1997; Liu et ai, 2001). 
A study by Cheng revealed a statistically significant trend of higher relative risk 
to have prostate cancer of 1.28 (Cl: 1.25-1.30) when compared between the 
highest to the lowest socioeconomic status (Cheng et ai, 2009). Another study 
on Norwegian population also found an increase of 30% risk to prostate cancer 
among higher socioeconomic status group. Higher education level also 
increase 56% risk of prostate cancer (Nilsen et ai, 2000). 
4.1.8 Family History 
Prostate cancer has been found in many studies to be associated with first 
degree relatives with cancer. The possibility of strong genetic link could be the 
explanation. A meta-analysis done for all epidemiological studies on looking at 
relationship between the 1st degree family i.e. father or brother with prostate 
cancer with patients of prostate cancer up to year 2002 has revealed increased 
risk of two to three fold with father and male siblings at 2 times and 3 - 4 
times respectively (Zeegers et ai, 2003). 
Prostate cancer was found in one study to have statistically significant odds 
ratio of 2.60 of adjusted family standardized incidence ratio (AFSIR) which 
meant increased risk due to family history (Kerber & O'Brien, 2005). In the 
same study, prostate was the only cancer that had strikingly the highest 
familial factors population attributable risk estimates at 57% compared to 
other types of cancers with breast cancer as second. 
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A case control study in Japan has found a statistically significant increased risk 
of 5.6 times of getting prostate cancer patients who have family history of 
similar cancer (Suzuki et ai, 2007). A study on Sweden population of 205,638 
cancer cases showed prostate cancer as having the highest proportion of 
familial association at 20.15% followed by breast cancer at 13.58% (Hemminki 
et ai, 2008). 
In terms of association with first degree relative with prostate cancer by age of 
diagnosis, young cancer patients of less than 60 years old have higher relative 
risk compared to those diagnosed at 60 years or above at 2.16 and 1.95 
respectively, meaning those with first degree relatives with prostate cancer will 
have higher chances of early onset of prostate cancer (Chen et ai, 2008). 
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4.2 Methodology 
4.2.1 Demographic Factors Definition 
4.2.1.1 Age 
Age in case subjects refers to age at the date of diagnosis obtained from GPs 
or hospitals records while for control subjects refers to age on the date when 
the questionnaire was returned to the researcher and recorded. 
4.2.1.2 Marital status 
Married and common law partnership were merged as one group, while 
widowed, divorced or separated as another group. Single is a group by itself. 
4.2.1.3 Country born 
Country born ask on whether born in United Kingdom or other countries. If 
other, country is named. 
4.2.1.4 Always live in UK 
Unless significant time out of UK, then subject would record the number of 
year's concrete in UK, otherwise always live in UK is same as age in years. 
4.2.1.5 Education 
Levels of education are recorded based on recognized qualification hierarchy in 
UK of four categories namely no education, GCSE/O level or equivalent, A level 
or equivalent and lastly Higher or professional qualification. 
4.2.1.6 Ethnic 
Using tick box selection ethnic list was done. Due to the smaller numbers of 
some of the ethnic group and for appropriate use of statistically test, they are 
collapsed into White, Black (Black-Carribean, Black-African & Black-Other), 
Indian or Pakistan, and lastly Others (Jewish, Sephardic, Askenazi, Chinese, 
etc) 
4.2.1.7 Social cla.s 
Social class classification was based on Standard Occupational Classification 
2000 (ONS, 2000) categorize into the following: 
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Class I 
Class II 
Class IIIN 
Class IIIM 
Class IV 
Class V 
Professional 
Managerial and Technical occupations 
Skilled Non-Manual 
Skilled Manual 
Partly Skilled occupation 
Unskililed occupation 
4.2.1.8 Family History 
Only subject's first degree relatives of biological origin i.e. parents, siblings and 
children are recorded as having family history. 
The analysis was done to look at family history of any cancer and specific 
family history of prostate cancer. 
4.3 Analysis 
All analysis were performed using statistical software SPSS version 17.0 
Central tendency measures of mean and median as well as dispersion standard 
deviation and inter-quartile range calculation were computed for age variable 
data to compare characteristics between cases and control group. The age data 
has also been categorized to assess p-value for trend and to identify age group 
with significant association with prostate cancer risk. 
All socio-demographic variables were tested for Chi-square test to study the 
differences in the proportion or characteristics between cases and control 
group. Level of significance was at a (alpha) =0.05, and 95% confidence 
interval (95%CI). For variables with statistically significant Chi-square test 
results, further analyses of univariate and age-adjusted logistic regression 
models were carried out to study their association towards prostate cancer 
risk. 
Multivariate analyses were completed among socia-demographic factors which 
have shown in univariately statistically significant regression modelling and 
with age-adjusted models, in order to identify potential confounders. The 
backward regression modelling method was employed. The best fitting model 
were identified by any factors which remained statistically significant. However 
a priori variable 'age' would be used in all regression analysis models on 
prostate cancer risk. 
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4.4 Results 
4.4.1 Overall Response Rate 
Response rates presented in Table 4-1 are the response rates after subjects' 
initial consent to participate the study. The true recruitment rates are 
unknown due to confidentiality issue as guided by ethics. Only subjects who 
consented were disclosed to study team (by GPs if they are controls and by the 
study partner ICR UK if they are cases). Letters and further consent forms to 
provide biological samples were sent. To obtain response rates, subjects who 
consented to complete the questionnaire and to provide biological samples 
were used as denominator. Subjects who sent back their questionnaire were 
used as nominator. 
Table 4-1 Response rate among case-control group 
Study Phase Case 0/0 
Phase 1 78.9 
Phase 2 91.0 
Overall Total 85.0 
Number of subjects with questionnaire data: 
Cases 
Controls 
Total 
1963 
2078 
4041 
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Control 0/0 
61.8 
87.0 
74.4 
4.4.2 Age 
Total: 4041 (4039 valid & 2 missing) 
Age was normally distributed (scatter plot- not shown) 
Table 4-2 The mean and median age of case-control groups 
Group No. Range Mean SD Median Interquartile 
range 
Case 1962 36-85 59.58 6.005 60 6 
Control 2077 36-76 59.13 6.551 59 7 
Independent t-test, p=0.020, which was statistically significant to show mean 
age is higher in cases group. 
Univariate logistic regression for age as continuous variable showed p=0.025 
with OR=1.011 (9S0f0CI: 1.001-1.021). 
Table 4-3 Cross-tabulation of age group among case-control group 
Group 
Age 
Control Case Total 
Category 
(Ofo) (Ofo) (Ofo) 
118 79 197 
49 and below 5.7% 4.0% 4.9% 
1094 875 1969 
50-59 52.7% 44.6% 48.7% 
668 872 1540 
60-69 32.2% 44.4% 38.1% 
197 136 333 
70 and above 9.5% 6.9% 8.2% 
2077 1962 4039 
Total 100.0% 100.0% 100.0% 
Majority of subjects (almost 87%) are in the category of 50-59 and 60-69 
years old. Between cases and control, there appear to have higher proportion 
of age group 50-59 among the control compared to cases, while at the same 
time, higher proportion of 60-69 age group among cases compared to control. 
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Chi-square test, p<O.OOl (statistically significant) confirmed the difference in 
the age group distribution. 
Table 4-4 Odds Ratio and Confidence Interval for Prostate Cancer Risk 
for Age Category 
Age Group Group OR P value 
(95% CI) 
Control Case 
(%) (%) 
49 and below 118 79 -Ref- <0.001 
(5.7%) (4.0%) 
50-59 1094 875 1.195 0.243 
(52.7%) (44.6%) (0.886-1.610) 
60-69 668 872 1.950 <0.001 
(32.2%) (44.4%) (1.441-2.638) 
70 and above 197 136 1.031 0.867 
(9.5%) (6.9%) (0.720-1.477) 
P for trend <0.001 
The above showed that age category 60-69 alone showed statistically 
significant increased in prostate cancer risk when compared to the youngest 
age group, at OR= 1.950 (95%CI: 1.441-2.638) or almost double the risk. P 
for trend, p<O.OOl, showed statistically significant trend increase in prostate 
cancer risk with increased in age. 
4.4.3 Marital status 
Table 4-5 Cross-tabulation of age group among case-control group 
Group 
Marriage Category Control Case Total 
(Ofo) (Ofo) (%) 
1725 1611 3336 
Married or partnership 
83.9% 83.3% 83.7% 
260 232 492 
Divorced, separated or widowed 
12.7% 12.0% 12.3% 
70 90 160 
Single 
3.4% 4.7% 4.0% 
2055 1933 3988 
Total 
100.0% 100.0% 100.0% 
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Chi-square p=0.119, was not statistically significant to show differences in the 
marital status and prostate cancer status, although univariate logistic 
regression showed 'single' status in comparison with 'married or partnership' 
status has statistical significance increase at p=0.05 of prostate cancer risk, 
OR=1.377 (95%C1: 1.000-1.895). 
Upon adjustment for age, the marital status variable was not statistically 
significant towards prostate cancer risk, however 'single' status remained 
statistically significant with increase prostate cancer risk of approximately 40% 
compared to the status of 'married or partnership). 
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Table 4-6 Odds Ratio and Confidence Interval for Prostate Cancer Risk for Marriage Category 
Marriage Category 
Married or partnership 
Divorced, separated or widowed 
Single 
aUnadjusted regression models 
bAdjusted for age, regression models 
Control 
n 
1725 
260 
70 
_ .. -
---
Case 
n 
1611 
232 
90 
-- -
ORa P OR" 
(950/0 C.I) value· (95% C.I) 
-Ref-
-Ref 0.121 
0.955 0.638 0.955 
(0.790-1.155) (0.790-1.155) 
1.377 0.050 1.396 
( 1.000-1.895) (1.014-1.923) 
-
P 
valueb 
0.102 
0.637 
0.041 
4.4.4 Country born 
Table 4-7 Cross-tabulation of Country born among case-control group 
Group 
Control Case Total 
Country Born (Ofo) (Ofo) (Ofo) 
1959 1806 3765 
UK 95.0% 93.3% 94.2% 
103 129 232 
Other 5.0% 6.7% 5.8% 
2062 1935 3997 
Total 100.0% 100.0% 100.0% 
Chi-square test, p=0.024 (statistically significant), with OR = 1.359 
(9S0f0CI: 1.040-1.774) or increased risk of 36% of those born in UK to 
develop prostate cancer compared to those born in countries other than the 
UK. 
Logistic regression adjusted for age showed that the odds ratio for country 
born in UK group, prostate cancer risk remains significant at p value 0.027 
and OR 1.351 (9s% CI: 1.035-1.764) or approximately 35% increased risk 
compared to those born outside UK. 
4.4.5 Always live in UK 
Table 4-8 Cross-tabulation of Always In UK among case-control group 
Group 
Always In UK Control Case Total 
(Ofo) (Ofo) (Ofo) 
No 231 246 477 
11.4% 12.9% 12.1% 
Yes 1797 1666 3463 
88.6% 87.1% 87.9% 
Total 2028 1912 3940 
100.0% 100.0% 100.0% 
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Chi-square test with p value of 0.156, suggesting no statistically significant 
association between status of always been in UK and staying in other countries 
to prostate cancer risk. 
4.4.6 Education 
Table 4-9 Cross-tabulation of Education category among case-control 
group 
Group 
Education Category Control Case Total 
(Ofo) (Ofo) (010) 
570 439 1009 
None 
27.8% 22.8% 25.4% 
343 362 705 
GCSE, 0 levels or equivalent 
16.7% 18.8% 17.7% 
151 136 287 
A levels, higher or equivalent 
7.4% 7.1% 7.2% 
Higher or professional 973 968 1941 
qualification e.g. degree, HND 47.4% 50.4% 48.8% 
15 17 32 
Other 
0.7% 0.9% 0.8% 
2052 1922 3974 
Total 
100.0% 100.0% 100.0% 
Chi-square test with p value of 0.007 showed statistical significant differences 
in the proportion of prostate cancer cases between different levels of 
education. 
Table 4-10 page 4-64 showed estimated risk of education and prostate cancer. 
P for trend, p=O.OOB showed a statistically significant trend across all 
education levels is associated with higher prostate cancer risk. 
Using group of those with 'No education' as reference, the risk of prostate 
cancer is suggestive of higher in all other categories (of OR>l) but found to be 
statistically significant only with groups GCSE/O levels education and 
Higher/professional qualification at OR = 1.370 (95%CI: 1.130-1.662) and 
1.292 (95%CI: 1.108-1.505) respectively. 
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After age adjustment, using 'No education' as reference, the risk of prostate 
cancer remains higher in all other categories (of OR>l) but only with groups 
GCSE/O levels education and Higher/professional qualification showed 
statistically significant at OR = 1.376 (95%CI: 1.134-1.657) and 1.296 
(95%CI: 1.112-1.511) respectively. 
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Table 4-10 Odds Ratio and Confidence Interval for Prostate Cancer Risk for Education Category in 
Unadjusted and Age-adjusted regression models 
Education Category Control 
n 
No Education 570 
GCSE, 0 levels or 343 
equivalent 
A levels, higher or 151 
equivalent 
Higher or professional 973 
qualification e.9. degree, 
HND 
Other 15 
P for trend =0.008 
aUnadjusted regression models 
bAdjusted for age, regression models 
Case 
n 
439 
362 
136 
968 
17 
-
ORB p valueB ORb 
(95% C.Il (95% C.I) 
Ref 0.007 Ref 
1.370 0.001 1.376 
(1.130-1.662) (1.134-1.657) 
1.169 0.243 1.170 
(0.899-1.521) (0.899-1.523) 
1.292 0.001 1.296 
(1.108-1.505) (1.112-1.511) 
1.472 0.283 1.473 
(0.727-2.979) (0.727-2.985) 
- ~ - - --- -- ---- ----
p valueD 
0.006 
0.001 
0.244 
0.001 
0.282 
4.4.7 Ethnic Group 
Table 4-11 Cross-tabulation of Ethnic category among case-control 
group 
Group 
Ethnic Category Control Case Total 
(Ufo) (Ufo) (Ofo) 
2029 1862 3891 
White 98.6% 96.4% 97.5% 
5 31 36 
Black 0.2% 1.6% 0.9% 
9 13 22 
Indian-Pakistan 0.4% 0.7% 0.6% 
Others such as 14 26 40 
Chinese Jewish etc 0.7% 1.3% 1.0% 
2057 1932 3989 
Total 100.0% 100.0% 100.0% 
White constitutes the majority of the study subjects at 97.5%. The proportion 
of White is higher in control groups, while the other ethnic categories are 
higher among the cases. Chi-square test, p<O.OOl, showed statistically 
significant difference in the proportion of ethnic types between case and control 
groups. 
Referring to Table 4-12, using White ethnic category as reference, there is 
statistically significant increased risk of prostate cancer in the Black and Others 
ethnic categories at OR = 6.756 (950f0CI: 2.622-17.411) and 2.024 
(95UfoCI: 1.054-3.881) respectively. 
The p value remains significant even after adjusted for age, at p<O.OOI with 
still statistically significant increased risk of prostate cancer in the Black and 
Others ethnic categories at OR = 6.942 (950f0CI: 2.692-1'.899) and 2.036 
(95UfoCI: 1.059-3.912) respectively when compared to white ethnic group. 
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Table 4-12 Odds Ratio and Confidence Interval for Prostate Cancer Risk for Ethnic Category in Unadjusted and Age-
adjusted regression models 
Ethnic Category 
White 
Black 
Indian-Pakistan 
Others such as Chinese Jewish etc 
aUnadjusted regression models 
bAdjusted for age, regression models 
Control 
n 
2029 
5 
9 
14 
Case OR-
n (95% C.I) 
1862 -Ref-
31 6.756 
(2.622-17.41U 
13 1.574 
(0.671-3.691) 
26 2.024 
(1.054-3.887) 
P value- ORb P valueD 
(95% C.I) 
<0.001 -Ref- <0.001 
<0.001 6.942 <0.001 
. (2.692-17.899) 
0.297 1.558 0.308 
(0.664-3.655) 
0.034 2.036 0.033 
(1.059-3.912) 
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4.4.8 Social Class 
Table 4-13 Cross-tabulation of Social Class among case-control group 
GrouD 
Social Class Control Case Total 
(Ofol (Ofol (Ofol 
228 238 466 
I 11.5% 12.6% 12.1% 
858 813 1671 
II 43.3% 43.2% 43.2% 
210 195 405 
IIIN 10.6% 10.4% 10.5% 
540 509 1049 
111M 27.3% 27.0% 27.1% 
113 111 224 
IV 5.7% 5.9% 5.8% 
31 18 49 
V 1.6% 1.0% 1.3% 
1980 1884 3864 
Total 100.0% 100.0% 100.0% 
The spread of social class category did not appear to show remarkable 
difference characteristics among cases and control group although slightly 
higher proportion of cases with social class I, whereas among control subjects 
higher social class V. Chi-square test, p=0.552 showed non-statistical 
significant association between social class and prostate cancer risk. 
Test for trend (p value 0.334) showed no association with ranking in social 
class with prostate cancer risk. 
Logistic regression analysis results are shown Table 4-14. The results showed 
no statistical association between highest social class (Class I as reference) to 
other classes in prostate cancer risk, although it was observed that social class 
V showed most protective risk at 0.556 (95%Cl: 0.303-1.022). 
After adjustment for age, there were still no statistically significant findings. 
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Table 4-14 Odds Ratio and Confidence Interval for Prostate Cancer Risk for Social Class in Unadjusted 
and Age-adjusted regression models 
Social Class Control 
n 
I 228 
II 858 
IIIN 210 
111M 540 
IV 113 
V 31 
~ ~
I 
~ ~ aUnadjusted regression models 
bAdjusted for age, regression model 
Case 
n 
238 
813 
195 
509 
111 
18 
ORa p value- ORb p valueb 
(95% C.I) (95% C.I) 
-Ref- 0.560 -Ref- 0.574 
0.908 0.356 0.908 0.357 
(0.739-1.115) (0.739-1.1151 
0.890 0.389 0.889 0.387 
(0.682-1.161) (0.681-1.1601 
0.903 0.360 0.912 0.408 
(0.726-1.123) (0.733-1.135) 
0.941 0.709 0.951 0.760 
lO.684-1.2941 (0.691-1.309) 
0.556 0.059 0.951 0.063 
(0.303-1.022L (0.691-1.309) 
4.4.9 Family History 
4.4.9.1 Family History of any cancer in lit degree relatives 
Table 4-15 Cross-tabulation of Family history of cancer among case-
control group 
Family history cancer 
Group 
Control Case Total 
(0J0) (0J0) 1000l 
1092 662 1754 
No 54.0% 35.0% 44.8% 
929 1230 2159 
Yes 46.0% 65.0% 55.2% 
2021 1892 3913 
Total 100.0% 100.0% 100.0% 
Chi-square test p<O.OOl, with statistically odds ratio of 2.184 (9S0f0CI: 
1.920-2.484). There is twice the risk of prostate cancer among those with first 
degree family history of cancer compared with those who have no history. 
Upon adjustment by age, the logistic regression model remained statistically 
significant at p<O.OOl and OR=2.173 (950J0CI: 1.910-2.472). 
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4.4.9.2 Family History of prostate cancer in 1st degree relatives 
Table 4-16 Cross-tabulation of Family history of prostate cancer among 
case-control group 
History of Prostate 
Group Total 
Cancer Control Case 
(Ofo) (Ofo) (Ofo) 
1911 1337 3248 
No 95.0% 71.2% 83.5% 
100 540 640 Yes 
5.0% 28.8% 16.5% 
2011 1877 3888 Total 
100.0% 100.0% 100.0% 
Chi-square test p<O.OOl, with statistically odds ratio of 7.718 (9S0f0CI: 
6.166-9.661). The risk of having prostate cancer among those with first degree 
family history of prostate Is 7.7 times fold compared to those without such 
history. 
Even after age adjustment, the prostate cancer risk for those with family history 
of Prostate cancer remains significant at p<O.OOl and OR=7.690 (9s% CI: 
6.142-9.629). 
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4.5 Discussion 
4.5.1 Response Rate 
In this study, efforts have been made to increase the response rate of both the 
cases and control subjects towards the filling up and returning of questionnaire 
booklet, as well as samples of toe-nail clippings through mail. A telephone 
helpline was provided at the back of the questionnaire for clarification of any 
queries or fulfilling any extra information required by subjects in order to fill in 
the answers to the best of their understanding. A reminder letter was sent out 
to those subjects whose questionnaire/toenails samples were not received after 
4 weeks duration of sending the questionnaire, vacant container for nails 
clippings and stamped return envelope. 
According to systematic review by Edwards, showed that personalized 
questionnaires and letters, usage of return stamped envelope as well as follow 
up contact were shown to have increased response rate to studies using 
questionnaires (Edwards et aI, 2002). 
The response rate for first phase and second phase were 78.9% & 91.0% among 
cases and 61.8% & 87.0% among controls, while overall response rate In total 
was 85.0% and 74.4% for cases and control respectively. This finding is better 
than a pooled analysis study of population based case-control study done in 
Germany (Stang et ai, 1999) which had response proportion of 80% among 
cases and 68% among controls. Another survey on case-control studies done in 
articles published in 2003 Science Edition of Journal Citation Reports of 
Thompson Corporation, Philadelphia, Pennsylvania by Morton (Morton et aI, 
2006) showed median response rate of 84% among cases and 74% among 
controls which is very similar with our study. Therefore overall on average, it is 
considered good and adequate response rate because of cost and time saving 
benefit obtained through this method applied well in case-control study design. 
Cases seem to be more receptive towards responding to this study probably 
could be explained due to their interests of what the outcome of the study would 
benefit prostate cancer patients like themselves and towards the prevention of 
this ailment among their loved ones or of the population on the whole, as well as 
contributing to science of knowledge In this area. However controls are selected 
by general practitioner (GP) and numbers of respondents would depend a lot on 
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persuasion manner used by GP and different GPs have different approaches. 
However, ultimately, potential control subjects may more likely refuse to 
participate in a study if they don't get any follow up with their GP by phone call, 
compared to cases who would be constantly under regular medical follow up by 
hospital or GP. 
4.5.2 Age 
The mean age for both caSes and control subjects in this study were 59.58 and 
59.13 respectively. EVen though age was frequency matched, the independent 
t-test revealed statistical significant increase of mean age among cases. 
Univariate logistic regression for age as continuous variable showed p=0.025 
with OR=1.011 (95%C1: 1.001-1.021). The prostate cancer risk increase 
estimated at 1.1% with each year increase in age. 
Similar analysis done in the median calculation although approximate value is 
close to mean, the median age for cases was 60 while for control was lower at 
59. It was both bell-shaped distributions. 
A case-control study of prostate cancer by Key was conducted in Oxfordshire, 
West Berkshire and Leeds, they reported older mean ages of cases and controls 
identical at 68.1 years, of which controls are matched with cases within 1 year 
of age In either way, with criteria of eligibility all cases diagnosed before 75 
years old (Key et aI, 1997). The marked difference in the mean age between 
our study and the other studies is because our study in Phase 1 was focused on 
prostate cancer patients of less than 60 years old, but in Phase 2 age was 
extended to cover all ages. 
By stratifying age into categories of 10 years interval, the analysis finding 
showed statistically significant p for trend, with the average 19% increase of 
prostate cancer risk or between the ranges of 9% to 30% for each ascending in 
age group category. (Refer Table 4-4 page 4-58) 
By using age 49 and below as reference group, the only statistically significant 
increase in prostate cancer risk are the age group '60-69 years old' of almost 
double the risk. 
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The Cancer Research UK (2010) age specific incidence rates for prostate cancer 
in United Kingdom in 2007 showed the rates steeply increase with age (CRUK, 
2010). Study in Iran has established as age increases, so does the risk of 
getting prostate cancer (Pourmand et aI, 2007). The Surveillance Epidemiology 
and End Results (SEER) data based in USA, showed between 2002 to 2007, the 
mean age of diagnosis of prostate cancer in men is 67 years old (Altekruse et aI, 
2010). 
4.5.3 Marital status 
Based on the results of this study, the majority (approximately 84%) of the 
subjects are either still married or in common law partnership with a smaller 
proportion of singles or not in relationship because of separation, divorce or 
death of partner. 
Initial cross-tabulation analysis did not show any statistically significant 
difference in the proportion of prostate cancer by marital status. However, upon 
comparison between marriage category by using 'married and partnership' as 
reference, it was observed that the 'single' was of borderline statistically 
significant at p=O.OSO with odds ratio (OR) = 1.377 or 37.7% higher risk. The 
prostate cancer risk became more statistically significant with age adjustment to 
the model (OR at 1.396, 95%CI: 1.014-1.923). 
The author could not locate prostate cancer studies in United Kingdom for 
comparison however study by La Vecchia on the population of case control study 
in Italy between 1985 to 1990 showed prostate cancer risk was protective in 
'never married' compared to married men at risk ratio (RR)=0.6 but not 
statistically significant (La Vecchia et aI, 1993). Only those who married twice 
or more showed a statistically significant increased risk of prostate cancer in 
comparison with never married man, at RR=3.2 (95%Cl: 1.2-8.9). Similar 
findings for the study by Harvei & Kravdal that showed significant excess 
incidence of about 20% in 'ever-married' compared to 'never married' men 
(Harvel & Kravdal, 1997). 
Another study by Nilsen suggested a higher risk of prostate cancer among men 
who divorced or separate compared to married man but was not statistically 
significant (Lund Nilsen et aI, 2000). 
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In this current study, there is possibility that 'single' status could mean having 
multiple partners instead of no partner and that could be associated with other 
probable factors such as sexual activity involving multiple partners with a higher 
possibility of sexual transmitted diseases which has been documented in some 
studies to increase risk to prostate cancer. 
4.5.4 Country born 
The majority of the subjects both cases and controls, were born in the United 
Kingdom (UK) at 94%. The prostate cancer risk was found to be higher in those 
born in UK at OR= 1.359, and after adjustment for age remain statistically 
significant at 1.351 or 35% increase in risk compared with those born outside of 
UK. 
Global Cancer registries such as 'Cancer Incidence in Five Continents' and data 
from 'Globocan' have shown higher reported incidence rates of prostate cancer 
among developed countries such as USA, Canada, Australia and most European 
countries and lower in Asian continent countries such as Japan, China and 
developing world regions (Curado. M. P. et ai, 2007; Ferlay et aI, 2008; Parkin 
et aI, 2002). The possible explanation could be due to environmental factors of 
exposure or habits of the population. 
It is also possible to say 'westernization' in the low-risk population of Asians has 
led to increase of incidence rate over the years when moving to the western 
country. A study on the international trends and patterns of prostate cancer 
incidence by Hsing concluded the possibility that this was due to a combination 
of genetic and environmental factors (Hsing et aI, 2000b). 
4.5.5 Always live in UK 
There was no difference in the proportion of prostate between those who always 
stay in UK and those who did not. 
4.5.6 Education 
Almost 50% of the subjects both of cases and control have a higher or 
professional qualification. There was a statistical significant difference in the 
proportion of prostate cancer between the levels of education. There was also 
an increased trend to develop prostate cancer as the level of education is higher 
(Refer Table 4-9 page 4-62). 
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When using those 'no education' as reference, only those who had education of 
'GCSE, 0 levels or equivalent' and also those with 'higher or professional 
qualification' shown a statistically significant increase risk of developing prostate 
cancer at 37% and 29% respectively. Even after adjustment for age, the 
prostate cancer risk remains statistically significant at OR 1.376 and 1.296 for 
'GCSE, 0 levels or equivalent' and 'higher or professional qualification' 
respectively (Table 4-10 page 4-64). 
A study by Nilsen on Norwegian men confirmed similar findings when the 
prostate cancer risk was elevated among men with high education compared to 
the least educated (RR = 1.56; 95% Cl 1.11-2.19) (Lund Nilsen etal, 2000). 
A cohort study among Icelanders population also showed elevated standardized 
incidence ratio of prostate cancer of 1.17 (95%CI: 1.05-1.30) for higher level of 
education (Vidarsdottlr et aI, 2008), while a cohort study in the USA population 
by Mouw using postgraduate education level as reference, showed a statistically 
significant trend of reduced risk of prostate cancer as the level education was 
lower (Mouw et aI, 2008). 
It is possible that higher educated people would seek healthcare providers and 
treatment earlier compared to less educated level, couple with better 
socioeconomic status and level of affordability in seeking earlier prostate 
screening could explain this finding or differences In diet and lifestyle may also 
be part of the explanation. 
4.5.7 Ethnic Group 
97.5% in this study listed themselves as 'White' ethnic group (refer Table 4-11 
page 4-65). The cross-tabulation analysis showed a statistically significant 
difference in proportion of different ethnic groups between cases and control. 
Further analysis using 'White' as reference ethnic group, showed that 'Black' and 
'Other ethnics' have increase prostate cancer risk. Upon adjustment of age in 
the logistic regression, the odds ratio remained statistically significant at 6.942 
(95%Cl: 2.692-17.899) and 2.036 (95%Cl: 1.059-3.912) for 'Black' and 'Other 
ethnic' respectively (refer Table 4-12 page 4-66). 
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Based on data from Cancer Incidence in Five Continents Vol. IX to a look at 
larger comparison between populations in world regions, and with age adjusted 
incidence rate of prostate cancer, on average, North America countries top the 
rates followed by Europe, South America and Oceania, then Africa with Asia 
showing the lowest rate (Curado. M. P. et ai, 2007). Although these are true 
reported cases, and could really be associated with true risk of prostate cancer, 
but bear in mind there is still a high possibility of advanced and wider screening 
methods done in developed countries resulting in more diagnosis of prostate 
cancer in such region, whereas there are more undiagnosed and unreported 
cases particularly in less developed countries due to poor reporting systems. 
4.5.8 Social class 
Analyses of social class classification were completed using both methods. Firstly 
the original classification of I, II, IUN, HIM, IV & V was used and secondly, 
social class was collapsed into three categories. None of the results showed any 
significant aSSOCiation with prostate cancer risk. Similarly, there was no trend 
across social class categories. 
The distribution of education and social class were not of normal distribution 
(refer Table 4-13 page 4-67). By looking further at the cross-tabulation data 
between education and social class, results did not reveal any trend of higher 
education resulting in social class level. This could be due to certain occupations 
being classified as Social Class II such as managerial job. Furthermore, the 
'Higher or professional qualification' which consist both of degree (Bachelor & 
postgraduate) and certification (C&G, HNC, HND) qualifications could dilute the 
effect of actual higher level of education and therefore resulting in some doing 
manual job in Social Class IIIM. 
All the above reasons could have resulted social class level not show any 
association with prostate cancer risk. 
4.5.9 Family History 
4.5.9.1 Family History of any cancer 
The findings in this study are consistent with previous literature review on family 
history of cancer or within 1st degree relatives (Hemmlnki & Chen, 2005). There 
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is approximate 2.2 times Increased risk to prostate cancer risk even after 
adjustment for age. 
4.5.9.2 Family History of prostate cancer 
The prostate cancer risk was 7.7 fold higher risk when there is history of 
prostate cancer in 1st degree relatives. A pooled relative risk of 13 case-control 
and cohort studies in a meta-analysis done by Johns and Houlston (2003) 
showed RR of 2.5 (95%CI: 2.2-2.8) in first degree relatives. If two affected 
relatives of prostate cancer history, the RR would increase to 3.5 (95%CI: 2.6-
4.8) (Johns & Houlston, 2003). 
Both findings above were of strong statistically significance at p<O.OOl. These 
findings are consistent with many studies of prostate cancer association for 1st 
degree relatives with cancer. An increased risk of prostate cancer of early onset 
in particular, is strongly affected by family history (Bratt, 2002). On average, 
hereditary prostate cancer is diagnosed 6 to 7 years earlier than sporadic 
prostate cancer. 
The possibility explanation could be due to a strong genetiC link. Thomas et al. 
(2008) in their genome-wide association study (GWAS) identified multiple loci 
with moderate effects associated with susceptibility to prostate cancer (Thomas 
et aI, 2008). Another GWAS study by Eeles, who is the leading members of the 
genetic part of this study project, had used some of the data from earlier phase 
of prostate cancer gene-environment interaction study. The results confirmed 
previous reports of common loci aSSOCiated to prostate cancer at 8q24 and 17q, 
as well as identified new possible susceptibility genes for prostate cancer namely 
MSMB, LMTK2 and KLK3 (Eeles et aI, 2008). 
The explanation for the unusually strong association of family history and 
prostate cancer seen in this study could possibly be due to case definition in the 
first phase in particular. The study first phase aims were to identify high 
penetrance genes and factors that contributing to the disease. Cases were 
recruited based on either their early onset of prostate cancer (age less than 60) 
or referral of any of their siblings who were also diagnosed with prostate cancer. 
This case series is indicative of genetiC predisposition enrichment thus could 
contribute to a higher risk. 
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As compared to other demographic factors in this study, family history has the 
highest strength in terms of contributory risk factor for prostate cancer based on 
multivariate analYSiS and -2 likelihood ratio test. 
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Identification of confounding factors using Multivariate Analysis 
Table 4-17 Multivariate Analysis among statistically significant 
univariate analysis demographic factors. 
950f0 
Sociodemographic Factors p Confidence 
value OR Interval 
Lower Upper 
Age 0.164 1.007 0.997 1.018 
Married or 0.148 Ref - -
Marriage 
partnership 
Category Divorced, separated 0.964 1.005 0.823 1.226 or widowed 
Single 0.051 1.402 0.999 1.967 
Born Country 0.343 0.852 0.612 1.186 UK 
None 0.02 Ref - -
GCSE, 0 levels or 0.002 1.377 1.126 1.684 equivalent 
A levels, higher or 0.248 1.176 0.893 1.548 
Education equivalent 
Higher or 
professional 0.007 1.249 1.064 1.467 qualification e.g. 
degree HND 
Other 0.276 1.523 0.715 3.246 
White <0.001 Ref - -
Black <0.001 14.74 4.243 51.206 
Ethnic Indian-Pakistan 0.044 2.689 1.026 7.047 
Others such as 0.002 3.199 1.525 6.711 Chinese Jewish etc 
Family history 
<0.001 2.227 1.951 2.542 of cancer 
The multivariate analysis result showed only education category, ethnic category 
and family history of cancer variables remained statistically significant 
associated with prostate cancer risk at p value 0.020, p<O.OOl and p<O.OOl 
respectively (refer Table 4-17 page 4-79). 
The above table also showed that prostate cancer risk is highest among those 
with a family history of cancer at OR=2.227 (950f0CI: 1.951-2.542), followed 
by ethnic category and education. 
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Table 4-18 Final Logistic Regression Model of Demographic Factors to 
Prostate Cancer Risk 
95% 
p Confidence Sociodemographic Factors 
value OR Interval 
Lower Upper 
None 0.026 Ref - -
GCSE, 0 levels or 0.002 1.364 1.116 1.667 
equivalent 
A levels, higher or 0.206 1.193 0.908 1.568 
equivalent 
Education 
Higher or 
professional 0.007 1.244 1.06 1.459 qualification e.g. 
degree, HND 
Other 0.318 1.469 0.691 3.123 
White <0.001 Ref - -
Black <0.001 12.965 3.893 43.176 
Ind ian-Pakistan 0.103 2.076 0.863 4.995 
Ethnic 
Others such as 0.012 2.386 1.206 4.719 Chinese Jewish etc 
Family history 
<0.001 2.234 1.958 2.548 cancer 
Backward logistic regression modelling, by Including each one of the other non-
significant variables into the model of significant variables showed no new 
statistically significant variable. 
The final best fitting model which included significant statistically 
sociodemographic variables were for education category, ethnic category and 
family history of cancer. 
However in adjusting the regression model for all other variables of interest In 
this study, age would be included as a-priori confounder. 
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Chapter 5 Body Size and Shape 
5.1 Literature Review 
Body shape or more commonly body size is often used to describe the 
characteristics of human body for purpose of health. Similarly some parameters 
such as weight, height, skin folds thickness have been developed into various 
health indices to allow comparison such as weight with height (calculation of body 
mass index or BMI), size of waist and hip (calculation of waist to hip ratio or 
WHR), and body fat mass calculated from bioelectric impedance analysis, while 
some have used lean body mass as an index (Liu et ai, 2005) or even dual x-ray 
absorptiometry (OXA) and total body water (TBW) (Funkhouser et aI, 2000). 
Bianchini described in an article in the Lancet, the eVidence that excess body 
weight is directly associated with risk of cancer of colon, breast (postmenopausal 
women), endometrium, oesophagus and kidney (Bianchini et ai, 2002). 
Many of the studies association between obesity and prostate cancer has 
produced mixed findings. The types of measurement or manner of describing 
body shape or size also differs in studies from using for example direct 
measurements of height, weight, waist size or hip size (Hernandez et aI, 2009; 
Hsing et aI, 2000a), to some based on body mass index (BMI)(Jackson et aI, 
2010; Robinson et ai, 2005), while others have used pictorial illustrations to 
describe relative body size (Glovannucci et ai, 1997). 
5.1.1 Body mass index (BMI) findings 
The World Health Organization (WHO) has recommended the use of Body Mass 
Index (BMI) to differentiate the levels obesity for health and clinical management 
purposes. BMI is calculated by weight in kilogram is divided by the squares of 
height in metres. WHO defined BMI of 25 and above as overweight and 30 and 
above as obese. Some studies that used BMI as comparison for body size have 
shown some association with prostate cancer (Oal Maso et aI, 2004; 
Oimitropoulou et aI, 2011; Freedland et aI, 2008; Littman et aI, 2007; MacInnis et 
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ai, 2003; Rodriguez et ai, 2007; Stocks et ai, 2010; Wright et ai, 2007). Among 
these, the majority showed obesity was associated with an increased risk for high 
grade cancer or fatal cancer (Dal Maso et ai, 2004; Littman et ai, 2007; MacInnis 
et ai, 2003; Rodriguez et ai, 2007; Stocks et ai, 2010; Wright et ai, 2007), 
however, some showed a reduction in risk for low grade prostate cancer 
(Dimitropoulou et ai, 2011; Littman et ai, 2007; Rodriguez et ai, 2007). There 
were also studies which did not indicate any association with prostate cancer 
(Hsing et ai, 2000a; Jackson et ai, 2010). 
5.1.2 Waist and Hip circumference 
The use of waist and hip circumference measurement and the waist to hip ratio as 
a proxy for obesity has been used to study its association with prostate cancer 
and the results has also been mixed. MacInnis et al. found that increased 
circumference for waist and hip was associated with Increased risk of aggressive 
(high grade, Gleason score ~ 8 ) ) prostate cancer (MacInnis et ai, 2003). However, 
another study showed hip circumference of more than 97.4cm has lower risk of 
prostate cancer at OR=0.46 (95%CI: 0.29-0.74) at p trend 0.0001 compared to 
lowest quartile of < 76cm (Hsing et ai, 2000a). 
In terms of waist to hip ratio (WHR), the calculation is made by dividing the waist 
circumference by the hip circumference measurements. In males, the 
recommended WHR by World Health Organization (WHO) as a cut-off point for 
risk of metabolic complications Is 0.90 or more while female is 0.85 or more, 
however there maybe some slight differences between regions and ethniC groups 
to reach optimal sensitivity and specificity (WHO Geneva. 2008). WHR is also 
good is describing the type of obesity. Abdominal adiposity has been described 
also as 'Apple' shape or 'android' obesity with higher WHR values due to wider 
waist circumference; also found more commonly in males. . 'Pear' shape obesity 
on the other hand, has wider hip Circumference compared to waist circumference 
is found more commonly in females than males. 
Higher waist to hip ratio (WHR) >0.92 has been reported to be associated with 
increased risk In prostate cancer up to three-fold by Hsing at OR=2.71 (95%CI: 
1.66-4.41) when compared to men with lowest quartile of WHR <0.86 (Hslng et 
ai, 2000a) . In other studies, higher WHR was found to be statistically 
Significantly associated with increased risk for high grade prostate cancer 
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(Jackson et aI, 2010; Pischon et aI, 2008), while others showed no significant 
association (Dimitropoulou et aI, 2011). 
5.1.3 Body Fat Distribution 
Determinants of body fat distribution could include environmental factors such as 
age, level of energy balance, composition of diet and physical activity. However 
heritability, genetic, gonadal or adrenal steroids could also influence truncal fat 
disposition (Bouchard et aI, 1990). 
The study of fat distribution or adiposity in males and females is important as it 
has been found to predict the metabolic complications of obesity. Abdominal 
adiposity or 'Apple' body shape has been associated with cardiovascular risk in 
general (Field et aI, 2001), but more importantly abdominal obesity which 
resulted in wider waist circumference and higher waist-hip ratio is also associated 
with the male hormones of free or total testosterone, dehydroepiandrosterone 
sulphate (DHEAS) and sex hormone-binding globulin (SHBG). Obesity predicts 
greater decline in testosterone and SHBG levels with age, while central obesity is 
an important predictor of decline in DHEAS (Derby et aI, 2006). 
Lower testosterone levels in obesity may impact on reduced prostate cancer 
development and progression due to its dependency on this hormone for growth, 
however at the same time also affecting differentiation of prostate cells, resulting 
in tumour cells poorly differentiated in histopathology. Some studies showed 
reduced non-aggressive prostate cancer risk while at the same time increased 
risk for aggressive or high grade prostate cancer (Littman et aI, 2007; Rodriguez 
et aI, 2007; Wright et aI, 2007). Hack et al. however found adiposity was not 
associated with aggressive prostate cancer (Hack et aI, 2010). 
5.1.4 Weight gain and weight changes 
There are few studies that specifically look at weight changes and prostate 
cancer. However in the literature, weight changes are sometimes analysed in 
addition to body mass index. Wright et al. found that adult weight gain (from age 
18 years and above) was associated with increased of fatal prostate cancer at 
p=0.009 but not with incident cases (Wright et aI, 2007). Rapp, however found 
that high weight gain of 0.50 kg/m2 per year or more, was inversely associated 
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with prostate cancer at hazard ratio of 0.43 (95%C1: 0.24-0.76) (Rapp et ai, 
2008), while Rodriguez found that a weight loss of 11 Ib or more in compared 
with those who lost 5 pounds or less, had reduced prostate cancer risk of non-
metastatic high grade at rate ratio (RR) = 0.58 (95%Cl: 0.42-0.79) (Rodriguez et 
aI, 2007). 
Hernandez who conducted a study stratified by ethnic group and discovered that 
increased weight gain in whites increased the risk for advanced and high-grade 
prostate cancer, and in African American man increased the risk for localized 
prostate cancer. However among Japanese men, increase weight reduced the 
risk for localized prostate cancer (Hernandez et aI, 2009). 
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5.2 Aims 
This Chapter aims to investigate an association of the following aspects to 
prostate cancer risk: 
a. Body shape size at age 20's, 30's. 40's and last 5 years 
b. Trend of change in body shape 
c. Body fat distribution or types of adiposity 
5.3 Methods 
This study used the method of gathering data through the questionnaires for 
both cases and control subjects with self-reported recalled information on body 
shape size in their 20's, 30's, 40's and last 5 years through pictorial illustration of 
body shape from thin to obese (scale of 1 to 9) with 1 representing thinnest body 
shape to 9 representing severe obese. The changes in the pictorial diagrams are 
made in such a way that can describe the amount muscle and fat proportion as 
reduced in thin, moderate in medium and increased in obese. Although the 
illustrations may be proportionally drawn based on the ordinal arrangement, the 
actual increases of body mass index or waist to hip ratio proportion are not 
known. 
somatotype drawings from 1 to 9 answers were used on the surviving 181 elderly 
in 1988 and compared with their measurements taken during the Harvard Growth 
Study 1922-1935. Must et al. has shown in their study on long-term recall of 
individuals' height, weight and body build by elderly subjects were of moderate 
correlations, sensitivities and high specificities in obesity classification including 
pictogram conveying valid information (Must et al. 1993). 
Body fat distribution in 4 different forms including Apple, Pear, Oval and 
Symmetrical were described in words in the questionnaire of their characteristics, 
and subjects were asked to select the best fit body fat distribution that described 
their body appearance adhered to most of their lives. 
Body fat distribution or type of adiposity has been described in words as follows: 
a. Apple shape: where your body fat is distributed mainly around your tummy 
area. 
b. Pear shape: where your body fat is distributed mainly on your hip and thigh. 
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c. Oval shape: where your body fat is distributed around your neck, your 
chest, your tummy area and also your thigh. 
d. Symmetric shape: where you are lean with no fat distribution around your 
body. 
5.3.1 Analysis 
5.3.1.1 Body shape and body shape changes from 20s to 40s 
The analysis included 1934 cases and 2050 controls. Data of ordinal score for 
body shape at age 20's, 30's, 40's and last 5 years collected were then cross 
tabulated for descriptive analysis and chi-square test. P for trend was also 
obtained for each decade of age. Data were then recoded into categories having 
and not having changes in body shape size. If there were changes, they are then 
recoded further in increasing or decreasing trend from age 20's to 40's. Last 5 
years' data were excluded in the trend of changes because of the vast differences 
in the age to describe last 5 years from age 40's to 70's. Trend of body shape 
changes were further analyzed into logistic regression modelling and adjusted for 
age and multivariate potential confounders. 
5.3.1.2 Body fat distribution 
The analysis was carried out in a smaller sample size. Only data collected from 
2007 onwards were included with 1343 cases and 817 controls. Body fat 
distribution data were analyzed descriptively. Chi-square test was performed to 
test the null hypothesis (no difference in distribution between case and control 
group). Further analysis of logistic regression modelling with age-adjusted and 
full multivariate potential confounders was carried out. 
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5.4 Results 
5.4.1 Body shape at 20's, 30'5,40'5 and last 5 years 
T bl 5 Oi t 'b ti f B d Sh t 20' fCC I G a e -1 5 rI U ono o IY ape a 5 or ase- ontro roup 
Group Total 
Shape 20's Control Case 
0/0 0/0 % 
1 51 44 95 
2.5% 2.3% 2.4% 
202 193 395 
2 9.9% 10.0% 9.9% 
485 454 939 3 
23.7% 23.5% 23.6% 
4 563 530 1093 
27.5% 27.4% 27.4% 
502 479 981 5 
24.5% 24.6% 24.8% 
6 148 155 303 
7.2% 8.0% 7.6% 
72 72 144 
7 3.6% 3.5% 3.7% 
23 5 28 8 
0.7% 1.1% 0.3% 
9 4 2 6 
0.2% 0.1% 0.2% 
Total 2050 1934 
3984 
100.0% 100.0% 100.0% 
Three-quarters of case and control group subjects reported their size of body 
shape that lies between 3 (thin) to 5 (medium). Chi-square p value of 0.14 did 
not reveal any statistically significant difference in body shape size distribution 
between case and control. Proportion of overweight and obese (body shape scale 
7 to 9) was approximately at 5%. 
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Table 5-2 Distribution of Body Shape at 30's for Case-Control Group 
Group 
Total 
Shape 30's Control Case 
0/0 0/0 0/0 
8 5 13 
1 
0.4% 0.3% 0.3% 
42 36 78 
2 
2.1% 1.9% 2.0% 
224 214 438 
3 
10.9% 11.1% 11.0% 
494 496 990 
4 
24.1% 25.6% 24.9% 
689 638 1327 
5 
33.7% 33.0% 33.3% 
392 367 759 
6 
19.1% 19.0% 19.1% 
153 156 309 
7 
7.5% 8.1% 7.8% 
41 22 63 
8 
2.0% 1.1% 1.6% 
4 0 4 
9 
0.2% 0.0% 0.1% 
2047 1934 3981 
Total 
100.0% 100.0% 100.0% 
Three-quarters of case and control subjects reported their size of body shape that 
lies between 4 to 6 (medium range). At p=0.217, chi-square test did not reveal 
any statistically significant difference in body shape size distribution between case 
and control. Proportion of overweight and obese (body shape scale 7 to 9) was 
also increased to approximately 9%. 
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Ta bl e 5-3 01 Ib I f d h str ut on 0 Bo IV S ape at 40 5 for Case-Control GrouD 
Group 
Total Shape 40's Control Case 
0/0 0/0 0/0 
2 1 3 
1 
0.1% 0.1% 0.1% 
10 
2 
11 21 
0.5% 0.6% 0.5% 
3 
79 58 137 
3.9% 3.0% 3.4% 
209 208 417 
4 
10.2% 10.8% 10.5% 
499 510 1009 
5 
24.4% 26.4% 25.4% 
605 576 1181 
6 
29.6% 29.9% 29.7% 
470 434 904 
7 
23.0% 22.5% 22.7% 
150 
8 
112 262 
7.3% 5.8% 6.6% 
22 19 41 
9 
1.1% 1.0% 1.0% 
Total 
2046 1929 3975 
100.0% 100.0% 100.0% 
Almost four-fifths of case and control subjects reported the size of body shape 
that lies between 5 (medium) to 7 (slight obese). The non significant Chi-square 
test of 0.418 suggested no difference in the body shape distribution at 40's 
among cases and control group. Proportion of overweight and obese (body shape 
scale 7 to 9) has increased further to approximately 30%. 
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Table 5-4 Distribution of Body Shape at last 5 years for Case-Control 
Group 
Shape during the last 5 
Group 
Total 
years Control Case 
0/0 0/0 0/0 
1 0 1 
1 
0.1% 0.0% 0.0% 
7 5 12 
2 
0.8% 0.4% 0.6% 
22 26 48 
3 
2.7% 1.9% 2.2% 
50 74 124 
4 
6.1% 5.5% 5.7% 
108 165 273 
5 
13.1% 12.2% 12.6% 
182 357 539 
6 
22.1% 26.5% 24.8% 
271 443 714 
7 
32.9% 32.8% 32.9% 
144 233 377 
8 
17.5% 17.3% 17.3% 
39 46 85 
9 
4.7% 3.4% 3.9% 
Total 
824 1349 2173 
100.0% 100.0% 100.0% 
Approximately 75% of case and control group subjects reported their size of body 
shape that lies between 6 (medium) to 8 (obese). Chi-square test showed p value 
of 0.155 which was not statistically significant. There was no difference in the 
body shape distribution at last 5 years among cases and controls. The proportion 
of overweight and obese (body shape scale 7 to 9) during the last 5 years was 
already slightly more than 50%. 
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S.4.2 Body shape changes between age 20's to 40's 
d h Table S-S Bo Iy 5 a, e Changes amonJl Case-Control Group 
Group 
Control Case Total 
Types of changes (Ofo) (Ofo) (Ofo) 
239 224 463 
No Change 11.7% 11.6% 11.7% 
39 24 63 
Decrease 1.9% 1.2% 1.6% 
1764 1677 3441 
Increase 86.4% 87.1% 86.7% 
2042 1925 3967 
Total 100.0% 100.0% 100.0% 
About 87% of subject had had their body shape size increase from their 20s 
through to 40s. The result of Chi-square test (p=0.246) suggested no differences 
in the proportion of body shape changes between case and control group. 
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Table 5-6 presents odds ratios of body shape changes and prostate cancer risk. 
No change of body shape was used as reference category. The point estimated 
risk in the fully adjusted model for decrease in body shape size from 20s to 40s is 
0.71 with 95% Cl 0.40-1.26 indicative of no association between decrease body 
shape size and prostate cancer risk. For increase in body shape size, point 
estimated risk is closed to 1 and confident interval also included 1 suggesting also 
no association between increase body shape size and prostate cancer risk. 
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Table 5-6 Logistic Regression Modelling for Body Shape changes and Prostate cancer Risk 
Body Shape 
changes Control Case 
No Change 239 224 
(11.7%) (11.6%) 
Decrease 39 24 
(1.9%) (1.2%) 
Increase 1764 1677 
(86.4%) (87.1%) 
aUnadjusted regression model 
bAge-adjusted regreSSion model 
Odds ratio· 
(95%CI) 
-Ref-
0.657 
(0.383-1.127) 
1.014 
(0.835-1.232) 
P Odds ratiob P Odds ratioC 
value- (950f0CI) valueb (950f0CI) 
- -Ref- - -Ref-
0.127 0.672 0.150 0.706 
(0.391-1.155) (0.396-1.262) 
0.886 1.030 0.768 1.076 
(0.848-1.251) (0.875-1.321) 
CMultivariate adjusted regression model for age, education, ethnic and family history of cancer 
P 
valuec 
-
0.240 
i 
0.488 I 
5.4.3 Body Fat Distribution 
Table 5-7 Types of Body Fat Distribution among Cases-Control Group 
Group Total 
Body fat distribution Control Case 
(Ofo) (Ofo) (Ofo) 
175 354 529 
Symmetric 
21.4% 26.4% 24.5% 
Apple 
507 740 1247 
62.1% 55.1% 57.7% 
17 52 69 
Pear 
2.1% 3.9% 3.2% 
Oval 
118 197 315 
14.4% 14.7% 14.6% 
817 1343 2160 
Total 
100.0% 100.0% 100.0% 
A quarter of subjects reported having a symmetrical body shape. Controls 
reported a higher percentage of apple shape as compared to cases (62.1% and 
55.1% respectively). The result of Chi-square test (p=O.002) shows a 
statistically significant difference in the distribution of body fat distribution 
between case and control groups. 
Table 5-8 presents estimated risks of different body shape and prostate cancer 
risk. A symmetrical body shape was used as reference category. Subjects with 
an 'apple' shape were at 30% risk reduction (OR in the fully adjusted model = 
0.689 with 95% CI 0.546-0.870). 'Pear' shape did not show any association with 
prostate cancer risk (OR = 1.382, 9S% CI 0.749-2.S49). Subjects with 'oval' 
shape also showed 27% risk reduction as compared to symmetrical body shape 
(OR = 0.731, 95% CI 0.S34-1.000) although at borderline of p=O.OSO. 
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Table 5-8 Regression Models of Body Fat Distribution on Prostate Cancer Risk 
Body fat Control case distribution 
Symmetric 175 354 (21.4%) (26.4%) 
Apple 507 740 (62.1%) (55.1%) 
Pear 17 52 (2.1%) (3.9%) 
Oval H8 197 (14.4%) (14.7%) 
aUnadjusted regression model 
bAge-adjusted regression model 
ORB p ORb P 
(950f0CI) valueB (95%CI) valueb 
-Ref-
-
-Ref- -
0.722 0.003 0.669 <0.001 (0.583-0.893) (0.537-0.833) 
1.512 0.160 1.599 0.120 (0.849-2.692) (0.884-2.889) 
0.825 0.196 0.77 0.087 (0.617-1.104) (0.571-1.039) 
-
-- .. _---------
CMultivariate adjusted regression model for age, education, ethnic and family history of cancer 
ORc p 
(95%CI) valuec 
-Ref- -
0.689 0.002 (0.546-0.870) 
1.382 0.300 (0.749-2.549) 
0.731 0.050 I (0.534-1.000 ) 
I 
5.5 Discussion 
5.5.1 Body shape at 20's 30's 40's and last 5 years 
Overall the age progression from 20's to 40's showed that men's body shape size 
increased from thin medium to medium obese (results are shown in Table 5-1 
page 5-87, Table 5-2 page 5-88, Table 5-3 page 5-89 and Table 5-4 page 5-90). 
The possible explanation for increase in body size is because of decreased 
metabolic rate with aging and accumulation over the years of unburned calorie 
intakes. Environmental factors such as eating high-fat foods or lack of exercise, 
as well as Sedentary Lifestyle Syndrome (SeDS) is to be blamed too (Wellman & 
Friedberg, 2002). 
We compared our results with the data obtained from Health Survey for England 
(2009), by taking into account the mean age of the study subjects of 59 years 
old. Comparison was made by looking back at prevalence data of overweight and 
obesity of relevant year. For example subjects reported data of body shape at 
age 40's (median age of 59 subtract by 45 =14 years backward) were compare 
with UK health survey data in 1995 .. The obesity (body shape 7 to 9) prevalence 
at age 40's is approximately 30% in our study (refer Table 5-3 page 5-89), but 
England data of overweight and obese in 1995 for age 35-44 and 45-54 were 
62.8% and 68.7% respectively (ONS, 2009). Similarly when last 5 years data is 
picked (refer Table 5-4 page 5-90), the data in our study showed obesity (body 
shape 7 to 9) prevalence at approximately 54%, but England data of 2005 to 
2009 for age 55 to 64 showed total obesity and obese prevalence between 76 to 
81 %. Our data seems to suggest a lower prevalence of overweight and obese 
compared to national survey data. 
The findings in this study showed that body shape size did not differ at age 20's, 
30's, 40's and last 5 years between cases and control. This finding agrees with 
some earlier studies on body size and prostate cancer risk. A multiracial cohort 
study of 2079 men of Kaiser Permanente Medical care programme In California 
USA by Habel, used body size measurement of height, weight, body mass index 
(BMI) found no association of body weight and BMI with prostate cancer risk and 
did not vary by decade of life Furthermore, other anthropometric measurements 
including sub scapular skin fold, posterior-anterior chest and abdomen diameters, 
transverse diameters of chest, bi-trochanteric and bi-iliac size and shoulder 
height did not reveal any association (Habel et ai, 2000). 
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Another cohort study by Lee et al. on 8922 men of Harvard Alumni Health Society 
using body mass index and waist girth as measurement for body size, also did not 
show any association with prostate cancer with obesity during middle age or 
older. When analyses were done examining BMI at college entry (age 18 most) 
to the association of prostate cancer development later in life also did not show 
any statistical significant findings (Lee et aI, 2001). 
An Australian case-control study by Giles et al. which investigated body mass 
index (BMI) and lean body mass at age 21, also found no statistically significant 
association with prostate cancer risk (Giles et aI, 2003a). Hack et al. in studying 
the association of BMI with aggressiveness of prostate cancer defined by Gleason 
score also did not show any significant statistical findings (Hack et aI, 2010). 
The fact that data was obtained by self report, recall bias should be taken into 
account when interpreted the results. The tendency is control subjects under-
reported levels of overweight or obesity and case subjects recalled more 
accurately or over re-ported. The application of pictorial illustration was to 
indicate change in body shape size throughout lifetime and not to absolute 
conversion to actual BMI or waist size In the measure of degree of obesity. It has 
been used before in some studies in studying the relationship of body size and 
prostate cancer (Glovannucci et aI, 1997). 
However, the use of pictorial illustrations in this study Is better for recalling the 
body size at earlier age because subjects do not normally or consistently weigh 
themselves or measure their waist and hip circumference, and even remember 
the figures later, but they will recall better in comparatively body shape size at 
different decades of life. 
5.5.2 Change of body shape 
The finding showed that almost 90% of both case and control subjects had 
history of changes in body shape. Our analysis also showed that the magnitude of 
changes of body shape from age 20's to 40's varies between individuals (result 
not shown here). Approximately 87% of those body shape changes were an 
increase in body size. The increase in body size is mostly due to environmental 
factors of diet and lifestyles behaviour, as well as reduced metabolic rate when 
aging. Leptin hormone may also play some roles. High levels of leptln are found 
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in obese persons. Leptin is released by white adipose tissues and its effect is an 
uninhibited hunger making obese people maintain their weight by keep eating 
(Mantzoros, 1999). 
The findings on estimated risk did not demonstrate any association between 
changes of body size and prostate cancer risk (Table 5-6 on page 5-93). These 
finding are in disagreement with most published studies that showed some 
relationship with prostate cancer (Hernandez et ai, 2009; Rapp et ai, 2008; 
Rodriguez et ai, 2007; Wright et ai, 2007). A possible explanation could be 
because the other studies used markers of measurements such as actual weight, 
BMI or waist circumference to indicate the change in body size, while our study 
use body shapes change. Furthermore, the other studies used multiple 
parameters to measure body size when trying to look at relationship with prostate 
cancer, therefore higher possibility of obtaining statistical significant findings in at 
least one of the measurement parameters. 
Secondly, there are many other factors that could confound the relationship of 
body shape changes and prostate cancer risk such as hormone. Leptin, a 
hormone produced by adipocytes in proportion to fat cell volume in the body, has 
been found to have correlation with body weight (Chang et ai, 2001) and those 
with higher leptin have increased risk of high volume (tumour size) prostate 
cancer at OR = 2.41 (1.16-5.01). 
The limitation of only looking at pictorial illustration is the inability of making the 
actual measurement of changes in body size in compared with usage of 
parameters such as weight, waist or hlp circumferences as well as BMI or body fat 
mass. The body shape although only shows the relativity of body size changes 
over the decades of life, are of more dependable based on recalling body shape in 
case-control studies, as numbers or figures if given may be more subjected to 
recall bias. Personal perception of body shape of each individual could introduce 
bias such as intention and classification bias. 
Cohort study is often used to obtain more valid data by measuring and recording 
body weight, waist/hip circumference, body fat mass, etc periodically. This 
procedure was not possible to Implement in this case-control study. Furthermore, 
some potential confounders need to be taken account or exclusion criteria need to 
be Introduced to subjects with certain conditions of endocrinal disease such hypo 
or hyperthyroidism and pituitary tumours. 
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5.5.3 Body fat distribution 
The cross-tabulation result showed that there were higher proportion of 'apple' 
type of body fat distribution among both cases and control (Table 5-7 on page 5-
94). This has been expected because 'apple' also known as 'android' type of fat 
disposition is most common in males where fat is concentrated over the abdomen 
or waist and chest area. It was also found in our study that 'apple' shape is more 
prevalent among control subjects at 62.1% in proportion compared to cases at 
55.1 %. The chi-squared test confirms the difference in the proportion between 
cases and control group. 
The author is not aware of any research done to see the prevalence of different 
types of body fat distribution in the population, however waist and chest 
circumference measurement in males are closest to describe whether one is 
'apple' shape or proxy of central adiposity (Wells et aI, 2007). Male shape seems 
to remain highly stable throughout adult life, therefore assumption can be made 
to suggest that characteristic of body fat distribution remains the same too. 
The results shown in the Table 5-8 page 5-95, suggested that subject with 'apple' 
shape where body fat is distributed mainly around tummy area, would have a 
reduction risk to prostate cancer at unadjusted OR = 0.722 (95%CI: 0.583-
0.893) when compared to those with 'symmetrical' shape. The Odds ratio for 
prostate cancer risk remained statistically significant even after adjusted for age, 
education, ethnic and family history of cancer at reduction risk of almost 30% 
(OR 0.689, 95%CI: 0.546-0.870). However, the 'pear' and 'oval' body shape did 
not show any statistically significant findings, although in the fully adjusted 
regression models showed that 'oval' shape had a borderline significance of 
reduced prostate cancer risk with odds ratio of 0.731 (95%CI: 0.534-1.000) 
when compared with those with 'symmetrical' shape. 
'Apple' body shape which corresponds with waist measures of abdominal fat, 
whereas hip circumference measures of subcutaneous fat or 'pear' shape. 
Measurement of waist circumference or hip circumference alone has been used 
before when trying to classify types of body fat distribution. 'Apple' body shape 
in true measurement would predict wider waist circumference (WC) or higher 
waist to hip ratio (WHR), which has been shown In studies using true 
measurement to increase risk in advanced or high grade prostate cancer (Jackson 
et aI, 2010; MacInnis et aI, 2003; Pischon et aI, 2008). 
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Our findings are unique in that none of the studies in the literature have used 
body shape as proxy measure of body fat distribution to describe its association 
with prostate cancer. The findings suggested that abdominal obesity maybe 
protective of prostate cancer. 
In this study, word descriptions in the questionnaire was used to capture the 
types of body fat distribution which is potentially less accurate than using a 3-
dimensional body shape scan as used in UK National Sizing survey (Wells et aI, 
2007), it is much cheaper than a costlier body scan. The accuracy of 3D body 
shape scan is higher, and the survey conducted in 2001 to 2002 in UK of cross-
sectional study over 9617 adults found that male body shape remained highly 
stable throughout adulthood. 
5.6 Conclusions and Recommendations 
An 'apple' body shape was associated with a reduced prostate cancer risk when 
compared to symmetrical shape. There is no difference in body size distribution at 
age 20's, 30's, 40's, and last 5 years between cases and controls. There is no 
association between body shape changes from 20s to 40s either increases or 
decrease of body size and prostate cancer risk. 
In future studies, it is recommended that records of endocrinal conditions should 
be included wherever possible in order to strengthen the exclusion criteria. 
Biomarkers indicative of any hormones related to obesity would also strengthen 
the findings. 
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Chapter 6 Chronic Diseases 
6.1 Literature Review 
6.1.1 Diabetes Mellitus and Prostate Cancer 
Diabetes Mellitus is a condition characterized by a group of heterogenous 
disorders with common elements of hyperglycemias and glucose intolerance due 
to insulin resistance or deficiency (lOF, 2006). A growing number of studies have 
identified a reduction or decreased risk of prostate cancer in men with diabetes 
mellitus. 
In particular, several studies have Identified diabetes mellitus as protective 
against the risk of prostate cancer in men through the approach of case control 
study (Baradaran et ai, 2009; Coker et ai, 2004; Gong et aI, 2006; Pou rmand et 
aI, 2007; Zhu etal, 2004) and cohort studies (Calton etal, 2007; Darbinian etal, 
2008; Kasper et ai, 2009; Leitzmann et aI, 2008; Rodriguez et aI, 2005; Waters 
et aI, 2009; Weiderpass et aI, 2002). Meta-analysis by Kasper & Glovanucci and 
Bonovas also showed an overall protective risk to prostatic cancer for men with 
diabetes (Bonovas et aI, 2004; Kasper & Giovannucci, 2006). 
A case-control study by Coker obtained adjusted odds ratio of 0.64 (95%Cl: 
0.45-0.91) and reported higher protection for those with diabetes and 
complications with adjusted OR of 0.61 (95%CI: 0.42-0.90), also African-
american men at adjusted OR of 0.36 (95%Cl: 0.21-0.62) (Coker et aI, 2004). 
Gong study focused the different grades of prostate cancer and showed diabetics 
had 47% reduction risk to low grade prostate cancer (Gleason score ~ 7 ) ) and 
28% reduced risk for high grade prostate cancer (Gleason score ~ 8 ) ) (Gong et aI, 
2006). 
However, there were some published studies which showed no significant 
association between prostate cancer and diabetes mellitus (Chan et ai, 2005b; 
Gallus et aI, 2007; Li et aI, 2010; Pierce et ai, 2008; Tavanl et aI, 200Sb; 
Wallstrom et ai, 2009; Will et ai, 1999). 
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Despite inconsistent evidence, some researchers have attempted to look at the 
possibility of anti-diabetic medication as the reason for the decreased risk of 
prostate cancer among diabetics. GonzaleZ-Perez and G. Rodriguez found that 
only treated diabetes showed significant reduction in prostate cancer risk and 
possibly due to insulin or sulphonylureas (Rodriguez et a', 2005). A specific study 
on the association of metformin usage in diabetics to the risk of prostate cancer 
reported a borderline significant decreased risk (Wright & Stanford, 2009). 
In another study, significant decreased odds ratio of prostate cancer risk were 
observed even when different types of anti-diabetic medications were taken, 
suggesting that diabetic status is the reason behind the protective event, not 
certain diabetic medication (Murtola et a', 2008). 
Some biological mechanisms have been proposed suggesting that diabetic men 
have lower androgen and growth factors such as Insulin, Insulin-like Growth 
Factor 1 (IGF-1), Insulin-like Growth Factor binding protein 3 (IGFBP-3), leptln, 
etc., therefore resulting in lower risk to prostate cancer (Giovannucci & Michaud, 
2007; Hsing et aI, 2001; Kasper et a', 2008; Stattin et a', 2000; Tavanl et aI, 
2002). 
Since diabetes mellitus seem to cause systemic microvascular abnormalities 
causing complications such as retinal blindness, there are hypotheses that this 
dysfunction can result in prostate ischaemia which in turn prevent the 
development of prostate cancer at the initiation phase through inhibition of 
angiogenesis, a similar mechanism to S-Alpha-reductase inhibitors such as 
Finasteride suggesting local Ischaemia may prevent prostate cancer initiation 
(Pareek et aI, 2003; Thompson et aI, 2009; Zhang & Hu, 2010). 
&.1.2 Hypertension and Prostate Cancer 
Hypertension commonly known as high blood pressure Is a condition when the 
systolic or diastolic blood pressure reading is above of normal values. In adult 
the normal average blood pressure Is 120/80 millimetre mercury (mmHg). A 
systolic and diastolic blood pressure reading of above 140 and 90 respectively 
would be considered as high blood pressure or hypertensive. In 1977, the First 
Joint National Committee (JNC) on Detection, Evaluation, and Treatment of High 
Blood Pressure established guidelines for management, Introduced the stepped-
care approach to hypertension treatment. In the latest development in the year 
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2003, the 7th JNC meeting has recommended the classification of pre-
hypertension if systolic and diastolic blood pressure of 120-139 and 80-89 Hg 
respectively. Stage I Hypertension, systolic and diastolic blood pressure are 140-
159 and 90-99 respectively and Stage II Hypertension as equal or more than 160 
and 100 mmHg for systolic and diastolic blood pressure respectively (Moser). The 
Health Survey for England data from Department of Health, in 2001 showed the 
prevalence of 16 years old and above males with high blood pressure was 8% 
(treated). The rate could rise to 29% if untreated individuals are included (ONS, 
2001). 
Evidence on hypertension being associated with prostate cancer has been 
inconsistent. Data from Cardiovascular Health Studies in US followed those age 
65 and above showed hypertension is not associated with prostate cancer, 
however the usage of anti-hypertensive medication was associated with reduced 
hazard ratio to 0.7 (CI: 0.5-0.9) (Fitzpatrick et aI, 2001). A case control study by 
Weinmann also found no association between hypertension and prostate cancer 
(Weinmann et aI, 2010). 
A Norwegian cohort study called CONOR showed a statistically significant trend of 
increase hazard ratio for prostate cancer with the increase systolic and diastolic 
blood pressure (Martin et ai, 2010). Increasing systoliC pressure also showed a 
significant trend for increase hazard ratio towards advanced prostate cancer. 
In another study using Swedish construction workers cohort, showed 
hypertension associated with reduced relative risk for prostate cancer. A 
significant trend was observed for higher systolic blood pressure aSSOCiated with 
reduced incident of prostate cancer (Stocks et ai, 2010). 
Although the actual mechanism of how hypertension is related to prostate cancer 
is not fully known, several hypotheses have been described. Gann hypothesized 
that if high blood pressure is due to increased central sympathetic tone, which 
also causes increased in adrenergic activity In human body, subsequently 
neurotrophins in the prostate, leading to androgen-mediated stimulation involving 
Nerve growth-like factor (NGF) peptide, Epidermal growth factor (EGF) and 
Insulin growth-like factor 1 (IGF-1), to cause prostate cancer growth (Gann et ai, 
1995). McCarty suggested that increase in blood pressure would down regulate 
IGF Binding protein-1 (IGFBP1), which caused higher IGF-I activity and in turn 
prostate cancer growth (McCarty, 1997), as previous studies meta-analysis by 
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Rowlands had shown that circulating IGF-I is positively aSSOCiated with prostate 
cancer risk (Rowlands et ai, 2009). 
However, detection bias is a concern and cannot be ruled out as all chronic 
diseases patients are under regular follow up by their general practitioner (GP), 
therefore are more likely to get screened for other diseases such prostate-specific 
antigen (PSA) testing (Martin et ai, 2010) compared to those without treatment 
for hypertenSion as such. 
6.1.3 Hypercholesterolemia and Prostate Cancer 
Hypercholesterolemia refers to increased or elevated levels of cholesterol. The 
usual test is to do fasting blood lipid profile and normally also measure 
biochemistry three cholesterol levels namely low density lipoprotein (LDL), high 
density lipoprotein (HDL) and total cholesterol. For the purpose of clinical 
management of patients, all three readings would be taken into account, however 
the normal diagnosis of high cholesterol or hypercholesterolaemia is based on the 
total cholesterol reading. Some of the known causes of hypercholesterolemia 
include familial hypercholesterolemia or genetic causes, abnormality in cholesterol 
metabolism, diet high intake of saturated fatty acids, and secondary causes such 
as hypothyroidism (Grundy & Vega, 1990). 
A normal or desirable total cholesterol level is defined as less than 200 mg of 
cholesterol per deciliter of blood (mg/dL) or 5.1 millimoles cholesterol per litre 
blood (mmol/I). Blood cholesterol is considered to be borderline high if in the 
range of 200 to 239 mg/dL (or 5.1 to 6.1 mmol/I). A total cholesterol level of 240 
mg/dL (6.2 mmol/I) or above is considered elevated or high. 
The National Institute for Health and Clinical Excellence (NICE) and Department 
of Health, UK, cholesterol guidelines uses normal total cholesterol as less than 
5.0mmol/l and LDL cholesterol as less than 3.0mmol/l. Whereas the Joint British 
Societies (a group of the main UK expert societies involved in cardiovascular 
disease) recommend different cholesterol limits for people who have, or are at 
risk of, coronary heart disease of normal total cholesterol of less than 4.0mmol/l 
and LDL cholesterol less than 2.0mmol/l. 
No data is available for prevalence of hypercholesterolemia in the UK, but the 
Centers for Disease Control and Prevention with US National Centre for Health 
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Statistics (2010) estimated that between the year 2005 to 2008, an average 
14.9% (13.4% and 16.0% for men and women respectively) of USA adult 
population has high total cholesterol or have total cholesterol level of 240mg/dl 
and above (CDC, 2010). 
Hypercholesterolemia study alone on its association with prostate cancer in case-
control study of 312 hospital cases and 319 primary care controls showed 
increased risk at adjusted odds ratio 1.58(CI: 1.11-2.24) (Magura et aI, 2008). 
Magura also revealed low HDL and high LDL increased the risk to prostate cancer 
at OR 1.57 (CI: 1.04-2.36) and 1.60 (CI: 1.09-2.34) respectively. 
Another hospital case-control study looking at possibility of differential effects of 
age, found OR= 1.51 (95%CI: 1.23-1.85) especially stronger in older age ~ ~ 65 
years at OR1.80 (95%CI: 1.34-2.40)(Bravi et aI, 2006). 
A study by Colli & Amling using data 1992 to 2000 from National Vital statistics 
system of Centers for Disease Control and Prevention in USA showed high 
cholesterol levels were aSSOCiated with lower prostate cancer mortality rates 
when statin use was high. With low statin use, there is no effect (Colli & Amling, 
2009). 
A different aspect in looking at grades of prostate cancer using Gleason score in a 
cohort study, the Prostate Cancer Prevention Trial between 1993 to 1996, showed 
those with lower blood serum cholesterol level or normal at ,S,200mg/dl have 
reduced risk for high grade prostate cancer (Gleason score 8-10) at OR=0.41 
(95%CI: 0.22-0.77), compared to those with elevated blood cholesterol. No clear 
association was seen in overall prostate cancer or In other lower grades, in 
relation to cholesterol level (Platz et ai, 2009). 
The mechanism underlying the association between hypercholesterolemia and 
prostate cancer is still unknown but possibility the association is only true for high 
grade or late diagnosed prostate cancer. 
6.1.4 Ischaemic Heart Diseases and Prostate Cancer 
Ischaemic Heart Diseases can be defined as any of a group of acute or chronic 
cardiac conditions resulting from insufficient supply of oxygenated blood to the 
heart. It is most synonymous with coronary artery disease and would be 
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diagnosed by clinicians through signs & symptoms, physical examination but 
confirmed through test of electrocardiogram (ECG), echocardiogram, stress test 
and other extra investigations such as computerized tomography (CT) scan. The 
prevalence of treated coronary heart disease for Wales & England 1998 among 
men was 37.2 per 1000 males which has been on a rising trend (ONS, 1998c). 
There are not many studies investigating the relationship between coronary 
artery disease and prostate cancer possibly because there was no immediate 
biologically plausible reason. However smoking has a high association with 
coronary heart disease and could be a confounder when studying the relationship 
between coronary heart disease and prostate cancer risk. 
A hospital based case-control study with Benign Prostatic Hypertrophy (BPH) as 
controls by Neugut showed adjusted prostate cancer odds ratio of OR=2.00 
(95%CI: 1.18-3.39) associated to coronary artery disease, however when further 
stratified to age group of 69 below and 70 or above was not statistically 
significant (Neugut et ai, 1998). 
A study by Stamatiou on coronary artery disease and histological prostate cancer 
autopsy in a case-control design, showed a statistically significant relationship of 
severity of coronary artery disease and prostate cancer risk (Stamatiou et ai, 
2007). The more severe types (IV-VI) of coronary artery disease had higher 
prostate cancer risk. However a nested case-control study by Driver provided a 
reverse result and showed that coronary artery disease provided a protective risk 
to prostate cancer at OR 0.72 (eI: 0.62-0.84) (Driver et ai, 2010). 
6.2 Aims 
The aim of this chapter is to look at the common chronic diseases in man and 
their association with prostate cancer risk. 
The specific aims are to look at prostate cancer risk in: 
i. Diabetes Mellitus 
ii. Hypertension or high blood pressure 
iii. Hypercholesterolemia or elevated blood cholesterol 
iv. Ischaemic heart disease or coronary artery disease 
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6.3 Methods 
Data was obtained through questionnaire. The questionnaire enquired: 
"Have you ever been told by doctor that you have/had any of the following 
conditions? Please state Yes/No and age at diagnosis of the conditions. 
; Diabetes 
i Heart Disease 
; Hypercholesterolaemia (high blood cholesterol) 
; High blood pressure 
; Other please specify ......... . 
The respondents would be considered as having the condition(s) of the listed 
chronic diseases or other as stated 'yes' in the questionnaire based on their 
knowledge of being told by the doctor(s) who has seen them. The age of when 
they were first told to have such condition(s) is the age at diagnOSis. 
No other record was used. 
6.4 Analysis 
In order to obtain the valid temporal relationship between the chronic disease 
condition and prostate cancer, we ensured among the respondents who answered 
'Yes' in having the condition in the questionnaire, by only qualifying those who 
had the condition prior to prostate cancer diagnosis were considered as valid 
'yes'. This was rectified by comparing the year of diagnosis of the prostate cancer 
(cytology confirmation) provided by hospital registry to the self reported 
datejyear of being diagnosed with diabetes, hypertension, ischaemic heart 
disease or hypercholesterolemia. In essence, year of onset chronic disease(s) 
must be prior to year of prostate cancer diagnosis in cases or in receiving 
questionnaire in controls. 
After this verification process, each subject was then put into different categories 
according to duration. Three aspects of categorizing the disease status (yes/no 
answer) were based on having or not having the condition, having the disease for 
5 years or more (before prostate cancer diagnosis) and lastly 10 years or more. 
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Only subjects from Phase II filled in the data on chronic diseases. Data from 
questionnaire have been entered into the Microsoft Access then the data on 
chronic diseases were extracted into Microsoft Excel for data cleaning and further 
classification before entered to SPSS vs 17.0 for statistical analysis using Chi-
square test, univariate binomial logistic regreSSion, followed by age-adjusted 
modelling of binomial logistic regression and further model adjustment using 
statistically significant demographic factors in the multivariate analysis and a 
priori confounders to obtain odds ratios (OR) and 95% confidence interval (95% 
CI). 
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6.5 Results 
6.5.1 Diabetes Mellitus (DM) 
Table 6-1 Cross-tabulation Diabetes Mellitus and Case-Control Groups 
DM DM 5 Years or DM 10 Years or 
more more 
Status Case Control Case Control Case Control 
(%) (010) (010) (010) (%) (%) 
68 66 31 46 17 27 
Yes 5.7% 9.4% 2.6% 6.6% 1.4% 3.9% 
1124 633 1161 653 1175 672 
No 94.3% 90.6% 97.4% 93.4% 98.6% 96.1% 
1192 699 1192 699 1192 699 
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
There were statistically significant differences in the diabetes mellitus proportions 
between cases and control at p=0.002, with controls reporting more diabetes 
mellitus (9.4% as opposed to 5.7%). 
Table 6-2 (page 6-110) showed self reported DM status. The result showed that 
after adjustment for age, the relationship remained significant at p value 0.010 
with the reduced prostate cancer risk of 38% among diabetics. However upon 
further adjustment of education, ethnic and family history of cancer, the 
aSSOCiation became not statistically significant at borderline p value level 
(p=0.056). 
Subjects who reported having had diabetes mellitus for a period of 5 years or 
more before prostate cancer diagnosis for cases or before control subjects 
enrolled this study showed a statistically Significant risk reduction towards 
prostate cancer among them at OR=0.379 (95%Cl: 0.238-0.604), 0.435 
(95%CI: 0.270-0.700) and 0.452 (95%CI: 0.272-0.753) of unadjusted, age-
adjusted and fully adjusted models respectively. 
Similar findings showed that for those who had been diabetic for 10 years or 
more, had statistically significant protective risk towards prostate cancer 
compared to those who are non-diabetic or had diabetes mellitus less than 10 
years duration (refer Table 6-2 page 6-110). 
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Table 6-2 Odds Ratio (OR) and Confidence Interval for Univariate/Unadjusted and Adjusted Regression models for 
Diabetes Mellitus and Prostate Cancer Risk 
Types of Control Case Odds ratio, P Adjusted p Adjusted 
Analysis n=699 n=1192 OR- value - ORb valueb ORc 
Classification No Yes No Yes (950f0CI) (95%CI) (950f0CI) 
n=1891 
Diabetes 633 66 1124 68 0.580 0.002 0.620 0.010 0.687 
Mellitus status (0.408-0.825) ( 0.432-0.890) (0.468-1.010) 
Diabetes M 5Y 653 46 1161 31 0.379 <0.001 0.435 0.001 0.452 
or more (0.238-0.604 ) (0.270-0.700) (0.272-0.753) 
Diabetes M 672 27 1175 17 0.360 0.001 0.440 0.011 0.442 
lOY or more (0.195-0.666 ) (0.235-0.826) (0.225-0.869) 
- _.- _.-
- - - -- - --
o aUnadjusted Regression Models 
bAdjusted Regression Models for age 
(Multivariate Adjusted Regression Models for age, education, ethnic and family history of cancer 
p 
valuec 
0.056 
: 
0.002 I 
0.018 
--
6.5.2 Hypertension (HPT) 
Ta bl 63 C e 
-
b I j ross-ta u at on H vpertenslon an dC ase-Contro Groups 
HPT HPT 5 Years or HPT 10 Years or 
more more 
Status Case Control Case Control Case Control 
(Ofo) (Ofo) (Ofo) (Ofo) (Ofo) (Ofo) 
416 298 285 207 153 130 Yes 17.5% 33.5% 40.1% 22.9% 27.9% 12.3% 
827 445 958 536 1090 613 
No 87.7% 82.5% 66.5% 59.9% 77.1% 72.1% 
1243 743 1243 743 1243 743 
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
The distribution of hypertension showed that there was a higher proportion of 
hypertension among controls (40.1%) as compared to cases (33.5%). Chi-square 
test showed statistically significant at p=0.003 (refer Table 6-3 page 6-111) 
Hypertension appeared to reduce risk for prostate cancer at odd ratios of 0.751 
(95%CI: 0.622-0.907), 0.770 (95%CI: 0.626-0.948) and 0.662 (95%CI: 0.513-
0.853) in unadjusted models of hypertensive status, hypertensive for 5 years or 
more, and hypertensive for 10 years or more respectively (refer Table 6-4 page 
6-112). In age adjusted and fully adjusted models, prostate cancer risks are no 
longer statistically significant with all confidence intervals include 1. 
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Table 6-4 Odds Ratio (OR) and Confidence Interval for Univariate/Unadjusted and Adjusted Regression models for 
HVDertension and Prostate Cancer Risk 
-- -- --------- ---
- - - - -- - - - - - - -
Types of Control Case 
Analysis n=743 n=1243 Odds ratio, P Adjusted p Adjusted p 
Classification OR- valueB ORb valueb OR
c 
valuec 
n=1986 No Yes No Yes (95%CI) (95%CI) (95%CI) 
Hypertension 445 298 827 416 0.751 0.003 0.841 0.080 0.854 0.129 
status (0.622-0.907) (0.693-1.021) (0.696-1.047) 
Hypertension 536 207 958 285 0.770 0.014 0.874 0.219 0.900 0.359 5Y or more (0.626-0.948) (0.705-1.083) (0.719-1.127) 
Hypertension 613 130 1090 153 0.662 0.001 0.797 0.091 0.804 0.120 lOY or more (0.513-0.853) (0.613-1.037) (0.610-1.059) 
aUnadjusted Regression Models 
0'1 bAdjusted Regression Models for age 
~ ~ CMultivariate Adjusted Regression Models for age, education, ethnic and family history of cancer 
.... 
IV 
6.5.3 Hypercholesterolemia (HCL) 
Table 6-5 Cross-tabulation Hypercholesterolemia (HCL) and Case-Control 
G rouDs 
HCL HCL 5 Years or HCL 10 Years or 
more more 
Status Case Control Case Control Case Control 
(0J0) (0J0) (0J0) (Ofo) (0J0) (0J0) 
315 232 183 150 88 75 
Yes 26.3% 32.4% 15.3% 21.0% 7.3% 10.5% 
884 483 1016 565 1111 640 
No 73.7% 67.6% 84.7% 79.0% 92.7% 89.5% 
1199 715 1199 715 1199 715 
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
There was a higher proportion of hypercholesterolemia among the controls 
(32.4%) as compared to cases (26.3%) (Refer Table 6-5 page 6-113). Chl-
square test of p=0.004 showed a statistically significant difference. 
Univariate analysis revealed a significant statistical association between prostate 
cancer and hypercholesterolemia, with a reduced risk of cancer among those with 
the hypercholesterolemia (OR=0.742, 95%C.I: 0.606-0.908). These findings of 
prostate cancer risks were similar when analyses were conducted on those having 
hypercholesterolemia of 5 years or more and 10 years or more, of approximately 
33% reduction in risks (refer Table 6-6 page 6-114). The age adjusted 
regression models were only statistical significant for overall 
hypercholesterolemia and those of 5 years and 10 years or more group at 
OR=0.800 (95%CI: 0.649-0.984) and 0.766 (95%CI: 0.599-0.979) respectively. 
However the multivariate adjusted models showed non-statistically significant OR 
for hypercholesterolemia condition at 5 years and 10 years or more. 
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Table 6-6 Odds Ratio (OR) and Confidence Interval for Univariate/Unadjusted and Adjusted Regression models for 
(J\ 
I 
.. 
. --- - -- - - ----
.. 
Types of Control 
Analysis n=715 
Classification No Yes 
n=1914 
HCL status 483 232 
HCL 5Yor 565 150 
more 
HCL lOY or 
more 
640 75 
.. 
~ ~ aUnadjusted RegreSSion Models 
~ ~ bAdjusted Regression Models for age 
. . 
- - - -- -- --. --
Case Odds ratio, Adjusted 
n=1199 ORB P ORb P 
No Yes (95%CI) value
B 
(95%CJ) value
b 
884 315 0.742 0.004 0.800 0.035 (0.606-0.908) (0.649-0.984 ) 
1016 183 0.678 0.001 0.766 0.033 (0.534-0.862) (0.599-0.979) 
1111 88 0.676 0.017 0.780 0.141 (0.489-0.934) (0.560-1.086) 
CMultivariate Adjusted Regression Models for age, education, ethnic, family history of cancer and statin status 
Adjusted 
ORc P 
(95%CJ) value
c 
0.979 0.877 
(0.745-1.286) 
0.879 0.377 
(0.660-1.170) 
0.900 0.569 
(0.628-1.292) 
6.5.4Ischaemic Heart Diseases (IHD) 
Table 6-7 Cross-tabulation Ischaemic Heart Diseases and Case-Control 
G rOUDS 
IHD IHD 5 Years or IHD 10 Years or 
more more 
Status Case Control Case Control Case Control 
(%) (%) (%) (%) (%) (%) 
95 76 70 60 40 38 Yes 
8.1% 8.7% 3,4% 5.5% 11.0% 6.0% 
1081 615 1106 631 1136 653 
No 
96.6% 94.5% 91.9% 89.0% 94.0% 91.3% 
1176 691 1176 691 1176 691 Total 
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
Ischaemic heart disease was higher among controls as compared to cases (11.0% 
among controls and 8.1% among cases). Chi-square test showed statistical 
significant difference at p=0.035 
Univariate analysis showed a statistically significant prostate cancer risk reduction 
among those with ischaemic heart disease of 5 years or more, and also 10 years 
or more, at OR::0.711 (95%CI: 0.518-0.977), 0.666 (95%CI: 0,465-0.953), and 
0.605 (95%CI: 0.384-0.953) respectively (refer Table 6-8 page 6-116). Upon 
adjustment of regression models using age alone and then with fully multivariate 
adjusted potential confounders variables (including smoking status), the 
relationship between prostate cancer risk and ischaemic heart disease became 
non-statistical significant. 
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Table 6-8 Odds Ratio (OR) and Confidence Interval for Univariatel Unadjusted and Adjusted Regression models for Ischaemic 
Heart Diseases IHD} and Prostate Cancer Risk 
Types of Control 
Analysis n=691 
Classification 
n=1867 No Yes 
IHD status 615 76 
IHD 5Yor 
more 
631 60 
IHD lOY or 
more 
653 38 
aUnadjusted Regression Models 
bAdjusted Regression Models for age 
Case 
n=1176 
No Yes 
1081 95 
1106 70 
1136 40 
Odds ratio, Adjusted Adjusted 
OR· P ORb P ORc 
value· valueb (950f0CI) (950f0CI) (950f0CI) 
0.711 0.035 0.848 0.323 0.906 
(0.518-0.977) (0.611-1.176) (0.638-1.288) 
0.666 0.025 0.814 0.276 0.843 
(0.465-0.953) (0.563-1.179) (0.566-1.255) 
0.605 0.029 0.796 0.341 0.770 
(0.384-0.953) 
____ ~ 0 . 4 9 8 - 1 . _ 2 7 3 ) ) (0.465-1.273) 
CMultivariate Adjusted Regression Models for age, education, ethnic, family history of cancer and smoking status 
P 
valuec 
0.584 
0.399 
0.308 
~ ~
6.6 Discussion 
6.6.1 Diabetes Mellitus (OM) 
To obtain the temporal relationship of chronic diseases such as diabetes mellitus 
and the risk developing prostate cancer, the self reported data were used and 
were censored to ensure only diabetes that existed before prostate cancer 
diagnosis were Included in the analyses. 
The proportion of diabetes mellitus is higher among controls (9.4%) as compared 
to cases (5.7%) (Refer Table 6-1, page 6-109). This pattern remains for those 
with a history of diabetes of 5 years or more and also diabetes of 10 years or 
more. When compared to data from England and Wales 1994-1998, on average, 
males age standardized was 9.9 per 1000 population (or 0.99%) which is much 
lower compared to the study figure, even if looking at specific age group age 55-
64 and 65-74, the England & Wales average was 28.7 and 42.3 per 1000 males 
or equivalent to 2.87% and 4.23% respectively (ONS, 1998a), these figures are 
still lower than study figures when mean age of phase II subjects' was used 
mean age 62.42 with standard deviation of 6.26 years). 
The findings in univariate logistic regression and adjusted models for age showed 
statistically significant reduced odds ratiO. On the fully adjusted models, the 
regression analysis result showed borderline statistically significant of having 
diabetes to reduce prostate cancer risk at p=0.056 of OR=O.687 (95%CI: 0.468-
1.010) (refer Table 6-2 page 6-110). However if subjects reported having had 
diabetes for a duration of 5 years or more, and 10 years or more, the risk for 
prostate cancer were reduced by 45.2% and 44.2% respectively. The protective 
risk In this present study appears to be higher than most cohort and case-control 
studies. 
These findings may suggest that chronic diabetes may act via a mechanism of 
lower androgen and growth factor levels such as Insulin, IGF-l, IGFBP-3 thus 
could have protective effect against prostate cancer. 
The finding of borderline significant risk reduction when timing of being diabetic 
was not taking into account could be partly due to possibility of lack of 
consistency In temporal relationship. Some prostate cancer may exist before 
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diabetes status, therefore it is possible the new diabetics (of only few years) 
could have cause a non-significant protective relationship towards prostate cancer 
and diluted the overall effect of diabetes status when analyzed subjects with or 
without diabetes. To be able to confirm diabetes mellitus offers a protection 
against prostate cancer, the former would have to exist before the latter. 
Similarly may be said of diabetes mellitus, which were not diagnosed earlier 
because, no routine medical screening or health check-up. The condition could 
have existed many years before the onset of carcinogenesis of prostate cancer, 
resulting loss years of documentation prior to prostate cancer diagnosis. 
The findings of diabetes of 5 years or longer duration were of similar to most 
studies. These studies suggested that diabetes mellitus condition has a 
protective action against prostate cancer. Diabetes was also associated with 
prostate cancer reduction of late stage tumours (Gong et ai, 2006; Zhu et ai, 
2004). 
At the molecular level, evidence was established through the link between genes 
in diabetes and prostate cancer. The study on HFF1B genes revealed SNPs 
rs11649743, rs4430796 and rs7501939 were association with reduced risk to 
prostate cancer but increased risk to diabetes mellitus. The JAZFl SNPs 
rs6968704 and rs10486567 were associated with reduced risk In prostate cancer, 
but relationship with diabetes was not established (Stevens et ai, 2010). 
One limitation in this study is the likelihood of under-diagnosed of diabetes 
mellitus or prostate cancer among the control subjects. Diabetes can be of two 
types therefore could mean Diabetes mellitus type I or type II. No differentiation 
was made in this study. Although type I diabetes Is hereditary and possibly 
triggered by Infection, there Is also an Influence of lifestyle behaviour. Similarly 
type II diabetes could have familial or genetiC relationship, but lifestyle is stili the 
most common associated risk for developing full blown diabetes mellitus. 
6.6.2 Hypertension 
The results displayed In Table 6-3 page 6-111 on hypertenSion status showed a 
higher proportion of hypertenSion among the control subjects as compared to 
cases at 40.1% and 33.5% respectively. When compared with England Wales 
1998 Data, our hypertensive prevalence Is much higher as theirs average age-
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standardized in 1998 was 2.83%, for specific age group 55-64, 65-74, 75-84 was 
7.34%, 11.5% and 13.1% respectively (ONS, 1998b). Subsequent Chi-square 
test detected a statistically significant difference in the proportion of hypertension 
between case and control group. 
Regression modelling analysis showed reduction in prostate cancer risk among 
those who have history of overall hypertension, of 5 years or more, and in 10 
years or more (refer Table 6-4 page 6-112). Both regression models adjusted for 
age and fully adjusted for age, education, ethnic and family history of cancer 
showed non-statistically significant protective risk against prostate cancer among 
those who were of hypertensive status, hypertensive for 5 years or more, and 
hypertensive for 10 years or more. 
Previous studies investigating the aSSOCiation of hypertension and prostate cancer 
have also shown non-statistically significant findings such as in Fitzpatrick and 
Weinmann (Fitzpatrick et aI, 2001; Weinmann et aI, 2010). 
Among the limitations of this study is the lack of medical record to confirm 
hypertensive diagnosis. Since true hypertension can only be diagnosed through 
several follow up readings by health professionals over weeks or months, any 
reading of hypertensive or high blood pressure based on one reading cannot rule 
out or rule in as hypertensive. Furthermore, measurement of blood pressure was 
not conducted in this study. Detection bias is also a possibility. 
Some studies have looked at the type of hypertension either of systolic 
hypertension which is more commonly diagnosed among elderly subjects or at 
both high systolic & diastolic blood pressure readings. Due to this study not 
taking any blood pressure readings or Information on hypertensive medication, 
such stratified analysis could not be carried out. 
6.6.3 Hypercholesterolemia 
From the cross-tabulation display for hypercholesterolemia of overall, 5 years or 
more and 10 years or more, the controls appeared to show higher proportion of 
history of hypercholesterolemia compared to cases (refer Table 6-5 page 6-113). 
The univariate logistic regression modelling analysis showed that having 
hypercholesterolemia (regardless of duration), having it for 5 years or more and 
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10 years or more were protective against prostate cancer at approximately 
25.6%, 32.8% and 33.4% respectively with all confidence intervals include 1 
(Refer Table 6-6 page 6-114). Upon adjustment for age, only those who have 
hypercholesterolemia overall and of 5 years or more had statistically significant 
protective risk against prostate cancer at approximately 20.0% and 23.4% 
respectively. Whereas upon fully adjusted regression model (controlled for age, 
education, ethniC, family history of cancer and statin use), none of the 
hypercholesterolemia categories were statistically significant. 
The study findings indicate that chronic hypercholesterolemia does not associate 
with prostate cancer risk. 
The usage of cholesterol reducing drugs or treatments among those who reported 
having had hypercholesterolemia could interfere with the actual level of 
cholesterol in the blood, but this cannot be validated as we do not have any 
record of blood/serum cholesterol level at any time of the study subjects. One 
previous study by Colli & Amling appeared to show similar protective risk that 
high cholesterol levels were associated with lower prostate cancer mortality rates 
when statin use was high but not in low dose (Colli & Amling, 2009). This clearly 
indicates there might not be a clear protective risk of having 
hypercholesterolemia towards prostate cancer. Instead statin may be reducing 
prostate cancer mortality rates. 
One of the previous studies by Magura showed the association of 
hypercholesterolemia as hazardous risk to prostate cancer with adjusted OR= 1.58 
(95%CI: 1.11-2.24) (Magura et ai, 2008). The results of further stratified for low 
HDL and high LDL posted increased risk for prostate cancer at OR 1.57 (95%CI: 
1.04-2.36) and 1.60 (95%CI: 1.09-2.34). 
Some limitations found in this study is the possible influence of statin over the 
association between hypercholesterolemia and prostate cancer. Secondly there 
was no documentation of the actual measuring level of cholesterol of the subjects 
over the years, it was presumed that when a subject was informed by the 
healthcare personnel that he has high cholesterol level, the status maintain for 
the person to keep having raised cholesterol level even if lowering cholesterol 
medication were to control the level. 
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Thirdly, it would most useful if measurement were recorded in patients' records if 
available at different period of time for further stratification to look at whether 
different levels of total cholesterol levels for the p-trend, and types of cholesterol 
of good and bad such as HDL and LDL have any association towards prostate 
cancer risks. 
6.6.4 Ischaemic Heart Disease (IHD) 
The ischaemic heart disease rate was higher among control subjects compared to 
prostate cancer cases at 8.1% and 11.0% respectively (refer Table 6-7 page 6-
115). This prevalence figures are comparable with data from England & Wales 
1998 both on average and specific age group. The 1998 England & Wales at age 
group of 55-64, 65-74 and 75-84 had prevalence of males coronary artery 
disease of 9.5%, 18.4% and 23.1% respectively (ONS, 1998c). Chi-square 
analysis revealed statistically significant difference. 
Univariate logistic regression modelling demonstrated lower prostate cancer risk 
of OR=0.711 (95%CI: 0.518-0.977), 0.666 (95%Cl: 0.465-0.953), and 0.605 
(95%Cl: 0.384-0.953) for IHD (regardless duration, IHD of 5 years or more, and 
IHD of 10 years or more respectively (refer Table 6-8 page 6-116). Although the 
logistic regression models of age-adjusted and further adjustment for education, 
ethnic group, family history of cancer and smoking status showed odds ratio of 
less than 1.0 or of protective risk against prostate cancer, the statistical test 
revealed a non-significant association between hypercholesterolemia and prostate 
cancer. 
The analysis of further adjustment for smoking status has been carried out due to 
its strong association with ischaemic heart disease. Chi-square test indicated 
difference in proportion of smoking as statistically significant between cases and 
control (result not presented here). However upon multivariate analysis, smoking 
status became non-statistically significant, but due to its strong potential 
confounder effect on ischaemic heart diseases (IHD), it Is appropriate to include 
smoking in fully adjusted multivariate regression models as a priori variable. 
Studies focused on the association of smoking and prostate cancer, the findings 
were inconsistent with mostly concluded to have found lack or weak association 
of smoking in Increasing prostate cancer risk (Adami et aI, 1996; Rohrmann et aI, 
2007) and risk is stronger related to younger age group (Rodnguez et aI, 1997). 
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The findings from British doctors who participated in a 50 years observation on 
cancer deaths related to smoking suggested prostate cancer to be unrelated (Doll 
et ai, 2005). 
Few studies were conducted to look at direct association between rHO and 
prostate cancer. An earlier study by Neugut indicated increase prostate cancer 
risk due to IHD (Neugut et ai, 1998), while a recent article by Driver suggested 
coronary artery disease protect against prostate cancer (Driver et ai, 2010). 
There is a potential limitation in terms of respondents understanding of heart 
disease in the questionnaire which was meant to indicate ischaemic heart disease 
and not other types of heart disease unrelated to lack of oxygen supply. Since 
the column only provide yes or no for answer, is it presumptive to say that if 
respondents were unsure, they may named their heart disease condition in a 
separate space of other disease to avoid bias. 
Since the biological plausibility explanation of how IHD might be associated with 
prostate cancer, there might be a place to look medication as a confounder 
because aspirin (act as a blood thinning agent) is normally given as common drug 
treatment for any case of IHO in order to reduce the episode of thrombosis or 
platelet aggregation. Another previous study has found aspirin to be associated 
with reduced cancer risk and also have a protective effect to prostate cancer. This 
will be discussed in more detail in relevant chapters. 
6.7 Conclusions and Recommendations 
Chronic diabetes of five years or more may be protective against prostate cancer. 
For other chronic disease such as hypertension, hypercholesterolemia and 
ischaemic heart diseases, none showed protective effect towards prostate cancer. 
Further study should be carried out to strengthen the findings such as controlling 
for potential confounders of these relationships by obtaining proper medical 
record of diabetes diagnosis and types, anti-diabetic medication, past records 
readings of blood pressure of hypertension, levels of blood cholesterol and other 
types at different age period and coronary heart disease medication usage and 
types, severity of conditions of chronic diseases and proper body mass index at 
different intervals and severity of prostate cancer. 
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Chapter 7 Statins 
7.1 Literature Review 
There are several types of statins which are normally prescribed by doctors to 
treat mainly the problem of patients with hypercholesterolemia (elevated blood 
cholesterol) and some for the presence of diseases such as ischaemic heart 
disease. Some of the commonly prescribed statin drugs include rosuvastatin 
(Crestor), atorvastatin (Upitor), Simvastatin (locor), Pravastatin 
(PravacoIjPravigard), Fluvastatin (Lescol) and Lovastatin (Mecavor). 
Since hypercholesterolemia has been associated with cardiovascular diseases, 
therefore by controlling blood cholesterol, statin may also act as a secondary 
prevention measure for ischaemic heart disease (IHD) death. A meta-analysis in 
2007 study of 61 prospective studies demonstrated that 1mmol/I of lower total 
cholesterol was associated with approximately 56%, 33% and 17% lower IHD 
mortality In both sexes at ages 40-49, 50-69 and 70-89 years age group 
respectively in most developed countries (PSC, 2007). 
A study on the prevalence usage of statin among European countries by Walley 
showed for UK during 1997-2002, the use per day was 23.86 per 1000 
population (Walley et aI, 2004). Actual data on prevalence usage of statins is not 
known however but they are prescribed mostly for those with cardiovascular risk. 
The most commonly used statins used are 5imvastatln and Atorvastatln. 
Nowadays statlns are mostly given through doctors' prescription, however low 
dose statins are available at pharmacy over the counter. 
Statln act to decrease cholesterol production by inhibiting 3-hydroxy-3-
methylglutaryl CoA reductase which normally produce mevalonate (a precursor of 
cholesterol) and tumorgenic molecules (Solomon & Freeman, 2008). However, 
findings on the effects of statin on cancer is not convincing as the results from a 
number of studies are mixed. 
Kritchevsky & Kritchevsky who did an epidemiologic review on serum cholesterol 
level and cancer risk examined two questions; is low cholesterol associated with 
increased risk of cancer and does reducing serum cholesterol increase cancer 
occurrence (Krltchevsky & Kritchevsky, 1992). Of the studies examined, showed 
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a median 30% increased risk of cancer among males with low serum cholesterol, 
mainly consistent in colon and lung cancers. 
A meta-analysis study by Davey Smith & Pekkanen of mortality during trials of 
primary prevention of coronary heart disease (of between late 1960's to early 
1990's) through lowering of cholesterol concentration by drug intervention 
showed a pooled odds ratio of 1.33 (95% CI: 0.93-1.89) of cancer deaths and 
other non-coronary deaths 1.69 (95%C1: 1.11-2.57), concluded uncertainty 
surrounding the benefits and risks of cholesterol lowering drugs for general use, 
although earlier in 1970's, more common cholesterol lowering drug was clofibrate 
while statins came later in 1980's (Davey Smith & Pekkanen, 1992). 
In 1990's, a population based study using drug prescription study was done on 
Denmark population from 1991 to 1994 and followed up for cancer occurrence 
found standardized incidence rations (SIR) of 1.0 (95%CI: 0.7-1.3) for all types 
of lipid lowering drugs and upon stratification showed among statin users and 
fibrates users of SIR 0.8 (95%CI: 0.5-1.3) and 1.2 (95%CI: 0.6-2.0) 
respectively, which was non-statistically significant (Olsen et ai, 1999). 
In contrast to concerns of statins carcinogenicity, there is growing literature to 
suggest statins may in fact have a chemopreventive potential against cancer 
(Boudreau et ai, 2010; Chan et aI, 2003). 
Statins or HMG-CoA inhibitors mechanism of action is by inhibiting HMG-CoA 
reductase and prevent conversion of HMG-CoA to mevalonate, thereby reduce 
mevalonate levels products or pathways for critical cellular functions such as 
membrane integrity, cell signalling, protein synthesis and cell cycle progression. 
By disrupting these processes, statins result in control of tumour initiation, 
growth and metastasis (Chan et aI, 2003), resulting also to apoptotic cell death 
(Dimitroulakos et ai, 1999). Laboratory study has demonstrated statins induced 
apoptosis (programme cell death) in cells lines including prostate stromal cells 
(Padayatty et ai, 1997). 
Studies that have shown that statin use was not associated with risk of overall 
prostate cancer (Boudreau et aI, 2008; Coogan et aI, 2002; Kaye & Jick, 2004). 
The meta-analyses papers by Jacobs, Kuoppala and Bonovas did not find 
significant association (Bonovas et aI, 2008; Jacobs et aI, 2007a; Kuoppala et aI, 
2008). 
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However some studies found statins to be associated with reduction in prostate 
cancer risk in certain categories of cancer namely advanced cases (Jacobs et aI, 
2007a; Murtola et aI, 2007; Platz et ai, 2006; Shannon et ai, 2005), or low grade 
cancer (Murtola et ai, 2010). 
7.2 Aim 
This study aims to investigate prostate cancer risk association with duration 
intake of common cholesterol lowering drugs of Statins family. 
7.3 Method 
Data was collected through questionnaire. Study subjects were asked to record 
the individual type of drugs above, duration used and reason for taking the 
medication. Data were entered through a Microsoft access database, before 
being extracted into excel document. 
7.4 Analysis 
Data on statin medication were only available in the second phase of the study 
only as this factor was added into the later questionnaire used in phase II with 
total of 2209 subjects (1371 cases and 838 controls). 
Data from Microsoft Access was extracted into excel document and was 
transferred to SPSS database. Statin use is defined as consuming Statins 
regularly within the last 10 years prior to prostate cancer diagnosis for case 
subjects, or anytime within last 10 years for control. Due to various types of 
statins reported in the questionnaires, during claSSification, the types of statins 
which have smaller number of users were classified as 'others'. Since the 
numbers of respondents who reported two or more types of main statins used 
were also small, they have also been classified in a group with 'others' category. 
Those who were Statins user were then selected for further coding of their 
duration using statins. Data on duration was then classified into coding of 5 years 
interval block as following called Statin Duration Block: 
'0' - None 
'1' - use statins less than 5 years 
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'2' - use statins for 5 years or more but less than 10 years 
'3' - use statins for 10 years or more but less than 15 years 
'4' - use statins for 15 years or more 
Based on the above data classification, p for trend analysis was done. 
The possibility of cumulative use of statins determining prostate cancer risk as a 
whole is studied by classifying the users into category of cumulative years use of 
statin of up to 5, 10, 15 and 20 years. 
Statistical software SPSS version 17.0 was used to analyze the data for 
descriptive cross-tabulation and analytical Chi-square, logistic regression and 
subsequent adjusted logistic regression modelling in looking at statins on prostate 
cancer risk to obtain odds ratios and confidence intervals. 
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7.5 Results It Discussion 
7.5.1 Types of Statin 
Table 7-1 Types of Statin use among case-control groups 
Group 
Total 
Type of Statin Control Case 
(%) (%) (Ofo) 
55 77 132 
Atorvastatin 
19.5% 22.4% 25.1% 
11 8 19 Pravastatln 3.2% 3.9% 2.6% 
8 9 17 Rosuvastatln 
2.9% 2.8% 2.9% 
Simvastatin 185 191 
376 
65.6% 62.2% 63.8% 
Others and In combination 23 22 45 8.2% 7.2% 7.6% 
282 307 589 Total 
100.0% 100.0% 100.0% 
Almost two-thirds of subjects reported using statin in this study used Simvastatin, 
followed by Atorvastatin approximately a quarter of all subjects. While some over 
the period of time of usage consumed of more than 1 type of statin or less 
common type (refer Table 7-1 page 7-127). 
7.5.2 Reason for taking Statin 
Table 7-2 Reason for taking Statln 
Reason use Statin 
Group 
Total Control Case 
Cholesterol 212 
242 454 
73.4% 77.8% 75.7% 
17 8 25 
GP advice 
5.9% 2.6% 4.2% 
Hypertension 11 18 29 
3.8% 5.8% 4.8% 
26 28 54 IHD 
9.0% 9.0% 9.0% 
Other 23 15 38 
8.0% 4.8% 6.3% 
Total 289 311 600 
100.0% 100.0% 100.0% 
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The above Table 7-2, page 7-127, showed that high blood cholesterol was the 
main reason for taking statin at average three quarters of all subjects. Chi-square 
test showed p value of 0.096 suggesting there is no statistical significant 
difference in the reasons for taking statin between case and control group. 
7.5.3 Statin Ever use 
Table 7-3 Cross-tabulation of Statin use among case-control group 
Group 
Total Statins Used Control Case 
(%) (Ofo) (0J0) 
No 530 1030 1560 
64.2% 76.1% 71.6% 
Yes 296 324 620 
35.8% 23.9% 28.4% 
Total 826 1354 2180 
100.0% 100.0% 100.0% 
The cross-tabulation Table 7-3 showed higher proportion of controls (35.8%) 
using statins compared to case group (23.9%). Chi-square test p value <0.001, 
showed statistically significant difference in proportion of prostate cancer of case-
control group. 
The Table 7-4 page 7-129, showed that all statin users has statistically significant 
reduction risk of prostate cancer at adjusted odds ratio for age, at OR=0.665 
(95%CI: 0.546-0.808) and when adjusted for age, education, ethnic and family 
history of cancer at OR=0.714 (95%CI: 0.580-0.878) when compared to non-
user of statin drug. 
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Table 7-4 Logistic Regression Modelling for Statin User to obtain Odds Ratio (OR) for Univariate/Unadjusted and 
Adjusted models Prostate Cancer Risk 
(n=2180) Control Case 
Yes No Yes 
Statin (oAJ) (%) (oAJ) 
Used 296 530 324 
_ (35.8%) (64.2%) ( 2 3 " - ~ o , t c » »
aUnadjusted Regression Models 
bAdjusted Regression Models for age 
No 
(oAJ) 
1030 
(76.1%) 
ORB ORb 
(950f0CI) P value
B 
(950f0CI) 
0.563 
<0.001 0.665 (0.466-0.681) (0.546-0.808) 
cMultivariate Adjusted Regression Models for age, education, ethnic and family history of cancer 
OR c p valueb (950f0CI) 
<0.001 0.714 (0.580-0.878) 
p valuec 
0.001 
7.S.4 Duration of Statin Usage 
The effect of statin duration of usage on prostate cancer risk in compared with 
non-statin user was studied by categorizing the users using duration block of 5 
years interval. 
Table 7-S Crosstabulation of Statin usage duration of Cases and Controls 
Group 
Total 
Statin Usage Duration Control Case 
% 0/0 % 
530 1030 1560 
Non user 
66.3% 77.7% 73.4% 
136 137 273 
Less than S Years 
17.0% 10.3% 12.8% 
77 105 182 
SY or more but less than lOY 
9.6% 7.9% 8.6% 
39 38 77 
lOY or more but less than ISY 
4.9% 2.9% 3.6% 
17 16 33 
ISY or More 
2.1% 1.2% 1.6% 
799 1326 2125 
Total 
100.0% 100.0% 100.0% 
Table 7-5 presents cross-tabulation of statin duration usage. The results showed 
higher proportion of longer duration of statin usage among the control group 
compared to cases. Chi-square test revealed p<O.OOl suggesting differences in 
statin usage duration between cases and controls. 
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Table 7-6 Odds Ratio and Confidence Interval of Statin Duration Block and Prostate Cancer Risk 
Statin Usage Duration Control (Ofo) 
Non user 530 (66.3%1 
Less than 5 Years 136 (17.0%) 
5 Years or more but less 77 
than 10 Years (9.6%) 
10 Years or more but 39 
less than 15 Years (4.9%) 
15 Years or More 17 (2.1 %) 
aUnadjusted regression model 
bAge-adjusted regression model 
Cases 
(Ofo) 
1030 
(77.7%J_ 
137 
(10.3%) 
105 
.(7.9%} 
38 
(2.9%) 
16 
__ (!.2°1QL 
ORa p valuea ORb (950f0CI) (950f0CI) 
-Ref- -Ref-
0.518 
<0.001 0.585 (0.400-0.672) ~ ~0.449-0.7641 
0.702 0.026 0.819 (0.514-0.9591 (0.594-1.129) 
0.501 0.003 0.667 (0.317-0.793) (0.416-1.070) 
0.484 0.040 0.625 (0.243-0.966) (0.310-1.262) 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer 
P for trend, p<O.OOl 
p valueb 
<0.001 
0.222 
0.093 
0.190 
ORc p 
(950f0CI) valuec 
-Ref-
0.617 0.001 (0.467-0.815) 
0.947 0.754 (0.674-1.330) 
0.666 0.106 (0.407-1.090) 
0.629 0.223 (0.298-1.327)_ 
- -------
The table above showed that logistic regression after adjusting for age or also 
inclusion of education, ethnic and family history variables, only those who 
reported using statins of less than 5 years appeared to show statistically 
significant reduced odds ratio of 0.585 (950f0CI: 0.449-0.764) and 0.617 
(950f0CI: 0.467-0.815) respectively. When further adjusted for 
hypercholesterolemia status, the OR for 'Less than 5 Years' remains significant at 
0.639 (950f0CI: 0.455-0.897). 
Although across other categories of usage duration do not show statistically 
significant adjusted models, they all displayed risk reductions. 
7.5.5 Cumulative Duration Use of Statins 
The possibility of cumulative use of statin determining prostate cancer risk as a 
whole is studied in the following analysis as shown in Table 7-7 page 7-133. 
The usage of statins in cumulative duration use of 5, 10, 15 or up to 20 years in 
compared with non-user, showed statistically significant findings in unadjusted, 
age-adjusted and fully adjusted models. 
Final regression models even after include adjustment for hypercholesterolemia 
status, the value of odds ratios remained statistically significant (results not 
shown here). 
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Table 7-7 Odds Ratios and Confidence Interval for Statin Cumulative Duration Use Prostate Cancer Risk 
Statin Control 
Cumulative No Yes Duration 
(n=2180) (Ofo) (%) 
Statin use 530 173 
up to 5 (75.4%) (24.6%) Years 
Statin use 530 237 
up to 10 (69.1%) (30.9%) Years 
Statin use 530 259 
up to 15 (67.2%) (32.8%) Years 
Statin use 530 268 
up to 20 (66.4%) (33.6%) Years 
aUnadjusted regression model 
bAge-adjusted regression model 
Case 
No Yes 
ORa p ORb 
(95%CI) value- (95%CI) (%) (lifo) 
1030 184 0.547 0.617 
(84.8%) (15.2%) (0.434-0.691) <0.001 (0.486-0.784) 
1030 261 0.567 0.654 
(79.8%) (20.2%) (0.462-0.695) <0.001 (0.529-0.808) 
1030 289 0.574 0.675 
(78.1%) (21.9%) (0.471-0.700) <0.001 ( 0.550-0.828) 
1030 295 0.566 0.666 
(77.7%) (22.3%) (0.466-0.689 ) <0.001 (0.544-0.815) 
~ . - - ~ ~
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer 
P OR c 
valueb (95ClfoCI) 
0.665 
<0.001 (0.518-0.854) 
0.712 
<0.001 (0.571-0.889) 
0.725 
<0.001 (0.585-0.899) 
0.712 
<0.001 (0.576-0.881 ) 
p 
valuec 
0.001 
0.003 
0.003 
0.002 1 
7.6 Discussion 
7.6.1 Statin use 
On the list of statins used by the respondents, Simvastatin was the highest at 
63.8%, followed by Atorvastatin (22.4%) and then Pravastatin and Rosuvastatin 
at 3.2% and 2.9% respectively (see Table 7-1 on page 7-127). There was no 
indication of reasons for the higher reported use of Simvastatin in this study. The 
possible explanation could be due to its most commonly available in the 
pharmacy stores or over the counter drug. Pricing could be another reason 
because different types of statin have different prices which may affect choices. 
The amount of dosages needed to have similar effect on lowering cholesterol 
properties and possible side effects could also potentially affect prescribed drug. 
The prevalence of statin usage among the control in this study is 35.8% 
compared to cases at 23.9%. A study on the prevalence usage of statin among 
European countries by Walley showed the rate for UK at that time 1997-2002, the 
average increasing rate on annual of statin amount used daily was 48% (Walley 
et aI, 2004). Actual data on prevalence usage of statin is not known however 
they are prescribed mostly for those with cardiovascular risk. A study in USA on 
outpatient visits between 1992 - 2002 by Ma et al showed statin usage as lipid-
lowering drug rose from 47% to 87% between those years (Ma et aI, 2005). The 
use among highest risk patients were between 4 - 19% while moderate risk 
patients were from 2 -14%. 
In our study since the majority of subjects were older, we would expect them to 
be mostly consisted of higher risk group of hyperlipidemia or had cardiovascular 
risk. The prevalence of hypercholesterolemia among the subjects in this study Is 
26.3% and 32.4% In case and control group respectively, whereas the prevalence 
of ischaemic heart disease is 8.1 % and 11.0% also respectively. These confirmed 
the likelihood reasons for them to be prescribed of statin at one time or 
continuously during the last 10 years of their history on taking statin medication. 
The finding of univariate analysis showed a protective effect on prostate cancer 
approximately of 43.7% (range: 31.9% to 53.4%) among users of statins. Upon 
adjustment of age, and further on education, ethnic and family history of cancer, 
the protective risk of statins remained statistically significant with protection 
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against prostate cancer at 33.5% (range: 19.2% - 45.4%) and 28.6% (range: 
12.2% - 42.0%) respectively (refer Table 7-4 page 7-129). No stratification of 
statin types was done due to small numbers in each category. 
The results suggested that the overall statin use affects prostate cancer risk by 
reducing the risk approximately of 28.6% compared to those who do not take it. 
The possibility of different statin types on prostate cancer risk will be discussed in 
later part of this chapter. 
7.6.2 Duration of Statln Usage 
Subjects who reported statin used were divided into groups according to their 
duration of 5 years interval in an ascending order. The univariate analysis showed 
a significant risk reduction across categories (p for trend <0.001). The results of 
the unadjusted odds ratios were all statistically significant with value of prostate 
cancer risk reduction of 48.2%, 29.8%, 49.9% and 51.6% for categories of: less 
than 5 years, 5 years or more but less than 10 years, 10 years or more but less 
than 15 years and 15 years or more, respectively. Upon age-adjustment and 
further multivariate model adjustment, only the category of using statin less than 
5 years was found to be statistically significant at OR=O.585 (95%CI: 0.449-
0.764) and 0.617 (95%CI: 0.467-0.815) (see Table 7-7, on page 7-133). 
The study findings are similar to the study by Jacobs and colleagues. They 
analysed 3413 cases of Incident prostate cancer, upon adjustment for potential 
confounders, current use of cholesterol lowering drugs for 5 years or more was 
not associated with overall prostate cancer incidence at rate ratio of 1.06 
(95%CI: 0.93-1.20), however the retail pharmaceutical estimation for statin used 
as cholesterol lowering drug was about 86% at that time, therefore not 
exclusively for usage of statln drugs alone but analysis included other non-statln 
cholesterol lowering agents as well (Jacobs et aI, 2007a). 
However, the nested case control study by Flick et al of 69,047 participants in a 
California Men's Health Study (a prospective cohort) in 2002, identified 888 
prostate cancer cases including 131 advance cases, found that use of statins for 
five or more years was associated with 28% lower risk In prostate cancer (Rate 
ratio: 0.72 (95%CI: 0.53-0.99) (Flick et aI, 2007). Another study of cohort 
subjects ascertainment of 2579 prostate cancer cases, of which 316 were 
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advanced cases also found risk of advanced disease was lower with longer statin 
use at p for trend 0.003 compared to never use statin (Platz et ai, 2006). 
Even though our results did not show statistically significant of using statin of 
more than 5 years onwards, the OR value remained in value < 1.0 thus suggestive 
of protective against risk of prostate cancer. 
7.6.3 Cumulative Duration Use of Statins 
The cumulative duration use was carried out to investigate cumulative effect of 
the drug on the prostate cancer risk based on time of the use of up to 5, 10, 15 
and 20 years period. 
The results displayed in Table 7-7 page 7-133 showed that in the multivariate 
adjusted modelling, the effect of statin cumulative use remained statistically 
significant for all categories of up to 5, 10, 15 and 20 years statin use at OR of 
0.665 (95%CI: 0.518-0.854), 0.712 (95%Cl: 0.571-0.889), 0.725 (95%Cl: 
0.585-0.899) and 0.712 (95%Cl: 0.576-0.881) respectively, suggesting 
protective effects against prostate cancer. 
There are not many studies that have employed this cumulative measurement 
which was based on duration. Other studies that used a cumulative method were 
based on cumulative risk as in exposure to substance that can have a "latent" 
effect such as exposure to chemical dye causing cancer, or combined risks of 
different exposures to risk of developing a condition. 
7.6.4 Overall Discussion 
Since the findings reported in the literature showed some potential effects of 
statin lowering cancer incidence whilst other studies did not show such 
correlation, it was suggested by Sivaprasad et al in their investigation of possible 
discrepancy of results. They suggested that it could be due to different types of 
statins on their efficacy In Inhibiting prostate cancer cell proliferation when 
mevastatin (a lovastatin homologue) was used as a control (Sivaprasad et aI, 
2006). They reported that Lovastatin, Fluvastatin and Simvastatin arrest all 
prostate cancer cells in the Gl phase of cell cycle. Pravastatin needs to be at 
least 200 times higher concentration of Lovastatin in order to achieve Similar 
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effect and at the same time less efficient in inhibiting HMG-CoA reductase, and 
high dosage could potentially cause toxic effect. 
Since Pravastatin is hydrophilic and also has lower lipophilicity compared to 
Atorvastatin and Fluvastatin of moderate lipophilicity, or Simvastatin and 
Lovastatin of highest lipophilicity as HMG-CoA reductase inhibitors, therefore its' 
uptake into cells is not efficient compared to other statins. Thus, this results in a 
different efficacy in inhibiting prostate cancer cell proliferation (White, 2002). 
The results in-vitro experiments suggest that clinically useful statins such as 
Lovastatin, Fluvastatin and Simvastatin may have beneficial effect on prostate 
cancer incidence and progression (Sivaprasad et aI, 2006). 
Browning & Martin conducted a systematic review on the association of statin 
(HMG-CoA reductase inhibitor) use and cancer risk of 38 individual studies of 26 
randomized trials and 12 observation studies (Browning & Martin, 2007). Four 
trials and one observation studies were on prostate and meta-analysis revealed 
statin therapy indicate no evidence of association at p=0.38, although there was 
a high degree of inconsistency between studies. The risk ratio for prostate cancer 
within the meta-analysis of randomized trials for prostate cancer was of 1.00 
(95%CI: 0.85-1.17). 
Some of the recent case controls studies focusing on the association between 
statin effect on prostate cancer risk has shown reduction risk. Besides Flick (Flick 
et aI, 2007), Jacobs also reported of reductive risk among statin user in a case 
control study using 55,454 men from Cancer Prevention Study II Nutrition 
Cohort, which Include prostate cancer cases of 3413 of which 317 cases are of 
advanced disease (Jacobs et aI, 2007a). The adjusted rate ratio showed marginal 
statistically significant prostate cancer risk of advanced type at RR=0.600 
(9S%CI: 0.36-1.00), although overall prostate cancer risk was not statistically 
significant. Murtola using data from Finnish Cancer Registry of a large cohort 
study population, with cases and matched control approach, also found 
statistically significant risk reduction of advanced type of prostate cancer among 
users of statin with overall OR=0.75 (95%CI: 0.62-0.91) (Murtola et aI, 2007). 
The statin types namely atorvastatin, lovastatin and simvastatin had individual 
adjusted odds ratios of 0.61 (95%CI: 0.37-0.98), 0.61 (95%CI: 0.43-0.85) and 
0.78 (95%CI: 0.61-1.01) respectively. 
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Solomon & Freeman suggested in their article, that in order to properly study 
statin as chemoprevention or therapy, there is a need to conduct randomized trial 
for prostate cancer and it's important to exclude patients on cholesterol-reducing 
therapy and to exclude those who do anything specifically to reduce cholesterol 
such as diet or exercise in both arms. The study should be longer than 5 years to 
be able to assess the true effect of statin (Solomon & Freeman, 2008). 
7.7 Conclusions and Recommendations 
The findings suggested that statins use has a protective effect against prostate 
cancer. 
It is recommended to study further types of statins and their association with 
prostate cancer risk, as well as stratification prostate cancer cases according to 
their clinical manifestations. It is also suggested to look at whether the dosage of 
statin used would have had any association in the prostate cancer risk. 
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Chapter 8 NSAIDs (Non-Steroidal Anti-Inflammatory 
Drugs) It Paracetamol 
8.1 Literature Review 
8.1.1 NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) 
NSAIDs (Non-steroidal anti-inflammatory drugs) are a group of drugs which have 
properties of analgesia (painkiller), anti-pyretic (reduce fever) and anti-
inflammatory effects. Some of the common products include aspirin, ibuprofen, 
Diclofenac and Indomethacin. They are used for symptomatic relief of pain in 
general, swelling of joints or body organs and tissues, as well as fever. NSAIDs 
acts by inhibiting cyclooxygenase (Cox) which is an enzyme responsible in the 
catalyzing production of prostaglandins (potent mediators of inflammation). 
aspirin however can also inhibit platelet aggregation by inhibiting thromboxane 
A2 and its use in reducing blood clot formation in high risk patients has found to 
reduce or prevent deaths for myocardial Infarct and ischaemic stroke, but 
increases haemorrhaglc stroke and major bleeding when used In primary 
prevention of cardiovascular diseases, as observed in a meta-analysis of 
randomized controlled trials by (Raju et aI, 2011). 
Current evidences suggests that inflammation may contribute to the 
carcinogenesis of prostate cancer as shown by both epidemiological and 
histopathological studies (De Marzo et aI, 2007). It was also estimated 20% of 
prostate cancer cases were as a result of chronic inflammation due to infectious 
agents and or environmental factors. 
In view of cyclo-oxygenase-2 (COX-2) being an important enzyme catalyst to 
prostaglandins formation from arachidonic acid conversion, which in turn 
mediates the inflammation process, COX-2 is an important potential target for 
preventive strategies. As such NSAIDs have been studied to see whether they 
have any association with prostate cancer risk. 
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However it is important to bear in mind that genetic variation in the inflammatory 
pathways itself has been found to be associated with prostate cancer as found in 
study by Zheng in the large Swedish case-control population (CAPS) (Zheng et ai, 
2006). 
NSAIDs have been shown over the recent years to be protective of prostate 
cancer. Most of this studies showed Significant amount use of aspirin of few days 
a week, over a period of long term, would reduce risk to prostate cancer 
(Dasgupta et aI, 2006; Garcia Rodriguez, 2004; Jacobs et ai, 2005; Jacobs et ai, 
2007bi Mahmud et ai, 2004; Perron et ai, 2003; Salinas et ai, 2010). 
However, the specific types of NSAIDs other than aspirin when analysed showed 
no significant association with prostate cancer in many of these studies except for 
ibuprofen (Jacobs et aI, 2005). Analysis involving all types of NSAIDs showed 
some significant association in some studies (Cheng et ai, 2007; Dasgupta et ai, 
2006; Jacobs et ai, 2005; Mahmud et aI, 2010), while others were not significant 
(Daniels et ai, 2009; Stock et ai, 2008). 
8.1.2 Paracetamol 
Paracetamol or acetaminophen is widely available as an over the counter drug for 
its function as an anti-pyretic (reduce fever) and analgesic (pain relieve). It acts 
through inhibition of cyclooxygenase (COX), and recent findings suggest that it is 
highly selective for COX2 (Hinz et ai, 2008). Therefore, it could potentially use 
similar mechanism as NSAIDs in inhibiting the pathway of inflammatory process, 
on cancer cell growth (Fris et al. 2002) 
Paracetamol association with regard to cancer risk has been inconsistent. An 
earlier study in year 2002 by Friis et al showed that those who received 
paracetamol prescription over 9 years follow-up in Denmark, had higher 
standardized incidence ratio (SIR) of overall cancers compared with those who 
didn't receive same prescription. Significantly higher SIR were found for 
esophageal and lung cancer. It was not significant for prostate cancer. 
A meta-analysis by Bonovas showed an inverse association between paracetamol 
use and ovarian cancer risk but of marginal statistical significance. It was found 
also that regular use was statistically Significantly 30% reduced in ovarian cancer 
risk compared to non-users (Bonovas et aI, 2006). 
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Another recent study by Walter has shown that high use of paracetamol of more 
than 4 days per week for 4 years or more was associated with an increased risk 
for haematologic malignancies with hazard ratio, HR=1.84 (95%CI: 1.35-2.50) 
and p-trend of 0.004. The statistically significant association was observed for 
myeloid neoplasms, non-Hodgkin's lymphomas and plasma cell disorders (Walter 
et aI, 2011). 
8.2 Aims 
This study aimed to investigate prostate cancer risk in association with duration 
of intake of common painkiller of specific types of NSAIDS, as well as 
acetaminophen: 
i. Aspirin 
ii. Ibuprofen 
iii. Paracetamol 
8.3 Method 
Data was collected through self administered questionnaire which detailed the 
individual type of drugs above and entered through a Microsoft access database, 
before being extracted into excel document. 
8.4 Analysis 
Subjects were asked to report any uses of Aspirin, Ibuprofen and Paracetamol. 
Each medication had to be taken regularly within the last 10 years prior to 
prostate cancer diagnosis for case subjects, or anytime within last 10 years for 
control at least 1 tablet per week for 3 months or more. Those who completed 
any of the above drugs used were then asked to provide information on duration 
using them. 
Data of each type of medication was re-coded and analysed to assess the 
followings. 
a) Distribution of each medication used in study subjects 
b) Association between drug used as define by Duration Block and prostate 
cancer risk 
c) Association between cumulative years use of up to 5, 10, 15 and 20 years 
and prostate cancer risk. 
For Aspirin and Ibruprofen, 'Duration Block' was classified by 10 years interval 
block as following: 
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'0' - None 
'1' - use less than 10 years 
'2' - use for 10 years or more but less than 20 years 
'3' - use for 20 years or more 
For paracetamol, 'Duration Block' was classified by 5 years interval block as 
following: 
'0' - None 
\ l' - use paracetamol less than 10 years 
'2' - use paracetamol for 10 years or more but less than 20 years 
'3' - use paracetamol for 20 years or more but less than 30 years 
'4' - use paracetamol for 30 years or more 
Based on this data classification above, p for trend analysis was done for each 
drug/med ication. 
The possibility of cumulative use of aspirin, ibuprofen and paracetamol 
determining prostate cancer risk as a whole is studied by classifying the users 
into category of cumulative years use of up to 5, 10, 15 and 20 years. 
Statistical software SPSS version 17.0 was used to analyse the data for 
descriptive cross-tabulation and analytical Chi-square, logistic regression and 
subsequent adjusted logistic regression modelling to obtain odds ratios and 
confidence intervals 
8.5 Results 
8.5.1 Aspirin 
Distribution of aspirin used among study subjects is shown in Table 8-1. 
Table 8-1 Cross-tabulation of Aspirin use among case-control group 
Group 
Control Case Total 
Aspirin use (0/0) ~ O f o i i ~ O f o ) )
660 1139 1799 
No 79.6% 83.9% 82.3% 
169 218 387 
Yes 20.4% 16.1% 17.7% 
829 1357 2186 
Total 100.0% 100.0% 100.0% 
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The results showed that the proportion of users of aspirin (prior to diagnosis in 
case group or receiving questionnaire in control group) is higher among controls 
compared to cases (20.4% as compared to 16.1%). Chi-square test p value = 
0.010, and showed statistically significant difference in proportion of aspirin 
users in the case and control group. 
Table 8.2 shows odds ratios and confidence interval for Aspirin user and prostate 
cancer risk. There is statistically significant reduced prostate cancer risk in those 
using aspirin in univariate analysis at OR=0.747 (95%CI: 0.598-0.934), 
however upon adjustment for age, and further adjustment for education, ethnic 
and family history of cancer, the association was not significant. 
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Table 8-2 Odds ratios and confidence interval for Aspirin user and prostate cancer risk 
Control Case 
Aspirin Yes No Yes No 
Used (Ofo) (Ofo) (%) (%) 
169 660 218 1139 
(20.4%) (79.6%) (16.1%) (83.9%) 
aUnadjusted Regression Models 
bAdjusted Regression Models for age 
OR- p ORb 
(9S0f0CI) valueB (9S0f0CI) 
0.747 0.010 0.797 
(0.S98-0.934 ") (0.634-1.002) 
~ u l t i v a r i a t e e Adjusted Regression Models for age, education, ethnic and family history of cancer 
P OR c p 
valueb (9S0f0CI) valuec 
0.052 0.814 0.096 
(0.639-1.037) 
8.5.1.1 Duration Block Aspirin Usage 
Table 8-3 Cross tabulation of duration Aspirin usage of cases and 
controls 
Group 
Total 
Aspirin Duration Block Control Case 
(%) (Ofo) (%) 
660 1138 1798 
None 
84.4% 88.7% 87.1% 
69 76 145 
Less than 10 Years 
8.8% 5.9% 7.0% 
10 Years or more but less 33 41 74 
than 20 Years 4.2% 3.2% 3.6% 
20 28 48 
20 Years or more 
2.6% 2.2% 2.3% 
782 1283 2065 
Total 
100.0% 100.0% 100.0% 
Table 8-3 shows that overall the control subjects had a higher proportion of 
duration of aspirin usage in any block duration compared to cases, especially 
duration of aspirin usage less than 10 years. Chi-square indicates statistically 
significant differences in proportion between cases and control at p=O.036. 
Table 8-4 showed that in a univariate model, aspirin duration showed statistically 
a significant association with prostate cancer risk. In unadjusted and age-
adjusted regression models only category that showed statistically significant 
association with prostate cancer risk is those who used aspirin for less than 10 
years when compared with non-user at OR=0.639 (95%Cl: 0.455-0.897) and 
0.657 (95%Cl: 0.463-0.931). There was no statistically significant OR in the fully 
adjusted model. 
8-145 
co 
I 
..... 
~ ~
0\ 
Table 8-4 Odds ratios and confidence interval for Aspirin duration usage and prostate cancer risk 
Aspirin Duration Control Usage (010) (n=2065) 
None 660 (84.4%) 
Less than 10 Years 69 (8.8%) 
10 Years or more but 33 
less than 20 Years (4.2%) 
20 Years or more 20 (2.6%) 
aUnadjusted regression model 
bAge-adjusted regression model 
Cases 
(%) 
1138 
(88.7%) 
76 
5.9%) 
41 
3.2%) 
28 
2.2%) 
OR- P ORb 
(95OfoCI) value· (950f0CI) 
-Ref- 0.037 -Ref-
0.639 0.01 0.657 (0.455-0.897) (0.463-0.931) 
0.721 0.17 0.897 (0.451-1.151) (0.553-1.455) 
0.812 0.483 0.794 (0.454-1.453) (0.435-1.450) 
'Multivariate adjusted regression model for age, education, ethnic, family history of cancer 
P for trend, p=O.030 
P ORc 
valueb (950f0CI) 
0.108 -Ref-
0.018 0.716 (0.496-1.035) 
0.66 0.817 (0.488-1.370) 
0.453 0.897 (0.477-1.686) 
Pvaluec 
i 
0.301 
0.076 I 
0.444 
0.735 
8.5.1.2 Aspirin Cumulative Duration Use 
Table 8-5 page 8-148 shows Odds ratios and confidence interval for Aspirin 
cumulative duration use and prostate cancer risk. Aspirin non-users was used as 
a reference category, the results showed that univariate analysis was statistical 
significantly associated with all categories of cumulative usages of aspirin with 
reduction in prostate cancer risk. When the regression model was adjusted for 
age, only aspirin usage of 5 years, 10 years, 15 years and 40 years or more 
categories remained statistical significant. In the fully adjusted model, all 
associations were non-significant statistically. 
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Table 8-5 Odds ratios and confidence interval for Aspirin cumulative duration use and prostate cancer risk 
Aspirin Control 
Cumulative No Yes 
Duration (%) (Ofo) 
Aspirin use 660 56 
up to 5 (92.2%) (7.8%) 
Years 
Aspirin use 660 89 
up to 10 (88.1%) (11.9%) 
Years 
Aspirin use 660 98 
up to 15 (87.1%) (12.9%) 
Years 
Aspirin use 660 106 
up to 20 (86.2%) (13.8%) 
Years 
Aspirin use 660 116 
up to 40 (85.1%) (14.9%) 
Years 
aUnadjusted regression model 
bAge-adjusted regression model 
Case OR- p ORb 
No Yes (95%CI) value- (950f0CI) 
(Ofo) (010) 
1138 60 0.621 0.013 0.631 
(95.0%) (5.0%) (0.426-0.906 ) (0.428-0.929) 
1138 105 0.684 0.013 0.736 
(91.6%) (8.4%) (0.508-0.922) (0.542-1.000) 
1138 116 0.686 0.010 0.743 
90.7%) (9.3%) (0.516-0.913) (0.554-0.997) 
1138 129 0.706 0.013 0.777 
(89.8%) (10.2%) (0.537-0.929) (0.586-1.031) 
1138 142 0.710 0.011 0.759 
(88.9%) (11.1%) (0.546-0.924 ) (0.579-0.996) 
CMultivariate adjusted regression model for age, education, ethniC, family history of cancer 
P OR c 
valueb (95%CI) 
0.020 0.702 
(0.468-1.053) 
0.050 0.755 
(0.545-1.045) 
0.048 0.764 
(0.559-1.042) 
0.081 0.803 
(0.595-1.083) 
0.047 0.781 
(0.587-1.041) 
p 
valuec 
0.087 
0.090 
0.089 
0.150 
0.091 
I 
8.5.2 Ibuprofen 
8.5.2.1 Ibuprofen use 
Table 8-6 Cross-tabulation of Ibuprofen use among case-control group 
Group 
Ibuprofen use Control Case Total 
(Ofo) (Ofo) (Ofo) 
No 707 1175 1882 
85.5% 86.4% 86.1% 
Yes 120 185 305 
14.5% 13.6% 13.9% 
Total 827 1360 2187 
100.0% 100.0% 100.0% 
The cross-tabulation in Table 8-6 showed that there is a similarity in the 
proportion of ibuprofen users between cases and control groups. Chi-square test 
p value =0.553, showed a non-statistically significant difference of case-control 
group of ibuprofen users proportion. 
Table 8-7 showed that there was no statistically significant association between 
ibuprofen ever use compared to non-user in prostate cancer risk, neither in 
unadjusted nor adjusted models. 
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Table 8-7 Odds ratios and confidence interval for Ibuprofen user and prostate cancer risk 
(n=2180) Control Case 
Ibuprofen Yes No Yes No (Ufo) (010) (0/0) (010) Used 120 707 185 1175 
- .. _- --
(14.5%) (85.5%) (13.6%) (86.4%) 
aUnadjusted Regression Models 
bAdjusted Regression Models for age 
OR· p value· ORb 
(950f0CI) (95%CI) 
0.928 p=0.553 0.810 
(0.724-1.189) (0.627-1.046) 
CMultivariate Adjusted Regression Models for age, education, ethnic and family history of cancer 
p valueb OR c p valuec 
(95%CI) 
0.106 0.771 0.057 
(0.591-1.007) 
8.5.2.2 Duration of Ibuprofen Usage 
Table 8-8 Crosstabulation of Ibuprofen duration usage of cases and 
controls 
Group 
Ibuprofen Duration Control Case Total 
(Ofo) (Ofo) (Ofo) 
None 707 1175 1882 
90.9% 91.2% 91.1% 
Less than 10 Years 36 42 
78 
4.6% 3.3% 3.8% 
10 Years or more but less than 15 43 58 
20 Years 1.9% 3.3% 2.8% 
20 Years or more 20 28 48 
2.6% 2.2% 2.3% 
Total 778 1288 2066 
100.0% 100.0% 100.0% 
The cross-tabulation table above showed that about 9% of study subjects 
reported Ibruprofen used. Chi-square indicate non-statistically significant 
differences in proportion between cases and control at p=0.104. 
In studying the association between different durations of usage of Ibuprofen and 
prostate cancer regression models, there was no statistically significant findings 
on odds ratios although the multivariate adjusted models showed borderline 
significant finding for Ibuprofen use of less than 10 years has odds ratio of 0.616 
(95%CI: (0.377-1.004) at p=0.052 when compared to none ibuprofen user 
(Table 8-9). 
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Table 8-9 Odds ratios and confidence interval for Ibuprofen duration usage and prostate cancer risk 
Ibuprofen Control Cases ORa ORb ORc Duration Usage (0/0) (0/0) (9S0f0CI) P valuea (9S%CI) P valueb (9S0f0CI) P valuec (n=2066) 
707 1175 
None (90.90%) (91.20%) -Ref- 0.109 -Ref- 0.178 -Ref- 0.118 
Less than 10 36 42 0.702 0.66 0.616 
Years (4.60%) (3.30%) (0.445-1.106) 0.127 (0.413-1.054) 0.082 (0.377-1.004) 0.052 
10 Years or more 15 43 1.725 1.346 1.224 
but less than 20 (1.90%) (3.30%) (0.951-3.128) 0.073 (0.735-2.464) 0.336 (0.661-2.268) 0.521 
Years 
20 28 0.842 0.748 0.659 
20 Years or more (2.60%) (2.20%) (O.471-1.507) 0.563 (0.411-1.364) 0.344 (0.352-1.233) 0.192 
- ----
- ~ ~ -- - - L . . . . - - - - ~ _ L . . . _ _ _ _ . . -- L . . . . ~ ~ ~ ~
aUnadjusted regression model 
bAge-adjusted regression model 
~ u l t i v a r i a t e e adjusted regression model for age, education, ethnic, family history of cancer 
P for trend, p=O.920 
8.5.2.3 Ibuprofen Cumulative Use 
Table 8-10 presents Odds ratios and confidence interval for Ibuprofen cumulative 
duration use and prostate cancer risk. The cumulative duration of ibuprofen 
when compared with non-user also did not show any statistically significant 
association with prostate cancer risk, though all ORs fall in value of less than 1.0 
which is of protective effect, all CIs included 1. 
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Table 8-10 Odds ratios and confidence interval for Ibuprofen cumulative duration use and prostate cancer risk 
Ibuprofen Control 
Cumulative No Yes 
Duration (Ofo) (%) 
Ibuprofen use 707 32 
up to 5 Years (95.7%) (4.3%) 
Ibuprofen use 707 45 
up to 10 (94.0%) (6.0%) 
Years 
Ibuprofen use 707 51 
up to 15 (93.3%) (6.7%) 
Years 
Ibuprofen use 707 59 
up to 20 (92.3%) (7.7%) 
Years 
Ibuprofen use 707 68 
up to 40 (91.2%) (8.S%) 
Years 
---'----- --- ---
aUnadjusted regression model 
bAge-adjusted regression model 
Case OR- p ORb 
No Yes (950f0CI) value- (950f0CI) 
(Ofo) (Ofo) 
1175 38 0.715 0.169 0.687 
(96.9%) (3.1%) (0.442-1.154) (0.420-1.124) 
1175 73 0.976 0.901 0.865 
(94.2%) (5.8%) (0.666-1.432) (0.583-1.284 ) 
1175 83 0.979 0.909 0.850 
(93.4%) (6.6%) (0.683-1.405) (0.586-1.233) 
1175 96 0.979 0.902 0.862 
(92.4%) (7.6%) (0.699-1.372) (0.609-1.220) 
1175 111 0.982 0.911 0.858 
(91.4%) (8.6%) (O.716-1.347) (0.620-1.189) 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer 
P OR c 
valueb (95%CI) 
0.135 0.651 
(0.390-1.087) 
0.472 0.801 
(0.531-1.207) 
0.391 0.787 
(0.535-1.157) 
0.403 0.800 
(0.558-1.147) 
0.358 0.787 
(0.561-1.104) 
p 
valuec 
0.101 
0.288 
0.223 
0.224 
0.165 
8.5.3 Paracetamol 
Paracetamol use 
Table 8-11 Cross-tabulation of Paracetamol use among case-control 
group 
Group 
Control Case Total 
Paracetamol use (%} -(%) (%) 
No 653 1094 1747 
78.4% 80.5% 79.7% 
Yes 180 265 445 
21.6% 19.5% 20.3% 
Total 833 1359 2192 
100.0% 100.0% 100.0% 
Table 8-11 showed that there is slight difference in the proportion of paracetamol 
users between case and control groups. Chi-square test p value =0.233, showed 
non-statistically significant difference. 
Table 8-12 presents the estimated risks of paracetamol use and prostate cancer 
risk and shows that there was no statistically significant association between 
paracetamol ever use compared to non-user In prostate cancer risk, neither in 
unadjusted nor adjusted models, although all OR values are suggestive of 
protective risk at OR< 1.0, all CIs included 1. 
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Table 8-12 Odds ratios and confidence interval for paracetamol user and prostate cancer risk 
Control 
(n=2180) 
Paracetamol Yes No 
Used (Ofo) (Ofo) 
180 653 
(21.6%) (78.4%) 
aUnadjusted Regression Models 
bAdjusted Regression Models for age 
Case OR- p OR D 
(95%CI) value- (950f0CI) 
Yes No 
(Ofo) (Ofo) 
265 1094 0.979 0.234 0.828 
(19.5%) (80.5%) (0.710-1.087) (0.665-1.031) 
'Multivariate Adjusted Regression Models for age, education, ethnic and family history of cancer 
P 
valueb 
0.091 
OR c p 
(950f0CI) valuec 
0.800 0.059 
(0.634-1.009) 
I 
8.5.3.1 Duration of Paracetamol Usage 
Table 8-13 Crosstabulation of paracetamol duration usage of cases and 
controls 
Group 
Paracetamol Duration Use Control Case Total 
(Ufo) (Ufo) (Ufo) 
None 654 1094 1748 
85.7% 87.7% 86.9% 
Less than 10 Years 45 61 106 
5.9% 4.9% 5.3% 
10 Years or more but less than 20 19 30 49 
Years 2.5% 2.4% 2.4% 
20 Years or more but less than 30 23 23 46 
Years 3.0% 1.8% 2.3% 
30 Years or more 22 40 62 
2.9% 3.2% 3.1% 
Total 763 1248 2011 
100.0% 100.0% 100.0% 
The cross-tabulation table showed that overall there is similar proportion of 
paracetamol users between different categories of duration. Chi-square indicates 
non-statistically significant differences in proportion between cases and control at 
p=0.388. 
Table 8-14 Odds ratios and confidence interval for paracetamol duration usage 
and prostate cancer risk. There were no statistically significant findings on odds 
ratios in unadjusted regression models. However, the age-adjusted and 
multivariate adjusted models showed that paracetamol use of '20 years or more 
but less than 30 years' duration had statistically significant lower odds ratio 
compared to non-user at OR=0.501 (95%CI: 0.272-0.921) and 0.534 (95%CI: 
0.287-0.993) respectively. 
8-157 
(X) 
I 
..... 
U1 
(X) 
Table 8-14 Odds ratios and confidence interval for paracetamol duration usage and prostate cancer risk 
Paracetamol Duration Control 
Usage (Ofo) 
(n=2011) 
None 654 
(85.7%) 
Less than 10 Years 45 
(5.9%) 
10 Years or more but less 19 
than 20 Years (2.5%) 
20 Years or more but less 23 
than 30 Years (3.0%) 
30 Years or more 22 
J2.9%) 
aUnadjusted regression model 
bAge-adjusted regression model 
Cases 
(Ofo) 
1094 
(87.7%) 
61 
(4.9%) 
30 
(2.4%) 
23 
(1.8%) 
40 
(3.2%) 
ORa p ORb 
(950f0CI) value- (95%CI) 
-Ref- 0.396 -Ref-
0.B10 0.299 0.766 
(0.545-1.205) (0.509-1.154) 
0.944 0.846 0.918 
(0.527-1.691) (0.505-1.670) 
0.598 0.085 0.501 
(0.333-1.074) (0.272-0.921 ) 
1.087 0.758 1.053 
(0.640-1.845) (0.612-1.815) 
cMultivariate adjusted regression model for age, education, ethnic, family history of cancer 
P for trend, p=0.396 
P ORc 
valueb (95%CI) 
0.166 -Ref-
0.202 0.700 
(0.455-1.077) 
0.780 0.836 
(0.442-1.580) 
0.026 0.534 
(0.287-0.993) 
0.851 1.018 
(0.577-1.798) 
p 
valuec 
0.163 
0.105 
0.581 
0.048 
0.951 
8.5.3.2 Paracetamol Cumulative Use 
In the univariate and age-adjustment model, the results did not reveal a 
statistically significant association. However, upon multivariate adjustment, the 
association became significant (Table 8-15). The odds ratios and confidence 
intervals were all less than 1.0 in the categories for paracetamol use cumulative 
duration of up to 20, 30,40 and 50 years at OR=0.713 (95%CI: 0.513-0.990), 
0.703 (95%CI: 0.518-0.954), 0.720 (95%CI: 0.538-0.965) and 0.745 (95%CI: 
0.560-0.991) respectively, all of protective risks. 
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Table 8-15 Odds ratios and confidence interval for Paracetamol cumulative use prostate cancer risk 
Paracetamol Control 
Cumulative 
Duration No Yes 
(Ofo) (0/0) 
Paracetamol 654 57 
use up to 10 (92.0%) (8.0%) Years 
Paracetamol 654 81 
use up to 20 (89.0%) (11.0%) Years 
Paracetamol 654 95 
use up to 30 (87.3%) (12.7%) Years 
Paracetamol 654 104 
use up to 40 (86.3%) (13.7%) Years 
Paracetamol 654 109 
use up to SO (85.7%) (14.3%) Years 
--
aUnadjusted regreSSion model 
bAge-adjusted regression model 
Case 
ORa P ORb 
No Yes (95%CI) value· (95%CI) 
(Ofo) (%) 
1094 84 0.881 0.478 0.843 
(92.9%) (7.1%) (0.621-1.250) (0.587-1.210) 
1094 110 0.812 0.177 0.759 
(90.9%) (9.1%) (0.600-1.099) (0.556-1.038) 
1094 130 0.818 0.162 0.756 
(89.4%) (10.6%) (0.617-1.084) (0.565-1.010) 
1094 145 0.833 0.186 0.772 
(88.3%) (11.7%) (0.636-1.092) (0.585-1.020) 
1094 153 0.839 0.193 0.787 
(87.7%) (12.3%) (0.644-1.093) (0.599-1.033) 
-_.-
--- -- -- -- -- - ----
CMultivariate adjusted regreSSion model for age, education, ethnic, family history of cancer. 
P 
valueb 
0.354 
0.084 
0.059 
0.069 
0.085 
OR c P 
(950f0CI) value
c 
0.767 0.174 
(0.523-1.125) 
0.713 0.044 
(0.513-0.990) 
0.703 0.024 
(0.518-0.954) 
, 
0.720 0.028 
(0.538-0.965) 
0.745 0.043 
(0.560-0.991) 
-- - ---
8.6 Discussion 
8.6.1 Aspirin 
Aspirin use 
Cross-tabulation of aspirin use (see Table 8-1 , page 8-142 and Table 8-2 0, page 
8-144) showed that there was higher proportion in the control subjects compared 
to cases, which was statistically significant and univariate analysis odds ratio of 
0.747 (95% CI: 0.598-0.934) indicates that those who reported ever use aspirin 
at least one tablet per week for more than three months in the last 10 years had 
a reduced their risk against prostate cancer at approximately 25.3% (range 6.6% 
-40.2%). After adjusted for age and multivariate confounders into the regression 
models of aspirin use, the odds ratios were not statistically significant at 
p=0.052, OR=0.797 (95%Cl: 0.634-1.002) and p=0.096, OR=0.814 (95%CI: 
0.639-1.037). 
The results of this study are similar to some studies looking at relationship of 
NSAIDs In specific aspirin use and prostate cancer. Platz et al. reported results 
on 1244 males of Baltimore Longitudial Study of Aging. They found that the rate 
ratio of 0.76 (95%CI: 0.54-1.07) to prostate cancer risk in comparison with never 
use of aspirin (Platz et ai, 2005). Menezes] in their case-control study of 1029 
men with primary incident of prostate and matched 1029 control of Roswell Park 
Cancer Institute in Buffalo, New York. Subjects who reported used aspirin 
regularly (at least once a week for 6 months) was compared to non-regular user. 
Their findings supported no association with prostate cancer risk (OR 1.05 with 
95%CI: 0.89-1.25) (Menezes et aI, 2006». 
Rodriguez & Gonzalez-Perez conducted a nested case-control study on 2,183 
cases and 10,000 controls. Data obtained from General Practice Research 
Database (GPRD) in the UK. The results showed that ever use of aspirin was 
associated with prostate cancer risk reduction at OR=0.70 (95%CI: 0.61-0.79) 
(Garcia Rodriguez, 2004). Another study by Liu on case-control matched of 532 
subjects in Ohio, USA found aspirin to be associated with reduction risk of 
advanced prostate cancer at OR=0.66 (95%CI: 0.51-0.86) (Liu et ai, 2006). 
While a study of 4175 subjects in Quebec Canada, using subjects of older age 
>67 who underwent prostate biopsy to separate cases and control, found 
protective risk among aspirin users at OR=0.84 (95%Cl: 0.74-0.96) (Dasgupta et 
al,2006). 
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The definition of aspirin use differs from one study to the others. For example, 
some studies would use at least continues 120 days use (Dasgupta et aI, 2006), 
while others are based on regularity use per week or month (Liu et aI, 2006; 
Menezes et aI, 2006), or some on ever use (Garcia Rodriguez, 2004; Jacobs et aI, 
2005; Murad et aI, 2011; Salinas et aI, 2010) which could result in some 
discrepancy in the reported odds ratios. 
8.6.1.1 Duration of Aspirin Usage 
The results presented in Table 8-4 (page 8-146) showed a statistical significant 
difference in the number of years aspirin used between cases and control, with 
higher % in each duration category among control group. Unadjusted regression 
model and age-adjusted model to look at number of years usage of aspirin to 
prostate cancer risk compared to non-user showed statistically significant OR of 
risk reduction for aspirin users category of less than 10 years. In the fully 
adjusted model, the results did not support any significant associations. 
One case-control study of age-matched hospital-based of 1029 and equally 5 year 
age group frequency matched control of similar numbers by Menezes , showed 
similar non-statistical significant adjusted OR for duration of use between 1 to 10 
years of aspirin use at 0.97 (95%CI: 0.79-1.19). Duration of more than 10 years 
also didn't show any statistical significant adjusted OR at 1.17 (95%CI: 0.93-
1.46) (Menezes et aI, 2006). 
Other case-control study stratified the number of years use of aspirin showed a 
statistically significant reduced odds ratio for aspirin usage of less than 4 years 
but not significant after If 4 years or more (Garcia Rodriguez, 2004). In contrast, 
a case control study by Salinas of 1001 registry case and 942 age-matched 
population based control showed statistically significant reduced odds ratio when 
aspirin was used more than 5 years when compared with non-user at adjusted OR 
0.76 (95%CI: 0.61-0.96) but not when used only less than 5 years (Salinas et aI, 
2010). 
Cohort studies also supported a statistically significant reduction in odds ratio for 
prostate cancer when aspirin Is used for 5 years or more but not when period of 
less than that (Jacobs et aI, 2005; Perron et aI, 2003). 
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There are not many large case-control studies that look at longer duration of 
aspirin usage, most would analyse their data at less than 10 years when 
stratifying to block duration of aspirin or NSAIDs usage. Our study did look at 
duration beyond 10 years on the effect of aspirin use on prostate cancer and 
found non-statistically significant association over long term use. 
The p for trend for duration block for aspirin usage was statistically significant at 
p=0.030 at univariate analysis, however upon adjustment for multivariate 
analysis became non significant (results not shown here). Study by Rodriguez & 
Gonzalez-Perez has reported a similar result with p-for trend at 0.220 in their 
fully adjusted model (Garcia Rodriguez, 2004). However Liu showed that aspirin 
p-trend was statistically significant at p=O.OOl and ORs <1.0 in all categories (Liu 
et aI, 2006). Similarly, Perron also reported p for trend at 0.0009 (Perron et aI, 
2003). 
In this study an interval of 10 years was used while previous studies used shorter 
duration, and at the same time the definition of aspirin use is different. Our 
findings, however, supported that there is no trend of risk reduction over the 
duration of years aspirin usage and prostate cancer risk. 
8.6.1.2 Aspirin Cumulative Duration of Use 
The cumulative duration of using aspirin on the prostate cancer risk based on 
time of the use of up to 5, 10, 15 and 20 years period (as shown in Table 8-5 
page 8-148). 
The unadjusted odds ratios of aspirin cumulative use of up to 5, 10, 15, 20 and 
40 years were all statistically significant at OR = 0.621 (95%CI: 0.426-0.906), 
0.684 (95%CI: 0.508-0.922), 0.686 (95%CI: 0.516-0.913), 0.706 (95%CI: 
0.537-0.929) and 0.710 (95%CI: 0.546-0.924) respectively, which were all of 
protective risk against prostate cancer. In age-adjusted model, only aspirin 
cumulative use of up to 20 years became not statistically significant, while the 
rest categories remained significant with odds ratio less than 1.0. 
The results of fully adjusted model showed that ORs of aspirin cumulative use all 
categories were less than 1 however all their CIs Included 1. 
Not many studies reported cumulative effect use of aspirin, however the benefit 
of using this method is to potentially look at the strength of association between 
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aspirin longer use to the prostate cancer risk. Our findings suggested no 
association between cumulative effect of aspirin use and prostate cancer risk. 
A study by Platz, the Baltimore Longitudinal Study of Aging subjects reported a 
non statistically significant rate ratios of aspirin use of 4 years or more at 
RR=1.27 (95%CI: 0.38-4.18), on prostate cancer risk (Platz et aI, 2005). 
Menenez demonstrated non-statistically significant finding for both duration use 
of less than 10 years or more than 10 years in comparison of non-users of aspirin 
on prostate cancer risk at adjusted OR =0.92 (95%CI: 0.65-1.29) and 1.14 
(95%CI: 0.79-1.65) respectively (Menezes et aI, 2006). 
On the other hand, a case control study by Perron using data from Quebec health 
insurance database of 2,221 cases and 11,105 control subjects, showed that 
aspirin use was associated with protection against prostate cancer after usage for 
5 years or more with OR=0.70 (95%CI: 0.520-0.950) Jacobs et al. (2005). in 
their American Cancer Society's Cancer Prevention Study II Nutrition Cohort of 
70,144 men, found the association only statistically significant after 5 years use 
at rate ratio (RR) at 0.85 (95% CI: 0.73-0.99) (Perron et ai, 2003). 
Similarly, Liu found 6 years or more of aspirin usage reduced risk of prostate 
cancer by almost 50% (OR= 0.54, with 95%CI: 0.37-0.78) (Liu et aI, 2006). The 
protective effect was also reported by Dasgupta. They collected data from 
Canadian Quebec population and found a 20% risk reduction with aspirin used 
more than 120 days (OR=0.84, with 95%CI: 0.74-0.96) (Dasgupta et aI, 2006) . 
Another study by Jacob reported using aspirin dosage of adult-strength of 32Smg 
minimum per day of 5 years or more had statistically rate ratio, RR at 0.81 
(95%CI: 0.70-0.94) (Jacobs et aI, 2007b). Similar finding was reported by 
Salinas in their Washington population. They reported only those using aspirin 
more than 5 years had statistically significant protective risk of prostate cancer at 
adjusted OR=0.76 (95%CI: 0.61-0.96) (Salinas et ai, 2010). 
Most studies have indicated that long term use of aspirin was statistically 
significantly associated with reduction in prostate cancer risk. However these 
studies defined long term as 4 -6 years onwards as long term. 
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8.6.1.3 Conclusions and Recommendations 
Our study using the fully adjusted multivariate regression model did not show a 
statistically significant association between usage of aspirin and prostate cancer 
risk although the OR values are less than 1.0. There was also no indication that 
longer use of aspirin would have any beneficial effect on reduction on prostate 
cancer risk, p-trend value was at 0.196 
Some of the limitations in this study is the lack of data on aspirin actual dosage 
and regularity, as well as small number of subjects of exposure compared to non-
exposed. Furthermore, the information of whether the current usage of aspirin 
should be taken into account in analysis as there are studies that have shown the 
need to differentiate the regularity of previous or recent duration. Even if data of 
regularity and doses are obtained, it would probably be data based on most 
recent dosage and regularity, which is recallable, compared to say five or ten 
years back. Further study should be made in looking at whether minimal dosage 
daily or regularity of aspirin usage as definition to ever use of aspirin, more 
specific history on aspirin consumption and reasoning of taking it, as well as 
usage of aspirin prescription from the medical record as a better choice indication 
of ever use aspirin and dosage wherever possible. 
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8.6.2 Ibuprofen 
Ibuprofen use 
The distribution of ibuprofen use (refer Table 8-6 on page 8-149) showed that 
there was no differences in the proportions between cases and control subjects 
with chi square p value of 0.55 and univariate analysis odds ratio of 0.93 (95% 
CI: 0.72-1.19) indicates that by taking ibuprofen at least one tablet per week for 
more than three months in the last 10 years did not associate with prostate 
cancer risk Table 8-7 page 8-150. In the age adjusted model, the odds ratio 
remained not statistically significant at p=0.106, OR=0.810 (95%CI: 0.627-
1.046). However with full adjustment of multivariate confounders, the odds ratio 
became borderline statistical significant at p=O.Os7 (OR = 0.771, 9s%CI: 0.591-
1.01) suggesting a protective effect of prostate cancer among ibuprofen user. 
There are not many studies that identify ibuprofen specifically in the NSAIDs 
group of drugs when trying to associate it with prostate cancer risk. In a case-
control study by Liu in Cleveland Ohio of 1012 subjects, showed ibuprofen use 
was not aSSOCiated with advanced prostate cancer risk at p value 0.22 and 
adjusted OR=0.79 (9s%CI: 0.54-1.16) (Liu et ai, 2006). Another study by 
Salinas which was population based case control using 1001 cases and 942 age-
matched control subjects from King County in Washington, also reported no 
association between non-aspirin NSAIDs (approximately half of subjects used 
ibuprofen) and prostate cancer risk (OR 1.05, 9s%CI: 0.84-1.32). The estimated 
risks for former user and current user In comparison with non-aspirin NSAIDs 
user also were also not statistically significant (Salinas et ai, 2010). 
Other studies of non-aspirin NSAIDs which did not specify the types used showed 
non-statistical significant association with prostate cancer risk include Rodriguez 
& Gonzalez-Perez (data based on current use, OR=1.14 (9s%CI: 1.00-1.29) 
(Garcia Rodriguez, 2004), and also Daniels but no specific p value given (Daniels 
et ai, 2009). 
However some studies indicated a risk reduction against prostate cancer with 
usage of non-aspirin NSAIDs. Dasgupta using Quebec Canada population of 
nested case control study, found statistically significant OR of 0.71 (9s%CI: 0.58-
0.86) suggesting risk reduction of prostate cancer among non-aspirin NSAIDs 
users (Dasgupta et aI, 2006). 
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In contrast, an earlier study by Langman on the UK population using general 
practice database of Department of Health of 1813 cases and 5354 control 
subjects found increased risk to prostate cancer among NSAIDs (mixed with 
aspirin) users (Langman et ai, 2000). 
The limitation in this study is the number of ibuprofen users in study subjects was 
small. There was also possible that ibuprofen users are also users of other types 
of non-aspirin NSAIDs thus suggesting difficulties in studying just a specific type 
of NSAIDs. The different findings across studies could also possibly due to 
different definition for user between studies. 
8.6.2.1 Duration of Ibuprofen usage 
Results from Table 8-8 on page 8-151, showed univariate and adjusted model 
analysis In this study did not show any statistical significant trend association 
between duration usages of ibuprofen to prostate cancer risk. Data from 
literature suggested not many studies investigated ibuprofen in association with 
prostate cancer risk. One case-control study comprised of 1012 men with 506 
cases and 506 age & ethnic matched controls in Ohio, USA showed non-statistical 
significant when ibuprofen was used for less than 4 pill-years period, however 
ibuprofen used beyond 4 years was statistically significant with protective effect 
against prostate cancer (OR=0.44 with 95%CI: 0.22-0.87). Most studies would 
describe ibuprofen as a group of non-aspirin NSAIDS, and these studies have 
shown the mixed effect of non-aspirin NSAIDS on prostate cancer. Long term 
exposure on non-aspirin NSAIDs in study by Dasgupta showed protective effect 
against prostate cancer at OR=O.71 (95%CI: 0.58-0.86) (Dasgupta et ai, 2006), 
while Rodriguez & Gonzalez-Perez found significant association at any duration of 
usage (Garcia Rodriguez, 2004). 
P for trend in our study on usage duration of ibuprofen was not significant at 
p=0.920. Similar results were also reported In other studies. Perron reported 
non-aspirin NSAIDs p-trend with duration of exposure at p=0.152 (Perron et ai, 
2003), while Rodriguez & Gonzalez-Perez showed p-trend value of 0.12 (Garcia 
Rodriguez, 2004). Another study on ibuprofen also showed p for trend at 0.08 
(Liu et ai, 2006). 
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8.6.2.2 Ibuprofen Cumulative Duration of Use 
The cumulative duration of use results (time of the use of up to 5, 10, 15, 20 and 
40 years period) showed no statistically significant association between each 
category of cumulative usage of ibuprofen to prostate cancer risk, although all 
ORs values were less than 1.0 (Table 8-10, page 8-154). 
The findings suggested that cumulative use of ibuprofen doesn't provide any 
protection against prostate cancer. 
A study by Perron on non-aspirin NSAIDs usage of 1 year or more and 
subsequent interval increase of 1 year in each category also found all association 
with prostate cancer as not statistically significant (Perron et ai, 2003). Similar 
non-statistically significant findings in association prostate cancer risk were also 
reported in studies by Rodriguez & Gonzalez-Perez and Salinas when trying to 
look at different categories of numbers of years exposure to ibuprofen or non-
aspirin NSAIDs (Garcia Rodriguez, 2004; Salinas et ai, 2010). 
In contrast, Dasgupta found that non-aspirin NSAIDs categories use of 60 days or 
higher was statistically significantly associated with reduced risk of prostate 
cancer at OR=O.77 (95%CI: 0.60-0.98) (Dasgupta et ai, 2006). Liu also found 
protective effect against advanced prostate cancer for those who use ibuprofen 4 
years or more at p=0.02 and OR=0.44 (95%CI: 0.22-0.87) (Liu et ai, 2006). 
One of the limitations in our study Includes the lack of information on details of 
ibuprofen use to enable stratification of data as current users or former users. 
Our definition for 'ibuprofen user' may not be comparable with other studies. 
The fact that there are a number of various types of non-aspirin NSAIDs, it is 
impossible to isolate the effect of ibuprofen with prostate cancer as the data 
collected could be mixed with other NSAIDs and not just ibuprofen alone. 
8.6.2.3 Conclusions and Recommendations 
There is no association between ibuprofen use and prostate cancer risk in this 
study. Suggestion would be to collect the types of NSAIDs in more detail manner 
with specific classifying recent or former user, as well as dosage and regularity of 
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consuming them. These further information would allow the analysis of true 
effect of the drug on prostate cancer risk. 
8.6.3 Paracetamol 
Paracetamol use 
The results from cross-tabulation table (see Table 8-11 page 8-155) showed a 
slightly higher proportion of paracetamol users among controls as compared to 
cases (Chi-square test p value 0.233). The regression model adjusted for age and 
potential multivariate confounders did not show any statistical significances 
(OR=0.828, 95%CI: 0.665-1.031 and OR=O.800, 95%CI: 0.634-1.009, 
respectively) . 
Our findings are in agreement with most studies in the literature that investigated 
paracetamol use and prostate cancer risk. A large cohort study on paracetamol in 
North Jutland county in Denmark using Pharmacoepidemiologic Prescription 
Database of 51,935 which represented 9% of the county population by Friis on 
many types of cancers including prostate cancer reported the standardized 
incidence ratio (SIR) for prostate cancer among paracetamol users was 1.0 
(95%CI: 0.9-1.3). Further exclusion of those who received prescription of 
Aspirin/NSAIDs prior or within one year after receiving to first prescription of 
paracetamol analysis also revealed SIR of non-statistically significant at 0.8 
(95%CI: 0.5-1.3) to prostate cancer risks among paracetamol users (FrIIs et a/, 
2002). 
Platz also using prescriptions to assess exposure on 1244 males of Baltimore 
Longitudinal Study of Aging population showed non-statistical significant 
association between paracetamol use and prostate cancer at rate ratio, RR=0.89 
(95%CI: 0.59-1.34) of ever use and 0.69 (95%CI: 0.39-1.20) for current use of 
paracetamol (Platz et ai, 2005). While Murad in their nested case control within 
ProtecT study (an on-going multicentre randomized controlled trial across UK) 
reported no association at OR=1.15 (95%CI: 0.86-1.53) after adjusted for any 
aspirin or non-aspirin NSAIDs used (Murad et ai, 2011). 
8.6.3.1 Duration of Par.cetamol Usage 
The results suggested that only those who used paracetamol for a period of 
between 20 years or more but less than 30 years would benefit a protective effect 
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against prostate cancer, as reported in the age-adjusted and multivariate-
adjusted regression models at OR 0.501 (95%CI: 0.272-0.921) and 0.534 
(95%CI: 0.287-0.993) respectively (Table 8-14 page 8-158). 
Previous case-control studies on acetaminophen effect on prostate cancer did not 
show any statistically significant association (Murad et ai, 2011; Salinas et ai, 
2010). Similarly results also reported in cohort and incidence studies (Friis et ai, 
2002; Platz et ai, 2005). These studies defined paracetamol as 'ever use'. 
There was no significant trend across categories. The fully adjusted model with 
potential multivariate confounders also showed a non significant p trend = 0.165 
and OR=0.925 (95%CI: 0.830-1.032) (result not presented in this thesis). 
There is one study in the literature that disagrees with our findings. The study by 
Rodriguez & Gonzalez-Perez used data from the UK General Practice Research 
Database (GPRD) and had shown p trend value of 0.02. Although the current use 
compared to non-user of paracetamol has non-statistically significant OR of 0.95 
(95%CI: 0.84-1.07), their study however showed the categories of longer 
duration of paracetamol usage showed reduction in prostate cancer (Garcia 
Rodriguez, 2004). 
Most other studies did not perform p-trend value for paracetamol probably 
because of the inconsistence OR value with each category of duration use. 
8.6.3.2Paracetamol Cumulative Duration of Use 
The result of univariate analysis of the different categories of duration usage of 
paracetamol in comparison with those who are non-user did not show any 
statistical significance, all the OR values were less than 1.0, all CIs Included 1. 
However in the multivariate adjustment of all potential confou nders, the 
estimated risks for paracetamol use of up to 20, 30, 40 and 50 years became 
statistically significant at OR=0.713 (95%CI: 0.513-0.990), 0.703 (95%CI: 
0.518-0.954), 0.720 (95%CI: 0.538-0.965) and 0.745 (95%CI: 0.560-0.991) 
respectively (Table 8-15 page 8-160). These results suggested that longer term 
paracetamol use reduce prostate cancer risk among users as compared to non-
users. 
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Other studies on duration use of paracetamol on prostate cancer risk showed 
mixed results. For example, a study by Platz reported non-statistical significance 
at RR=0.93 (95%CI: 0.61-1.44) and 0.88 (95%CI: 0.34-2.33) for less than 4 
years and 4 years or more respectively (Platz et ai, 2005). Rodriguez & 
Gonzalez-Perez however found that paracetamol at 1-2 years and 4 years or 
more showed statistically significant risk reduction (OR=0.67, 95%CI: 0.49-
0.92) and 0.50, 95%CI: 0.38-0.65 respectively) (Garcia Rodriguez, 2004). 
8.6.3.3 Conclusions and Recommendations 
In this study, paracetamol use was not associated with prostate cancer risk. 
There was also no indication of trend across increase duration. However the 
cumulative odds ratios for usage of paracetamol use of up to 20, 30, 40 and 50 
years were statistically significant in multivariate adjusted model with reduction in 
prostate cancer risk. 
In order to interpret the result validly, it is important to further look at possible 
existence of confounders due to other painkiller medication such as NSAIDs 
because their similarity in mechanism of action. 
Among three drugs, paracetamol is the most frequent use as compared to others. 
It would be difficult to conclude that this is a true effect because we are unable to 
identify subjects who only used paracetamol not other pills (due to small numbers 
making estimated risk less precise). 
Further study would need to use reporting using prescription as such. Since 
paracetamol is widely available over the counter and many brands existed and 
probably not monitored properly, would result in mixed efficacy at its function as 
COX inhibitors for inflammatory process. 
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Chapter 9 Skin Complexion, Colour, Sun effect and 
Sunlight Exposure 
9.1 Literature Review 
9.1.1 Skin type, sun effect, sun protection behaviour &. Prostate cancer 
The study of skin type and prostate cancer are scarce in literature however the 
association of skin type and other cancers such as skin cancer i.e. basal cell 
carcinoma and melanoma are many due to the fact for its organ related. The 
type of skin complexion and colour were found to be of relevant to the manner of 
skin reaction towards exposure such as how well individuals sunburn or suntan 
(Astner & Anderson, 2004). Fitzpatrick Skin Phototypes is widely used for 
estimating UV (ultraviolet), photochemotherapy and ultraviolet A radiation 
(PUVA) laser treatment doses. 
Different skin phototype and complexion would react differently towards long 
hours of exposure to sunlight. Skin phototype was used in studying the risk of 
skin cancer with highest risk among type I and lowest risk In type VI. Astner & 
Anderson also described based on the table below that skin phototype I to VI are 
constitutive of colour from Ivory white to White, then Beige-Olive to moderate 
brown, and lastly dark brown to black (Astner & Anderson, 2004). Burns occur 
mostly among the fairer skin, while tanning occur best among the darker skin, 
with in-between having both processes. 
Table 9-1 Skin Phototype based on susceptibility to sunburn in sunlight 
and tanning ability 
Skin Phototype Sunburn Susceptibility Tanning Ability 
I High None 
II High Poor 
III Moderate Good 
IV Low Very Good 
V Very Low Excellent 
VI Very Low Excellent 
, th Adapted from. Fitzpatrick s Dermatology In General Medlclne.7 Edition. 2008 
(Fitzpatrick & Wolff, 2008) 
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Sunburn and tanning are the most obvious effects of ultraviolet radiation (UVR) 
acute clinical effects (Fitzpatrick & Wolff, 2008). This was useful in describing the 
sun-sensitivity according to skin phototype as shown in Table 9-1 above. Most 
human ultraviolet radiation comes from sunlight but use of tanning devices is 
increasingly popular. Sun ultraviolet radiation exposure could be intentional or 
unavoidable and much is depended on behaviours and time spent outdoors, as 
well as any usage of photoprotection strategies. 
Although ultraviolet radiation (UVR) was recognized as a risk to skin cancer 
(Fitzpatrick & Wolff, 2008), there is interest that sunlight UVR interaction with 
skin type might show association towards internal cancers such as lymphoid 
malignancies. There are studies suggesting a positive association between most 
reactive and palest skin types with non-Hodgkin lymphoma (NHL) and Hodgkin 
lymphoma (HL) (Grandin et ai, 2008). 
The mechanism on how skin type and internal cancers such as prostate cancer 
were related is still unclear although Vitamin D was Implicated through its 
synthesis by sunlight (Bodiwala et ai, 2003a). A case-control study was 
conducted on 453 prostatic adenocarcinoma cases and 312 benign prostatic 
hypertrophy (BPH) control subjects by Bodhiwala to look at how the ability to 
pigment as assessed by skin type, influences the extent of exposure to UVR and 
whether skin type is associated with prostate cancer susceptibility. The results 
showed that prostate cancer subjects with sensitive to sun i.e. skin type type 1 
(always burn or never tan), had lower cumulative exposure of sunlight per year at 
statistically significant p=O.0014 and lower sunbathing score (p<0.0001) in 
comparison with type 4 (rarely burn or easily tan), possibly due to tendency to 
avoid exposure. The study also showed that cumulative exposure to sunlight per 
year and sunbathing score were significantly lower in cancer cases than BPH 
control at p<O.OOl and p<O.OOl respectively. However there was no association 
between skin type 1 versus type 4 and prostate cancer risk. 
The usage of childhood sunburn history was also associated with reduced prostate 
cancer risk in some studies (Bodiwala et ai, 2003a; Bodiwala et ai, 2003b; 
Luscombe et ai, 2001). 
The author has not yet found articles that described specifically the habits use of 
protective clothing from the sun with the prostate cancer risk. It is possible at 
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this time, more studies has been carried out to see using variables on usage of 
protective clothing against long exposure of daylight towards confounding the 
affect of sunlight exposure on subject by reducing the actual amount of sunlight 
received and consecutively of lesser Vitamin D production than intended. 
In terms of suntan cream usage habit to avoid getting sunburn or reduce skin 
reactions due to long exposure under the sun, the author did not find direct any 
study association with prostate cancer, although it was reported higher SPF (sun-
protection factor) seems to increase duration of recreational sun exposure of 
young Europeans (Autier et aI, 1999). 
9.1.2 Sunlight, Vitamin D " Prostate cancer 
The study of relationship of sunlight or ultraviolet radiation exposure and prostate 
cancer in the last decade has been of interest especially when trying to 
investigate how sunlight and vitamin D could be related. Proposed mechanisms of 
how sunlight exposure and vitamin D are related to cancer has been described in 
literature. 
Glovannucci described (refer Figure 9-1, page 9-175) how ultraviolet radiation 
(UVR) is required to convert 7-dehydrocholesterol into vitamin D (cholecalciferol) 
in the skin. Vitamin D main sources are sunlight and diet or supplements. 
Vitamin D are then hydroxylated in the liver to produce 25(OH)D which in the 
blood circulation concentration is the best indicator for vitamin D status. 
2S(OH)D may be converted into 1,25{OHhD by kidney 1-alpha-hydroxylase 
regulation activity. Darker skin due to melanin, aging and obesity has been 
associated with reduction production of 2s(OH)D (Giovannucci, 2005). 
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Figure 9-1 Proposed pathways Vitamin 0 production and metabolism in 
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Through circulation, various cells are exposed to either 25(OH}D or l,25(OHhD. 
It was through this mechanism that levels either one or both types of vitamin 0 
could affect cancer risk by inhibiting tumour growth by controlling cell 
differentiation and proliferation (Schwartz, 2005). However the levels or 
concentration of these hydroxylated forms of vitamin D could be directly 
associated with amount of sources of vitamin D such as sunlight UVR, 
diet/supplements, and regulation of activity of enzymes or hormones of liver, 
kidney and parathyroid such as l-alpha-hydroxylase, parathyroid hormone, as 
well levels of calcium, phosphorus etc. 
1 Adapted from Giovannucci E (2005) The epidemiology of vitamin D and cancer 
incidence and mortality: a review (United States). Cancer Causes Control 16(2): 
83-95. 
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Several studies have shown that increased cumulative sunlight or ultraviolet 
radiation exposure has been associated with reduced risk in prostate cancer 
(Bodiwala et ai, 2003a; Bodiwala et ai, 2003b; John et ai, 2004; John et ai, 2007; 
Rukin et ai, 2007). 
Ecological studies use trend surface analysis or mapping to define the residence 
amount of ultraviolet (UV) sunlight exposure or residential sunlight for early life 
(Freedman et ai, 2002; John et ai, 2004; John et ai, 2007; Schwartz & Hanchette, 
2006). Most of these studies were American studies therefore the results 
somewhat share the similar conclusions. Those who reside or longest reside in 
the South (nearer to earth Equator) or born in the state with the hig hest solar 
radiation have reduced relative risk for prostate cancer (John et ai, 2004; John et 
ai, 2007) or reduce mortality rate for prostate cancer (Freedman et ai, 2002; 
Schwartz & Hanchette, 2006). 
Similarly studies assessed history of regular sunbathing and foreign holidays were 
also showed association with reduction in prostate cancer risk (Bodiwala et ai, 
2003a; Bodiwala et aI, 2003b; John et aI, 2007; Luscombe et ai, 2001). While 
some use place of birth as a measure of UVR level and also showed decreased 
risk in prostate cancer with lower latitude area (John et aI, 2004; John et ai, 
2007). 
However, when circulation plasma levels of vitamin 0 such as 2S(OH)O are used, 
it was not associated with prostate cancer risk (Ahn et aI, 2008; Barnett et aI, 
2010; Park et ai, 2010). 
9.2 Alms 
The aims of this chapter are to Investigate the relationship of the following factors 
with prostate cancer risk: 
i. Skin complexion 
ii. Skin colour 
iii. Types of sun effect reactions 
iv. Sunlight exposure time during outworking 
v. Sunlight exposure time during non-working 
vi. Habits of protection when exposed to sunlight 
vii. Frequency usage of suntan cream 
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The above factors are used as surrogate marker for vitamin D sources from 
sunlight exposure and prostate cancer risk was also reviewed. The dietary intake 
of vitamin D in association with prostate cancer would be discussed in another 
chapter of this thesis in the diet topic. 
We proposed a scoring method for prostate cancer risk, by combining the above 
variables as surrogate markers for Vitamin D production through skin and 
sunlight exposure. 
9.3 Methodology 
Only data collected in Phase II of the study was used in all analyses. The total 
number of subjects is 2209. Data were self reported on: 
i. Skin complexion type 
ii. Skin colour when not sun tanned 
iii. Effect of too long under the sun on skin 
iv. Amount of hours outdoor during daytime working or non-working at age 
20's, 30's, 40's, and last 5 years 
v. Habits of protection when outdoors in the day time at age 20's, 30's, 40's, 
and last 5 years 
vi. Frequency usage of suntan oil, lotion or cream to protect skin when out in 
the sun at age 20's, 30's, 40's, and last 5 years 
vii. Scoring for each aspect in proposed table scoring method for prostate 
cancer risk 
9.3.1 Definition 
Skin complexion choice of answers was of oily, dry, combination or normal. Skin 
colour when not sun tanned and effect of too long under the sun on skin, were 
choice answers loosely based on Fitzpatrick classification scale that was 
developed in 1975 by Harvard Medical School dermatologist, Thomas Fitzpatrick. 
The scale classifies a person's skin and their tolerance to sunlight as shown in 
Table 9-2 on page 9-178: 
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Table 9-2 Fitzpatrick Skin Classification (1975) 
Skin Skin Colour Characteristics 
Type 
I White; Fair Always burn, never tans 
II White; Fair Usually burns, tans with difficulty 
III Cream white; fair Sometimes mild burn, gradually tans 
IV Brown; typical Mediterranean skin Rarely burns, tans with ease 
V Dark brown; mid-eastern skin Very rarely burns, tans very easily 
VI Black Never burns, tans very easily 
For skin colour, choices provided in the study questionnaire are very fair, fair, 
medium, olive and very dark. For sun effect on skin, answer choices are painful 
bad blistering peeling, blistering followed by peeling, burns sometimes, rarely 
burns and never had bourns. 
The subjects were further asked to identify on average number of hours they 
were spent time outdoor during working and non-working hours at various stages 
in life as markers of probable sunlight exposure. The ranges are from less than 1 
hour, 1-2 hours, 3-4 hours and 5 hours or more. They were also asked to record 
if they used any protection from the sun when they were outdoor with choices of 
answer ranging from; always seek a sun tan, wear very little, wear normal 
summer clothing, try to cover oneself up from the sun, and did not spend time 
outdoors at all. 
Lastly the frequency of using suntan oil, lotion or cream when they were out in 
the sun; from always, sometimes to rarely or never. 
9.3.2 Analysis 
Data were analyzed descriptively and p value for trend analYSis was performed 
with variables of ordinal scales. Chi-square test was carried out to see any 
differences in the distributions of answers between cases and controls. 
Logistic regressions are carried out to yield risk estimates and their confident 
intervals. The models include univariate, followed by age-adjusted modelling and 
lastly fully adjusted multivariate potential confounders including education, ethnic 
and family history of cancer with a-priori variable of age and skin colour. 
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For outdoor daylight exposure during working and non-working, duration of 'less 
than 1 hour' daily was used as reference. Whereas for protection habits when 
under the sun, 'always seek a sun tan' was used as reference category, and 
regression modelling for suntan cream frequency usage, 'never use suntan' was 
the reference category. 
proposed Scoring Method for Vitamin D and prostate Cancer Risk 
Since vitamin D exposure can be affected by factors relevant to skin and sunshine 
exposure, as well as diet, therefore we proposed a scoring method by applying a 
surrogate score to each of the factors for each individual. The scores were then 
summed to obtain a total single score of probable vitamin D exposure at various 
stages in life. The scoring table is summarized in Table 9-3 page 9-181. The 
factors in the study questionnaire were put together in the table. 
The fact that more than 90% of vitamin D requirement comes from source of 
casual exposure to sunlight (Gillie, 2006). Dietary intake of vitamin D source is 
probably the balance of 10%. Ideally, the calculation of total sum scores should 
apply this principal of ratio 90%: 10% between vitamin D source from skin and 
sunlight and dietary intake. However the study only collected diet history over the 
last 5 year whilst skin and sunlight exposure was available throughout lifetime 
(20s, 30s, 40s and during the last 5 years) thus limit the application of scoring 
method throughout lifetime exposure. The total sum score of vitamin D exposure 
at age 20s, 30s and 40s was calculated from skin and sunlight exposures. The 
total sum score of vitamin D exposure during the last 5 years was calculated from 
skin/sunlight exposure and dietary Intake of vitamin D during the last 5 years. 
Vitamin D exposure during the last 5 years 
The skin *'d sunlight exposures consist of 7 variables and total vitamin D intake 
is a single variable. 7 out of 8 aspects of scoring is equivalent to proportion of 
87.5%. Similarly, the possible maximum total score obtained from skin and 
sunlight source of vitamin D is 30. Dietary vitamin D maximum score is 4 making 
a total possible maximum score of 34 (when combining skin/sunlight vitamin D 
and dietary intake vitamin D) therefore at score of 30 from sunlight and skin 
exposure alone (30 out of maximum 34) is equivalent to proportion of 88.2%. 
The maximum score of 4 from diet alone Is equivalent to 11.8%. 
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Possible derived score 
For vitamin D exposure during the last 5 years, the lowest and highest possible 
total score is 8 and 34 respectively. For vitamin D at age 20s, 30s and 40s, the 
possible score range from 8-30. 
The sum score of each individual at each period in life was then assigned into 
quartile range based on control scores. The total score would be greater for those 
who have more sunlight exposure and Vitamin D production by skin or highest 
quartile dietary intake of vitamin D. The hypothesis is that higher score leads to 
lower risk for prostate cancer, at the same time, lower score means higher risk to 
prostate cancer. 
Logistic regression was carried out to obtain odds ratiOS and confidence intervals 
and trend of risk across quartiles was also assessed. 
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Table 9-3 Proposed Scoring Method for aspects of Skin complexion, colour, Sun effect, Working &. non-working Sunlight 
exposure, Protection clothing used and Suntan cream usage affecting habits to be under the sun, for subsequent effects on 
duction by Skin. and _0 
- ---------- - - - - ---- - -- - -- - - - --- --- -- - -----
- --------- -
Score 
Aspects 5 4 3 2 1 Aspect Score 
Skin Complexion Normal Combination Dry Oily 
Skin Colour Very dark Olive Medium Fair Very Fair 
Sun effect Never bums Rarely burns Burn sometimes Blister with peeling Painful blister and peeling 
Working Sunlight 
- 5 hours or more 3 to 4 hours 1 to 2 hours <1 hour exposure daily 
Non-working Sunlight 
- 5 hours or more 3 to 4 hours 1 to 2 hours <1 hour exposure daily 
Always seek a sun Wear normal Try to cover up from the Protection habits - Wear very little sun or did not spend time tan summer clothing outdoors at all 
Suntan cream usage - Always Sometimes Rarely Never 
Dietary Intake Vitamin 
4th Quartile 3rd Quartile 2nd Quartile 1st Quartile D Amount* 
--
- .. -
___________ ~ _ _ _ T o t a L S c ~ r e _ _
Example: 
A White man at age 20's with dry skin complexion, fair skin colour, who experienced blister with peeling when spend a few hours under sunlight with less 
than 1 hour under the sun while working but spend 3 to 4 hours under sunlight when not working, and habits of wearing normal summer clothing when 
exposed to sunlight, sometimes use suntan cream and dietary intake of Vitamin D at 2nd quartile, would score = 2+2+2+1+3+2+3 + 2= 17 
Score 17 is the possible amount of Total Vitamin D production by skin and dietary intake at age 20's for association study for prostate cancer risk. 
*Dietary Intake Vitamin D amount was taken only for last 5 years, therefore only used when scoring for age period 'last 5 years'. 
I 
9.4 Results 
9.4.1 Skin Complexion 
Ta bl 9 Sk' C e -4 In h I I b omDI eXlon c aracter st cs etween C C t I G up ase- on ro ro 
Group 
Complexion Control Case Total 
0/0 % 0/0 
86 146 232 
Oily 
10.4% 10.7% 10.6% 
90 159 249 
Dry 
10.9% 11.7% 11.4% 
90 186 276 
Combination 
10.9% 13.7% 12.6% 
562 869 1431 
Normal 
67.9% 63.9% 65.4% 
828 
Total 
1360 2188 
100.0% 100.0% 100.0% 
'Normal' skin complexion is the most common skin type among case and control 
groups at approximately two-thirds. The percentage of cases and controls 
reported oily, dry and combination are similar. Chi-square test (p value=0.185) 
did not show any statistical significant difference between skin types of case and 
control group. 
The logistic regression models displayed on Table 9-5 page 9-183 did not reveal 
any statistical significant association between different skin complexion with 
prostate cancer when compared to 'normal' skin. 
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Table 9-5 Odd I t ~ ~
- -- - - - - - -- - - - - - - - - -
d 95% Confid Int 
- - - - - - --------- ------ --
Skin Complexion Control 
Normal 562 67.9% 
Oily 86 10.4% 
Dry 90 10.9% 
Combination 90 10.9% 
aUnadjusted regression model 
bAge-adjusted regression model 
cases 
ORa 
(950f0CI) 
869 
-Ref-63.9% 
146 1.098 
10.7% (0.824-1.463) 
159 1.143 
11.7% (0.864-1.511 ) 
186 1.337 
13.7% ( 1.017-1.756) 
I of Sk· d Prostate C Risk 
-_. ----- -------- ----- - - --_.--- ---- --- ------
p ORb P ORc 
value- (950f0CI) valueb [95%CI) 
- -Ref- - -Ref-
0.523 0.983 0.911 0.898 (0.733-1.320) _(0.660-1.223J 
0.350 1.136 0.382 1.133 (0.853-1.513) _{0.839-1.529 J 
0.037 1.110 0.469 0.985 (0.838-1.470) (0.735-1.321) 
\0 CMultivariate adjusted regression model for age, education, ethnic, and family history of cancer 
~ ~ P for trend = 0.231 (X) 
w 
p 
valuec 
-
0.496 
0.416 
0.922 
9.4.2 Skin Colour 
Table 9-6 Distribution of skin colour in studY subiects 
Group 
Colour Control Case Total 
0/0 % 0/0 
39 77 116 
Very Fair 
4.7% 5.6% 5.3% 
313 510 823 
Fair 
37.8% 37.4% 37.6% 
443 695 1138 
Medium 
53.6% 51.0% 52.0% 
29 61 90 
Olive 
3.5% 4.5% 4.1% 
3 20 23 
Very Dark 
0.4% 1.5% 1.1% 
827 1363 2190 
Total 
100.0% 100.0% 100.0% 
'Medium' skin colour was the most common reported at approximately 52%, 
followed by 'fair skin' at 37%. There is no difference in skin colour between both 
cases and controls (Chi-square test p value of 0.069). The odds ratios results of 
logistic regression models of skin colour on prostate cancer risk did not show any 
statistically significant association (refer Table 9-7 page 9-185). P for trend also 
was not statistically significant at 0.574 
9-184 
ID 
I 
.... 
(X) 
U1 
Table 9-7 Odds ratios and 950/0 Confidence Interval of Skin Colour and Prostate Cancer Risk 
Skin Colour Control 
Very Fair 39 4.7% 
Fair 313 37.8% 
Medium 443 53.6% 
Olive 29 3.5% 
Very Dark 3 0.4% 
aUnadjusted regression model 
bAge-adjusted regression model 
Cases 
77 
5.6% 
510 
37.4% 
695 
51.0% 
61 
4.5% 
20 
1.5% 
OR- p ORb P 
(950f0CI) value- (950f0CIl valueb 
Ref - Ref -
0.825 0.359 0.929 0.730 (0.548-1.244) (0.610-1.413) 
0.795 0.264 0.859 0.470 (0.531-1.189) (0.569-1.298) 
1.065 0.832 1.099 0.758 (0.593-1.915) (0.603-2.000) 
3.377 0.061 3.584 0.052 (0.945-12.062) (0.989-12.984) 
--
CMultivariate adjusted regression model for age, education, ethniC, and family history of cancer 
P for trend = 0.574 
ORc P (950f0CI) valuec 
Ref -
0.917 0.702 (0.590-1.427) 
0.812 0.346 (0.526-1.253 ) 
0.920 0.801 (0.482-1.756) 
1.905 
(0.454-7.994) 0.378 
- - - - - - - - - ~ - - - - - -
9.4.3 Sun Effect reaction on skin 
Ta bl e 9-85 ff un E ect reactions on skin between case-control group 
Group Total Sun effect Control Case 
0/0 0/0 0/0 
Painful bad blister II peel 
52 87 139 
6.3% 6.4% 6.4% 
Blister with peel 118 235 353 
14.3% 17.3% 16.2% 
426 684 1110 
Burns sometimes 
51.8% 50.5% 51.0% 
Rarely burns 
185 278 463 
22.5% 20.5% 21.3% 
Never had burns 42 
71 113 
5.1% 5.2% 5.2% 
823 1355 2178 Total 
100.0% 100.0% 100.0% 
Chi-square test p value=0,410 
Half of the subjects in case and control group reported having had burns 
sometimes when exposed to the sun under long duration. Second most common 
answer was 'rarely burns' at approximately 21% followed by 'blister with peel' at 
16%. Chi-square test did not show any statistically significant difference in the 
characteristics of sun effect reaction on skin between case and control group (p 
value=0,410). 
Results showed in Table 9-9 on page 9-187, suggested that different types of sun 
effect on skin did not associate with prostate cancer risk. P for trend also was not 
statistically sig nificant. 
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Table 9-9 Odds ratios and 95010 Confidence Interval of Sun Effect on Skin and Prostate Cancer Risk 
Sun Effect on Skin Control 
Painful bad 52 
blister. peel 6.3% 
118 Blister with peel 14.3% 
426 Bums sometimes 51.8% 
185 Rarely burns 22.5% 
42 Never had burns 5.1% 
aUnadjusted regression model 
bAge-adjusted regression model 
Cases 
87 
6.4% 
235 
17.3% 
684 
50.5% 
278 
20.5% 
71 
5.2% 
OR- P ORb P 
(950f0CI) valueB (950f0CI) valueb 
Ref - Ref -
1.190 1.340 0.170 0.403 (0.882-2.035) (0.791-1.791) 
0.960 1.015 0.937 0.825 (0.700-1.472) (0.667-1.381 ) 
0.898 1.042 0.839 0.590 (0.699-1. 555) (0.608-1.327) 
1.010 1.221 0.459 0.968 (0.605-1.688) (0.720-2.069) 
CMultivariate adjusted regression model for age, education, ethnic, and family history of cancer 
P for trend = 0.226 
ORc 
(95OfoCI) 
Ref 
1.350 
(0.870-2.094) 
1.024 
(0.692-1.516) 
1.090 
(0.715-1.664) 
1.090 
(0.611-1.943) 
p 
valuec 
-
0.181 
0.905 
0.688 
0.771 
9.4.4 Outdoor sunlight exposure while working 
Between ages 20s to 40s and over the last 5 years prior to case diagnosis or 
control to receiving their questionnaire (refer to Table 9-10 on page 9-188, Table 
9-11 on page 9-189, Table 9-12 on page 9-189, and Table 9-13 on page 9-190), 
the figures showed that almost half of subjects in both case and control groups 
reported exposed to the sunlight less than 1 hour while at work, while between 
20% to 23% worked between 1-2 hours outdoor, and less proportion exposed for 
more than 3 hours. With progression of age, it was observed that a smaller 
proportion of subjects of both cases and controls spent time working outdoor for 
5 hours or more, starting at 21% at age 20s down to 15% in the last 5 years. 
Table 9-10 Time spent outside at aae 20's among Case-control grouJ 
Working outside with Group Total 
sunlight exposure at age Control Case 
20's 010 a/a a/a 
Less than 1 hour 352 607 
959 
44.7% 47.6% 46.5% 
175 246 421 1-2 hours 20.4% 22.2% 19.3% 
3-4 hours 94 147 241 
11.9% 11.5% 11.7% 
5 hours or more 166 274 440 
21.1% 21.5% 21.3% 
Total 787 1274 2061 
100.0% 100.0% 100.0% 
Chi-square test p value=0.386 
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Ta bl 'd e 9-11 Time spent OUtSI e at age 30 s among Case-control group 
Working outside with sunlight 
Group 
Total 
exposure at age 30's Control Case 
0/0 0/0 0/0 
Less than 1 hour 355 600 955 
45.3% 47.2% 46.5% 
175 286 461 
1-2 hours 
22.5% 22.5% 22.3% 
3-4 hours 
111 153 264 
14.2% 12.0% 12.9% 
5 hours or more 142 231 373 
18.1% 18.2% 18.2% 
Total 783 
1270 2053 
100.0% 100.0% 100.0% 
Chi-square test p value=0.553 
T bl 9 12 T' t t'd t a e - Ime SDen ou SI e a aGe 4 0' S among C ase-contro arOUD 
Working outside with sunlight 
Group Total 
exposure at age 40's Control Case 
0/0 Ofo 0/0 
349 637 986 Less than 1 hour 
44.9% 50.6% 48.4% 
1-2 hours 202 276 478 
26.0% 21.9% 23.5% 
100 149 249 3-4 hours 12.2% 12.9% 11.8% 
5 hours or more 126 198 
324 
16.2% 15.7% 15.9% 
Total 
777 1260 2037 
100.0% 100.0% 100.0% 
Chi-square test p value=0.069 
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Table 9-13 Time spent outside in the last 5 years among Case-control 
group 
Working outside with sunlight 
Group Total 
exposure in last 5 years Control Case 
0/0 0/0 0/0 
Less than 1 hour 251 493 744 
44.9% 49.8% 48.1% 
137 210 347 
1-2 hours 
24.5% 21.2% 22.4% 
85 131 216 
3-4 hours 
15.2% 13.2% 14.0% 
86 155 241 
5 hours or more 
15.4% 15.7% 15.6% 
559 989 1548 Total 
100.0% 100.0% 100.0% 
Chi-square test p value=0.210 
All Chi-square tests for different decades of age did not reveal any statistically 
Significant difference in number of hours working outside between cases and 
controls. 
The p values for trend at all decades of age didn't reveal any statistically 
significant findings (P for trend at 20's p=0.645, at 30's p= 0.452, at 40's 
p=0.130 and last 5 years, p=0.283). 
The results of regression models for sunlight exposure when working outdoor are 
shown in Table 9-14 page 9-191). Univariate regression analysis showed 
statistically significant odds ratio (OR= 0.749, 95%CI: 0.599-0.936) in '1-2 
hours' category when compared with those 'less than 1 hour' of outdoor sunlight 
exposure while working during age 40's. 
For age-adjusted modelling, only '1-2 hours' category of outdoor sunlight 
exposure at age 20's was found to be statistically significant or prostate cancer 
risk association at OR=0.776 (95%CI: 0.610-0.988). All other regression models 
did not reveal any association between sunlight outdoor exposures while working 
with prostate cancer risk. 
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Table 9-14 Odds ratios and 95Ofo Confidence Interval of hours working outside at age 20's, 30's, 40's and last 5 
- -- -_ ...... -- --
Cancer Risk 
Age Amount of time 
Less than 1 hour 
1-2 hours 
20's 
3-4 hours 
5 hours or more 
Less than 1 hour 
1-2 hours 
30's 
3-4 hours 
5 hours or more 
Less than 1 hour 
1-2 hours 
40's 
3-4 hours 
5 hours or more 
Less than 1 hour 
1-2 hours 
Last 5 Years 
3-4 hours 
5 hours or more 
-- ---- ---
aUnadjusted regression model 
bAge-adjusted regression model 
Control Cases 
352 607 
44.7% 47.6% 
175 246 
22.2% 19.3% 
94 147 
11.9% 11.5% 
166 274 
21.1% 21.5% 
355 600 
45.3% 47.2% 
175 286 
22.3% 22.5% 
111 153 
14.2% 12.0% 
142 231 
18.1 % 18.2% 
349 637 
44.9% 50.6% 
202 276 
26.0% 21.9% 
100 149 
12.9% 11.8% 
126 198 
16.2% 15.7% 
251 493 
44.9% 49.8% 
137 210 
24.5% 21.2% 
85 131 
15.2% 13.2% 
86 155 
15.4% 15.7% 
OR- P OR" P ORc (95%CI) valuea C95%CI) valueb (95%CI) 
-Ref- -Ref- -Ref-
0.815 0.087 0.776 0.039 0.803 (0.645-1.030) (0.610-0.9S8) (0.623-1.034 ) 
0.907 0.940 0.954 
(0.678-1.212) 0.509 (0.697-1.267) 0.685 (0.598-1.304) 
0.957 0.713 1.024 0.847 1.006 (0.758-1.209) (0.805-1.302) (0.774-1.307) 
-Ref- -Ref- -Ref-
0.967 0.774 0.997 0.977 1.014 (0.769-1.216} (0.787-1.25U . {0.793·1.297J 
0.816 0.150 0.876 0.364 0.905 (0.618-1.0762 (0.659-1.165) lO.669-1.224) 
0.963 0.751 1.025 0.851 1.026 (0.752-1.232) {0.795-1.321J (0.774-1.358) 
-Ref- -Ref- -Ref-
0.749 0.011 0.800 0.832 (0.599-0.936) 0.057 (0.635-1.007) (0.654-1.059) 
0.816 0.163 0.869 0.348 0.870 (0.614-1.086) (0.649-1.165 ) (0.638-1.186) 
0.861 0.257 0.910 0.485 0.911 (0.665-1.115) (0.698-1.187) (0.675-1.229) 
-Ref- -Ref- -Ref-
0.780 0.065 0.815 0.134 0.856 (0.600-1.016) (0.623-1.065) (0.646-1.136) 
0.785 0.857 0.929 
(0.574-1.072) 0.128 (0.623-1.179) 0.342 to.661-1.306) 
0.918 0.580 0.990 0.949 1.087 (0.677-1.244) (0.726-1.350) 
.-
(0.767-1.541) 
CMultivariate adjusted regreSSion model for age, education, ethnic, family history of cancer and skin colour 
P 
valuec 
0.089 
0.768 
0.965 
0.912 
0.516 
0.860 
, 
0.136 
0.378 
0.543 
0.282 
0.672 
0.639 
9.4.5 Outdoor sunlight exposure while not working 
The results are shown in Table 9-15 page 9-192, Table 9-16 page 9-193, Table 9-17 
page 9-193 and Table 9-18 page 9-194. There are trends that control group spend 
longer hours (3 hours or more categories) outdoor to sunlight exposure on non-working 
setting, compared to case group who tended to spend 2 hours or less for sunlight 
exposure in all stage of age decades. 
Chi-square tests revealed all statistically significant p value of <0.001 which suggested 
that there is difference in the numbers of sunlight outdoor exposure while not-working 
at age 20's, 30's, 40's and last 5 years between case and control group. 
Table 9-15 Time spent outside when not working at age 20's among Case-
control group 
Non-working outside with 
Group Total 
sunlight exposure at age 20's Control Case 
0/0 0/0 0/0 
45 128 173 Less than 1 hour 8.9% 6.0% 10.7% 
306 533 839 1-2 hours 43.2% 41.1% 44.5% 
3-4 hours 265 360 
625 
35.6% 30.0% 32.2% 
5 hours or more 128 178 
306 
17.2% 14.8% 15.7% 
Total 744 1199 1943 
100.0% 100.0% 100.0% 
ChI-square test p<O.OOl 
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Table 9-16 Time spent outside when not working at age 30's among Case-
control group 
Non-working outside with 
Group 
Total Control sunlight exposure at age 30's Case 
0/0 0/0 0/0 
Less than 1 hour 43 123 166 
5.7% 10.2% 8.5% 
1-2 hours 306 540 846 
40.9% 44.9% 43.4% 
272 382 654 
3-4 hours 
36.4% 31.8% 33.5% 
5 hours or more 
127 157 284 
17.0% 13.1% 14.6% 
Total 748 
1202 1950 
100.0% 100.0% 100.0% 
Chi-square test p<O.OOI 
Table 9-17 Time spent outside when not working at age 40's among Case-
control group 
Non-working outside with sunlight 
Group Total 
exposure at age 40's Control Case 
010 0/0 0/0 
Less than 1 hour 49 137 186 
6.6% 11.4% 9.6% 
1-2 hours 302 541 843 
40.8% 45.2% 43.5% 
3-4 hours 
275 366 641 
37.2% 30.6% 33.1% 
5 hours or more 114 153 267 
15.4% 12.8% 13.8% 
740 1197 1937 
Total 
100.0% 100.0% 100.0% 
Chi-square test p<O.OOI 
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Table 9-18 Time spent outside when not working in last 5 years among Case-
control group 
Non-working outside with 
Group 
Total 
sunlight exposure in last 5 years Control Case 
0/0 0/0 0/0 
Less than 1 hour 53 160 213 
6.9% 12.9% 10.6% 
1-2 hours 242 475 
717 
31.4% 38.3% 35.7% 
3-4 hours 
279 401 680 
36.2% 32.3% 33.8% 
5 hours or more 196 
204 400 
25.5% 16.5% 19.9% 
770 1240 2010 
Total 100.0% 100.0% 100.0% 
Chi-square test p<O.001 
The estimated risks for prostate cancer risk with history of sunlight exposure while not 
working are shown in Table 9-19 page 9-195. The results suggested statistically 
significant throughout age decades at 20's, 30's, 40's and last 5 years in all univariate, 
age-adjusted and fully adjusted multivariate potential confounders and a-priori 
variables when all the categories of hours exposure to sunlight while they were outdoor 
being compared with those of 'less than 1 hour' with exception for multivariate adjusted 
model at age 30's for exposure of '1-2 hours'. The P for trend also showed in each 
stage of age decade showed statistically significant p<O.001. 
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Table 9-19 Odds ratios and 95% Confidence Interval of time spent outside when not working at age 20'5, 30'5, 40'5 and 
last 5 years on Prostate Cancer Risk 
Age Amount of time 
20's Less than 1 hour 
1-2 hours 
3-4 hours 
5 hours or more 
30's Less than 1 hour 
1-2 hours 
3-4 hours 
5 hours or more 
40's Less than 1 hour 
1-2 hours 
3-4 hours 
5 hours or more 
Last 5 Years Less than 1 hour 
1-2 hours 
3-4 hours 
5 hours or more 
iUnadjusted regression model 
bAge-adjusted regression model 
Control cases 
45 128 
6.0% 10.7% 
306 533 
41.1% 44.5% 
265 360 
35.6% 30.0% 
128 178 
17.2% 14.8% 
43 123 
5.7% 10.2% 
306 540 
40.9% 44.9% 
272 382 
36.4% 31.8% 
127 157 
17.0% 13.1% 
49 137 
6.6% 11.4% 
302 541 
40.8% 45.20/0 
275 366 
37.2% 30.6% 
114 153 
15.4% 12.8% 
53 160 
6.9% 12.9% 
242 475 
31.4% 38.3% 
279 401 
36.2% 32.3% 
196 204 
25.5% 16.5% 
OR" P ORb P 
(95DfoCI) value" (95DfoCI) valueb 
-Ref- -Ref-
0.612 0.009 0.629 0.016 
~ 0 . 4 2 4 - o . 8 8 4 4 ) (0.432-o.917) 
0.418 <0.001 0.498 <0.001 
(0.328-0.695 ) (0.339-0.7311 
0.489 0.001 0.501 0.001 
(0.325-0.136) (0.330-0.162) 
-Ref- ·Ref-
0.617 0.011 0.651 0.029 
(0.424-0.897) (0.444-0.956) 
0.491 <0.001 0.530 0.001 
(0.336-0.718) (0.359-0.783) 
0.432 <0.001 0.447 <0.001 
(0.284-0.657) (0.291-0.687) 
-Ref- -Ref-
0.641 0.014 0.663 0.028 
(0.449-0.914) (0.460-0.956) 
0.416 <0.001 0.497 <0.001 
(0.332-0.684 ) (0.342-0.721) 
0.480 <0.001 0.476 <0.001 
(0.320-0.721) (0.313-0.723) 
-Ref- -Ref-
0.650 0.015 0.615 0.007 
(O.460-o.920) (0.430-0.878 ) 
0.416 <0.001 0.498 <0.001 
(0.337-0.673) (0.349-o.711} 
0.345 <0.001 0.367 <0.001 
(0.239-0.498) (O.252-o.535) 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer and skin colour 
ORc P 
(95DfoCI) valuee 
-Ref-
0.671 0.045 
(0.454-0.992) 
0.541 0.003 
_(0.363-0.8061 
0.534 0.005 
(0.345-0.828) 
-Ref-
0.704 0.087 
(0.471-1.052) 
0.584 0.010 
(0.389-0.879 ) 
0.469 0.001 
(0.298-0.736) 
-Ref-
0.669 0.039 
(0.458-0.979) 
0.505 0.001 
(0.342-0.744) 
0.469 0.001 
(0.302-0.728) 
-Ref-
0.613 0.010 
(O.423-0.888 ) 
0.499 <0.001 
(0.345-0.722) 
0.380 <0.001 
(0.256-0.565) 
9.4.6 Protection habits while outdoor under the sun 
There is no difference over the habits of wearing protection when they spent time 
outdoor under the sun between cases and controls as indicative by Chi-square results 
(all p values are greater than 0.05) for all age decades (refer Table 9-20 page 9-196, 
Table 9-21 page 9-197, Table 9-22 page 9-197 and Table 9-23 page 9-198). However, 
it is evident that there are trends of protection habits change from less protection 
categories (as in 'always seek a sun tan' or 'wear very little') to more protection from 
the sun (as in 'wear normal summer clothing' or 'try to cover up from the sun') as 
subjects aged. The majority of the subjects in all decades reported 'wear normal 
summer clothing'. 
Table 9-20 Types of protection habits when spent time outdoor at age 20's 
t I among case-con ro grOUD 
Group 
Total Protection habits when outdoor at 
age 20's Control Case 
DID DID DID 
126 196 322 
Always seek a sun tan 
15.2% 14.5% 14.8% 
168 277 445 
Wear very little 
20.3% 20.4% 20.4% 
480 782 1262 
Wear normal summer clothing 
58.0% 57.7% 57.8% 
Try to cover up from the sun or did 53 101 154 
not spend time outdoors at all 6.4% 7.4% 7.1% 
827 1356 2183 
Total 
100.0% 100.0% 100.0% 
Chi-square test, p=0.798 
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Table 9-21 Types of protection habits when spent time outdoor at age 30's 
I among case-contro group 
Protection habits when outdoor at 
Group 
Total 
Control age 30's Case 
0/0 0/0 0/0 
Always seek a sun tan 73 117 190 
8.9% 8.6% 8.7% 
Wear very little 151 281 432 
18.3% 20.7% 19.8% 
Wear normal summer clothing 531 828 1359 
64.40% 61.1% 62.3% 
Try to cover up from the sun or did 69 130 199 
not spend time outdoors at all 8.4% 9.6% 9.1% 
Total 824 
1356 2180 
100.0% 100.0% 100.0% 
Chi-square test, p=0.350 
Table 9-22 Types of protection habits when spent time outdoor at age 40's 
I among case-contro group 
Protection habits when outdoor at 
Group Total 
age 40's Control Case 
0/0 0/0 Ofo 
Always seek a sun tan 48 76 124 
5.8% 5.6% 5.7% 
125 206 331 Wear very little 
15.2% 15.2% 15.2% 
Wear normal summer clothing 540 848 1388 
65.5% 62.6% 63.7% 
Try to cover up from the sun or did 112 225 337 
not spend time outdoors at all 13.6% 16.6% 15.5% 
Total 825 1355 2180 
100.0% 100.0% 100.0% 
Chi-square test, p=0.290 
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Table 9-23 Types of protection habits when spent time outdoor over the last 5 
t I years among case-con ro group 
Protection habits when outdoor last 5 
Group 
Total 
years Control Case 
0/0 0/0 0/0 
Always seek a sun tan 41 70 111 
5.0% 5.2% 5.1% 
Wear very little 90 145 235 
10.9% 10.8% 10.9% 
Wear normal summer clothing 453 732 1185 
55.0% 54.7% 54.8% 
Try to cover up from the sun or did not 240 390 630 
spend time outdoors at all 29.1% 29.2% 29.2% 
Total 824 1337 
2161 
100.0% 100.0% 100.0% 
Chi-square test, p=0.995 
The p for trend for all age decades was not statistically significant (P for trend at 20's= 
0.494, at 30's= 0.827, at 40's == 0.287 and last 5 years P for trend = 0.907). The 
estimated risks of protection habits at different age decades when outdoor under the 
sun and prostate cancer did not show any statistically significant findings even in the 
adjusted models (Table 9-24 page 9-199). 
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Table 9-24 Odds ratios and 95% Confidence Interval of Protection habits when exposed to sunlight at age 20's, 
-
,- Aft'_ --d last 5 years on Prostate Cancer Risk 
- --
Age Protection Habits 
Always seek a sun tan 
Wear very little 
20's Wear normal summer clothing 
Try to cover up from the sun or did 
not spend time outdoors at all 
Always seek a sun tan 
Wear very little 
30's Wear normal summer clothing 
Try to cover up from the sun or did 
not spend time outdoors at all 
Always seek a sun tan 
Wear very little 
40's Wear normal summer clothing 
Try to cover up from the sun or did 
not spend time outdoors at all 
Always seek a sun tan 
; LastS 
Wear very little 
. Years Wear normal summer clothing 
Try to cover up from the sun or did 
not spend time o u t d o o ~ a ~ a I L _ _
aUnadjusted regression model 
bAge-adjusted regression model 
Control Cases 
126 196 
168 277 
480 782 
53 101 
73 117 
151 281 
531 828 
69 130 
48 76 
125 206 
540 848 
112 225 
41 70 
90 145 
453 732 
240 390 
-
- - -- _.- ----
OR- P ORD P 
(9s%CI) valuea (9s%CI) valueb 
Ref - Ref -
1.060 0.699 1.008 0.957 (0.789-1.423) (0.745-1.364) 
1.047 0.718 1.084 0.537 10.815-1.3461 (0.838-1.403) 
1.225 0.321 1.312 0.194 (0.821-1.829) (0.871-1.977) 
Ref - Ref -
1.161 0.407 1.160 0.420 (0.816-1.653) (0.808-1.665) 
0.973 0.863 1.017 0.917 (0.712-1.329) (0.739-1.400) 
1.176 0.443 1.260 0.285 (0.778-1. 777) (0.825-1.923) 
Ref - Ref -
1.041 0.853 1.074 0.747 (0.681-1.591) (0.696-1.657) 
0.992 0.966 1.040 0.842 (0.680-1.446) (0.707-1.529) 
1.269 0.274 1.273 0.278 (0.828-1.944) (0.823-1.969) 
Ref - Ref -
0.944 0.808 0.994 0.982 (0.592-1.505) (0.618-1.600) 
0.946 1.020 
(0.633-1.416) 0.789 (0.676-1.538) 0.925 
0.952 0.817 1.091 0.690 ~ ~ (0.627-1.445) (0.712-1.670) 
~ u l t i v a r i a t e e adjusted regression model for age, education, ethnic, family history of cancer and skin colour 
ORe p 
(9s%CI) valuec 
Ref -
0.941 0.706 (0.684-1.293) 
1.006 0.966 (0.766-1.322) 
1.221 0.380 (0.782-1.907) 
Ref -
1.126 0.542 (0.770-1.646) 
0.988 0.946 (0.704-1.387) 
1.147 0.559 (0.725-1.813) 
Ref -
1.177 0.484 (0.746-1.855) 
1.100 0.645 (0.733-1.651) 
1.322 0.239 (0.831-2.103) 
Ref - I 
1.110 
0.679 i (0.676-1.825) 
1.066 
0.773 i (0.692-1.64Q) 
1.075 
0.753 I (0.686-1.685) 
9.4.7 Frequency using suntan cream while spent time outdoor 
The results are shown in Table 9-25 page 9-200, Table 9-26 page 9-201, Table 9-27 
page 9-201 and Table 9-28 page 9-202). For frequency of suntan cream usage at age 
20's, 30's, 40's and last 5 years, there appear to be higher proportion of control group 
reporting using suntan cream as 'always' or 'sometimes', while cases use suntan cream 
rarely or never compared to control group. 
Chi-square test however did not show statistically significant difference In the 
distribution of cases and controls. 
P for trend was only statistically Significant at age 20's (p value of 0.027, Table 9-25) 
and marginally non-significant p=0.052 during the last 5 years (Table 9-28), while at 
age 30's and 40's, there is no trend across categories (p=0.253 and 0.148 respectively 
Table 9-26 and Table 9-27). 
Ta bl 9 25 F e 
-
h requency us ng suntan cream w en out d oor at aae 20's 
Group Total Suntan cream usage Control Case 
0/0 0/0 0/0 
Always 60 72 132 
7.3% 5.3% 6.1% 
Sometimes 313 483 796 
38.0% 35.7% 36.6% 
Rarely 253 438 691 
30.7% 32.4% 31.7% 
Never 198 360 558 
24.0% 26.6% 25.6% 
Total 
824 1353 2177 
100.0% 100.0% 100.0% 
Chi-square test, p=0.124 
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Ta bl h e 9-26 Frequency uSing suntan cream w en out d oar at age 30' s 
Group 
Suntan cream usage Control Case Total 
0/0 0/0 0/0 
108 162 270 Always 
13.2% 11.9% 12.4% 
346 576 922 Sometimes 
42.3% 42.1% 42.4% 
217 335 552 
Rarely 
26.4% 24.7% 25.3% 
150 284 434 Never 19.9% 18.3% 20.9% 
821 1357 2178 
Total 
100.0% 100.0% 100.0% 
Chi-square test, p=0.384 
Table 9-27 FreQuencv using suntan cream when outdoor at aae 4 0'5 
Group 
Suntan cream usage Control Case Total 
0/0 0/0 0/0 
Always 182 288 470 
22.1% 21.2% 21.6% 
Sometimes 354 554 908 
43.1% 40.9% 41.7% 
Rarely 162 278 440 
19.7% 20.5% 20.2% 
124 236 360 Never 
15.1% 17.4% 16.5% 
Total 822 1356 2178 
100.0% 100.0% 100.0% 
Chi-square test, p=0.454 
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Ta bl e 9-28 Frequency uSing suntan cream w h en outdoor in last 5 years 
Group Total Suntan cream usage Control Case 
0/0 0/0 0/0 
290 440 730 Always 
35.3% 32.9% 33.8% 
300 472 772 Sometimes 36.5% 35.3% 35.8% 
124 209 333 
Rarely 
15.1% 15.6% 15.4% 
108 216 324 Never 
13.1% 16.2% 15.0% 
Total 
822 1337 2159 
100.0% 100.0% 100.0% 
Chi-square test, p=0.237 
The results of the association between prostate cancer risks and different suntan cream 
usage habits at each decade of life are shown in Table 9-29 page 9-203. 
At age 20's, the estimated risks derived from univariate, age-adjusted and fully 
adjusted models were statistically significant. Subjects who reported 'always' use 
suntan cream were at 38% risk reduction when compared with subjects who reported 
'never use' suntan cream. Subjects who reported use of suntan cream 'sometimes' was 
at 26% prostate cancer risk reduction. 
At age 30's, only subjects who used suntan cream 'sometimes' were at 42% risk 
reduction (OR of fully adjusted model 0.762, 95%CI: 0.582-0.997). 
At age 40's, the results showed that 'always' and 'sometimes' category was inversely 
associated with prostate cancer risk (OR 0.678, 95% CI 0.490-0.936 and OR 0.740, 
95% CI 0.555-0.986, respectively) 
In last 5 years, the results also suggested that 'always' and 'sometimes' category was 
inversely associated with prostate cancer risk (OR 0.613, 95% CI 0.449-0.837 and OR 
0.632, 95% CI 0.465-0.861, respectively). 
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Table 9-29 Odds ratios and 95% Confidence Interval of Suntan cream frequency use at age 20's, 30's, 40's and 
last 5 years on Prostate Cancer Risk 
Age Suntan cream Control 
freQuency use 
20's Never 198 
24.0% 
Always 60 
7.3% 
Sometimes 313 
38.0% 
Rarely 253 
30.7% 
30's Never 150 
18.3% 
Always 108 
13.2% 
Sometimes 346 
42.1% 
Rarely 217 
26.4% 
40's Never 124 
15.1% 
Always 182 
22.1% 
Sometimes 354 
43.1% 
Rarely 162 
19.7% 
Last 5 Never 108 
Years 13.1% 
Always 290 
35.3% 
Sometimes 300 
36.5% 
Rarely 124 
15.1% 
-
aUnadjusted regression model 
bAge-adjusted regression model 
cases 
360 
26.6% 
72 
5.3% 
483 
35.7% 
438 
32.4% 
284 
20.9% 
162 
11.9% 
576 
42.4% 
335 
24.7% 
236 
17.4% 
288 
21.2% 
554 
40.9% 
278 
20.5% 
216 
16.2% 
440 
32.9% 
472 
35.3% 
209 
15.6% 
ORB PvalueB ORb Pvalueb ORc 
(95%CI) (950f0CI) (95%CI) 
-Ref- -Ref- -Ref-
0.660 0.034 0.539 0.002 0.615 
(0.450-0.969) (0.362-0.800) (O.405-0.934) 
0.849 0.152 0.719 0.006 0.742 
(0.678-1.062) (0.570-0.908) (O.578-0.953) 
0.952 0.679 0.867 0.243 0.896 
(0.755-1.201) (0.682-1.102) (O.693-1.157) 
-Ref- -Ref- -Ref-
0.792 0.146 0.594 0.002 0.707 
(0.579-1.084) (0.428-0.824) (O.497-1.004) 
0.879 0.290 0.723 0.010 0.762 
(0.693-1.116) (0.563-0.927) (0.582-0.997) 
0.815 0.126 0.746 0.033 0.849 
(0.628-1.059) (0.570-0.977) (0.636-1.133) 
-Ref- -Ref- -Ref-
0.831 0.206 0.617 0.002 0.678 
(0.625-1.107) (0.457-0.833) (0.490-0.936 ) 
0.822 0.133 0.679 0.004 0.740 
(0.637-1.061) (0.521-0.886) (0.555-0.986) 
0.902 0.486 O.BIB 0.190 0.923 
(0.674-1.206) (0.605-1.105) (O.669-1.273) 
-Ref- -Ref- -Ref-
0.759 0.049 0.599 <0.001 0.613 
(0.577-0.998) (0.449-0.798) (0.449-0.837) 
0.787 0.084 0.626 0.001 0.632 
(0.599-1.033) (0.471-0.833) (0.465-0.861) 
0.843 0.295 0.726 0.059 0.777 
(0.612-1.161) (0.521-1.012) (0.545-1.109) 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer and skin colour 
P valuec 
0.022 : 
0.020 ! 
0.399 
0.053 
0.048 
0.267 
0.018 
0.040 
0.625 
0.002 
0.004 
0.165 
9.4.8 Scoring Method for Vitamin D towards association with prostate 
cancer risk 
Table 9-30 page 9-205 shows the results of analysis of the proposed scoring 
method for prostate cancer risk. The total scoring of individual subject were 
based on study subjects' characteristics of their skin, reaction to sun, as well as 
amount of exposure to sunlight, protection habits using clothes, suntan cream 
and Vitamin 0 dietary intake of are true extraction from the database. However 
for age period of 20's, 30's and 40's total score did not take account of dietary 
vitamin 0, due to data available only for last 5 years. 
The results showed the distribution of cases and control group based on the 
scoring which has been regrouped into quartiles from lowest to highest score 
using controls' score as the reference. The results also display the odds ratios and 
regression modeling of univariate, age-adjusted and multivariate adjusted OR of 
the total score (possible amount of vitamin 0 production from sunlight and 
dietary intake) towards prostate cancer. 
At age 20's, the total score based on 7 aspects as in Table 9-30 page 9-205, 
showed all quartiles of higher score (Q2, Q3 and Q4) gave statistically significant 
protective risk odds ratios when compared to lowest score quartile even at 
multivariate-adjusted regression model with OR = 0.730 (95%CI: 0.544-0.981), 
0.668 (95%CI: 0.516-0.864) and 0.740 (95%CI: 0.554-0.989) respectively. 
While at age 30's and 40's, only the 3rd and 4th quartlles showed statistically 
significant but still reduced risk for prostate cancer. As for the last 5 years, at 
multivariate-adjusted models, odds ratios were not statistically Significant. 
Chi-square test at 20's, 30'5, 40'5 and last 5 years are 0.007, 0.029, 0.006 and 
0.337 respectively, while P for trend at 20's, 30's, 40's and last 5 years are 
0.006,0.005,0.002 and 0.103 respectively. 
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Age Quartile (Total S c o r e ~ ~
Ql 
(16 and below) 
Q2 
(17) 20's Q3 
(18 - 19) 
Q4 
(20 and above) 
Ql 
(16 and below) 
Q2 
(17) 30's Q3 
(18 - 19) 
Q4 
(20 and above) 
Ql 
(16 and below) 
Q2 
(17) 40's Q3 
.(18 - 19) 
Q4 
. {20 and abovlD 
Ql 
_(18 and below) 
Q2 
(19-20) Last 5 Years· Q3 
(21-22) 
Q4 
(23 an<Labove) 
"Unadjusted regression model 
bAge-adjusted regression model 
Control 
244 
35.1% 
125 
18.0% 
195 
28.1% 
131 
18.8% 
237 
34.2% 
117 
16.9% 
204 
29.5% 
134 
19.4% 
252 
36.7% 
96 
14.0% 
207 
30.1% 
132 
19.2% 
149 
31.5% 
120 
25.4% 
113 
23.9% 
91 
19.2% 
cases OR" 
p 
. (950f0Cl) value· 
483 
-Ref-43.2% -
176 0.711 0.016 15.8% (0.540-0.938) 
263 0.681 
23.5% (0.536-0.867) 0.002 
195 0.752 0.038 17.50/0 (0.574-0.985) 
450 
-Ref-40.3% -
200 0.900 0.457 17.9% (0.682-1.188) 
278 0.718 
24.9% (0.565-o.912) 0.007 
190 0.747 0.035 17.0% (0.569-0.980) 
470 
-Ref-42.5% -
185 1.033 0.825 16.7% (0.773-1.381 ) 
274 0.710 
24.8% (0.560-0.899) 0.005 
178 0.723 0.020 16.1% (0.551-0.949) 
301 
-Ref-36.2% -
198 0.817 0.186 23.8% (0.605-1.102) 
193 0.845 
23.2% jO.624-1.146) 0.279 
139 0.756 0.096 16.7% (0.544-1.051) 
'Multivariate adjusted regression model for age, education, ethnic, and family history of cancer 
*Indude score for dietary intake of Vitamin 0 
ORb 
. (950f0Cl) 
-Ref-
0.745 
{0.560-o.990} 
0.673 
(0.525-0.863 ) 
0.742 
(0.562-0.980) 
-Ref-
0.928 
(0.697-1.235) 
0.719 
(0.562-0.921 ) 
0.715 
(0.540-o.945) 
-Ref-
1.093 
(0.810-1.474) 
0.691 
(0.541-0.882) 
0.704 
(0.532-0.932) 
-Ref-
0.800 
(0.589-1.085) 
0.847 
(0.622-1.154) 
0.754 
(0.539·1.054) 
d last 5 p tate C 
--- - --- - - ------ ------
r Risk 
P ORC P 
valueb (95%Cll valuec 
-
-Ref- -
0.043 0.730 0.037 (0.544-0.981 ) 
0.668 0.002 (0.516-0.864) 0.002 
0.035 0.740 0.042 (0.554-0.989) 
- -Ref· -
0.607 0.957 0.770 (0.711-1.287) 
0.700 0.009 (0.541-0.905) 0.006 
0.019 0.725 0.032 (0.540-0.972) 
-
-Ref-
-
0.561 1.081 0.623 (0.793-1.472) 
0.675 0.003 (0.523-0.870 ) 0.002 
0.014 0.696 0.016 (0.518-0.936) 
- -Ref-
-
0.151 0.791 0.148 (0.575-1.087) 
0.801 0.293 (0.580-1.107) 0.179 
0.098 0.780 0.166 
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9.5 Discussion 
9.5.1 Skin Complexion 
The result did not show any differences in the types of skin complexion between 
cases and controls. There is no available statistics to compare the findings. 
Based on the study findings, types of skin complexion of oily, dry or combination 
when compared with normal complexion did not give any statistical significance 
odds ratio with prostate cancer risk (refer Table 9-5 page 9-183). 
9.5.2 Skin Colour 
'Medium' skin colour is the median skin colour in this study and 'fair' skin colour 
come as second most common skin colour among our study subjects who are 
majority 'White' in ethnic group (approximately 97%) (Refer Table 9-6 and page 
9-184). Our findings are in agreement with a study on self reporting phototype 
versus physician diagnosed skin phototype (Chan et ai, 2005a). Subjects who are 
'white' subjects mostly rated themselves as 'medium', whilst physicians as the 
'gold standard' scored them as 'fair' skin phototype. 
Chen and colleagues studied whether skin colour correlates well with race or 
ethnic group (Chan et ai, 2005a). Skin phototype is best characterised by 
physician when correlating with race. The higher correlation was observed at 
r=O.55 (p<O.Ol) as compared to subjects' self reported skin phototype at r=O.28 
(p<O.Ol). Association between skin colour and race didn't show much correlation 
among 'whites' at correlation, r=0.40, however associations between race and 
skin phototype is better with darker skin colour at r=O.60. 
The study results did not show any statistically significant difference In the 
characteristics of skin colour between cases and control group. Similarly odds 
ratio value and confidence intervals for logistic regression models for skin colour 
did not reveal any aSSOCiation with prostate cancer (refer Table 9-7 page 9-185). 
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9.5.3 Sun effect reaction on skin 
Due to non-statistically significant findings earlier in the association between skin 
colour and prostate cancer risk, we expected that sun effect reactions on skin 
between cases and control group should also be not statistically significant, 
because susceptibility to sunburn in sunlight and tanning ability is based on skin 
phototype as explained earlier in Table 9-1, page 9-172. The association 
between prostate cancer and different types of sun effect reaction on skin, the 
odds ratios in logistic regression were not equally statistically significant (refer 
Table 9-9 page 9-187). 
9.5.4 Outdoor sunlight exposure while working 
With progression of age, it was observed less proportion of subjects of both cases 
and control spent outdoor for 5 hours or more while working, starting at 21% at 
age 20s to 15% in the last 5 years (refer Table 9-10 page 9-188, Table 9-11 
page 9-189, Table 9-12 page 9-189, and Table 9-13 page 9-190). There was 
however no statistical significant difference in the proportion of number of hours 
with outdoor sunlight while at work between cases and control group from age 
20's to 40's or even last 5 years. Regression models as shown in Table 9-14 
page 9-191, upon full multivariate adjusted did not show any statistical significant 
finding. 
The study results did not agree with most studies in the literature. Other studies 
reported sunlight as beneficial in reducing prostate cancer risk (Bodiwala et ai, 
2003a; Bodiwala et ai, 2003b; John et ai, 2004; Rukin et ai, 2007). One point to 
be made is that our study cannot be compared with other studies because we 
look at specific amount of sunlight exposure during work while most studies 
combined both work and recreational sunlight exposure when reporting the 
results. 
However, John et al whose study was based on cohort subjects in National Health 
and Nutrition Examination Survey I Epidemiologic Follow-up Study in United 
States, managed to stratified small sample of 161 prostate cancer cases and 
3367 control subjects among non-Hispanic white men for occupational self 
reported occupational sun exposure obtained non-statistical significant difference 
in prostate cancer risk between those had occasional or frequent sunlight 
exposure at work to those who had none or rare exposure (John et ai, 2007). 
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The strength of our study although did not show any significant findings is to 
identify specific purpose of sunlight exposure i.e. work or recreational, that would 
have affect on prostate cancer risk. Our study also would be able to study at the 
types of occupation which requires greater outdoor exposure of sunlight 
compared to those who are more incline to stay indoor or office type of 
occupation, in association with prostate cancer risk, although in this case no 
association was seen between sunlight exposure while working and prostate 
cancer risk. 
9.5.5 Outdoor sunlight exposure while not working 
The results suggested that control group spent longer hours (3 hours or more 
categories) outdoor on non-working or recreational, compared to case group 
(refer to Table 9-17 page 9-193 and Table 9-18 page 9-194). P for trend also 
was significant at p<O.OOl in all age decades at 20's, 30's, 40's and last 5 years. 
History of sunlight exposure during non working time has shown to be aSSOCiated 
with prostate cancer risk throughout age decades at 20's, 30's, 40's and last 5 
years with exception for multivariate adjusted model at age 30's for exposure of 
'1-2 hours' (refer Table 9-19 page 9-195). 
The multivariate adjusted odds ratiOS for prostate cancer were all of reduction risk 
at OR< 1.0 across all age categories with highest reduction risk in category of 
exposure to sunlight at non-working of '5 hours or more' when compared with 
lowest category of 'less than 1 hour' as reference. The multivariate adjusted OR 
values for age 20's, 30's, 40's and last 5 years for '5 years or more' of sunlight 
exposure while not working are 0.534 (95%CI: 0.345-0.828), 0.469 (95%CI: 
0.298-0.736), 0.469 (95%Cl: 0.302-0.728), and 0.380 (95%Cl: 0.256-0.565) 
respectively when compared to lowest amount of hours category. 
The study findings are in keeping with several other studies that compared the 
highest and lowest category amount of ultraviolet radiation or sunlight exposure 
(Bodiwala et at, 2003a; Bodlwala et at, 2003b; John et at, 2004; John et aI, 2007; 
Rukln et aI, 2007). In Bodiwala case-control study with 453 cases and 312 
control subjects using mean hours cumulative exposure, age-adjusted odds ratio 
was 0.999 (95%CI: 0.999-1.000), p=O.OOOl (Bodiwala et at, 2003a). Another 
separate case-control study by Bodiwala on 212 cases and 135 controls showed 
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estimated risk of 0.998 (95%CI: 0.997-0.999) when mean weeks cumulative 
exposure was used (Bodiwala et aI, 2003b). 
Rukin performed a case-control study on 528 prostate cancer patients and 365 
control subjects using the measurements of average of daily exposure, weekday 
exposure and weekend exposure to sunlight also obtained protective risk against 
prostate cancer at age and skin type adjusted odds ratios of 0.78 (95%Cl: 0.72-
0.85), 0.85 (95%Cl: 0.80-0.91) and 0.79 (95%CI: 0.73-0.86) respectively 
(Rukin et aI, 2007). John et al using a cohort subjects in United States of 161 
prostate cancer cases and 3367 control subjects among non-Hispanic white men 
only obtained statistically significant protective age-adjusted relative risk of 
RR=0.47 (95%Cl: 0.23-0.99) for fatal prostate cancer (John et aI, 2007). 
9.5.6 Protection habits while outdoor under the sun 
There was no statistically significant difference in the protection habits while 
outdoor under the sun between cases and control group (refer Table 9-20 page 9-
196, Table 9-21 page 9-197, Table 9-22 page 9-197 and Table 9-23 page 9-198). 
The trends of characteristics of both groups subjects' protection habits change 
gradually as they aged from less protection categories: 'always seek a sun tan' or 
'wear very little'; to more of some amount of protection from the sun: 'wear 
normal summer clothing' or 'try to cover up from the sun'. The bulk of the 
subjects remained within the middle category of 'wear normal summer clothing'. 
Our study finds this protection habit is of Importance because it could be a 
potential confounder or could affect the relationship between the amounts of 
sunlight exposure on the skin for Vitamin 0 production in the human body. In 
most studies, the types of protection used against the sun especially outdoor 
exposure of hot summer sun, were not considered when trying to quantify the 
actual amount of sunshine that reach the skin. In true calculation, when wearing 
protective clothing, only face, neck, hands are exposed to direct sunlight or 
ultraviolet radiation to produce vitamin D for association studies to prostate 
cancer risk. Some studies uses habits of sunbathing in order to justify true 
measurement of higher sunlight or ultraviolet radiation to prostate cancer risk 
(Bodiwala et aI, 2003a; Bodlwala et aI, 2003b; John et aI, 2007; Luscombe et aI, 
2001). 
Since our analysis on the protection habits when outdoor did not find any 
statistical significant difference between cases and control group (refer Table 9-24 
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page 9-199, we assumed that this factor may have an overall same effect on both 
groups and may not be a strong confounder when trying to associate the 
relationship of sunlight exposure whether at work or non-working outdoor 
towards prostate cancer risk. 
9.5.7 Frequency using suntan cream while outdoor 
The frequency of suntan cream usage of 'always' or 'sometimes' at age 20's, 30's, 
40's and last 5 years, seems higher proportion among control group, while case 
group has more proportion than control to likely use suntan cream 'rarely' or 
'never'. Chi-square test however did not detect statistically significant difference 
in the proportion. 
P for trend for odds ratio of prostate cancer risk was found to be only statistically 
significant at p=0.027 for age 20's. 
The regression modelling for suntan cream usage to prostate cancer risk (refer 
Table 9-29 on page 9-203) revealed that subjects who 'always' use suntan cream 
when outdoor at 20's, 40's and during the last 5 years were at reduce prostate 
cancer risk in comparison with those who 'never' use suntan cream. Those in 
category of 'sometimes' used of suntan cream was found to have statistically 
significant reduction in prostate cancer risk In age-adjusted and multivariate 
adjusted regression models at all age decades. 
The direction of the findings of this analysis seems to point out that higher 
frequency usage of suntan cream or lotion would result In lower risk of prostate 
cancer. Suntan cream lotion containing SPF (Sun-protection factor) is used to 
delay skin erythemal reaction induced by solar radiation. Habits of usage of 
suntan cream have been associated with increase duration in recreational sun 
exposure as shown in a double blind randomized trial (Autier et ai, 1999). 
Therefore, suntan cream usage can be used as a proxy measurement or 
surrogate marker for sunlight exposure, to correlate the likelihood amount of sun 
exposure mainly for recreational activities such as sunbathing or just outdoor 
activities of non-working. 
One limitation in our study is that we were not able to define the types of suntan 
cream that was use throughout the different age period, as by stratifying the 
groups, we would have a better picture whether suntan cream of higher SPF 
(sun-protection factor) I.e. SPF-30 versus SPF-15 would differ in its association 
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with prostate cancer risk. SPF-30 with higher UV block could resulted lower 
production of Vitamin D from sunlight and in our hypothesis cause a non-
statistically significant association with lower risk of prostate cancer, when 
compared with those using lower SPF suntan cream. 
In summary, in coherent with biological plausibility, the higher amount of suntan 
cream usage, resulting higher exposure to the outdoor sunlight or ultraviolet 
radiation to the skin, as discussed earlier would then resulted in higher vitamin D 
production and could explain the protective risk from prostate cancer found in this 
study. 
9.5.8 Scoring Method for Total Vitamin D towards association with 
prostate cancer risk 
The findings indicative of higher production of vitamin D from sunlight and skin 
and dietary intake (based on total scoring method), is associated with protective 
or reduced odds ratio and especially appears stronger at early stage in life (age 
20's), followed by age 30's and 40's scoring (where only the two highest quartile 
obtained statistically significant protective odds ratios). For the last 5 years, the 
results were no longer significant. The findings suggested that vitamin D 
exposure earlier in life is protective against prostate cancer. 
This study attempted to investigate all factors involving the source of vitamin D 
from ultraviolet light or sunlight exposure by exploring different aspects of factors 
that could affect the actual amount of Vitamin D produced by skin. The ideas 
were based on current knowledge and on literature review of available scientific 
articles and books, as well as current understanding of the factors that could 
account for production of Vitamin D by skin. The current evidence show sunlight 
provides protective against risk for prostate cancer when compared to those with 
lower exposure of sunlight (Bodlwala et ai, 2003a; Bodiwala et aI, 2003b; 
Freedman et aI, 2002; John et aI, 2004; John et aI, 2007; Luscombe et aI, 2001; 
Rukin et aI, 2007; Schwartz & Hanchette, 2006). Meta-analysis by Gilbert et al 
concluded the limited support for the protective effect of sunlight to prostate 
cancer. The author mentioned in their article that heterogeneity between studies 
could not be tested due to small numbers of studies leading to weak aSSOCiation 
or null results (Gilbert et aI, 2009). 
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Although the analysis of each isolated factor showed 'non-working sunlight 
exposure' and 'suntan cream usage' to be statistically significantly associated with 
prostate cancer risk, the other factors also involved in vitamin D production did 
not show any statistically significant. These factors have been described in detail 
on basis of biological plausibility existed in current knowledge therefore should be 
included to provide the bigger picture of potential vitamin D production. 
The applied scoring method using the characteristics of skin complexion, color, 
reaction to prolonged sunlight, amount of sunlight exposure at work and while 
non-working, cloth protection from sun habits, frequency of using suntan cream 
and dietary vitamin D intake were able to provide coherent understanding of the 
relationship between productions of vitamin D in association with prostate cancer. 
The study, however, had a limitation of applying score from diet at various stages 
in life, other than the last 5 years. 
The strength of scoring method includes firstly, the study places together all 
characteristics of skin and amount of sunlight exposure which are both important 
components in the production of vitamin D of non-diet origin, and maybe 
predictive of amount of production of vitamin D by human body. Although dietary 
Intake vitamin D is vital, it only contributes 10% of Vitamin D (Gillie, 2006). 
Secondly, measurement of circulating vitamin D In human may not be reliable 
(Ahn et aI, 2008; Barnett et aI, 2010; Park et aI, 2010) when studying exposure 
of sunlight at different age period and the cumulative effect towards prostate 
cancer risk thus surrogate score can be used as alternative. 
Thirdly, the proposed scoring model could provide prediction to an Individual of 
prostate cancer risk, provided that the data is analyzed as a population sample 
and caution to be made when the model is applied to different region latitude, 
because location further from equator would provide lesser exposure from 
sunlight (John et aI, 2004; John et aI, 2007) and similarly climate or cloudy 
condition. However this is the first study proposed to use the scoring model and 
could be applied in geographical and climate area Similar to the UK and Its 
population. 
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9.6 Conclusions. Recommendations 
In conclusion, this study showed that greater time of non-working outdoor 
exposure is associated with reduced prostate cancer risk. Higher frequency of 
usage of suntan cream is also associated with lower risk of prostate cancer 
compared to those who never applied cream when exposed to the sun. This may 
reflect amount of sunlight or ultraviolet radiation exposure. 
To strengthen the study the association between vitamin D and prostate cancer 
risk, diet component of food containing dietary intake of vitamin D through 
various stages in life should be taken into account when calculating the risk. 
There's a need to improve further on how to best to assess the actual hours of 
under the sun and not just outdoor per se and this should be addressed in the 
questionnaires, so as to get the closest amount of hours of actual sunlight 
exposure daily average. Further details of history of sunbathing and holidays in 
tropical country with details of duration accumulative should be collected. 
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Chapter 10 Diet Isoflavones (Phytoestrogens), 
Selenium, Vitamin D and Lycopene 
10.1 Literature Review 
10.1.1Isoflavones (Phytoestrogens) and Prostate Cancer 
Phytoestrogens defined by Ganry as estrogenic compounds found in plant food 
and broadly classified as isoflavones (e.g. genistein, diadzein, glycitein etc), 
lignans (e.g. enterolactone), flavonoids (e.g. quercetin, kaempferoi) and 
coumenstans (sometimes classified under isoflavones). Isoflavonoids are found 
in soybean and soy products, while coumenstans in sprouts and beans. Lignans 
are found in seeds, whole grain cereals, berries etc, while flavonoids are high in 
fruits and vegetables such as apples, pears and onions (Ganry, 2005). Soy foods 
have been subject of considerable investigations since 1960s due to its potential 
health effects of soy isoflavones (Hsu et aI, 2010). 
Isoflavonoids phytoestrogens such as genistein, daidzeln and glyciteln, showed 
similarities structure with mammalian estrogens and have been most extensively 
studied. They have weak estrogenic activity and can interfere intracellular steroid 
metabolism (Adlercreutz, 2002). Phytoestrogens can therefore act as estrogen 
agonists and antagonists competing for estradiol at the receptor complex ERj3 
(Bingham et aI, 1998). 
In vitro study. It Is suggested that genistein's mechanism of action reducing cell 
viability that induces apoptosis of prostate cancer cell lines Indirectly inhibit cell 
growth, while control of tyrosine kinase phosphorylation has also been described 
(Kyle et aI, 1997). However there is possibility that Isoflavones have a biphasic 
effects, at low dose promote cell growth but at higher doses inhibit growth 
(Zhang et aI, 2003). 
In vivo studies involving mice also showed growth inhibition and increase 
apoptosls in LNCaP prostate cancer cell xenografts (Bylund et aI, 2000; Rice et aI, 
2002). Genistein of Isoflavones, also Inhibits the activity of 5-alpha-reductase, an 
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enzyme required for androgen synthesis, such as testosterone which plays a role 
in prostate cancer cells growth (Evans et aI, 1995). Similarly isoflavone rich soy 
protein isolate was found to suppress androgen receptor expression, which could 
benefit in preventing prostate cancer (Hamilton-Reeves et aI, 2007). 
Several case control studies have confirmed the beneficial protective effects of 
isoflavones dietary intake towards prostate cancer risk. Lee study in Chinese 
population of 133 cases and 265 controls found isoflavones genistein of highest 
versus lowest quartile intake, had Odds ratio ofO.53(95%CI: 0.29-0.97) (Lee et 
aI, 2003), while Nagata in Japanese population of 200 cases and 200 controls 
showed similar protective effect with Odds ratio of 0.42 (95%C1: 0.24-
O.72)(Nagata et aI, 2007). When soy food or soy products such as tofu was used 
to represent isoflavone intake, reduced odds ratios also were observed in Lee's 
study at OR 0.51 (95%CI: 0.28-0.95) and 0.58 (95%CI: 0.35-0.96) respectively 
(Lee et ai, 2003). Another study in multiethnic population of USA and Canada, 
demonstrated reduced OR 0.62 (95%CI: 0.44-0.89) for groups with highest soy 
food intake compared to lowest quintile (Kolonel et aI, 2000). Heald who used 
Scottish population, obtained protective odds ratiO of 0.52 (95%CI: 0.30-0.91) 
when comparing those who consumed soy food and those who do not (Heald et 
aI, 2007). One cohort study also described reduction In relative risk for prostate 
cancer among intake of soymilk more than once a day compared to never at RR= 
0.3 (95%C1: 0.1-0.9) (Jacobsen et aI, 1998). 
However there is a study which showed Increased risk of prostate risk such as 
case control study by Jlan et al in southeast Chinese population of 130 cases and 
274 controls, with OR=2.02 (95%CI: 1.08-3.78) when taking fermented soy 
products at highest compared to lowest tertlle (Jian et aI, 2004). 
Other studies did not show any statistically significant association towards 
prostate cancer for isoflavones intake (Heald et aI, 2007) or soy products 
(Nomura et aI, 2004; Sonoda et ai, 2004). 
Several studies used serum phytoestrogens or isoflavones level Instead of using 
diet FFQ when determining their association with prostate cancer. Ozasa who did 
validity study to compare the dietary habits and serum phytoestrogens found that 
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serum isoflavones genistein and daidzein was statistically significant correlation 
with the baseline dietary intake of soy tofu (Ozasa et aI, 2005). Higher quintile 
serum isoflavone genistein was found to have lower relative risk at RR 0.71 
(95%Cl: 0.53-0.96) in the European population (Travis et aI, 2009), but 
serum/plasma isoflavones was not statistically significantly associated with 
prostate cancer other studies (Kurahashi et aI, 2008; Ward et aI, 2008). 
Similarly urinary isoflavones excretion has also been validated as a biomarker on 
its significant correlation with dietary intake of soy protein (Maskarinec et aI, 
1998). Park found higher level of urinary excretion level of isoflavones daidzein 
and genistein were associated with reduced odds ratio when compared with the 
lowest quintile (Park et aI, 2009). 
10.1.2 Selenium and Prostate cancer 
Selenium is an essential micronutrient trace element for human and the amount 
in diet depends on the soil of the region where the plants and animals come from 
(Nadiminty & Gao, 2008). Selenium first entered the food chain from soil to the 
plants (Rayman, 2008). Large variations in content of selenium In food are 
determined by geological or environmental factors, supplementation of selenium 
in fertilizers or animal feed, as well as absorption (Fairweather-Tait et aI, 2010; 
Rayman, 2008). Bioavailability issue has been brought up in much study due to 
complex metabolic transformation to biological active metabolites (Fairweather-
Tait, 1997; Fairweather-Tait et aI, 2010; Finley, 2006; Levander, 1987). 
Glutathione peroxidase (GPx) activity and tissue selenium has been used as 
criteria to study bioavailability. Absorption of selenium of all forms would vary 
according to selenium status of subject. Wheat and meats have high 
bioavailability, and fish have relatively high content of selenium but may have 
lower bioavailability (Finley, 2006). Selenlzed yeast has been the primary form of 
selenium available for use as a dietary supplement. 
Greater awareness of the importance of selenium was partly due to publication by 
Clark et al. of a randomized clinical trial on studying effects of selenium 
supplementation for cancer prevention in patients with skin carcinoma in USA. 
Although selenium treatment did not reduce incidence of basal cell or squamos 
cell carcinoma, the secondary end point results showed reduction total cancer 
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deaths and incidence among those in the selenium group including prostate 
cancer. 
Several mechanisms have been suggested to explain the function of selenium as 
anti-cancer. Nadiminty and Gao in their review stated specific mechanisms for 
prostate cancer are inhibition of AR (androgen receptor) Signalling, reduction in 
the mRNA, and protein levels of androgen receptor, recruitment of corepressors 
to the AR elements in the promoters of androgen responsive genes, inhibition of 
signalling pathways like NF-kB, IL-6, Stat3 and induction of apoptosis. 
Selenoproteins has also been associated with prostate cancer cells expression and 
progression (Nadiminty & Gao, 2008). 
Evidence on selenium and prostate cancer risk indicate mixed findings. Studies 
using nested case-control design and measurement of serum selenium are most 
common. Among these, some have shown inverse relationship of selenium and 
prostate cancer risk. Li et al obtain OR =0.52 (95%CI: 0.28-0.98) when 
comparing the highest quintile level of plasma selenium to the lowest of 586 
cases and 577 control, of advanced prostate cancer risk in Physicians' Health 
Study population (Li et ai, 2004). Nomura study of 249 cases and 249 matched 
controls revealed OR 0.5 (95%CI: 0.3-0.9) which compare with highest quartile 
and lowest serum selenium level, with more notable for advanced prostate cancer 
as well (Nomura et aI, 2000). Pormand obtained reduced odds ratio of 0.16 
(95%CI: 0.06-0.47) in Iran (Pourmand et aI, 2008), while Gill study population of 
467 cases and 936 controls obtained OR value 0.59 (95%CI: 0.38-0.93) when 
comparing serum selenium in the highest tertile to the lowest (Gill et aI, 2009). 
However there are also many studies which did not show any association between 
selenium and prostate cancer risk. These Include case-control studies (Allen et 
aI, 2008; Allen et aI, 2004; Peters et aI, 2007a; Peters et aI, 2008; Zhang et aI, 
2009), cohort study (Hartman et aI, 1998) or randomized control trials (Krlstal et 
aI, 2010; Lippman et aI, 2009). Toenail selenium was also used as marker of 
selenium in the body (Allen et aI, 2004; Brinkman et ai, 2006), however not 
many studies used dietary questionnaire to assess selenium Intake in association 
with prostate cancer. 
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None of the studies from the literature showed that selenium increases prostate 
cancer risk. 
10.1.3 Vitamin D and Prostate cancer 
Major source of Vitamin D comes from human's skin exposure to sunlight 
ultraviolet ray (Schwartz, 2005) with smaller contribution from dietary intake. 
Vitamin D content in food is rare. Due to concern of skin cancer, many have 
avoided direct sun exposure and they would depend on Vitamin D from dietary 
sources. Vitamin D in food mainly comes from oily fish such as salmon. However 
fortified dairy products with vitamin D are available in US and Canada, such as 
milk, while in Europe, margarine is normally fortified (Chen et ai, 2007). 
Supplementary form of vitamin D i.e. Calciferol is also available (Giovannucci, 
1998). 
The active form of Vitamin D as 1,25 (OHhD and 25(OH)D and their hypotheses 
mechanism of actions and its relationship to anti-cancer process has been 
explained earlier in the chapter on skin and sunlight of this thesis. 
There are not many studies that studied the effects of vitamin D intake and 
prostate cancer risk. The case control study and cohort studies concluded non-
statistically significance association (Park et ai, 2007; Tavanl et ai, 2005a; Tseng 
et ai, 2005). A meta-analysis done by Gilbert et al when conducting pooled 
random-effects odds ratio estimate per 1000 IU increase vitamin D intake was 
0.83 (95%CI: 0.28-2.43) which is not statistically significant (Gilbert et aI, 2011). 
10.1.4 Lycopene and Prostate cancer 
Lycopene is a type of carotenoid without provitamin A activity, present in fruits 
and vegetables. Tomato products including ketchup, tomato juice and pizza 
sauces are riches US diet at more than 80% for source of Iycopene (Arab & Steck, 
2000). However fruit such as watermelon, papaya and pink guava also contains 
Iycopene. Lycopene from processed and cooked tomatoes was found to be more 
bioavailable than of fresh tomatoes (Gartner et ai, 1997). 
The hypothesis mechanism of action of Iycopene on prostate cancer was through 
the mediation of endocrine factor of IGF-1 (Insulin-like Growth Factor-1) which 
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has been described by Wolk et al that elevated serum 1GF-1 levels may be an 
important predictor of risk for prostate cancer (Wolk et aI, 1998). Study by Mucci 
obtained result that consumption of cooked tomatoes was associated with inverse 
levels of 1GF-1 with a mean reduction percentage of 31.5% (95%C1: 7.9% -
49.1%)(Mucci et aI, 2001). Lycopene was also later found to inhibit 1GF-1 signal 
transduction and growth in normal prostate epithelial cells by decreasing DHT 
(Dihydrotestosterone) modulated IGF-1 production in co-cultured reactive stromal 
cells (Liu et aI, 2008). 
The results on the association of serum, plasma or diet Iycopene and 
tomato/tomato products intake towards prostate cancer risk have been of 
equivocal. Some case-control studies that used dietary intake reported reduction 
in prostate cancer risk (Jain et aI, 1999; Jian et aI, 2005; McCann et aI, 2005; 
Norrish et aI, 2000a). A cohort study was reported Similar effect (Glovannuccl et 
aI, 2002). A number of studies that used plasma or serum level of Iycopene as 
variable of interest towards prostate cancer risk also showed reduction odds 
ratios and relative risks when compared with lowest level category (Gann et aI, 
1999; Karppi et aI, 2009; Key et ai, 2007; Lu et ai, 2001; Wu et aI, 2004; Zhang 
et aI, 2007). 
However, there are articles that dshow non-statistically significant association 
between Iycopenes, tomato/tomato products to prostate cancer (Bell by et aI, 
2010; Bosetti et aI, 2004; Chang et aI, 2005; Kirsh et aI, 2006; Kristal et ai, 
2010; Kristal et ai, 2011; Peters et ai, 2007b). 
10.2 Aim 
The aim of this chapter is to investigate the relationship of specific components in 
diet and prostate cancer risk: 
i. Isoflavones (Phytoestrogen) 
ii. Selenium 
iii. Vitamin D 
iv. Lycopene 
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10.3 Method 
Data on specific nutrient components were collected through the adaptation of 
the European Prospective Investigation into Cancer and Nutrition (EPIC) Food 
Frequency Questionnaire (FFQ). The validated FFQ was developed by Medical 
Research Council Dunn Nutritional Unit of Cambridge for UK, European 
Prospective Investigation of Cancer (EPIC) in Nutrition (Bingham, 1997b; 
Bingham et ai, 1997a; Riboli, 1992). The EPIC FFQ was modified to be suitable 
for the retrospective case-control study. The questionnaire used in phase I of 
this study has been further expanded in Phase II. Additional items further to main 
Food Table include soy milk and spices, while in Vitamins & Supplements Table, 
saw palmetto, garlic, pomegranate, soy-based drink and tomato were added. 
Subjects were asked to recall on their typical dietary in the last 5 years before 
prostate cancer diagnosis in the cases, or receiving questionnaire in the controls. 
The 130 food items were broadly categorized into: 
i. Meat and fish 
ii. Bread and savoury biscuits 
ii i. Cereals 
iv. Potatoes, rice and pasta 
v. Dairy products and fats 
vi. Sweets and snacks 
vii. Soups, sauces and spreads 
viii. Fruits 
ix. Vegetables 
x. Drinks 
xi. Milk 
xii. Spices 
xiii. Vitamins and supplements 
The amount of food was indicated as medium serving size or In the units of slice 
or teaspoon. The average frequencies of intake for each food were measured by 
categorizing the answers (refer Table 10-1 page 10-221). Photographs examples 
of small, medium and large food portion were placed in the FFQ to aid the 
subjects In estimating portion size of medium as described by Ministry of 
Agriculture, Fisheries and Food (MAFF, 1993). 
10-220 
The FFQ questionnaire of this study has been used before in the UK population 
(Lophatananon et aI, 2010; Muthuri, 2004; Muthuri, 2010). 
Data included in all analyses here was obtained from both Phase I and phase II of 
the study. 
10.4 Analysis 
10.4.1 Calculation of nutrient daily intake 
Daily intake of each specific nutrient was calculated by the nutritional software 
designed by the study teams. The calculation program was previously validated 
by comparing values of daily intake of all nutrients (from 10 randomly selected 
subjects from other study) derived from the program created by the study team 
to values derived from the EPIC calculation program by Cambridge group. The 
adjustments were made until the discrepancies of values between two 
calculations were less than 10%. 
The calculation program includes sections for calculating nutrient Intakes from 
EPIC FFQ, milk, cereal and Vitamins/supplement sections of the questionnaire. 
The algorithm was based on the equation below. 
Total nutrient intakes (grams per day) = 
Portion size (amount consumed) x seasonality factort x edible portion:f: x 
frequency of intake per day x nutrient** as percentage of all 130 food items 
*Where, t shows seasonal food availability and '*' shows proportion of food edible 
** The nutritional composition values for each food were derived from Ministry of 
Agriculture, Fisheries and Food composition tables (MAFF, 1993). 
Frequency of each food was converted into daily value based on Table 10-1: 
Table 10-1 Coding scheme for frequency of intake per day 
Code Frequency of Intake (FFQ Frequency of intake per response) day (value to replace) 
1 Never or less than once/month 0.01 
2 1 - 3 per month 0.07 
3 Once a week 0.14 
4 2 - 4 per week 0.43 
5 5 - 6 per week 0.79 
6 Once a day 1 
7 2 - 3 per day 2.5 
8 4 -5 per day 4.5 
9 6+ per day 6.5 
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Total energy intake was calculated for each individual and was further used to 
adjust for the nutritional intake of the specific nutrient components such as 
Isoflavones, Selenium and Vitamin D (all measured in unit of I-Ig) by the residual 
method as described and proposed by Willet (Willett, 1998). This residual method 
has also been applied in other studies (Bingham & Day, 1997c). 
10.4.2 Data cleaning 
Only subjects with total calorie intakes lay within two standard deviations were 
included in the analyses. This was done to exclude measurement bias due to 
extreme values or outlier. 
Further data validation was done by comparing 'body shape of last 5 years' for 
individuals of low and high end total calorie. The lowest and highest individual 
total calorie intakes should be comparable of their body shape of severe thin or 
obese respectively. Any individual with incoherent between two variables were 
excluded from the analyses. The body shape variable has been described In 
detail in another chapter of this thesis. 
From a total of 3,944 eligible subjects, 151 (3.83%) were excluded as outlier or 
not within the two standard deviation of the total calorie Intake for individuals. 
From 3793 left, a further 21 subjects data were excluded from the analysis due to 
incomparable values of their total calorie intakes in the last 5 years diet history to 
their 'last 5 years body shape'. The final number of subjects' data eligible for diet 
analysis was 3772 (1815 cases and 1957 controls). 
10.4.3 Nutrient analysis 
SPSS version 17.0 was used to conduct statistical analysis and obtain odds ratios 
(OR) and confidence intervals through logistic regression. Each nutrient absolute 
intake was categorized into quartiles based on the distribution of energy-adjusted 
value of controls. 
Since Iycopene was not listed in the calculation program, Lycopene was analyzed 
separately by using frequency of intake of tomato (medium serving of 57g) and 
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tomato ketchup (medium serving of 30g). There were studies suggesting that 
tomato and tomato products such as tomato ketchup are good representatives as 
they are high in Iycopene (Joanne M. Holden et aI, 1999). 
For selenium, estimated risks were calculated based on total daily Intake from 
actual diet and vitamin supplement. The analyses were also conducted 
separately from these two selenium sources. 
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10.5 Results 
10.5.1 Energy intake 
The mean Total calorie intake for control subjects and cases were 2431.08 ± 2sd 
(18.17) and 2638.55± 2sd (21.57) respectively. 
10.5.2Isoflavone 
The mean daily intake of total isoflavones in all study subjects is 1471.54 I-Ig 
(standard deviation of 1.56 I-Ig), or median 1471.55 1-19 (interquartile range 26.98 
I-Ig). Our study subjects' median value is higher than the median value obtained 
in an EPIC Norfolk arm in UK of average less than 1000 I-Ig with Interquartile 
range 390 to 820 I-Ig which uses 7-day food diary method (Mulligan et aI, 2007). 
Table 10-2 Distribution of Isoflavone between cases and controls 
Group 
Total Isoflavone Amount 
(pg) Control Case 
0/0 0/0 0/0 
Q1 406 519 925 
«1470.84) 25.0% 34.7% 29.7% 
Q2 407 377 784 
(1470.84-1471. 70) 25.1% 25.2% 25.1% 
Q3 407 324 731 
(1471. 70-1472.45) 25.1% 21.7% 23.4% 
Q4 403 275 678 
C . ~ 1 4 7 2 . 4 5 ) ) 24.8% 18.4% 21.7% 
Total 1623 1495 3118 
100.0% 100.0% 100.0% 
Chi-square test p<0.001 
The results showed higher proportion of cases as compared to controls In the first 
and the second quartile. The lowest proportion of cases was In the fourth or 
highest quartile. Chi-square test at p<O.OOl suggested there Is a statistically 
significant difference in the distribution of Isoflavone Intake between cases and 
controls. 
The logistic regression results (Table 10-3 page 10-226) showed statistically 
significant odds ratio values in all models. In the fully adjusted model, the odds 
ratios value for 2nd , 3rd , and 4th quartile are 0.689 (95%Cl: 0.563-0.843), 0.559 
(95%Cl: 0.455-0.688) and 0.464 (95%Cl: 0.374-0.577) respectively. The P for 
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trend at p<0.001 also showed statistically significant trend of risk reduction 
across quartiles (as shown in Table 10-3). 
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·Calorie-adjusted regression model 
bAge and calorie adjusted regression model 
~ u l t i v a r i a t e e adjusted regression model for age, education, ethnic, family history of cancer and calorie 
P for trend, p<O.OOl 
.. . -
- -
.. 
.. ------
Odds ratioC P valuec (95OfoCI) 
Ref -
0.689 
<0.001 (0.563-0.843) 
0.559 i 
(0.455-0.688) <0.001 . 
0.464 
<0.001 (0.374-0.577) 
10.5.3 Selenium 
Total selenium mean daily intake in the study population is 52.12 IJg (s.d. 8.38 
IJg). It is considered higher than the estimated selenium intake in the UK in 
1997, although it has been suggested that the dietary selenium intakes In the UK 
has been falling over the last 20 years (Jackson et aI, 2003). However it is still 
below the current UK reference nutrient intake (RNI- recommended amount of 
nutrient to prevent deficiency for different age group for UK population from 
Department of Health) for adult men at 75 1J9 per day (Department of Health, 
1991; Jackson et aI, 2004). 
10.5.3.1 Total Selenium Intake 
Table 10-4 Cross-tabulation of Total Selenium Intake and Case-Control 
Group based on Intake Amount Quartile 
Group 
Total Total Selenium Amount 
(1I9) Control Case 
0/0 0/0 0/0 
Ql 478 343 821 
( <44.76) 24.6% 19.0% 21.9% 
Q2 488 402 890 
(44.76-50.48) 25.1% 22.3% 23.8% 
Q3 488 442 930 
(50.48-56.63) 25.1% 24.5% 24.8% 
Q4 487 617 1104 
( ~ 5 6 . 6 3 ) ) 25.1% 34.2% 29.5% 
Total 1941 1804 3745 
100.0% 100.0% 100.0% 
ChI-square test, p<O.OOl 
The results showed that in the 3rd and 4th quartiles, there were a greater 
proportion of cases as compared to controls. Chi-square of p<O.OOl showed 
statistically significant difference in the total selenium intake between cases and 
control. 
Results from analyses of logistic regression modelling (refer Table 10-15 page 10-
239) showed consistent statistically significant odds ratiOS of all models for all 3rd 
and 4th quartiles when compared to lowest quartile. The fully multlvarlate-
adjusted regression models showed Increased odds ratios of 1.314 (95%CI: 
10-227 
1.072-1.610) and 1.997 (95%Cl: 1.636-2.438) for 3rd and 4th quartiles as 
compared to reference (Q1) respectively. All P for trends was also statistically 
significant (p<O.OOl) suggesting increased selenium intake is associated with 
increased prostate cancer risk. 
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Total Control Case Odds ratio· P value· Odds ratio
b 
P valueb Selenium (95%CI) (95%CI) 
Ql 478 343 Ref - Ref -
Q2 488 402 1.148 0.158 1.199 0.066 (0.948-1.390) (0.988-1.454) 
Q3 488 442 1.262 0.016 1.343 0.003 (l.045-1.525) (1.108-1.628) 
Q4 487 617 1.766 <0.001 1.933 <0.001 
_ U · ~ 7 1 - 2 . 1 1 9 ) )
----
(1.fjQl-2.333) 
aCalorie-adjusted regression model 
bAge and calorie adjusted regression model 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer and calorie 
P for trend, p<O.OOl 
Odds ratioC P valuec (95%CI) 
Ref -
1.198 0.082 (0.977-1.468) 
1.314 0.009 (1.072-1.610) 
1.997 
<0.001 ( 1 . 6 3 § - = _ ~ ~ ~ J J ~ ~_ 
10.5.3.2 Selenium intake from food source and from supplement 
The mean selenium intake based on food source alone and on supplement alone 
is 44.89 I-Ig (s.d. 9.37 I-Ig) and 7.12 I-Ig (s.d. 1.19 I-Ig) respectively, and had a 
ratio of 6.3 to 1 
a. Food Intake Selenium 
Table 10-6 Cross-tabulation of Food origin Selenium Intake and Case-
Control Group based on Intake Amount Quartile 
Food origin Selenium Group Total 
Amount Control Case (pg) 
0/0 0/0 0/0 
Q1 489 349 838 
«37.21) 25.0% 19.2% 22.2% 
Q2 490 400 890 
(37.21-43.18) 25.0% 22.0% 23.6% 
Q3 489 472 961 
(43.18-49.83) 25.0% 26.0% 25.5% 
Q4 489 594 1083 
C ~ 4 9 . 8 3 ) ) 25.0% 32.7% 28.7% 
Total 1957 1815 3772 
100.0% 100.0% 100.0% 
Chi-square test, p<O.OOl 
When selenium intake was analysed based on values from diet alone, the higher 
proportion of cases are in quartlles 3rd and 4th at 26.0% and 32.7% respectively. 
Chi-square test was statistically significant (refer Table 10-6 page 10-230). 
Results of logistic regression models (refer Table 10-7 page 10-231) showed 
increased risks for 3rd and 4th quartlles when compared to 1st quartile (OR 1.416, 
95%Cl: 1.158-1.731 and OR 1.933, 95%Cl: 1.584-2.358 respectively). Test for 
trend was also statistically significant. 
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Table 10-7 Odds Ratios and Confidence Intervals of Food Origin Selenium Intake Amount Quartile and Prostate 
Cancer Risk 
Food Origin Control Case Odds ratio· P valueB Odds ratio
b 
P valueb Selenium (950f0CI) (95%CI) 
Ql 489 349 Ref - Ref -
Q2 490 400 1.144 0.167 1.197 0.067 (0.945-1.384) (0.987-1.450) 
Q3 489 472 1.352 0.002 1.437 <0.001 ( 1.122-1.630) (1.189-1.738) 
Q4 489 594 1.702 (1.419-2.042) <0.001 
1.858 
<0.001 (1.540-2.241 ) 
aCalorie-adjusted regression model 
bAge and calorie adjusted regression model 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer and calorie 
P for trend <0.001 
Odds ratioC 
(950f0CI) 
Ref 
1.210 
(0.988-1.481) 
1.416 
(1.158-1.731) 
1.933 
(1.584-2.358) 
P valuec 
-
0.066 
0.001 
<0.001 I 
b. Selenium supplement 
Table 10-8 Cross-tabulation of Tablet Supplement Selenium Intake and 
Case-Control Group based on Intake Amount Ouartile 
Tablet Supplement Group Total 
Selenium Amount Control Case (a.lg) 
0/0 0/0 0/0 
Ql 489 574 1063 
( <6.55) 25.0% 31.6% 28.2% 
Q2 489 421 910 
(6.55-7.02) 25.0% 23.2% 24.1% 
Q3 490 377 867 
(7.02-7.50) 25.0% 20.8% 23.0% 
Q4 489 443 932 
( ~ . 7 . 5 0 ) ) 25.0% 24.4% 24.7% 
Total 1957 1815 3772 
100.0% 100.0% 100.0% 
Chi-square test p<O.OOl 
A higher proportion of controls were in the 2nd, 3rd and 4th quartile when 
compared with controls. Chi-square test showed that there is statistically 
significant difference between the distribution of cases and controls among 
quartiles. 
The logistic regression models In Table 10-9 page 10-233, showed statistically 
significant reduced odds ratios values for univariate, age-adjusted and 
multivariate adjusted regression models. Those who reported higher intake of 
selenium supplement were at reduced prostate cancer risks. The multivariate 
model gave odds ratio values of 2nd, 3rd and 4th quartlles at OR 0.685 (95%CI: 
0.568-0.0.827), 0.611 (95%CI: 0.505-0.741) and 0.670 (95%CI: 0.555-0.810) 
respectively. Test for linear trend was also statistically significant at p-values of 
0.001 suggesting a linear trend of risk reduction across quartlles. 
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Table 10-9 Odds Ratios and Confidence Intervals of Tablet Supplement Intake Selenium Amount Quartile and 
Prostate Cancer Risk 
Tablet Odds ratio· Odds ratiob Supplement Control Case (950f0CI) P value- (950f0CI) Pvalue
b 
Selenium 
Ql 489 574 Ref - Ref -
Q2 489 421 0.733 0.001 0.712 <0.001 (0.614-0.876) (0.596-0.852) 
Q3 490 377 0.655 <0.001 0.627 <0.001 (0.547-0.785) (0.523-0.753) 
Q4 489 443 0.772 0.004 0.738 0.001 (0.647-0.921) (0.617-0.882) 
aCalorie-adjusted regression model 
bAge and calorie adjusted regression model 
'Multivariate adjusted regression model for age, education, ethnic, family history of cancer and calorie 
P for trend =0.001 
Odds ratioC 
(950f0CI) P value
c 
Ref -
0.685 
<0.001 (0.568-0.0.827) 
0.611 
<0.001 {0.505-0.741} 
0.670 
<0.001 I (0.555-0.810) 
10.5.4 Vitamin D 
The mean dietary intake for Vitamin D in this study is 6.49 I-Ig (s.d. 1.29 I-Ig). The 
average dietary intake of vitamin D from food sources for men age 19 to 64 in 
the UK based on year 2000/2001 food and nutrient intake survey was 3.7 I-Ig 
(s.d. 2.25 I-Ig) and from all diet sources was 4.2 I-Ig (3.06 I-Ig), with those age 50 
to 64 years old at 4.9 I-Ig (s.d. 3.25 I-Ig) (Henderson et aI, 2003). The study 
figure is higher than the UK national average but still lower than national figure of 
US or Japan (Calvo et aI, 2005). 
Table 10-10 Distribution of Vitamin D Dietary Intake in cases and 
controls 
Group 
Total Dietary Vitamin D Amount 
(1-19) Control Case 
0/0 0/0 0/0 
Ql 478 353 831 
( <5.48) 24.6% 19.6% 22.2% 
Q2 488 402 890 
(5.48-6.17) 25.1% 22.3% 23.8% 
Q3 488 478 966 
(6.17-7.04) 25.1% 26.5% 25.8% 
Q4 487 571 1058 
( ~ 7 . 0 4 ) ) 25.1% 31.7% 28.3% 
Total 1941 1804 3745 
100.0% 100.0% 100.0% 
Chi-square test, p<O.OOl 
The greater proportion of cases as compared to controls was observed at 3rd and 
4th quartiles. Chi-square at p<O.OOl showed statistically significant difference in 
the proportion of intake amount between cases and controls. 
The logistic regression models showed statistically significant Increased odds 
ratios for 3rd and 4th quartlles when compared with lowest (first) quartile (refer 
Table 10-11 page 10-235). The multivariate adjusted odds ratios for 3rd and 4th 
quartile is 1.401 (95%CI: 1.149-1.709) and 1.632 (95%CI: 1.342-1.985) 
respectively. P for trend was also found to be significant statistically at p<O.OOl 
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Dietary Control Case Odds ratio· P valueill Odds ratio
b 
P valueb Vitamin D (950f0CI) . {950f0CI} 
01 478 353 Ref - Ref -
Q2 488 402 1.115 0.261 1.126 0.224 (0.922-1.350) (0.930-1.363) 
Q3 488 478 1.326 0.003 1.374 0.001 ( 1.101-1.598) (1.138-1.658) 
Q4 487 571 1.588 <0.001 1.649 <0.001 (1.322-1.907) (1.371-1.984) 
aCalorie-adjusted regression model 
bAge and calorie adjusted regression model 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer and calorie 
P for trend, p<O.OOl 
- . 
- -
----- .. -.. _ .... 
Odds ratioC P valuec (95%CI) 
Ref -
1.168 0.129 (0.956-1.429) 
1.401 0.001 (1.149-1.709) 
1.632 
<0.001 (1.342-1.985) 
10.5.5 Lycopene 
a. Lycopene from tomato 
Table 10-12 Dlstr ib' f utlon 0 Tomato Intake in Case-Contro Group 
Group 
Total 
Tomato Intake Frequency Control Case 
0/0 0/0 0/0 
Never or < 1 per month 176 148 324 
9.1% 8.2% 8.7% 
1 - 4 per month 555 458 1013 
28.6% 25.5% 27.1% 
2 - 6 per week 1060 1042 2102 
54.6% 58.0% 56.2% 
Once or more per day 150 148 298 
7.7% 8.2% 8.0% 
Total 1941 1796 3737 
100.0% 100.0% 100.0% 
Chi-square test p=0.100 
A slightly higher proportion of cases reported eating tomato 2-6 times per week 
and once or more per day. Chi-square test did not reveal any significant 
difference. 
The logistic regression results were displayed In Table 10-13 page 10-237. The 
results suggested no aSSOCiation between tomato intake and prostate cancer risk. 
Test for linear trend however showed statistically significant at p values of 0.033, 
suggesting increased prostate cancer risk with Increased tomato Intake. 
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Table 10-13 Odds Rat' d Confid Int' 'fT' ,to L Intake F d Prostate C Risk ~ . . ____ .. ~ ~ ~ ~ ~ ~ ~ ~ _ _ ~ ~ ~ ~ ~ ~ _ ~ ~ ~ ~ · r e q u e n c y y an __ ~ ~ ~ ~ _ ~ ~ ~
Tomato Odds ratio· • Odds ratiob b Odds ratioC C 
Lycopene Control Case (95%CI) P value (950f0CI) P value (95%CI) P value 
Never or < 1 176 148 Ref _ Ref - Ref _ 
per month 
1 - 4 per 555 458 0.981 1.023 1.017 
month (0.763-1.262) 0.883 (0.796-1.322) 0.841 (0.781-1.325) 0.899 
2 - 6 per week 1060 1042 1.169 0 192 1.210 0 113 1.187 0 173 (0.924-1.478) . (0.956-1.533) . (0.928-1.519) . 
Once or more 150 148 1.173 1.244 1.119 
per day (0.856-1.608) 0.320 (0.905-1.711) 0.179 (0.801-1.563) o . ~ ~
aUnadjusted regression model 
bAge-adjusted regression model 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer 
P for trend, p=O.033 
b, Ketchup Lycopene 
T bl 10 14 D' t 'b t' a e 
-
IS n u Ion 0 etc up n a e n fK hIt k i C C ase- ontro IG roup 
Group 
Total 
Ketchup Lycopene Intake Frequency Control Case 
0/0 0/0 0/0 
Never or < 1 per month B96 772 166B 
46.3% 43.0% 44.7% 
1 - 4 per month 743 645 13BB 
38.4% 35.9% 37.2% 
2 - 6 per week 272 350 622 
14.1% 19.5% 16.7% 
Once or more per day 24 2B 52 
1.2% 1.6% 1.4% 
Total 1935 1795 3730 
100.0% 100.0% 100.0% 
Chi-square test, p<0.001 
Cases reported taking ketchup more frequent than control (refer Table 10-14 
page 10-238). 
The logistic regression models (refer Table 10-15 page 10-239) showed that 
subjects who reported ketchup Intake 2-6 times per week were at increased 
prostate cancer risk (OR in the fully adjusted model 1.559, 95%CI: 1.283-1.894). 
P for trend was statistically significant. 
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Ketchup Control Lycopene 
Never or < 1 896 
per month 
1 - 4 per 743 
month 
2 - 6 per week 272 
Once or more 24 
per day 
aUnadjusted regression model 
bAge-adjusted regression model 
Case 
772 
645 
350 
28 
Odds ratio· P valueB (950f0CI) 
Ref -
1.008 0.918 (0.873-1.162) 
1.493 <0.001 ( 1.241-1.798) 
1.354 0.283 (0.778-2.355) 
k, copene .lnta .. . -
Odds ratiob 
[950f0CI) 
Ref 
1.007 
(0.873-1.162) 
1.519 
(1.261-1.829) 
1.435 
(0.823-2.501) 
CMultivariate adjusted regression model for age, education, ethnic, family history of cancer 
P for trend, p<O.OOl 
--
.-
- - - --- --
'k 
- - -- --
P valueb Odds ratio
C 
P valuec (950f0CI) 
- Ref -
0.923 1.035 0.656 (0.890-1.202) 
<0.001 1.559 <0.001 (1.283-1.894) i 
0.203 1.430 0.232 I (0.796-2.569) 
10.6 Discussion 
10.6.1 Isoflavones 
The results of the multivariate adjusted model showed that isoflavones at 2nd, 3rd 
and 4th quartile intake were all statistically significantly associated with reduction 
risk to prostate from 31.1% (range: 15.7% - 43.7%) In 2nd quartile to 53.6% 
(range: 42.3% - 62.6%) in the highest intake quartile (4th) (refer Table 10-3 
page 10-226). The study findings are In agreement with most case-control 
studies involving measurement of dietary soy food or isoflavones (Heald et ai, 
2007; Kolonel et ai, 2000; Lee et aI, 2003; Nagata et ai, 2007). 
Test for trend of the odds ratio across all quartiles was also significant at 
p<O.OOl, suggesting higher intake of soy food or food containing rich isoflavones 
protect against prostate cancer. The odds ratios obtained in the present study 
are very much similar to those obtained from other case-control studies either the 
studies from the Far-east countries or from the western including the UK and 
Scotland. 
The study findings add further evidence for the role of Isoflavones In reducing risk 
of prostate cancer for western countries as previously evident on Far East Asian 
population studies such as Lee and Nagata (Lee et aI, 2003; Nagata et ai, 2007). 
When considering time recalling typical diet history of last 5 years, one would 
anticipate some behavioural diet changes which would have taken place within 
this period particularly among those who were diagnosed with prostate cancer 
(cases subjects) due to awareness of current understanding of 'high anti-oxidant 
diet' strategy and to believe of its chemo preventive properties. This may affect 
the estimated risks in the reverse order due to cases take more isoflavones than 
controls. However, the reduced risk observed in this study did not support the 
above assumption. 
10.6.2 Selenium 
The regression models revealed statistically significant increased risk for prostate 
cancer for categories of 3rd and 4th quartiles (at higher intake of selenium) when 
compared with lowest intake (refer Table 10-5 page 10-229). 
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Selenium from dietary intake suggested increased prostate cancer risk with 3rd 
and 4th quartile as compared to reference with OR 1.416 (95%CI: 1.158-1.731) 
and OR 1.933 (95%CI: 1.584-2.358) (refer Table 10-7 page 10-231). Further 
results from analysis of supplement intake suggested an inverse relationship of 
selenium supplement and prostate cancer risk (quartiles of2"d, 3rd and 4th 
compared to the lowest quartile-1st quartile) with odds ratios of 0.685 (95%CI: 
0.568-0.0.827), 0.611 (95%CI: 0.505-0.741) and 0.670 (95%CI: 0.555-0.810) 
respectively (refer Table 10-9 page 10-233) 
The findings of total selenium intake which suggested increased prostate cancer 
risk when increased selenium intake could be due to the fact that cases were well 
aware of their prostate cancer conditions and were told of the possible risk 
factors. Among dietary recommendation for prostate cancer prevention, selenium 
has been one of the foremost nutrients. There is lots of bombardment of 
materials through the mass media on some of the preventive methods of lifestyle 
to prevent or lower risk of cancer, and among these dietary changes to a 
healthier. This is evident by higher mean intake of total selenium as compared to 
the average UK population. 
Since diet history record of 5 years were obtained in this study, there could be a 
possibility that cases may not report the true account of the diet in the last 5 
years to represent their diet of lifetime. 
On the contrary, selenium supplement supported protection against prostate 
cancer. There is a possibility that this is a true account of the long healthy diet 
lifestyle since dietary selenium in the UK on average is getting lower In the last 
20 years (Jackson et ai, 2003). If selenium supplements are made of selenlzed 
yeast (Finley, 2006), It has been considered the best source of selenium 
compared to the selenium from other food, therefore there Is biological 
plausibility to explain both effects of steady intake of selenium in supplement 
combined high bioavailability which would result In higher level of blood/serum 
selenium in circulation. 
The author was not able to locate comparative articles that used case-control 
study design and investigate selenium of dietary intake in aSSOCiation with 
prostate cancer risk. One cohort study which uses FFQ to measure the dietary 
and supplement selenium intake in order to monitor their cohort subjects 
obtained non-statistical significant relative risks (Hartman et ai, 1998). Other 
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studies used nested case-control study design but measuring only FFQ for 
selenium intakes obtained non-statistically significant findings (Kristal et aI, 2010; 
Peters et aI, 2008; Zhang et aI, 2009). A randomized, placebo-controlled trial of 
35,533 men from US, Canada and Puerto Rico aimed to study selenium 
supplements as preventive treatment also obtained non-statistically significant 
results (Lippman et aI, 2009). 
Based on the literature review, the studies that successfully obtained statistically 
significant inverse relationship with prostate cancer came from using plasma or 
serum level of selenium (Gill et aI, 2009; Li et aI, 2004; Nomura et aI, 2000; 
Pourmand et aI, 2008). Attempts to assess selenium amount through FFQ or 
dietary questionnaire proved to be a challenge and limitation due to complex 
metabolism of selenium compounds between individuals and issue of absorption, 
when bioavailability of selenium is used as an exposure (Falrweather-Tait, 1997; 
Fairweather-Tait et aI, 2010; Finley, 2006; Levander, 1987). 
Blood selenium levels are better representative of selenium status than plasma 
selenium, as the later reflects shorter term of selenium status (Levander, 1987). 
The first limitation in this present study Is to use FFQ and not supplement with 
blood selenium specimen to support the correlation in the dietary data. 
Secondly, even though this is a large case-control study, due to limited details of 
prostate cancer diagnosis in the database, we were not able to stratified cases 
into grades or aggressive of prostate cancer. Since previous studies have 
demonstrated selenium to be protective for aggressive or poor prognosis, and 
high grade prostate cancer (L1 et aI, 2004; Nomura et aI, 2000). Further studies 
also indicate the role of genetiCS in this relationship (Penney et aI, 2010; Platz, 
2010) and as how to reconcile the contradictory findings of prostate cancer risk 
results in the two randomized control trial I.e. SELECT (Selenium and Vitamin E 
Cancer Prevention Trial) and NPC (Nutritional Prevention of Cancer). 
Thirdly, the effect of selenium on prostate may not be a linear association. Bleys 
et al in their paper has made a hypothesis that dose responds of selenium to 
prostate cancer risk could be a 'u' shape. Using Restricted quadratic splines 
statistical analYSiS, he was able to demonstrate and identified a non-linear 
association of serum selenium with all cause and cancer mortality. Similar hazard 
ratios plot of 'u' shape was obtained for prostate cancer (Bleys et aI, 2008). 
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Other researchers also support of this hypothesis (Fairweather-Tait & Hurst, 
2009; Rayman et aI, 2009). 
10.6.3 Vitamin D 
The dietary intake of Vitamin D obtained in this study 6.49 \.Ig (s.d. 1.29 \.Ig) is 
higher than the median daily intake of vitamin D from food sources in men aged 
19-64 years old at 112 IU (s.d. 72) (the UK National Diet and Nutrition Survey) 
(Bates et aI, 2010). It is possible that higher vitamin D intake in study subjects 
for both case and control groups are from men with mean age of 59 years which 
could have been taking vitamin D in response to bone health issues in older age. 
The logistic regression models showed statistically significant increased risks in 
the 3rd and 4th quartiles (refer Table 10-11 page 10-235). The study findings 
suggested increase risk for prostate cancer among those with higher intake of 
vitamin D. The author is unable to confer to any studies of case-control design 
that obtained similar finding. 
The study findings of higher risk among higher vitamin D intake may not be a 
true finding and cautious should be made when interpret the results. 
Firstly, dietary vitamin D is normally obtained from fortified dairy food such as 
milk and margarine (Chen et aI, 2007). However it is also showed that dairy 
products also contains calcium and phosphorus, and has been aSSOCiated with 
increase prostate cancer risk. High intakes of calcium and phosphorus would 
lower circulating 1,25(OHhD level by suppressing Its production, when actually 
1,25(OHhD is doing the work of inhibiting prostate carcinogenesis (Giovannuccl, 
1998). 
Secondly, the limitation of dietary intake of last 5 years as used in this study for 
vitamin 0 may not be able to capture of whether the subjects may have low 
vitamin D in earlier life, as process of prostate cancer carcinogenesis is likely to 
begin early in life (Giovannucci, 2007). In the study results on sun exposure to 
skin (as discussed in separate chapter in this thesis), we were able to capture the 
amount of sunlight (for vitamin D production) at different age periods i.e. 20's, 
30's, 40's etc. 
Thirdly, there's a high possibility that due to aSSOCiation of prostate cancer with 
the manifestation of losing weight and secondary metastasis to bones in higher 
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advanced stages of cancer, cases would have been prescribed with Vitamin D 
supplements as well as advised to consume more dairy products fortified with 
vitamin D for their bone health. 
10.6.4 Lycopene 
Lycopene from tomato is not associate with prostate cancer (refer Table 10-13 
page 10-237). However test for linear trend still showed statistically significant 
value of 0.033 suggesting estimated risks are on increasing trend with increase 
consumption frequency of tomatoes. 
By referring Table 10-14 page 10-238, most of the subjects in both groups fall 
into the category of consuming tomato ketchup 'never or less than once a month' 
between 43.0 to 46.3%, followed by 1-4 intakes per month (between 35.9-
38.4%). The intake frequency of ketchup overall is less than tomato intake, 
although it was discussed earlier in the literature that processed tomato provides 
more Iycopene nutrient compared to fresh tomatoes through better bioavailability 
(Gartner et aI, 1997). 
The logistic regression modelling for ketchup showed increased odds ratio In 
univariate, age-adjusted and multivariate adjusted models for those who 
consumed ketchup at '2-6 times per week' as compared to those who reported 
'never or less than once per month' (OR 1.559, 95%CI: 1.283-1.894) (refer 
Table 10-15 page 10-239). The P for trend showed <0.001 of increasing trend of 
OR values with increasing intake of ketchup. 
The results of Iycopene nutrient In aSSOCiation with prostate cancer risk were 
based on intake frequency of tomatoes and ketchup. The findings are different 
from previously published articles. Most of these research results were of Similar 
study design and showed reduction risk of prostate cancer (Jain et aI, 1999; Jlan 
et aI, 2005; McCann et aI, 2005; Norrlsh et aI, 2000a) or at least a null 
association (Sosetti et aI, 2004). 
The limitation of the dietary intake of last 5 years history, would somewhat affect 
the findings. In terms of public health view pOint, one would definitely expect 
behavioural changes In terms of healthy eating or higher intake of anti-oxidant 
foods believed to be anti-cancer (Stahl et aI, 1998), most abruptly among those 
who have been diagnosed of prostate cancer. Widely available access to material 
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reading for cancer patients on healthy lifestyle which constitute a lot on diet 
adjustment, would resulted in what appear as increased risk of prostate cancer 
among those taking ketchup more frequently. 
Secondly, issue of Iycopene bioavailability as absorption and metabolism differs in 
individuals; therefore it could affect the actual amount of Iycopene in the 
circulation. Some limitation exists when compared dietary history to 
measurement of serum or plasma Iycopene. Studies that have made comparison 
between dietary Iycopene intake with the circulating Iycopene, had shown weak 
correlation " at approximately 0.25 (VandenLangenberg et aI, 1996). Another 
study using Mediterranean diet which is rich in tomatoes and tomato products as 
seen in Greek EPIC cohort (AI-Delaimy et aI, 2004), also shown weak correlation 
between diet score and plasma Iycopene, therefore considered poor predictors of 
blood Iycopenes (Jenab et aI, 2005). 
Thirdly, our limitation of using type of food intake was based on what is believed 
to be of highest amount of Iycopene sources, as we do not have the actual 
Iycopene nutrient value database in food of European region at this moment. 
Therefore surrogate foods as marker of Iycopene intake was used instead. 
Fourthly, even though tomatoes and ketchup Intakes were recorded and probably 
contributed 85% of Iycopene exposure, the exclusion of the types of tomato or 
how it was consumed was not recorded. Examples whether It was taken as raw or 
cooked, in juice form, or even in soup. The content of each of the types differed 
a lot in terms of the Iycopene nutrient values (Campbell et aI, 2004). 
10.7 Conclusions and Recommendations 
Higher dietary intake of isoflavones and tablet supplement of selenium has been 
shown to reduce risk to prostate cancer. Selenium supplement associates with 
reduced prostate cancer risk. This study also concludes no association between 
tomato frequency intake with prostate cancer risk, however ketchup intake of '2-
6 times per week' when compared with those who reported frequency of intake 
as' Never or less than once per month' was statistically significant with increase 
odds ratio. Vitamin 0 dietary intake is associated with moderate increased 
prostate cancer risk. 
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For future studies, isoflavones could be strengthen further by measuring baseline 
blood sample for serum isoflavones or its' urinary excretion, in order to 
investigate the correlation with the dietary history among our subjects. 
Vitamin D dietary intake should not be analysed alone but in combination with 
exposure to sunlight, as production of Vitamin D is more from skin exposure of 
sunlight. Comprehensive Iycopene assessment of major resources In food should 
be explored, in order to capture better nutritional value of Iycopene in all food 
and forms of tomatoes intake. Nutritional values of Iycopene Is to be used instead 
of surrogate types of food to ensure differences in types of preparation or tomato 
products form of Iycopene content are taken into account. Longer period 
assessment of diet at younger age should be recorded In order to see the 
temporal effect of selenium, vitamin D and Iycopene intake towards prostate 
cancer risk. 
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Chapter 11 Conclusions 
This thesis aimed to investigate the epidemiological aspects of the association of 
six main areas that may contribute to prostate cancer risk namely (1) body shape 
& body fat distribution, (2) chronic diseases/conditions I.e. diabetes mellitus, 
hypertension, ischaemic heart diseases and hypercholesterolemia, (3) statln 
medications (4) painkillers (NSAIDs Aspirin & Ibuprofen and paracetamol), (5) 
skin type, suncream & sunlight exposures and (6) diet (isoflavones 
(Phytoeastrogens), selenium, vitamin D & Iycopene). The exposures at different 
stages of life at age 20's, 30's, 40's and last 5 years, as well as cumulative risk 
for prostate cancer was carried out. 
In view of the results of the quantitative analyses of data obtained through 
questionnaires for both cases and controls subjects, it was successful In view of 
the large samples obtained of 1963 cases and 2078 controls at ratio 1: 1, as this 
study has one of the highest number of subjects for a study of prostate cancer 
alone in United Kingdom using the case-control study design. 
Summary of Findings. Interpretation 
Initial multivariate analysis of statistically significant univariate analyses of 
sociodemographic factors revealed that education category, ethnic group and 
family history of cancer showed consistent statistically significant associations 
with prostate cancer risk. These together with the a-priori variables of age, were 
included into the subsequent logistic regression modeling In all the analysis of the 
factors studied. The main findings were: 
i. 'Apple' body fat distribution was associated with reduction of prostate 
cancer risk of 31 % when compared to symmetrical shape. 
ii. Body shape changes (Increased or decreased) between age groups 
20's to 40's was not associated with prostate cancer. 
iii. Diabetes mellitus status of 5 years or more showed protection against 
prostate cancer risk (approximately 55% reduction) compared to non-
diabetic. 
iv. Hypertension, hypercholesterolemia and Ischaemlc diseases did not 
show any association with prostate cancer. 
v. Statln usage was associated with protective risk against prostate 
cancer at almost 30% reduction compared to non-user. 
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vi. Longer use of statin showed a statistically significant cumulative risk 
towards reducing prostate cancer compared to non-user. 
vii. Use of paracetamol duration of 20 to 30 years at regular Interval 
showed a statistically significant risk reduction towards prostate cancer 
at almost 50% when compared non-user, while cumulative risk was a 
reduction risk of 30% if use paracetamol 20 years or more. 
viii. Aspirin and Ibuprofen were not associated with prostate cancer. 
ix. Skin type was not associated with prostate cancer. 
x. Overall usage of suntan cream of 'always' and 'sometimes' frequency 
at age 20's, 30's, 40's and last 5 years was associated with reduction 
in prostate cancer risk (approximately between 24 - 39%) compared 
never use. 
xi. Outdoor exposure of sunlight of categories more than 1 hour at age 
20's, 30's, 40's and 50's when not working was associated with 
reduced prostate cancer (approximate protective risk between 33 -
62%) compared to those who are exposed less than 1 hour. 
xii. Higher intake of isoflavones (phytoestrogens) and selenium tablets 
were associated with protective effect against prostate cancer at 
between 31-54% and 33-39% respectively. 
xiii. However higher Intake of total selenium (food & tablet form), vitamin 
D and Lycopene of tomato ketchup were associated with an Increased 
of cancer. 
xiv. Lycopene from tomatoes was not associated with prostate cancer. 
The majority of the results obtained from our data supported our earlier 
hypotheses presented in chapter 2. Our results also Indicated some similarity to 
the majority of the findings in other case-control and cohort design studies 
namely on family history of cancer, abdominal obesity, diabetes mellitus, statln, 
sunlight exposure, isoflavones and selenium supplement Intake. The strength of 
the odds ratios of prostate cancer risk In our study are also similar to other 
studies. 
In contrast, our study indicated that higher intake of aspirin, total selenium, 
vitamin D and Iycopene was not associated with reduction In prostate cancer risk. 
We did not antiCipate our findings which seem to suggest the positive relationship 
between total selenium, dietary vitamin D and Iycopene (from tomatoes) towards 
prostate cancer risk. The absence of associations between aspirin and Iycopene 
from tomato ketchup intake was also not expected, as the majority published 
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studies seem to show inverse associations. It should be noted at this point that 
one of the key differences in this study compared to others is in the age structure 
of the case and control population which was deliberately chosen to be of younger 
age. 
A further possible explanation for these would be 'reverse causation' or dilution 
effect by other exposures. Reverse causation in this context, whereby higher 
dietary intake of selenium, Vitamin D, and Iycopene seems to indicate higher risk 
of prostate cancer could be due the fact that cases upon diagnosis would report 
changing the dietary behavior in their last 5 years of life to a healthy and full of 
anti-cancer or food containing high anti-oxidant in the believe that they will have 
reduced recurrence rate or could be as part of the treatment plan. Furthermore, 
they were bombarded during their visit to health check up facilities with posters 
or pamphlets of 'healthy and high anti-oxidant diet' information. Non cancer 
patients tend to maintain Similar diet over time and may remain same in the last 
10 years. Our food frequency questionnaire is only able to capture diet of last five 
years due to the strict ruling of validity in the information given. As for the aspirin 
intake, there is a limitation to the amount of dosage taken as the supply of 
aspirin is either in the tablet of 75mg or 320mg and these has not been indicated 
clearly in the questionnaire as the habits and dosage change overtime. 
We also obtained a statistically significant inverse association of paracetamol with 
prostate cancer. This is the first time findings of long exposure use of 
paracetamol regularly of 20 years or more would reduce prostate cancer by 
almost 50% compared to non-regular user. Although it is biologically plausible as 
recent findings suggest that it is highly selective for COX2 (Hinz et aI, 2008), 
there is still a need to study further on the dosage intake and the possibility of 
confounders' effect on the relationship. 
Issues arising from the study 
The results obtained from the analysis of this study although showing much 
agreement and at the same time some disagreement to the current knowledge 
literature could be due to a number of reasons: 
Firstly, the comparison and extrapolation of this study's findings should only be 
specific for Similar type of study designs, population, ethnic, skin colour and 
environment in a developed country. This would account some similarity in 
exposures such as the amount of sunlight and dietary habits. 
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Secondly, we do highlight that analyses combined both the data of younger onset 
cases (Phase I) of less than 60 years old and of all age group populations cases 
(Phase II). Since prostate cancer incidence is associated with increasing age, it is 
possible that those who are above 60 years and in the control group are not 
necessarily be free of prostate cancer. These controls have not been screened or 
diagnosed for prostate cancer because this disease is often asymptomatic for 
many people or they may be developing cancer at early stage or in the latent 
stage. 
Even if simple screening methods such as prostatic specific antigen (PSA) testing 
are done (although not agreed to be used as wide screening method), it cannot 
be assumed that all those controls with higher than 4 ng/ml PSA level will have 
abnormal findings in their digital rectal examination (DRE), and therefore would 
decide not to proceed further for biopsy of prostate for histology due to believe 
that they are less likely to be suffering from prostate cancer or refused to be 
investigated further due to old age. This is a limitation in any control subject (in 
case-control study design or non-cases in cohort study) even if we do matching 
for age between cases and controls. However by taking only those with negative 
biopsy for prostate cancer or low PSA, as a control group would definitely reduce 
the possibility of bias. 
However, with the inclusion of 'cases' in the control group would have the effect 
of attenuating the estimates of risk and as such, any significant risks seen would 
if anything be underestimated of the true values. 
Thirdly, the possibility of bias introduced when selecting the controls from 
Nottinghamshire alone during phase II due to poor responses from some GPs and 
potential controls when matching the area with case population base which was 
done as the first phase and which remains the best design option. The second 
option of choosing controls from elsewhere was more feasible with the 
development of the computer software medical 'Read' code to help GPs Identify 
potential controls for each case by age frequency and fulfilled other inclusion 
criteria. It is of interest that the center for data collection was in Nottingham at 
that time. The environmental exposure could well have been very different given 
the matching of case and control was just based up on age characteristics. They 
came from different area of the country with unknown population biases. 
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Fourthly, a case-control study design was used due to its convenience in 
obtaining the exposure histories from both cases and controls as well as cost and 
time savings. The advantage of case-control study is the exploration of many 
new areas of exposures that could be associated with a disease, either because 
the presence of the exposure or the length of exposure and even dose of 
exposure. This is necessary before further work of the findings be refined when 
conducting a cohort or clinical trial study design. Since the survival rate of 
prostate cancer patients in UK is more than 80% for 2-5 years, we were able to 
obtain history information on these cancer cases. A limitation is however to the 
amount of accuracy or reliability on the account of both cases and control in 
remembering remote information especially on body weight or dietary intake 
values. Therefore diet history of last 5 years were obtained, based on usage of 
valid food frequency questionnaire which has been described in earlier chapters. 
Food frequency questionnaire is the closest data on subjects dietary habits as 
most do have a sensible memory record of their diet In the last 5 years. 
Literature review will only reveal common food/diet associated with certain 
ethnics groups, culture or even their country of origin, and these habits do 
change when they moved to a new country due to change of lifestyle and 
adaptation to available food. Food frequency questionnaire is very cheap 
especially when applied to individuals in providing specific favoritism in cooking 
and taste. 
Although we do not rule out the limitation of the possibility of Intention bias or 
misclassification bias in the responses given in the questionnaire, we only include 
sections of valid and tested questionnaires of different areas of exposures and 
combined them into our prostate cancer questionnaire in order to study as many 
factors as possible. 
Contribution of this Study and the way forward 
During the past 13 years since this study's inception, progress has been made In 
the study of factors/risks aSSOCiated with genetic or environmental exposures 
through epidemiological studies. This study also has further contributed to 
understanding of the interaction of risk factors for prostate cancer and the 
capacity needed to further enhance understanding of the risks in other 
populations/ethnic groups involved and exploring new areas of risk. The genetiC 
component of these gene-environmental Interaction studies has opened up better 
epidemiological evidence to the possibility of studying cause and effect. One 
interesting opportunity could occur If the case-control methodology was replicated 
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in Malaysia as the ethnic, environmental and genetic differences would permit 
further exploration. 
In order to strengthen and or further justify the current findings in this thesis, we 
would proceed with trying to understand whether there are aspects of genetics 
which could link the statistically Significant association environmental risk 
exposures; hence the study of genomic screening to identify some common 
predisposing genes or polymorph isms in repair genes would be appropriate. 
Furthermore, we hypothesize that certain environmental exposures could interact 
with such predisposing genes by creating a further increase or decrease to the 
risk to prostate cancer even if they are not acting as a direct causal agent. 
The study from this thesis alone has identified new areas of exposure that need 
to be investigated further using other methodologies, refining the following 
criteria: 
i. Prostate Cancer diagnosis through histology classification to be 
explored further according to the Gleason grade or scoring because 
some exposure such as obesity or body fat distribution could behave 
differently as risk to aggressive (fatal) or non-aggressive prostate 
cancer. 
ii. Control subjects should be matched best with cases according to 
similar county/districts to reduce the bias due to effect of ecological 
reason such as food and water supply, industry or enVironmental non-
working related factors. 
Iii. Control subjects should be those that have been screened for at least 
PSA (Prostatic specific antigen) and/or DRE (Digital rectal 
examination) for those above 50 years old and all suspicious cases, 
and investigate further when necessary for prostate biopsy histology in 
order not to miss out undiagnosed prostate cancer cases and to reduce 
bias. 
iv. To focus on young onset «60 years old) prostate cancer cases and 
controls with matched age, because of the potential outcome of the 
research will contribute more for the prevention/reducing risk exposure 
or at the same time promote good exposure to factors that reduced 
risk to prostate cancer such as diet or sunlight. 
v. Since genetic factors which couple with Interaction between types of 
exposures could contribute to the risk to prostate cancer, the 
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epidemiological findings should be combined in order to strengthen the 
pred ictive modeling. 
vi. Cluster sampling of minority ethnic groups should be represented more 
in both cases and controls in order to better extrapolate the results of 
the samples to bigger population area and country or regions. 
vii. Some possibility of verifying the data from questionnaire such as 
photos of subjects at age 20's to 40's and current for body shape, as 
well as medical records for other diseases/condition presence should 
be obtained as part of the validity checking process besides the validity 
of entering data to the database. List of medications received may help 
although subjects can always buy non-prescribed medication from the 
pharmacy OTe. 
The exploration of new surrogate indicators obtained in this study such as body 
fat distribution and suntan cream usage, or scoring for vitamin D from sunlight 
exposure should be studied further through stronger methodology study design 
such as cohort studies. Besides exploring new proxy-markers, the use of cohort 
populations will improve the variable definitions, the measurement records 
obtained from follow ups in each visit, recorded by reliable methods and 
evaluator, new conditions or illness maybe reported every 5 years and subject's 
medical records for specific data may be obtained from relevant GPs upon 
consent from the patients and relevant hospitals. Under these Circumstances, 
nested case-control study could also be done towards a time when 
prevalence/incidence of prostate cancer cases are ample for analYSis. 
Final Conclusions 
The results of this study can be used to strengthen further the current findings of 
the association of certain exposures such as diabetes mellitus, usage of statins, 
obesity and exposure of sunlight to reduce prostate cancer. On one hand, some 
of the protective behaviours such as higher duration of sunlight exposure In daily 
life should be taken together with correct health understanding that vitamin 0 is 
important for our health and the sunlight is our main source of vitamin D. 
However, the interpretation of how diabetes mellitus status, abdominal obesity or 
statlns could reduce prostate cancer risk should not send a wrong message to the 
public, because these morbid conditions are risk themselves to the health of a 
person. The conclUSion to be made as such would be to strengthen our 
understanding of the new knowledge in hypothetical or theoretical mechanisms 
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involved in preventing the initiation of carcinogenesis or how these actions stop 
the progress or recurrence of prostate cancer, which will be used towards public 
health preventive control measures of prostate cancer. Furthermore, through 
knowledge on genetic factors i.e. predisposing genes and their interaction with 
such environmental exposures, could help researchers to create better strategies 
towards the prevention of prostate cancer in public health as a whole. 
As a clinician, the understanding of modifiable and non-modifiable risk factors to 
a disease such as prostate cancer is very useful when tackling queries or 
counseling patients and their relatives. The ability to provide some information 
using evidence based epidemiological findings could help them to understand 
what predisposed them to the condition. This is particularly true when dealing 
with those who have non-modifiable factors such as family cancer of cancer in 1st 
degree relatives, where the risk is higher towards prostate cancer. However this 
is only one part of the attributable risks. There are numerous environmental 
factors that are modifiable but could contribute to increase risk to prostate 
cancer. On the contrary some environmental factors could also attribute to lower 
risk of prostate cancer such as higher sunlight exposure or phytoestrogens intake. 
My initial intention was to conduct similar research project on prostate cancer in 
Sabah, Malaysia, but in view of the problem of getting funding and time 
constraint, the study had to be postponed till later. This experience and 
knowledge that I've gained in the UK will strongly influence my approach to 
epidemiology work I will embark upon in Malaysia upon my return. 
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Appendices 
Cancer Registry and Report of Prostate Cancer Prevalence & Incidence in Asia and 
Malaysia 
Progress of Gene-Environment Interactions in Prostate Cancer Research (United 
Kingdom) 
Prostate Cancer Questionnaire 
Cancer Registry and Report of Prostate Cancer Prevalence It Incidence in 
Asia and Malaysia 
Prostate cancer reporting in Asia is mainly through reported cases In hospitals with 
confirmation through histology. The highest level of evidence is through the 
International Agency for research on Cancer CIARC) and International Association of 
Cancer Registries: Cancer Incidence in Five Continents which Is produced every 5 
years through collaborations of cliniCians, preclinical staffs, epidemiologists, and 
statisticians contributing to accurate diagnosis and correct coding of cancer. This 
population based cancer registry is a recognised reference source covers incidence of 
cancer in population around the world. In Asia, the countries in the report include 
China, India, Japan, South Korea, Thailand, Malaysia, Philippines, Singapore, 
Pakistan, Oman, Bahrain, Kuwait, Israel, Cyprus and Turkey. 
In terms of prostate cancer (ICD-10 code C61), the age-standardized (world) 
incidence rate (per 100,000) in specific cancer registry In Asian countries are as 
shown in Table 1, based on latest report of Cancer Incidence in Five Continents: 
2007 (Year 2002-2006). 
1 
Table 1 Prostate Cancer Age-standardized (world) Incidence rate (per 
100,000) 
Age-standardized (world) 
Country Region Incidence rate 
(per 100,000) 
Vol. VIII 2002 Vo. IX 2007 
(Year 1997- (Year 2002-
2001) 2006) 
Bahrain Bahraini NA 14.3 
China Beijing 2.9 NA 
Guangzhou City NA 6.7 
Hong Kong 8.6 15.0 
Jiashan 1.9 1.4 
Nangang district, Harbin NA 2.1 
Qidong County 1.1 NA 
Shanghai 3.0 6.9 
Taiwan 11.9 NA 
Tianjin 2.0 NA 
Wuhan 2.0 NA 
Zhongshan NA 2.3 
Cyprus Cyprus NA 40.8 
India Ahmedabad 3.6 NA 
Bangalore 3.8 NA 
Chennai (Madras) 4.9 3.9 
New Delhi 6.8 8.4 
Karunagappally 2.3 4.4 
Mumbai (Bombay) 7.4 6.9 
Nagpur 3.4 3.0 
Poona 6.6 6.4 
Trivandrum 4.0 5.6 
Israel Israel 43.2 50.2 
Jews 43.4 49.2 
Jews born in Israel 47.5 NA 
Jews born in Europe or 43.4 NA 
2 
Age-standardized (world) 
Country Region incidence rate 
(per 100,000) 
Vol. VIII 2002 Vo. IX 2007 
(Year 1997- (Year 2002-
2001) 2006} 
America 
Jews born in Africa or Asia 41.3 NA 
Non-Jews 14.8 20.0 
Japan Aichi Prefecture NA 14.2 
Fukui Prefecture NA 13.6 
Hiroshima 14.1 21.5 
Miyagi Prefecture 12.7 22.0 
Nagasaki Prefecture 12.6 20.0 
Osaka Prefecture 9.0 11.3 
Saga Prefecture 10.5 NA 
Yamagata Prefecture 9.3 13.4 
Korea Korea NA 8.5 
Busan 7.1 7.3 
Daegu 6.6 7.7 
Daejeon NA 5.8 
Gwangju NA 9.0 
Incheon NA 7.8 
Jejudo NA 11.8 
Kangwa County 5.4 NA 
Seoul 8.S 12.7 
Ulsan NA 8.6 
Kuwait Kuwaitis 11.4 10.5 
Non-Kuwaitis 10.9 9.4 
Malaysia Penang NA 11.3 
Sarawak NA 5.8 
Oman Omani 8.9 10.5 
Pakistan South Karachi 5.3 10.1 
Philippines Manila 22.3 25.3 
3 
Age-standardized (world) 
Country Region incidence rate 
(per 100,000) 
Vol. VIII 2002 Vo. IX 2007 
{Year 1997- (Year 2002-
2001) 2006) 
Rizal 16.6 NA 
Singapore Singapore NA 17.3 
Chinese 14.4 18.6 
Indian 9.9 11.1 
Malay 13.3 16.1 
Thailand Bangkok 6.B NA 
Chiang Mai 4.2 5.3 
Khon Kaen 2.4 NA 
Lampang 3.9 4.9 
Songkhla 4.0 4.6 
Turkey Antalya NA 19.1 
Izmir NA 13.7 
Vietnam Hanoi 1.5 NA 
Ho Chi Minh City 3.8 NA 
(Data excerpted from Cancer Incidence In Five Continents Volume VIII & IX. Parkin 
et al. 2002 & Curado et al. 2007) 
*NA- not available 
The Cancer Incidence in Five Continents report showed an overall increase in the age 
standardized incidence rate of prostate cancer between 2002 to 2007. A higher 
incidence rate in countries (middle-east and west Asia) close to Europe like Turkey, 
Israel, Cyprus; in countries of Eastern part of Asia, more developed countries like 
Japan, Singapore but not South Korea also have higher incidence compared to 
neighbouring countries. The increased incidence rates between the two reports could 
be due to better reporting and active detection of cases on all countries, but could 
also be due to a true increase in the number of new cases every year, due to 
environmental risk factors. The higher Incidence rate observed in developing 
countries could in part be caused by lifestyle or environmental factors. Even if the 
incidence rate of prostate cancer is higher in the developed countries situated on 
4 
eastern part of Asia the rates were still lower compared to countries of middle-east 
or West Asia. Attempts to find the risk factors for this difference in rates between 
these two regions in Asia (West and East Asia) could lie in the genetic and 
environmental interaction. 
Globocan reference data incidence and mortality rates are based on calculations from 
population based cancer registries as in Cancer Incidence in Five Continents report 
which is produced once every five years. The rates for Asia have been calculated as 
the population-weighted average of Eastern, South-Eastern, South-Central and 
Western Asia. The calculation based on country e.g. Malaysia, was by utilising on 
the Malaysia National Cancer Registry Report 2001 & 2002, and Regional Cancer 
Registry of Penang & Sarawak. Prior to 2003, calculation of rates was based on the 
closest neighbouring country with a similar population ethnic structure i.e. 
Singapore, population based cancer registry. 
Prostate cancer in 2008 was ranked 6th in Asia overall but 9 th in China, 4th in Japan 
and 3 rd in Singapore. In Malaysia, prostate is ranked 5th among male cancers. In 
World data, Prostate cancer was ranked 2nd after lung cancer in terms of incidence 
rate, while developed country like Great Britain in Europe, it was ranked first, 
similarly the USA in North America. 
5 
Progress of Gene-Environment Interactions in Prostate Cancer Research 
(United Kingdom) 
The Study of Gene-Environment Interactions in Prostate Cancer is a large scale 
case-control study and ongoing. The study is in collaboration between the 
University of Nottingham, Warwick and the Institute of Cancer Research UK, and 
began in 1999, aims to investigate environmental exposures risk to prostate 
cancer and explore genetic components involved in disease aetiology. The data 
collection was divided in to two phases, the first phase focusing on young onset 
cases «60 years of age) began in March 1999 and was frozen in December 2004 
for the purpose of interim analysis, to review/modify questionnaire and 
simplify/improve data collection process. The second phase was extended to also 
cover subjects of 60 years and above was started in December 2007 and data 
collection was also frozen in September 2009 to assess new leads of both 
genetics and environmental exposures. The third phase is proposed to start in 
2010. 
During the past 11 years since the study inception, progress has been made in 
the study of factors/risks associated through genetic or environmental exposures 
through evidence based epidemiological studies. The study also has contributed 
to the further understanding on the interaction of gene-environment towards 
prostate cancer, the capacity for further refining the risks Involved and to explore 
other new risk factors. Genetic component of these gene-environmental 
interaction studies has opened up better epidemiological eVidence to the 
possibility of studying to the cause and effect. 
The number of original article publications has also Increased over the years from 
this case control study. Below is a summary of the areas or factors studied, as 
well as their main finding(s) (Refer to Table 2). 
1 
Table 2. Summary of Published Research Findings from Gene-Environment Interaction Prostate Cancer Research (UK) 
Aims Subjects Results! Conclusions Author Publicatio 
n 
Hand 1524 cases and 3044 Those with index finger longer than ring finger (or low Rahman et al. 2010. 
pattern and controls information on 20:40) has protective risk against prostate cancer British 
prostate right hand 2nd and 4th compared to those with index ginger longer than the ring Journal of 
cancer risk fingers' length were finger (or high 2D:4D) at OR 0.67 (95% CI: 0.57-0.80). Cancer 
obtained. Those less than 60 years old have even lower risk at OR 
0.13 (95% CI: 0.09-0.21). 
Finger length through 2nd to 4th digit ratio can be suggested 
as a marker for J,restate cancer risk. 
Dietary fat 512 cases and 838 Increased risk with statistical significant trend (p<0.001) Lophatananon 2010. 
and early controls were for higher intake of total fat, SFA, MUFA and PUFA. et al. British 
onset administered with FFQ Adjusted OR between highest quintile to lowest quintile Journal of 
N prostate intake of total fat SFA, MUFA and PUFA were 2.53 (95% Nutrition 
cancer risk CI: 1.72-3.74), 2.49 (95% CI: 1.69-3.66), 2.69 (95% CI: 
1.82-3.96) and 2.34 (95% CI: 1.59-3.46) respectively. 
Sexual 431 cases and 409 Higher frequency activity of masturbation at age 20's and Dimitropoulou 2008. 
activity and controls information on 30's was statistically Significant associated with increased et al. British 
early onset sexual activity in risk of early onset prostate cancer. Journal of 
prostate particular frequencies of While frequent overall sexual activity in 20's increase Urology 
cancer risk intercourse and disease risk, at age 50's appeared to be protective, I 
masturbation were although both were not statistically Significant. 
obtained. 
Diagnostic Matched 431 cases and Increased risk were observed for barium enema OR 2.06 Myles et al. 2008. 
radiation 409 controls below 60 (95% CI: 1.01-4.20), hip x-rays at least 5 years before British 
procedures years were asked on their diagnosis, OR 2.23 (95% CI: 1.43-3.49). Journal of 
to early exposure to their past For those with family history of cancer, earlier exposure to Cancer 
onset diagnostic imaging hip x-rays dated 10 years and 20 years before diagnosis 
prostate experiences. showed higher risk at OR 5.01 (95% CI: 1.64-15.31) and 
cancer risk 14.23 (95% CI: 1.83-110.74). All are adjusted ratios. 
- ---
w 
Aims Subjects 
Association 805 cases and 1283 
of Omega 3 controls of below 
and Omega years were given FFQ 
6 PUFAs to 
risk of early 
onset 
prostate 
cancer 
*PUFA - Polyunsaturated Fatty Acids 
*SFA - Saturated Fatty Acid 
*MUFA - Monounsaturated Fatty Acid 
*FFQ - Food Frequency Questionnaire 
60 
Resultsl Conclusions Author Publicatio 
n 
Findings suggested genetic factor interaction with 
diagnostic radiation exposure towards early onset prostate 
cancer risk. 
Dietary intake of Omega 3 PUFAs showed protective trends Undergraduat 2009. 
to risk of early onset Prostate cancer while Omega 6 es of medical Research 
showed increase risk, although both were not statistically school project. 
significant. 
As the case control data gathering is still on-going, this bigger mass of data will 
inevitably increase the strength of the case-control database. 
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ID number 
Official use only 
R The University of Nottingham 
Gene-Environment Interactions in 
Prostate Cancer 
This study is being conducted by the Division of Epidemiology and Public Health, 
University of Nottingham, Institute of cancer Research and the Royal Marsden Hospital 
NHS Trust. We are investigating factors that may be involved in the occurrence of 
prostate disease. 
We would be very grateful if you could complete this questionnaire. This should only take 
about 30-45 minutes and we hope you will find it interesting. Your information will be 
treated in the strictest confidence. 
Please DO NOT write your name anywhere on the questionnaire. You will be identified 
only by the unique ID number at the top of this page. 
Please return the completed questionnaire at your earliest convenience in the enclosed 
prepaid envelope - no stamp is required. 
Thank you for your help. 
Dr Aneela Rahman (Researcher) Tel: 0115-8230495 
Study Team from The University of Nottingham 
Prof. Ken Muir 
Dr Artitaya Lophatananon 
Dr Aneela Rahman 
Ms Jo-Fen Liu 
(Principal Investigator) 
(Research Officer) 
(Researcher) 
(Research Officer) 
Study Team from The Institute of Cancer 
Research/The Royal Marsden Hospital NHS Trust 
Dr Rosalind Eeles 
Prof. Douglas Easton 
Prof. David Dearnaley 
(Principal Investigator) 
(Co- Investigator) 
(Consultant Oncologist) 
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ID Number ,-I _____ -, 
Official use only 
Section 1: About you 
We would like to ask about your personal details. 
1) Date of birth 
00/00/00 
Date Month Year 
2) Your marital status (please tick the appropriate box) 
o Married 0 Widowed 0 Single 
o Divorced 0 Separated D Other, please spedfy .................. . 
3) Please indicate which group you belong to (please tick the appropriate box) 
D White D Black- Caribbean 
o Black- African 0 Black- other 
o Indian 0 Pakistani 
D Jewish 0 Sephardic 
o Ashkenazi 0 Chinese 
o Other, please spedfy ........................ . 
4) In which country were you born? (Please tick the appropriate box) 
D UK D Other, please specify .............................................. .. 
5) Have you always lived in the UK? (Please tick the appropriate box) 
D Yes (go on to question 7) D No (go on to question 6) 
6) How long have you been living in the UK? (Please specify number of years) 
......................... years 
7) What is the highest educational qualification you have obtained? 
(Please tick the appropriate box) 
DNone 
o GCSEs, "a" levels or equivalent 
o "A" Levels, higher or equivalent 
D Higher or professional qualifications e.g. degree, HND 
D Other, please spedfy .. .......... .. ...... .... ............... .. 
- 1 -
CONTROL QUESTIONNAIRE RevtsN 5th chit 06 ~ ~ 07 
Section 2: Employment 
9 t 
This section is about the jobs you have had since you left school. 
8) can you briefly describe all the jobs you have had for mOre than 1 year. 
(Please start with your current job or your latest job). 
lob title Full time Started Finished Self-Employed 
and description of duties (FT) (year) (year) (SE) 
or or 
Part time Employed (E) 
CPT) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
- 1 -
J 
Did you 
supervise 
any others? 
(Yor N) 
COfffROL QUES710NNAlRE R.w.d 5th <hit Oil Feb 07 
Job title Full time Started Finished Self-Employed Did you 
and description of duties (fT) (year) (year) (SE) supervise 
or or any others? 
Part time Employed {E} (Y or N) 
(PT) 
10 
11 
12 
13 
14 
---
9) Have you ever been exposed to chemical substances in any of your jobs? 
D Yes (please complete the table below) 0 No (go on to Section3) 
Degree of Regularity Total From which 
Chemical substances (YIN) exposure i.e. I.e. dally, number job?- please 
high, weekly of give the Job 
intermediate years number from 
or bac:lcgl'Ound exposed the list above 
Paints/varnishes/lacquers 
Solvents/degreasing agents 
Petrol/dlesel/hydrocarbons 
Weed killers/herbicides 
Radiation 
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Section 3: Your hormones J 
Evidence has suggested a possible relationship between male hormones and prostate 
disease. The effect of hormones can be seen physically, for example, pattern of hair 
loss, frequency of shaving, acne or hand pattern. In this section we would like to 
ask you about these factors at various ages. 
Please choose the NUMBER corresponding to the hair pattern nearest to your own 
at the ages below. Please select one answer to each question. If you can't 
remember precisely, please make your best estimate. 
1 2 3 4 
5 6 7 
10) In your 20s D 11) In your 305 D 12) In your 405 D 
13) From the picture below, could you please look at the IDlIu and the IiDR fingers 
on your right hand by putting your hand on the table and compare these to the 
patterns below. Please tick the appropriate box for the pattern that is nearest to 
your own. 
Right hand 1 
D 
Right hand Z 
D 
Right hand ~ ~
D 
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14) In your 20s, how often, on average, did you need to shave in order to keep clean 
shaven? 
D Once a day 
D Less than every other day 
D Twice a day 
D Do not shave 
15) Did you have acne when you were young? 
D Every other day 
D Yes (if yes go on to question 16) D No (go on to Section 4) 
16) Did you still have acne when you were: 
Yes No 
In your 20s D D 
In your 30s D D 
- s - CONTROL QUESTIONNAIRE R ~ ~ 5th <hit (¥ FfIb 07 
Section 4: Smoking 
We would like to know a bit more about your smoking habit in this section. 
17) How would you describe yourself? (Please tick one box only) 
D Current smoker, smoke daily (go on to question 18) 
D Current smoker, smoke occasionally (go on to question 18) 
D Ex-smoker, don't smoke at all now (go on to question 21) 
D Never smoked (go on to Section 5) 
Smokers only J 
18) In a day, I usually smoke (please tick the box - you can tick more than one box and write 
down the number of cigarettes/ dgars or amount of pipe tobacco you 'smoke per day or per week) 
D Cigarettes number ........ per day or number ........ per week (go on to questions 19,20) 
D Cigar number ........ per day or number ........ per week (go on to questions 19) 
D Pipe amount ... .. ... per day or amount.. ...... per week (go on to questions 19) 
19) The cigarettes I normally smoke are: (Please tick appropriate box) 
D High tar level D Middle tar level D Low tar level 
20) I have been a smoker for ........ years (please write down a number and go to next section) 
Ex-smokers only J 
21) I have been an ex-smoker for: (please tick appropriate box) 
D Less than a year 
D 4-10 years 
D 1-3 years 
Dover 10 years 
22) When I was smoking, I used to smoke (please tick the box - you can tick more than one 
box and write down the number of cigarettes/ cigars or amount of pipe tobacco you smoke per day or 
per week) 
D Cigarettes number ......... per day or number ......... per week 
D Cigar number ......... per day or number ......... per week 
D Pipe amount .. ....... per day or amount.. ....... per week 
- 6 -
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Section 5: About sex 
The prostate gland is responsible for producing fluid that helps sperm to survive 
when they enter the female reproductive tract following ejaculation. Changes in the 
prostate gland may occur depending on how often you have sexual intercourse or 
masturbate. Some sexual activities may also be related to hormone levels or may 
lead to an increased risk of infection. To help us find out if there is an association 
between prostate changes and sexual activities we need to know about past and 
present sexual practices. 
We realise that this is a very sensitive subject but we would be very grateful if you 
could complete this section. Please answer these questions only if you feel 
able to do so. 
All your answers will be treated as STRICTLY CONFIDENTIAL AND NO 
INFORMATION WILL BE PASSED ON TO ANYONE OUTSIDE THE STUDY 
INCLUDING YOUR FAMILY DOCTOR. 
23) At what age did you first have sexual intercourse? (Please tick appropriate box) 
D Never D Under 15 years old 
D 15-19 years old D 20-24 years old 
D 25-29 years old D 30 years or older 
24) How often on average did you have sexual intercourse? (Please tick one box and 
indicate yes or no as appropriate) 
Less Once to Two to Four to Condom 
than three Once three six normally 
In your Never once a times a a times a times a Daily used 
month month week week week Yes No 
20s D 0 
30s D D 
40s D D 
50s 0 D 
- 7 -
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25) In your lifetime, how many women in total have you had sexual intercourse 
with? (Please tick appropriate box) 
D None DOne 
D Three to five D Six to ten 
D More than twenty 
D 
D 
Two 
Eleven to twenty 
26) From your answer to question 25, how many of them would you have classified 
as your "partner" (i.e. someone you have/had sexual intercourse with once a week or more for a 
period of 3 months or longer). 
D None Done 
D Three to five D Six to ten 
D More than twenty 
D 
D 
Two 
Eleven to twenty 
27) In your lifetime, have you ever paid money to women for sexual intercourse? 
(Please tick appropriate box) 
D Yes (go on to question 28) D No (go on to question 29) 
28) Did you normally use condoms on those occasions? 
DYes D No 
29) At what age did you first masturbate? (Please tick appropriate box) 
D Never D Under 15 years old 
D 15-19 years old D 20-24 years old 
D 25-29 years old D 30 years or older 
30) How often on average did you masturbate? 
Less than 1-3 2-3 4-6 
once a times a Once a times a times a 
In your Never month month week week week 
20s 
30s 
40s 
50s 
Daily 
31) Overall, did you regard yourself has having a problem with sexual activity at 
different ages? (please tick appropriate box) 
In your 20s DYes 
30s DYes 
40s DYes 
50s D Yes 
D No 
D No 
D No 
D No 
- 8 -
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32) In your 20s, 30s, 40s and 50s, did you encounter any of the following 
statement(s) that might have restricted you from sexual activity? (you can tick "; more 
than 1 statement) 
5l&1temeot5 In ~ o u r r205 305 405 50s 
1. Were not in any relationships 
2. Your partner had physical! emotional difficulties 
3. You suffered from the following conditions which 
0 restricted your sexual activity. 0 0 0 
( You can tick more than 1 box.) 
- depression 
- diabetes (high blood sugar) 
- high blood pressure 
- arthritis or rheumatism 
- prostate cancer 
- enlarged or swollen prostate 0 0 
- back problem 
- impotence / erectile dysfunction 
- lack of desire/ too tired 
- other, please specify 
..... ..... ......... ....... ... ..... ... ...... ..... .. ... .... .... .... ... .. .......... ..... .. ... .. , .... 
0 0 0 0 
.. ...... .................................. .... ....... ......... .. .... .... .. .. .......... ... ... .... , 
33) In your lifetime, have you ever attended a sexually transmitted disease (STD) or 
special (VD) clinic? (Please tick appropriate box) 
o Yes 0 No 
34) Have you ever been told by a doctor that you had any of the following 
conditions, even if it was a long time ago? (Please tick appropriate box) 
Gonorrhoea 0 Yes 0 No 
Syphilis 0 Yes D No 
Genital herpes DYes D No 
Genital warts (ie.warts on your penis/anal area) 0 Yes D No 
Non-specific urethritis (NSU) D Yes D No 
Any other type of venereal disease DYes D No 
35) Have you ever had sores or ulcers on your penis? 
D Yes (go on to question 36) D No (go on to Section 6) 
36) Have you ever had sexual intercourse while you had sores or ulcers on your 
penis? (Please tick appropriate box) 
DYes ONO 
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Section 6: About your skin and sun exposure 
There is growing evidence on the relationship between UV radiation exposure from 
sunlight and prostate diseases. Thus we would like to ask you questions about your 
skin colour and also lifetime sun exposure. 
Please tick appropriate box for each question: 
37) What type of complexion do you have? 
D Oily D Dry D Combination D Normal 
38) What is your skin colour when you are not sun tanned? 
D Very fair D Fair D Medium 
D Olive D Very dark 
39) What happens when you stay in the sun too long? 
D Painful, bad blistering and peeling 0 Blistering followed by peeling 
o Burns sometimes D Rarely burns 
D Never had burns 
40) On average looking back at the various stages of your life, in the daytime, how 
long were you out of doors during your working and non working hours? (If during the 
last 5, 10 or 20 years you did not work please answer only non working time.) 
In your Less 1-2 3-4 More than 1 hours hours than 5 hour hours 
205 Working 
Non- working 
305 Working 
Non- working 
405 Working 
Non- working 
During the last 5 years Working 
Non- working 
- 1 0 -
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41) On average looking back at the various stages of your life in the day time 
when outdoors, did you generally try one of the following? Please put v under the activity. 
You can answer more than one activity. If you did not spend time outdoors at all, please put v under 
the far right column 
When outdoors you .. ...... Did not 
Always Wear Wear Try to cover spend 
In your seek a very normal yourself up time 
sun tan little summer from the sun outdoors 
clothing at all 
205 
305 
405 
During the last 5 years 
42) Did you use suntan oil, lotion or cream to protect your skin when you were out in 
the sun? Please tick v 
In your Always Sometimes Rarely Never 
205 
305 
405 
During the last 5 years 
Section 7: About the health of your family 
Some prostate diseases may be hereditary. We would like to ask if any of your 
family have ever been diagnosed with prostate problems or any type of cancer. 
43) Have any male members of your family been told by a doctor that he has/had 
any of the following? (If there is no one, please go on to question 44) 
D Yes (Please answer the following) 
D A swollen or enlarged prostate 
(benign prostatic hyperplasia) 
D Prostatitis 
(infection of the prostate) 
D No (please go on to question 44) 
- I 1 -
Identify relationship to you 
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Certain cancers are known to have a genetic or familial component. Please 
record below any cancers that you are aware of and that have occurred in your 
first degree relatives (parents, siblings or your children). 
44) Have any of your first degree relatives have cancer of any type? 
D Yes (go on to question 45) D No (go on to Section 8) 
45) If yes, please specify their relationship to you and type of cancer that they have 
(including prostate cancel'), 
Relationship to you Type of cancer Age at Date of 
diagnosis birth 
(if known) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
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Section 8: Physica I activity 
In this section we would like you to think about the physical activity you have 
undertaken in a typical day at various stages of your life. 
On average have you undertaken at least 30 minutes of moderate phvsical 
activity per day - either at home or at work. (These activities can be made 
up of many components, for example, moving a table, pushing a vacuum cleaner, 
bowling or playing golf). 
46) In your 20s 
47) In your 30s 
48) In your 40s 
49) During the last 5 years 
DYes 
DYes 
DYes 
DYes 
D Not applicable 
D Not applicable 
D Not applicable 
D Not applicable 
On average have you undertaken 20 minutes or more of energetic activity at 
least 3 times per week whilst NOT at work. (These include, for example, keep 
fit, dancing or exercises, swimming or other brisk sport, long walks, jogging or 
running, hard work in a job at home or in the garden, cycling). 
50) In your 20s 
51) In your 30s 
52) In your 40s 
53) During the last 5 years 
D Yes 
DYes 
DYes 
DYes 
- I 3 -
o Not applicable 
D Not applicable 
o Not applicable 
D Not applicable 
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Section 9: Your general health and medication 
In this section we would like to know more about your general health, medication 
(use of steroids, hormone treatments, or pain killers etc), as well as any X-ray 
procedures you have ever had at various stage of your life time. 
54) Have you had a vasectomy? 
D Yes (go on to question 55) D No (go on to question 56) 
55) How old were you? D D 
56) Have you ever taken any of the following? (If no please go on to question 57) 
Yesl At Treatment for Duration of use 
No age (mm/vv) 
Androgens or testosterone 
Anabolic steroids 
Oestrogen 
Cortisone not as a skin cream 
Cortisone or corticosteroids as 
a skin cream 
Thyroid drugs 
- 14-
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One of the questions researchers want to know is whether the exposure of medical 
diagnostic procedures such as X-ray, is associated with prostate disease. In order to 
answer this question, we will need to collect detailed information about any X-ray or 
radiological procedures you have ever had. 
57) Have you ever had any of the following x-ray procedures? (if yes, please give 
details with your best estimates) 
Yesl Number Details of procedure procedure At age I Purpose of x-ray and No of times date site (if aHlicablftl 
1 
lIiulum mill 2 
i.e. x-rays of your 
stomach taken after 3 
swallowing a glass of 
chalky liquid 4 
5 
1 
Cbolecy&toqram 2 
i.e. x-ray of your gall 3 bladder taken after _. - - - - - - ~ - - - - - - - - -- -------- -- - - -----
swallowing a glass of 4 thick liquid 
5 
1 
2 
~ ~
Kidney X-ray following 3 
an Injection 
4 
5 
1 
2 
X-[IV of blOd, 3 
Ibguldl[ II[ I[ml 
--
4 
. - - . - ~ - - -
5 
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Yesl Number Details of procedure Procedure At age I Purpose of x-ray and No of times date site (If applicable) 
1 
2 
X - r l n ~ ~ gf !.IR. I ~ ~ Q[ 3 
tbigh ~ - - ~ - - . - - ~ - - ----
4 
5 
1 
2 
X-[Ilf gf biRllHllfi, 3 IUkm 
4 
5 
1 
LlfmRbangioq@m 2 
i.e. x-ray taken of 
3 different parts of the 
body after dye has 
4 been injected 
5 
1 
CAT scan 2 
i.e. x-ray of your body 3 taken inside a machine 
where the equipment 
4 rotates around you 
5 
1 
rntBQ[ ~ B I I 2 (mlgoldi, resonlOS::C 
imaging) Scan 
3 
i. e. where you are put 
4 inside a large magnet 
5 
- 1 6 -
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Yesl Number Details of procedure Procedure Atagel Purpose of x-ray and No of times date site (if applicable) 
1 
2 
RllIlgIs;;tiB - - - - - - - - - . - ~ - . - - . .
gr isotope injections 3 
with pictures or x-ray 4 
taken afterwards 
5 
1 
2 
yenggram 
i.e. x-rays of vein after 3 
dye has been injected 
4 
5 
1 
AOaliHIlllm g[ 
iU.BOQ9mm 2 
i.e. an x-ray to view 
your heart or body 3 
blood vessels taken 
after a tube has been 4 
passed into your arm or 
groin 5 
58) Have you ever been told by doctor that you have/had any of the following 
conditions? 
Conditions Yes/No Age at diagnosis 
Diabetes 
Heart disease 
Hypercholesterolaemia (high blood cholesterol) 
High blood pressure 
Other please specify 
.................................................................... 
........................................................................ 
__ ~ ~_______ J 
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Some medications may be associated with prostate diseases. In order to study this 
question in detail, we would like to ask you some questions about your use of 
prescription or non-prescription painkillers in the past. 
59) Have you ever regularly taken statin (e.g, Atorvastatin, Cerivastatin, Simvastatin) 
in the past 10 years? 
D Yes (go on to question 60) D No (go on to question 61) 
60) If Yes, could you please let us know 
(a) Which type of statin (or brand name) you have taken? 
(b) The dosage of pills or capsule? .................. mg or ............... \-Ig 
(c) Roughly how often do you take the medicine? 
(d) For how many years have you been taking the medicine? .................. years 
(e) Reason for taking statin? ................................................................................... . 
61) Have you ever regularly taken any non-prescription painkillers bought over the 
counter from a chemist or a supermarket in the last 10 YEARS? 
(By regularly, we mean at least one tablet per week for more than three months.) 
D Yes (go on to question 62) D No (go on to question 63) 
62) We would like to know more details about the painkiller(s) you have regularly 
taken. Could you please let us know: 
a) Which type of painkiller(s) you have taken? 
b) Do you recall the dose? 
c) Roughly how often do you take the tablets or medicine? 
d) For how many years have you been taking the tablets or medicine? 
e) For what reason do you take them? 
Please provide the information in the table on next page. 
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c) Average frequency 
b) Dose Tick one box per Ii ne d) Duration 
At least 
e) Reason for Dosage of Never or once a Number of 
a) Name of Painkiller pills/capsules less than month but At least years of taking 
or teaspoons once a not every once taking painkillers 
each time month day a day painkillers 
1 Aspirin or preparation 
containing aspirin eg 
Alka-Seltzer, Disprin 
2 Ibuprofen - e.g. 
Nurofen, Ibufen, Advil, 
Migrafen 
3 Paracetamol or 
preparation containing 
Paracetamol - eg 
Panadol, Co-proxamol, 
Co-codamol 
4 Other pain medication 
(please specify) 
.......................................... 
......................................... 
63) Do you have any side-effects if you take aspirin? 
o Yes (go on to question 64) 0 Don't know/ I don't use aspirin (go on to question 65) 
D No (go on to question 65) 
64) Do the side effects make you stop taking aspirin? 
D Yes (go on to question 65) 
D No, I still take aspirin because ................................................................................... . 
........................................................................................................................................................ 
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In 
your 
20s 
30s 
40s 
50s 
In this section, we would like you to think about the three most commonly used 
painkillers in various stages in your adult life. This includes painkillers available in 
pharmacy or supermarket (i.e., over the counter: OTC), as well as those prescribed 
by doctor. 
65) Have you been taken any painkilling medication on a regular basis (at least once 
a week for more than three months) duriOO your adult life, either prescribed by your 
GP or bought over the counter COTe). 
D Yes (go on to question 66) D No (go on to section 10) 
66) If Yes, please can you give us more details 
A Painkiller 1 B Painkiller 2 C Painkiller 3 
No of No of 
Name From years Name From years Name From 
used used 
GP 0 GP 0 GP 0 
aTe 0 OTe 0 OTe 0 
GP 0 GP 0 GP 0 
aTe 0 aTe D aTe D 
GP 0 GP D GP 0 OTe D OTe 0 aTe 0 
GP 0 GP D GP D 
aTe 0 OTe 0 OTe 0 
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No of 
years 
used 
Section 10: Further details about you J 
In this section we would like to know more about your body size and body shape. 
This includes the changes of your weight or trouser size in the past years. Please 
give as approximate estimates if you can and 
67) Please can you tell me your current weight and height? 
My weight is ........... Stones .... .. ... .... Pounds or .... ......... . Kilograms 
My height is .... ...... .. Feet.. ............. .. .Inches or ............... Centimetres 
68) Has your weight changed over the last 5 years? 
o Yes my weight was ................ Stones ...... ... . Pounds or ... ........ .. Kilograms 
ONo 
69) What is your collar-size? 
inches 
70) Please can you tell me your waist and your approximate hip circumference, 
either in inches or in centimetres? If you cannot remember your waist 
circumference, can you recall your trouser size (for example size 30)? 
Waist/ Trouser Size Hip 
inch em inch em 
In your 205 
In your 305 
In your 405 
During the last 5 years 
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Please select the shape you think you were at different ages. (Please write down the 
number you think you were). 
1 2 3 4 5 6 7 8 9 
71) In your 20s 0 
72) In your 30s D 
73) In your 40s D 
74) During the last 5 years D 
Overall please select one of the descriptions below that suit you the most. 
(please write down number in the box) 
1. Apple shape- where your body fat is distributed mainly around your tummy 
area. 
2. Pear shape- where your body fat is distributed mainly on your hip and thigh . 
3. Oval shape- where your body fat is distributed around your neck, your chest 
your tummy area and also your thigh. 
4. Symmetric shape- where you are lean with no fat distribution around your 
body. 
75) My body shape is D 
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Food Frequency Questionnaire J 
This section of the questionnaire asks for information about what you eat. Dietary 
factors are thought to be very important in terms of influencing the risk of prostate 
disease. Your help in completing this section is particularly important and 
appreciated. 
Please answer every question. If you are uncertain about how to answer a question 
then do the best you can, but please do not leave a question blank. If you have 
any problems with the questions please phone the number at the end of the 
questionnaire. 
Your answers will be treated as strictly confidential and will be used only for medical 
research. 
• 2 3 -
About Your Diet J 
We would like to ask about your typical diet in the past 5 years. 
Please start by thinking and identify any major events that may have marked this 
time period. This should help you to recall this particular time. 
For each food the amount shown is, either a "medium serving" or a common 
household unit such as a slice or teaspoon. Please put a tick ( ..J) in the box to 
indicate how often, on average, you have eaten the specified amount of each food . 
Please complete each line as shown in the following examples. 
Foods and Amounts AVERAGE USE OVER THE LAST 5 YEARS 
BREAD AND SAVOURY Neller or less 1-3 per Once 2-4 per 5-6 Once 2-3 4-5 
BISCUITS than month a week per a day per per 
(one slice or biscuit) once/month week week day day 
White bread and rolls ~ ~
For chips, the amount is a "medium serving", so if you had a helping of chips twice a 
week you should put a tick in the column headed "2-4 per week". 
POTATOES, RICE AND PASTA Neller or less 1-3 per Once 2-4 per 5-6 Once 2-3 4-5 
(medium serving) than month a week per a day per per 
Clips 
once/month week week day day 
~ ~
For very seasonal fruits such as strawberries and raspberries you should estimate 
your average use when the fruits are in season, so if you ate strawberries or 
raspberries about once a week when they were in season you should put a tick in the 
column headed "once a week". 
- 2 4 -
6+ 
per 
day 
6+ 
per 
day 
Please estimate your average food use as best you can based on a "medium portion". 
For example, for beef, a medium serving is as shown in the middle. Please answer every 
question - do not leave ANY lines blank. 
Mediym serving 
PLEASE PUT ONLY ONE TICK ON EVERY UNE 
Foods and Amounts AVERAGE USE OVER THE LAST 5 YEARS 
MEAT AND FISH Never or less 1-3 Once 2-4 5-6 Once 2-3 4-5 
(Medium serving) than per a per per a per per 
once/month month week week week day day day 
Beef: roast, steak, mince, stew or 
casserole 
Beefburgers 
Pork: roast, chops, stew or slices 
Lamb: roast, chops or stew 
Olicken or other poultry e.g. turkey 
Bacon 
Ham 
Corned beef, spam, luncheon meats 
Sausages 
Savoury pies, e.g. meat pie, pork 
pie, pasties, steak & kidney pie, 
sausage rolls 
Live, liver pate, liver sausage 
Fried fish in batter, as in fish and 
chips 
Fish fingers, fish cakes 
Other white fish, fresh or frozen, 
e.g. cod, haddock, plaice, sole, 
halibut 
Oily fish, fresh or canned e.g. 
mackerel, kippers, tuna, salmon, 
sardines, herring 
Shellfish, e.g. crab, prawns, mussels 
Fish roe, taramasalata 
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Please estimate your average food use as best you can based on a "medium portion". 
For example, for cereal, a medium serving is as shown in the middle. Please answer every 
question - do not leave ANY lines blank. 
Medium serving 
PLEASE PUT ONLY ONE TICK ON EVERY UNE 
Foods and Amounts AVERAGE USE OVER THE LAST 5 YEARS 
BREAD AND SAVOURY Never or less 1-3 Once 2-4 per 5-6 Once 2-3 4-5 
BISCUITS than per a week per a day per per 
(one slice or biscuit) once/month month week week day day 
White bread and rolls 
Brown bread and rolls 
Wholemeal bread and rolls 
Cream crackers, cheese biscuits 
Crispbread e.g. Ryvita 
CEREALS (one bowl) 
Porridge, Readybrek 
Breakfast cereal such as 
Cornflakes, muesli etc. 
POTATOES, RICE AND 
PASTA(medium serving) 
Boiled, mashed, instant or jacket 
potatoes 
O'Iips 
Roast potatoes 
Potato salad 
White rice 
Brown rice 
White or green pasta, e.g. 
spaghetti macaroni noodles 
Wholemeal pasta 
Lasagne, moussaka 
Pizza 
- 2 6 -
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day 
Please estimate your average food use as best you can based on a "medium portion". 
For example, for Quiche, a medium serving is as shown in the middle. 
Please answer every question - do not leave ANY lines blank. 
Medium serving 
PLEASE PUT ONLY ONE TICK ON EVERY UNE 
Foods and amounts AVERAGE USE OVER THE LAST 5 YEARS 
DAIRY PRODUCTS AND FATS Never or less 1-3 Once 2-4 5-6 Once 2-3 
than per a per per a per 
once/month month week week week day day 
Single or sour cream (tablespoon) 
Double or dotted cream (tablespoon) 
Low fat yoghurt, fromage frais (125g 
carton) 
Full fat or Greek yoghurt (l25g carton) 
Dairy desserts (125g carton) 
Oleese e.g. Oleddar, Brie, Edam 
(medium serving) 
Cottage cheese, low fat soft cheese 
(medium serving) 
Eggs as boiled, fried, scrambled etc.(one) 
Quiche (medium serving) 
Low calorie, low fat salad cream 
(tablespoon) 
Salad cream, mayonnaise (tablespoon) 
French dressing 
Other salad dressing (tablespoon) 
... AND A TEASPOON OF THE FOLLOWING ON BREAD OR VEGETABLES 
Butter 
Block margarine, e.g. Stork, Krona 
polyunsaturated margarine (tub) e.g . 
Flora sunflower 
Other soft margarine, dairy spreads (tub) 
e.g. Blue Band, Gover 
Low fat spread (tub) e.g. Outline, Gold 
Very low fat spread (tub) 
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4-5 6+ 
per per 
day day 
Please estimate your average food use as best you can based on a "medium portion". 
For example, for SPONGE CAKE, a medium serving is as shown in the middle. 
Please answer every question - do not leave ANY lines blank. 
--
Medium serving 
PLEASE PUT ONLY ON E TICK ON EVERY UNE 
Food and Amounts AVERAGE USE OVER THE LAST 5 YEARS 
SWEETS AND SNACKS Never or 1-3 Once 2-4 5-6 Once 2-3 
(medium serving) less than per a per per a day per 
once/month month week week week day 
Sweet biscuits, chocolate e.g. digestive 
(one) 
Sweet biscuits, plain e.g. Nice, ginger 
(one) 
Cakes e.g. fruit, sponge, home baked 
Cakes e.g. fruit, sponge, ready made 
Buns, pastries e.g. scones, flapjacks, 
home baked 
Buns, pastries e.g. croissants, 
doughnuts, ready made 
Fruit pies, tarts, crumbles, home baked 
Fruit pies, tarts, crumbles ready made 
Sponge puddings, home baked 
Sponge puddings, ready made 
Milk puddings e.g. rice, OJstard trifle 
Ice cream, choc ices 
Chocolates, single or ~ u a r e s s
Chocolate snack bars e.g. Mars, 
Crunchie 
Sweets, toffees, mi nts 
Sugar added to tea, coffee, cereal 
(teaspoon) 
Crisps or other packet snacks, e.g. 
Wotsits 
Peanuts or other nuts 
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4-5 6+ 
per per 
day day 
Please estimate your average food use as best you can based on a "medium portion". 
Please answer every question - do not leave ANY lines blank. 
PLEASE PUT ONLY ONE TICK ON EVERY UNE 
Food and Amounts AVERAGE USE OVER THE LAST 5 YEARS 
SOUPS, SAUCES AND SPREADS never or less 1-3 once 2-4 5-6 once 2-3 
than once/month per a per per a per 
month week week week day day 
Vegetable soups (bowl) 
Meat soups (bowl) 
Sauces e.g . white sauce, cheese 
sauce, gravy (tablespoon) 
Tomato ketchup (tablespoon) 
Pickles, chutney (tablespoon) 
Marmite, Bovril (teaspoon) 
Jam, Marmalade, honey (teaspoon) 
Peanut butter (teaspoon) 
4-5 6+ 
per per 
day day 
FRUIT (1 fruit or medium serving). For very seasonal fruits such as strawberries, please estimate your average use when 
the fruit is in season for example if you ate strawberries about once a week when they were in season you should put a 
tick in the column headed "once a week" 
Apples 
Pears 
Oranges, satsumas, mandarins 
Grapefruit 
Bananas 
Grapes 
Melon 
Peaches, plums, apricots 
Strawberries, raspberries, kiwi fruit 
Tinned fruit 
Dried fruit, e.g. raisins, prunes 
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Please estimate your average food use as best you can based on a "medium portion". 
For example, for BAKED BEANS, a medium serving is as shown in the middle. 
Please answer eb. q U ! ? ~ ~ ~ ~ ".[ BY..! AN,Y iiI ~ l i l l , : :k : :.... ' __ 4 4 ~ ~
Medium serving 
PLEASE PUT ONLY ONE TICK ON EVERY UNE 
Food and Amounts AVERAGE USE OVER THE LAST 5 YEARS 
Vegetables Never or less 1-3 Once 2-4 5-6 Once 2·3 
Fresh, frozen or tinned than per a per per a per (medium serving) once/month month week week week day day 
Carrot 
Spinach 
Broccoli, spring greens, ka le 
Brussels sprouts 
Cabbage 
Peas 
Baked beans 
Marrow, courgettes 
CaUliflower 
Parsnips, turnips, Swedes 
Leeks 
Onions 
Garlic 
Mushrooms 
Sweet peppers 
Bean sprouts 
Green salad, lettuce, cucumber, celery 
Watercress 
Tomatoes 
Sweet corn 
Beetroot 
Coleslaw 
Green beans, broad beans, runner beans 
Avocado 
Dried lentilS, beans, peas 
Tofu, Soya meat, lVP, Vegeburger 
• 3 0 -
4-5 6+ 
per per 
day day 
Please estimate your average food use as best you can based on a "medium portion". 
Please answer every question - do not leave ANY lines blank. 
PLEASE PUT ONLY ONE TICK ON EVERY UNE 
Food and Amounts AVERAGE USE OVER THE LAST 5 YEARS 
Drinks never or less 1-3 once 2-4 5-6 once 2-3 
than per a per per a per 
once/month month week week week day day 
Tea (cup) 
Coffee, instant or ground (cup) 
Coffee, decaffeinated (cup) 
Coffee whitener e.g. Coffee-mate 
(teaspoon) 
Cocoa, hot chocolate (rup) 
Horlicks, ovaltine (cup) 
Wine (glass) 
Beer, lager or cider (half pint) 
Port, sherry, vermouth, liqueurs 
(glass) 
Spirits, e.g. gin, brandy, whisky, 
vodka (single) 
Low calorie or diet fizzy soft drinks 
(glass) 
Fizzy soft drinks, e.g. Coca cola, 
lemonade (glass) 
Pure fruit juice - 100% e.g. orange, 
apple juice (glass) 
Fruit squash or cordial (glass) 
Soya Milk (glass) 
- 3 1 -
4-5 6+ 
per per 
day day 
76) Did you have curry more than once a week, either home-cooked, tinned sauce, 
take-away or from supermarket? 
DYes D No 
f I" t b I I yes, please IS eow 
Type of curry Usual serving size Number of times 
(e.g., Korma, Thai green curry) (small, medium or large) eaten each week 
77) Are there any other foods, which you ate more than once a week? 
DYes D No 
I" t b I If yes please IS eow 
Food Usual serving size Number of times 
eaten each week 
78) What type of milk did you most often use? Select one only 
o Full cream 
D Skimmed 
D Dried milk 
o None 
D Semi-skimmed 
D Channel Islands 
DSoya 
D Other, specify ... ..... ......... ...... .... .... ........ .. .. 
79) How much milk did you drink each day, including milk with tea, coffee, cereals 
etc? 
DNone 
D Quarter of a pint 
D Half a pint 
D Three quarters of a pint 
DOne-pint 
D More than one pint 
80) Did you usually eat breakfast cereal? (excluding porridge and Ready Brek 
mentioned earlier?) 
DYes D No 
If yes, which brand and type of breakfast cereal, induding muesli, did you usually 
eat? 
List the one or two most often used 
Brand Type 
- 3 2 -
81) What kind of fat did you or your wife/partner most often use for frying, roasting, 
grilling etc? Select one only 
D Butter D Solid vegetable fat 
D Lard/dripping D Margarine 
D Vegetable oil D None 
If you used vegetable oil, please give type e.g. corn, sunflower . 
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82) What kind of fat did you or your wife/partner most often use for baking cakes 
etc? Select one only 
D Butter D Solid vegetable fat 
D Lard/dripping D Margarine 
D Vegetable oil D None 
If you used margarine, please give name or type e.g . Flora, Stork . 
....... ... .. .................... .... .. ...... ..... .......................... ... .. .... ... ... ....... ......... 
83) How often did you or your wife/partner use the following spices in cooking? 
AVERAGE USE OVER THE LAST 5 YEARS 
never or less 1-3 once 2-4 5-6 once 2-3 4-5 6+ SPICES than per a per per a per per per 
(1 TEASPOON) once/month month week week week day day day day 
Curry powder 
Turmeric powder 
Worcester sauce 
Mix herb dried 
Oregano dried 
Thyme dried 
Rosemary dried 
Tarragon dried 
84) How often did you eat food that was fried at home? 
D Daily D 1-3 times a week 
D 4-6 times a week D Less than once a week 
D Never 
- 3 3 -
85) How often did you eat fried food as a takeaway or away from home? 
D Daily D 1-3 time a week 
D 4-6 times a week D Less than once a week 
D Never 
86) What did you do with the visible fat on your meat? 
D Ate most of the fat D Ate as little as possible 
D Ate some of the fat D Do not eat meat 
87) How often did you eat grilled or roast meat? 
D limes a week 
D Do not eat meat 
88) How well cooked did you usually have grilled or roast meat? 
D Well done/dark brown D Ughtly cooked/rare 
D Medium 0 Did not eat meat 
89) How often did you or your wife/partner add salt to food while cooking? 
D Always D Usually 0 Sometimes 
D Rarely D Never 
90) How often did you add salt to any food at the table? 
D Always D Usually 0 Someti mes 
o Rarely D Never 
91) Did you regularly use a salt substitute (e.g. LoSalt?) 
DYes D No 
If yes, which brand ............................................... . 
92) D i d ~ U U use soy margarine? 
U Yes (go on to question 93) D No (go on to question 94) 
93) How often did you use soy margarine (at least a teaspoon or more)? 
D Never D 3 times per month 
D Once a week D 2-4 times per week 
D Once a day D 2-3 times per day 
94) Did you use soy sauce? 
D Yes (go on to question 95&96) D No (go on to question 96) 
95) How often did you use soy sauce (at least a teaspoon or more)? 
D Never D 3 times per month 
D Once a week D 2-4 times per week 
o Once a day 0 2-3 times per day 
- 3 4 -
The following question asks about vitamin supplements and other functional foods you 
have taken. 
96) Have you taken any vitamins supplements or functional food during the last 5 
years? 
D Yes (please complete the table below) D No (go on to question 97) 
Vitamin and Average frequency 
supplements Tick one box per line to show how often on 
average you consumed supplements 
YIN Dose or quantity Never or 2-4 Once 
(no. of pills/capsules, less than per a day 
teaspoons, or glass once a week 
consumed each time) month 
Multivitamins and minerals 
Selenium [not as part of i 
multivitamins] 
Vitamin C [not as part of 
multivitamins] 
CalCiferol 
Fish oil 
Saw palmetto 
--
. - ~ - - , - ~ ~
Garlic as tablet 
Pomegranate drink 
Soy-based drink 
Tomato juice 
Other (please specify) 
• 35 -
2-3 
per 
day 
, .. - . , - . - ~ ~
--
We are particularly interested in your patterns of consumption of the following foods 
over your lifetime. 
97) How has your use of the following foods changed over your lifetime? 
Food Age Never or less 1-3 per Once a 2-4 5-6 Once 2-3 4-5 
than month week per per a day per per 
once/month week week day day 
Whole milk In your 205 
In your 305 
Butter In your 205 
In your 305 
Margarine In your 205 
In your 305 
Fruits In your 205 
In your 305 
Vegetables In your 205 
In your 305 
Meat In your 205 
In your 30s 
Whole wheat In your 20s 
bread In your 305 
Alcohol In your 205 
In your 305 
May we have your permission 
- To contact you if we need further information to resolve any queries? 
D Yes Contact telephone number: ............................................... .. 
D No Email: ................................................................................... . 
- To look at your medical record 
DYes D No 
If you are planning to move house in the near future, please may we have 
your new address? 
My new address will be ....................................................................................... .. 
.............................................................. " ....................... Post oode .................... . 
New telephone number (if known} ........................................................................... . 
E-Mail: ............................................................................................................................. . 
- 3 Ii -
6+ 
per 
day 
.. -
Thank you very much once again 
for taking the time and trouble to 
fill in this questionnaire, your help 
is really appreciated and will be 
invaluable to this research 
project. 
Please return your answers in the pre-paid 
envelope as soon as possible to: 
Dr Aneela Rahman 
Division of Epidemiology and Public Health 
School of Community Health Sciences 
Queen's Medical Centre 
University of Nottingham 
Nottingham NG12UH 
Tel 0115-8230495 
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